Overview - Clinical Trials

1 Terminated (The clinical trial has ended prema 1 NCT05735756
1 Terminated (too busy for recruitment) 2 NCT05338125

1 Withdrawn (No participants were enrolled in th 3 NCT05279222
1 Terminated (Due to a delayed start-up and dela 4 NCT05268926
1 Terminated (Inclusion rate too low.) 7 NCT05194176
1 Terminated (Recruitment was dependent on find 13 NCT04844346
1 Terminated (Aimed sample size could not be re 17 NCT04733898
1 Withdrawn (Lack of inclusion / COVID-19 regu 18 NCT04648436
1 Terminated (A limited number of inclusions d 21 NCT04420455
1 Terminated (Currently almost no patients admi 23 NCT04362332
1 Terminated (We decided to stop inclusions and 24 NCT04311047
1 Terminated (Due to the COVID-19 pandemic th 26 NCT04267276
1 Terminated (Despite the extension of the origi 33 NCT04163094
1 Terminated (stopped prematurely due to too lo 34 NCT04132791
1 Terminated (Slow accrual.) 36 NCT04051853
1 Terminated (As a result of a slower inclusion 43 NCT03877198
1 Withdrawn (no participants enrolled) 44 NCT03863301
1 Terminated (slow enrolment) 58 NCT03439150
1 Terminated (Inclusion rate not reached and d 59 NCT03435575
1 Withdrawn (Difficulty finding eligible patients) 64 NCT03326219
1 Terminated (Slow inclusion rate (partly due to 68 NCT03214809
1 Terminated (Unexpected low recruitment rate) 69 NCT03211494
1 Terminated (Conflicting recruitment with PE 70 NCT03150628
1 Terminated (it was not possible to recruit the 75 NCT03026049
1 Terminated (Slow accrual) 78 NCT02975739
1 Terminated (slow inclusion rate) 79 NCT02941835
1 Terminated (Only 1 inclusion in 2 5 years) 82 NCT02905396
1 Terminated (Low enrollment number) 83 NCT02856373
1 Terminated (Slow inclusion) 84 NCT02853162
1 Terminated (Inclusion of patients slow) 86 NCT02836340
1 Terminated ( Insufficient rates of participant 95 NCT02632279
1 Terminated (Insufficient recruitment during th 96 NCT02629055
1 Terminated (patients did not want to participat 100 NCT02584400
1 Terminated (Not enough patients eligible for r 101 NCT02548533
1 Terminated (Due to a change in medication guid 103 NCT02530203
1 Terminated (It was not possible to recruit and 106 NCT02524886
1 Terminated (Minimal to no inclusion.) 108 NCT02469506
1 Terminated (Lack of recruitment) 110 NCT02403518
1 Suspended (We recruited 25 of the 40 partic 111 NCT02361957
1 Terminated (Sponsor withdrawn due to low inc 112 NCT02349659
1 Terminated (Recruitment target could not be 113 NCT02333916
1 Terminated (Insufficient number of participants 114 NCT02329171
1 Terminated (insufficient eligable subjects an 116 NCT02319733
1 Withdrawn (no participants) 118 NCT02295163
1 Terminated (patients did not want to participat 123 NCT02233387
1 Terminated (Low inclusion rate) 126 NCT02210949
1 Terminated (inclusion was too slow) 127 NCT02185937
1 Terminated (Low recruitment rate) 129 NCT02152930
1 Withdrawn (no eligible patients; study stopped 130 NCT02110316
1 Terminated (Expectation that within the set tim 132 NCT02062372
1 Terminated (Delayed/poor inclusion rate.) 134 NCT02029781
1 Terminated (slow enrollment study device una 138 NCT01982032
1 Terminated (Severe difficulties with recruiting 140 NCT01921062
1 Terminated (Failure to recruit sufficient partici 141 NCT01887119
1 Withdrawn (No local inclusions) 142 NCT01886625
1 Terminated (Inclusion of patients was slow. Co 143 NCT01882660
1 Terminated (Insufficient number of participant 145 NCT01796340
1 Terminated (slow inclusion) 153 NCT01654328
1 Terminated (Terminated because of insufficien 154 NCT01638260
1 Terminated (Lack of accrual) 157 NCT01577212
1 Terminated (Poor accrual) 158 NCT01575782
1 Terminated (It was decided to discontinue the 159 NCT01540786
1 Terminated (Insufficient number of participant 162 NCT01425242
1 Terminated (patient enrollment too slow) 163 NCT01407614
1 Terminated (only 1 inclusion in 1.5 years due to 166 NCT01367405
1 Terminated (Inclusion rate insufficiënt) 167 NCT01360918
1 Terminated (slow enrolment of patients and ne 171 NCT01329250
1 Terminated (Inclusion rate insufficient) 172 NCT01319747
1 Terminated (insufficient patients enrolled) 173 NCT01276834
1 Terminated (low recruitment numbers) 176 NCT01262183
1 Terminated (Accrual stopped) 178 NCT01210378
1 Withdrawn (too limited number of eligible pati 179 NCT01193712
1 Terminated (Due to very specific inclusion cr 181 NCT01124227
1 Terminated (slow recruitment) 182 NCT01107184
1 Terminated (Slow recruitment) 183 NCT01079364
1 Terminated (recruitment was unsuccesfull only 188 NCT00962299
1 Terminated (poorly recruiting) 189 NCT00953459
1 Terminated (too slow recruitment; lack of fund 190 NCT00922844
1 Terminated (Due to limited rate of patient incl 193 NCT00866034
1 Terminated (Due to a very slow inclusion rate. 194 NCT00866008
1 Terminated (Recruitment faillure. Similar stud 196 NCT00856817
1 Withdrawn (Suitable subjects could not be recr 200 NCT00826566
1 Terminated (Enrollments slowed down significa 205 NCT00703157
1 Terminated (Poor recruitment) 206 NCT00687986
1 Terminated (The study was discontinued early o 207 NCT00687609
1 Terminated (acrual too slow) 208 NCT00684216
1 Terminated (Primary endpoint reached slow a 209 NCT00661570
1 Terminated (Unable to recruit enough patients 212 NCT00637624
1 Terminated (Due to poor patient accrual) 213 NCT00631267
1 Terminated (Inclusion rate too low due to a lac 214 NCT00599287
1 Withdrawn (conduct (recruitment) not feasible 218 NCT00509847
1 Terminated (Insufficient recruitment) 221 NCT00504244
1 Terminated (Low enrollment rates) 222 NCT00480077
1 Terminated (it was not possible to recruit ne 223 NCT00452166
1 Terminated (Study was terminated after enrollme 227 NCT00422942
1 Terminated (enrollment insufficient 228 NCT00413543
1 Withdrawn (no actual patients recruited within 232 NCT00371579
1 Terminated (This study was terminated due to 235 NCT00302770
1 Terminated (recruitment of patients did not re 237 NCT00294905
1 Terminated (lack of enrollment) 238 NCT00289055
1 Terminated (slow recruitment rate) 240 NCT00223587
1 Withdrawn (Too few inclusions) 245 NCT00202371
1 Terminated (no accrual achieved) 254 NCT00145665
1 Terminated (Did not recruit) 255 NCT00128908
1 Withdrawn (Closed prematurely because the a 262 NCT03850028
1 Terminated (Number of subjects could not be 263 NCT03026829
1 Terminated (low recruitment rate) 265 NCT02935387
1 Terminated (Too limited accrual) 267 NCT02729558
1 Terminated (insufficient patient enrollment ins 268 NCT02473562
1 Terminated (difficulties with inclusion) 270 NCT02096133
1 Terminated (Because the inclusion rate was l 273 NCT01820962
1 Terminated (As advised by the DSMB the stud 275 NCT01613235
1 Withdrawn (No patients) 279 NCT01178151
1 Terminated (slow accrual) 281 NCT00929019
1 Withdrawn (it was not possible to recruit any p 285 NCT00169923
1 Terminated (Problems with inclusion >80% of 291 NCT01823809
1 Terminated (The study was early terminated du 295 NCT02722603
1 Terminated (bad recruitment of suitable partici 297 NCT02077309
1 Terminated (low accrual) 302 NCT00003152
1 Terminated (Inclusion of the study didn't go a 304 NCT00823472
1 Terminated (Inclusion rate too low. Recruitment 305 NCT00647192
1 Terminated (Slow accrual due to COVID-19 an 306 NCT03984019
1 Terminated (Insufficient inclusion rate (due 308 NCT03846570
1 Terminated (Insufficient tumor-to-background r 311 NCT02743975
1 Terminated (Low accrual rate) 312 NCT02685046
1 Terminated (interim results concluded no added 314 NCT02040909
1 Terminated (Poor enrolment; only 6 subjects en 317 NCT01562522
1 Terminated (Interim analyses showed insufficien 319 NCT00940979
1 Terminated (Very slow recruitment) 320 NCT00807170
1 Terminated (Extremely difficult recruitment. Pr 322 NCT00512655
1 Withdrawn (Lack of patients who are eligible fo 324 NCT03389061
1 Terminated (Insufficient participating sites a 326 NCT05254808
1 Terminated (At interim analysis insufficient b 329 NCT03147040
1 Terminated (Due to the rigorous nature of the 330 NCT02804087
1 Terminated (In the Netherlands we wanted to a 331 NCT02621515
1 Terminated (enrollment to slow insufficient fu 332 NCT01856738
1 Terminated (low inclusion rate) 334 NCT01708265
1 Terminated (Insufficient funds) 335 NCT01393028
1 Terminated (Inclusion speed too slow no longe 336 NCT01334775
1 Terminated (Due to our experience the small 342 NCT02256124
1 Terminated (due to introduction of another int 346 NCT02566707
1 Terminated (low recruitment with registratio 351 NCT00889590
1 Terminated (Poor recruitment.) 356 NCT03152084
1 Terminated (Difficulties with recruitment) 358 NCT02949232
1 Terminated (Insufficient accrual rate) 359 NCT02607501
1 Terminated (insufficient effectiveness) 365 NCT03784599
1 Terminated (81 patients included difficult incl 366 NCT03655821
1 Terminated (Antiviral activity was considered 373 NCT01391117
1 Terminated (The clinical study was stopped d 375 NCT03275246
1 Terminated (completed for the primary study 386 NCT03082014
1 Terminated (very slow inclusion) 391 NCT02407795
1 Terminated (DSMB recommendation; enrollme 392 NCT01276093
1 Withdrawn (Study CCX115383 has been terminat 396 NCT01658605
1 Terminated (insufficient enrollment) 399 NCT01866553
1 Terminated (Enrollment was stopped to facili 405 NCT04335786
1 Terminated (Difficult recruitment despite sever 406 NCT03728855
1 Terminated (Insufficient inclusion of subjects) 407 NCT03616639
1 Terminated (accrual to slow target not achieva 413 NCT02775006
1 Terminated (recruiting rate was to low) 414 NCT02421458
1 Terminated (Slow accrual and changing treat 415 NCT02414750
1 Terminated (slow accrual rate) 420 NCT02112682
1 Suspended (slow recruitment rate) 421 NCT04506372
1 Terminated (Telaprevir will not be used in NL 424 NCT01841502
1 Terminated (due to low accrual rate) 427 NCT01392586
1 Terminated (Study terminated after 240 patien 428 NCT01385774
1 Terminated (Recruitment problems patients ref 433 NCT00989820
1 Terminated (no personnel for recruitment) 434 NCT02507986
1 Terminated (Low recruitment) 437 NCT00444639
1 Terminated (Low accrual) 443 NCT02470533
1 Terminated (Poorly recruiting) 448 NCT03763422
1 Terminated (Protracted recruitment timeline 454 NCT03600818
1 Terminated (Investigational device changes; 462 NCT01226290
1 Terminated (Study termination due to insufficie 471 NCT01687998
1 Terminated (Slow enrollment) 473 NCT01712412
1 Terminated (Sponsor discretion (low recruitme 474 NCT02656329
1 Terminated (The DMC made the recommendation t 481 NCT02308111
1 Terminated (The steering committee had decide 490 NCT02006069
1 Terminated (Protracted recruitment timeline 499 NCT03600805
1 Terminated (Due to slow inclusion of patients) 500 NCT01164046
1 Terminated (Positive FAIR-HF study data are 503 NCT00821717
1 Terminated (This study terminated prematurel 510 NCT03152552
1 Terminated (The study was discontinued prema 522 NCT00361868
1 Terminated (insufficient recruitment of patien 527 NCT01773083
1 Terminated (Lack of funding and recruitment.) 537 NCT01626755
1 Terminated (low enrollment rate) 545 NCT01869738
1 Terminated (Insufficient enrollment) 546 NCT00522418
1 Terminated (Challenges to recruit qualified par 549 NCT01711619
1 Terminated (Study terminated due to enrolment 553 NCT01402440
1 Terminated (Inclusion-rate does not seem feasi 555 NCT00449813
1 Terminated (This clinical trial was terminated 564 NCT00986258
1 Terminated (The study was terminated early d 572 NCT00578097
1 Terminated (Study early terminated due to low 590 NCT03968419
1 Terminated (Insufficient Enrollment) 599 NCT03519256
1 Terminated (Edwards acquired CardiAQ and opte 604 NCT02478008
1 Terminated (This study terminated enrollment d 613 NCT02461524
1 Terminated (Low recruitment of patients) 614 NCT02660138
1 Terminated (DLBCL and FL cohorts met the pre- 617 NCT02413489
1 Terminated (As recruitment rate was lower tha 628 NCT01772108
1 Terminated (Ceased production of the study dr 642 NCT01163942
1 Terminated (Surgical practice evolution chang 645 NCT01083472
1 Terminated (The study was terminated prematu 652 NCT00805740
1 Terminated (Failure to recruit patients with m 666 NCT00368264
1 Terminated (Accrual and treatment with CG 670 NCT00133224
1 Terminated (Sufficient enrollments under curre 671 NCT02227121
1 Terminated (Low enrollment) 673 NCT02872298
1 Terminated (Rate of enrollment too slow to al 678 NCT04333654
1 Terminated (Study terminated due to insufficie 690 NCT03843125
1 Terminated (Study terminated due to insufficie 697 NCT03616912
1 Terminated (terminated due to low enrollment 704 NCT03339401
1 Terminated (insufficient recruitment) 718 NCT02780180
1 Terminated (IDMC recommended that enrolment 720 NCT02703272
1 Terminated (National Comprehensive Cancer Ne 722 NCT02683941
1 Terminated (In the post-market environment t 724 NCT02637947
1 Terminated (Following recommendation by SO 728 NCT02588261
1 Terminated (Due to lower than expected recrui 740 NCT02258464
1 Withdrawn (Withdrawn due to difficulties in to 749 NCT01762852
1 Terminated (The study was stopped solely bas 751 NCT01693120
1 Terminated (early termination due to Sponsor 754 NCT01602315
1 Terminated (Slow and low enrollment) 755 NCT01528345
1 Terminated (Enrollment Difficulty) 758 NCT01483183
1 Terminated (Enrollment suspended; follow up 762 NCT01110070
1 Terminated (The study was terminated early due 763 NCT01246635
1 Terminated (Inadequate recruitment resulting i 764 NCT01242748
1 Terminated (Biosense stopped Study enrollment 766 NCT01116557
1 Terminated (Termination of study enrolment t 771 NCT00979134
1 Terminated (Recruitment was fully completed f 781 NCT00476996
1 Terminated (The Data Monitoring Committee term 784 NCT00334685
1 Terminated (LPLV reached on 30Jan2023. Study 794 NCT03996473
1 Terminated (Due to poor patient recruitment an 796 NCT03070574
1 Terminated (delay in recruitment lack of additi 804 NCT01616043
1 Terminated (Due to a challenging protocol inclu 805 NCT01308346
1 Terminated (Poor recruitment due to a change i 810 NCT03705507
1 Terminated (Failed to recruit sufficient number 814 NCT02441309
1 Terminated (Recruitment was terminated early b 815 NCT03393806
1 Terminated (After extensive efforts to improv 820 NCT05321524
1 Terminated (Phase 2 completed as planned. Due 824 NCT04828161
1 Terminated (Unsuccessful enrollment) 852 NCT03314675
1 Terminated ((Recruitment was early terminated 855 NCT03236311
1 Terminated (The study was terminated early due 857 NCT03221842
1 Terminated (Recruitment halted prematurely d 865 NCT03064854
1 Terminated (Insufficient efficacy terminated b 867 NCT02999854
1 Terminated (recruitement problem) 888 NCT01583114
1 Terminated (lack of recruitment) 893 NCT02509273
1 Terminated (Major challenge for enrollment of 896 NCT02468661
1 Terminated (Study terminated due to slow enr 906 NCT00542828
1 Terminated (Due to slow accrual) 925 NCT00298324
1 Terminated (Low or poor accrual) 938 NCT01508000
1 Terminated (This study was terminated early du 947 NCT01370863
1 Terminated (Trial terminated strategically due 951 NCT01316263
1 Terminated (The study was closed due to the s 953 NCT01283971
1 Terminated (Lack of Recruitment) 957 NCT01200992
1 Terminated (difficulty in the enrolment) 965 NCT01023269
1 Terminated (Lack of accrual lack of continued 966 NCT01013623
1 Terminated (Slow accrual rate) 969 NCT00981799
1 Terminated (study progress and recruitment ra 972 NCT00700739
1 Terminated (Low enrollment rate) 976 NCT00885677
1 Terminated (Despite considerable efforts to bo 978 NCT00866281
1 Terminated (This protocol terminated prematur 979 NCT00836875
1 Terminated (AVE5530 in hypercholesterolemia 983 NCT00766688
1 Terminated (AVE5530 in hypercholesterolemia 984 NCT00729027
1 Terminated (Lack of subject recruitment) 986 NCT00679484
1 Terminated (The study was closed to further 987 NCT00642941
1 Terminated (The study was terminated prematu 988 NCT00640016
1 Terminated (MTD was established and patients 990 NCT00401401
1 Terminated (A post-PMA begun in 1998; enrollm 991 NCT00590889
1 Terminated (This study was closed to enrollm 1005 NCT00372996
1 Terminated (Accrual goal for interventional pa 1011 NCT00107081
1 Terminated (lower than anticipated events;slo 1023 NCT00118573
1 Terminated (poor accrual) 1027 NCT00056056
Effect of Cita Ci-FCP Terminated No Results Ava
Functional CheDrug: Citalop Global assessm
Electrophysiology of the HumTerminated No Results Ava
Pituitary Aden Procedure: Mi Electrophysiol
Window of Trainability in Rel Withdrawn No Results Ava
Stroke Other: Gait adaEmory Function
TreatIng MicroTIMOTHY Terminated No Results Ava
Albuminuria Drug: Dapaglifurinary albumi
The Effect of VIREX PURE Terminated No Results Ava
Blunt Chest T Device: VirtualInspiration vo
Plant Stanol Esters and COVTerminated No Results Ava
Overweight anDietary SuppleVaccine specif
Social Health Games: The UsTerminated No Results Ava
Loneliness Other: SamenS Loneliness ind
Evaluation of RESET-ASDHWithdrawn No Results Ava
Intracranial H Other: Early n Glasgow Outc
The Effects of Enoximone in Terminated No Results Ava
COPD Exacerba Drug: EnoximoPEEP|Lung com
Chloroquine, HARCHAIC Terminated No Results Ava
COVID-19 Drug: ChloroquComposite endp
Preoperative NANO-PANC Terminated No Results Ava
Pancreatic CanDiagnostic Te Accuracy of U
A Study in Healthy Men to T Terminated Has Results Healthy VoluntDrug: Part 1: Part 1: Mass B
Ovarian CanceOLIVIA Terminated No Results Ava
Ovarian CanceDrug: W_ova1Change from bas
TIME ASPIRIN: TImE ASPIRINTerminated No Results Ava
CardiovasculaOther: placeboIncidence rate
Sorafenib PK SORBE Terminated No Results Ava
BCLC Stage CDrug: SorafeniSorafenib expo
Comparison ofCOCkPIT Terminated No Results Ava
Premature InfaDevice: Automa Proportion of
MRI-guided SinABLATIVE-2 Withdrawn No Results Ava
Breast CancerRadiation: MR-Pathologic comp
Resistance STEMI Study Terminated No Results Ava
STEMI|Acute My Diagnostic TesPrimary endpoi
BOOSTH: Serious Gaming inTerminated
C No Results Ava
Physical Activ Device: Boost change in mode
Endoveneous Histologic Stu Withdrawn No Results Ava
Varicose VeinsProcedure: ClaOcclusion of t
The Use of a PMETUS Terminated No Results Ava
Dyspnea|ComaDiagnostic TesConcordance bet
Does Automated AiRDRoP Terminated No Results Ava
ARDS Device: INTELL Transpulmonary
Cytoreductive CISCA Terminated No Results Ava
Gastric CancerDrug: PerioperMorbidity|Mort
Stent Versus CSTEVECO Terminated No Results Ava
Deep-Venous D T evice: deep vQuality of Life
Feasibility of HIT Terminated No Results Ava
RadioisotopesDevice: HolmiuTotal amount of
Preoperative Br PROBI Terminated No Results Ava
Breast CancerRadiation: pre-Postoperative
Spinal Cord StSFN-SCS Terminated No Results Ava
Small Fiber N Device: SpinalPain relief|Pa
Renal Nerve StRedress VT Terminated No Results Ava
Arrhythmias, CProcedure: R Induction of v
Ablative tReat ARREST Terminated No Results Ava
Renal Cell Ca Radiation: AR Number of part
TIBOHCA: Safet TIBOHCA Terminated No Results Ava
Cardiac ArrestDrug: 2-IminobNumber of pati
Tryptophan Depletion in PD Terminated No Results Ava
Parkinson's DiDietary SuppleMood|Motor sc
Respiratory EMG for NIV TitrTerminated No Results Ava
Chronic Obstr Other: Respir Nocturnal gas
Tumor HypoxiaHX4 SD Terminated No Results Ava
Prostatic Neo Drug: InjectionVisualization
Fractional Laser Assisted ToTerminated No Results Ava
Cicatrix Device: AFXL|Pain, as score
Spinal Cord StiSCS-PAF Terminated No Results Ava
Atrial Fibrillati Device: Spina Atrial fibrill
Deep Brain Stimulation for P Terminated No Results Ava
Tardive DyskinDevice: GPi DB DBS efficacy a
The LIPMAT Stu LIPMAT Terminated No Results Ava
Renal Dialysi Drug: PEG-lip Cephalic vein d
NeuromuscularANKL-ES Terminated No Results Ava
ImmobilizationDevice: Neurom Percentage chan
Clinical Outcomes of the Fr Terminated No Results Ava
Chronic Low Ba Device: Freed Percentage of
The Effect of t CUPIDO Suspended No Results Ava
Ulcerative ColitDietary SuppleIntestinal perm
A Multi-CentreSMASHING Terminated No Results Ava
Chronic InguinDevice: ImplanPercentage of
Effect of Exer FeedEX Terminated No Results Ava
Overfeeding aOther: overfeed Change in 24-h
Imiquimod TreTOPIC Terminated No Results Ava
Cervical IntraeDrug: Imiquim Treatment effic
Plaque Stabilization and ResTerminated No Results Ava
Vulnerable Pl Device: Bioreschange in plaq
BloodtranfusioFIBTEG Terminated No Results Ava
Hemorrhage|Th Drug: Haemoco Number of tran
Stellate Ganglion Block for Withdrawn No Results Ava
Prostate CancProcedure: SteHot flush scor
PET CT With HHX4-cervix Terminated No Results Ava
Cervix CancerOther: injecti Visualisation
Pre-operative Treatment WithTerminated No Results Ava
Heart; DysfuncDrug: ErythropThe number of
Influence of a ABILITY Terminated No Results Ava
Gastrointestin Dietary Suppleimatinib area
The Effects of FISHTIC Terminated No Results Ava
Intermittent Cl Drug: Omega-3 Maximal walkin
Bioavailability of Voriconazol Withdrawn No Results Ava
Voriconazole|Bio Other: DosageThe bioavailabi
Spatial Analysis and Validat Terminated No Results Ava
Glioblastoma Device: 7 T MR The co-localis
The Laparoscop APPLE Terminated No Results Ava
Appendicitis Procedure: LANegative appe
Edwards SAPIEN ELECT Terminated No Results Ava
Periprosthetic Procedure: TraPAR (expressed
Motor ImageryMIDRF
i Terminated No Results Ava
Distal Radius Behavioral: MoHand function
Aldosterone Antagonism andTerminated No Results Ava
Abdominal Obes Drug: EplerenoChange in capi
Single-port Thoracoscopic Withdrawn No Results Ava
Complex RegioProcedure: uniChange in perc
Pre-operative DECO Terminated No Results Ava
Colon Cancer Drug: DecitabiWnt target gen
Cue Exposure Training for OTerminated No Results Ava
Overweight|ObBehavioral: FoEating in the
Oral Versus InINOVATIO Terminated No Results Ava
Radiographic Drug: Sodium The ch primary end
GLP-1 and Non-exercise ActiTerminated No Results Ava
Type 2 DiabeteDrug: Liraglut Change in HbA1
Individualized IDEAL-VMAT Terminated No Results Ava
Stage III Non- Radiation: IndiPulmonary toxic
Chloroquine asChloroquine Terminated No Results Ava
Small Cell Lu Drug: Chloroq Number of Part
An Exploratory Study to Inv Terminated No Results Ava
Healthy SubjecProcedure: Hi Identify objec
Study on Anti- PISA Terminated No Results Ava
Hypertension| Drug: Aliskire Change in aneu
The Tilburg Vasospasm StudTerminated No Results Ava
Brain IschemiaProcedure: extClinical signs
Comparing Surg COSMIC Terminated No Results Ava
Central Spina Procedure: SurDutch transla
Concomitant Epi CONTROL-AFTerminated No Results Ava
Atrial Fibrillati Device: EpicarRecurrence of at
Pharmacokineti MFX468 Terminated No Results Ava
Tuberculosis Drug: MoxifloxBound area und
Video-AssistedVATCAT Terminated No Results Ava
Atrial Fibrillati Procedure: PVRecurrence of
Comparison ofNOCTX-2 Terminated No Results Ava
Renal TransplaDrug: everolimchange in coron
Radio-chemothPANORAMIC Terminated No Results Ava
Irresectable Drug: CRT + P1-year overal
Nitroglycerin Nitroglycerin Terminated No Results Ava
Non Small CelDrug: NitroglycIncrease of 2
Endocardial Pacing in On-ta Withdrawn No Results Ava
Heart Failure Procedure: temchange in acut
Peritoneal DialPDinCHF Terminated No Results Ava
Congestive Hea Drug: icodextriNumber of patie
Remote Ischemi RICO Terminated No Results Ava
Atrial Fibrillati Procedure: RePost-operative
Better AcceptaBASAAL PLUSTerminated No Results Ava
Diabetes Melli Drug: Insulin gGlycosylated H
Effectiveness ICS@ADP Terminated No Results Ava
Wheezing|DysDrug: BeclomeNumber of unsc
Sunitinib Malate in Treating Terminated No Results Ava
Lung Cancer Drug: sunitini Disease contro
The Effect of ESIVAN Terminated No Results Ava
Hypotension Drug: SevoflurTotal amount o
Cetrotide Treatment OptimizaTerminated Has Results In Vitro Fertil Drug: CetrotideLive Birth Rat
A Study of the Effects of a N Terminated No Results Ava
In Vitro Fertili Drug: Ovarian Proportion of
Heme Oxygenase (HO) Activit Terminated No Results Ava
Atheroscleroti Drug: L-argini Adenosine indu
Anti-inflammatory Effects of Withdrawn No Results Ava
Chronic Obstr Dietary SupplePlasma concent
Surgical or CatSCALAF Terminated Has Results Atrial Fibrillati Procedure: CatChange in AF B
Trial of Either ROSEL Terminated No Results Ava
Lung Cancer Radiation: ste local and regio
Pilot Evaluati PEACE Terminated Has Results Attention Defi Drug: AtomoxeAttention Defi
Second-line Endocrine Treat Terminated No Results Ava
Breast CancerDrug: capecitaQuality of life
Long-term Clinical Feasibilit Terminated Has Results Total Larynge Device: ProvoxDevice Life Ti
Stenting of HaSHARE Terminated No Results Ava
Outflow StenosDevice: Viabahn stent-graft
N-AcetylCysteiNAC-PNP Terminated No Results Ava
Carcinoma, NoDrug: N-AcetylThe occurrence
CoNCReTe-trial CoNCReTe Terminated No Results Ava
Colles' FracturProcedure: Man To determine th
Methylphenidate, Rivastigmine Terminated No Results Ava
Delirium Drug: Haloperiduration of del
Predictive Va FDG-PET lungTerminated No Results Ava
Lung Cancer| Other: 18F-de Tumour respons
A Study on theLIST Withdrawn No Results Ava
StaphylococcalDrug: human laHaematology, b
Myfortic Versus Azathioprin Terminated No Results Ava
Systemic LupuDrug: switch toSLEDAI|BILAG|r
Diagnostic OutDOT-HF Terminated Has Results Heart Failure Device: Progr Number of Part
Rosiglitazone and Insulin ResTerminated No Results Ava
Chronic KidneyDrug: rosiglita Insulin sensiti
A Pharmacokinetic and Pharm Terminated Has Results Rheumatoid Art Drug: rituxima Change From Ba
Pulmonary Rehabilitation fo Terminated No Results Ava
Chronic Obstr Other: early puExercise tolera
Rosuvastatin for Hepatitis C Withdrawn No Results Ava
Hepatitis C Drug: rosuvastoccurrence of
Efficacy of Quetiapine in GenTerminated No Results Ava
Social Anxiety Drug: quetiapi Change on Lebo
Implementation of an EvidenTerminated No Results Ava
COPD Behavioral: ImPrimary outcom
The Study to CDURAVEST Terminated No Results Ava
Arterial Occlu Device: stent| Primary patenc
Seasonal Allergic Rhinitis andTerminated No Results Ava
Seasonal Allerg Other: 1 week Driving test: S
Can Tadalafil Maintain Erect Terminated No Results Ava
Prostate Cance Drug: tadalafil To assess the e
Transfusion Effects in MyelodWithdrawn No Results Ava
MyelodysplastProcedure: Red fatigue|Health
The Role of Fluorothymidine Terminated No Results Ava
Colorectal Ne Procedure: FLcorrelation FLT
Sequential HIV Therapy in TrTerminated No Results Ava
HIV Infections Drug: StandardChanges in pla
Molecular Imaging Using RadWithdrawn No Results Ava
Diffuse Large Other: 89Zr-a Biodistributio
Sound Therapy for Tinnitus RTerminated No Results Ava
Tinnitus, Hear Device: CART Quantification
REMission INDu REMINDRA Terminated No Results Ava
Arthritis, Rhe Other: Taper proportion of p
Local Radiotherapy FollowingTerminated No Results Ava
Brain Neoplas Radiation: loc local control r
Varenicline Tr VESPA Terminated No Results Ava
Parkinson's DiDrug: VarenicliDaytime sleepi
Vitamin D3 and the Stress-axTerminated No Results Ava
Multiple ScleroDrug: CholecalThe area under
Concentrated Citrate LockingTerminated No Results Ava
HematologicalProcedure: hepcentral venous
Induced HyperHIMALAIA Terminated No Results Ava
Cerebral Isch Other: InducedThe main outco
Denervation ofDIASTOLE Terminated No Results Ava
Diastolic Hear Procedure: renChange from ba
Study of EveroEVAMP Withdrawn No Results Ava
Peutz-JeghersDrug: Everoli To determine t
Messenger Ribonucleic Acid Terminated No Results Ava
Uveal Melano Biological: au immunological
Anti-InflammatHercules Withdrawn No Results Ava
Chronic KidneyDrug: rosiglita intima media th
Non-invasive aCOMFORT Terminated No Results Ava
Coronary ArterDevice: adenoDiagnostic acc
Study to Compa GABA-1 Terminated No Results Ava
Chronic Pain Drug: gabapent Pain score|Per
Effect of LinagLina-Plaque Terminated No Results Ava
Diabetes Melli Drug: Linaglip Effect of linag
Chemotherapy Plus Interferon Terminated No Results Ava
Lymphoma Biological: filgrastim|Biolog
Trial ComparinLITE Terminated Has Results in Vitro Fertili Drug: Mild stimProportion of
EPLERAF-Study: EPLERAF Terminated No Results Ava
Atrial Fibrillati Drug: Epleren Atrial fibrilla
Cardiac Change HALO Terminated No Results Ava
Lung Cancer SDiagnostic TesPercentage of
Formoterol-becFORZA Terminated No Results Ava
BronchiectasisDrug: FormoteClinical effec
Near-infrared PENGUIN Terminated No Results Ava
Pancreatic Ca Drug: Bevaci Tracer accumul
Imatinib as Pr ImPACCT Terminated No Results Ava
Colonic Neopl Drug: Imatinib Effects of tre
Optimizing ProNEOPROP2 Terminated No Results Ava
Anesthesia IntDrug: Propofoladequate propo
Evaluation of EXPEDIENT Terminated No Results Ava
Prostate CancOther: PsycholSufficient int
Trial Using In ITT Terminated No Results Ava
Arterial Obstr Procedure: App Postoperative
Investigate the Maximum TolTerminated No Results Ava
Non-small Cel Drug: ZD6474 To investigate
Trial to ReduceCP Terminated No Results Ava
Accidental FallBehavioral: FaFalls incidence
BioequivalenceCRUSADE-1 Withdrawn No Results Ava
HCV Drug: sofosbuvi
AUC|Cmax|Adv
EXtended UseEXFOCY
o Terminated No Results Ava
Urinary Tract IDrug: Fosfomyc Time to recove
AssessinG EffiGELATO Terminated No Results Ava
Breast CancerDrug: CarboplaNumber of pati
Controlling A CALM-STARTTerminated No Results Ava
Hypertension Device: MobiuThe difference
Nivo/Ipi CombiCA209-322 Terminated No Results Ava
Melanoma|BraiDrug: NivolumThe best overa
CholinesteraseCHEVAL Terminated No Results Ava
Parkinson's DiDrug: Rivastig time to start
The Dutch Asym Dutch AMR Terminated No Results Ava
Heart; Disease, Other: Watchful
Composite endp
Computed Tomo CRESCENT Terminated No Results Ava
Angina PectoriOther: CardiacChest pain|Cla
Comparison of Self-adheringTerminated No Results Ava
Inguinal Herni Procedure: Ope Difference in e
Chloroquine asChloroquine IVTerminated No Results Ava
Small Cell Lu Drug: Chloroq To determine t
Effect of LamoNF1-EXCEL Terminated No Results Ava
NeurofibromatDrug: LamotrigPerformance in
PharmacokinetPRADAII Terminated No Results Ava
HIV-1 InfectionDrug: Atazanav Area under the
Adjuvant ZoledHR-GCT Terminated No Results Ava
Giant Cell Tu Drug: ZoledronDetermine if a
Radiation Therapy and Chemot Terminated No Results Ava
Bladder CanceDrug: cisplatin|Drug: fluorour
The Study WillDAPASALT Terminated Has Results Diabetes Melli Drug: DapaglifChange in 24-h
Prednisolone Addition for Pa Terminated No Results Ava
Schizophrenia|Drug: PrednisoChange in symp
European eCLIP EESIS Terminated No Results Ava
Saccular AneuDevice: ImplanSafety End Poi
Radiotherapy or RadiosurgerTerminated No Results Ava
Brain and CenProcedure: adju Progression-fre
T-DM1 and OsiTRAEMOS Terminated No Results Ava
Carcinoma, NoDrug: Trastuz Safety (intensi
Dose IndividuaIMPROVE-II Terminated No Results Ava
Non Small CelDrug: PemetreExposure (AUC)
Autologous Skin Substitute f Terminated No Results Ava
Varicose UlcerDrug: TiscoverProportion of
TMC649128HPC1002 - a Trial Terminated
i No Results Ava
Hepatitis C VirDrug: placebo Change in the
Establish Imp X-PSI Terminated Has Results Knee Osteoarthr Device: X-PSI Mechanical Leg
Effects of Aml TREAT-SVDs Terminated No Results Ava
Cerebral SmallDrug: AmlodipiChange from Ba
Conventional W RACOST Terminated No Results Ava
Spinal Metast Radiation: conv Pain reduction
Pulmonary Vein PAVANE Terminated No Results Ava
Atrial Fibrillati Procedure: PVIRecurrence of e
A Study to Investigate the Ef Withdrawn No Results Ava
Colitis, UlceratDrug: GSK1605 Efficacy of GS
Nilotinib Plus Pegylated Inte Terminated No Results Ava
Chronic MyeloDrug: Nilotinib the proportion
Pre- Versus Pos PAPBI-2 Terminated No Results Ava
Breast Cancer|Radiation: partiCosmetic outco
Valsartan for Prevention of Terminated No Results Ava
Acute Respira Drug: Valsartafirst occurrenc
Effects of Self MIEB Terminated No Results Ava
Medication SafBehavioral: SeProportion of m
Neurotoxic AdvMOSART Terminated No Results Ava
Pain|Terminal Drug: OxycodoOccurrence of
Docetaxel Versus Intercalat Terminated No Results Ava
Carcinoma, NoDrug: Docetaxe progression fre
Comparing Two COOPERATIOTerminated No Results Ava
Head and NecRadiation: 6 x time to loco-re
Vemurafenib PlREPOSIT Terminated No Results Ava
Metastatic Me Drug: Vemurafe Progression Fr
Omitting Completion Axillary Terminated No Results Ava
Breast NeoplaProcedure: Com Regional recur
Management of AIPOP Suspended No Results Ava
Surgery|AngiotDrug: PerioperPostoperative a
Interaction Be ROLEX Terminated No Results Ava
Hepatitis C In Drug: Paroxetiparoxetine are
Systemic Thera SUBMIT Terminated No Results Ava
Metastatic BreProcedure: upfSurvival|Quali
SUPER Study;SUPERS Terminated No Results Ava
Intermittent Cl Procedure: PerDisease specif
A Trial Using SELECT-AMI Terminated No Results Ava
Acute Myocardi Other: CD133+PRIMARY SAFETY
Efficacy of Hyperbaric OxygeTerminated No Results Ava
OsteoradionecDrug: hyperbarabsence of exp
Mobile PhonesMOBILE-AF Terminated No Results Ava
Atrial Fibrilla Device: SinglePercentage of d
Study to Assess the Non-inf Terminated No Results Ava
Prostate CancDrug: Triptore Percentage of p
Transarterial TRENDY Terminated No Results Ava
Liver Neoplas Radiation: RadTime to progres
Trial in Low G IWOT Terminated No Results Ava
Low-grade Gli Drug: TemozolNext interventi
Evaluation of the Efficacy a Terminated Has Results Polymyalgia RDrug: Sarilum Percentage of
Fibroid Ablati FAST-EU Terminated No Results Ava
Leiomyoma|Ute Device: VizAb Mean percentag
A Study of EvaACCELERATETerminated Has Results CardiovasculaDrug: EvacetraNumber of Part
Phase 2a Study of IW-9179 tTerminated No Results Ava
Dyspepsia|Func Drug: IW-9179Rate of treatm
International ADMIRE-ICD Terminated Has Results Heart Failure Drug: Iobenguan All-cause Mort
Phase 4 StudyCOBALT Terminated Has Results Liver Cirrhosis,Drug: ObetichoTime to the F
MOre REsponse MORE CRT MTerminated Has Results Heart Failure Device: MPP Percentage of
Evaluation of Efficacy and S Terminated Has Results Giant Cell ArterDrug: Sarilum Percentage of
Long-term TreLongheva Terminated No Results Ava
Venous ThromDrug: low moleSymptomatic rec
EFfect of Ferr EFFICACY-HFTerminated No Results Ava
Chronic Heart Drug: Ferinjec The distance c
A Dose Finding Study to Asse Terminated Has Results Diabetes Melli Drug: LIK066|D Change From Ba
Fenofibrate and Metformin F Terminated No Results Ava
Dyslipidemia|GDrug: fenofibr HbA1c/TG|Lipi
Trial of Nebul Hepburn Terminated No Results Ava
Inhalation Inju Drug: unfracti Number of vent
Prevention of PLATA Terminated No Results Ava
Phantom LimbProcedure: SciPoint prevalen
Chemotherapy Plus Radiation Terminated No Results Ava
Lung Cancer Drug: cisplatin|Drug: gemcita
Combination Chemotherapy Pl Terminated No Results Ava
Lung Cancer Drug: cisplatin|Drug: etoposi
MGuard™ Prime MASTER-II Terminated No Results Ava
ST Elevation MDevice: MGuarrate of comple
Study Comparing Best Medical Terminated Has Results Epilepsy|PartiaDevice: Vagal Overall Qualit
SubQStim: A Post-market StuTerminated Has Results Failed Back S Device: subcuEffectiveness
Chemotherapy and Bevacizuma Terminated No Results Ava
Colorectal CanBiological: be Survival rate
Study of AEB071 (a Protein KTerminated No Results Ava
Diffuse Large Drug: AEB071Frequency of D
The CONQUEST-Study. Evalua Terminated No Results Ava
GastroesophagDrug: Pantopr Rate of miscla
Gefitinib After ChemotherapyTerminated No Results Ava
Lung Cancer Drug: gefitinib Overall surviv
Evaluation of Effectiveness Terminated Has Results Pain|Chronic PDrug: TapentaNumber of Part
Involved-Field Radiation TheTerminated No Results Ava
Lymphoma Radiation: radiDisease-free s
Efficacy and Safety Study of Terminated No Results Ava
Overactive BlaBiological: Bo Number of epis
Breast-Conserving Therapy Terminated No Results Ava
Breast CancerProcedure: conventional surge
This Study WilCANOPY-N Terminated Has Results Non-small Cel Drug: CanakinMajor Patholo
A Study of NivCheckMate 9UTerminated Has Results Urinary Bladd Biological: Ni Number of Part
A Clinical Study of the Car Terminated No Results Ava
Mitral Insuffi Device: Cardi Composite Maj
Chemotherapy With or Withou Terminated No Results Ava
Bladder CanceDrug: mitomycin C|Procedure
Endurant Evo International CliTerminated No Results Ava
Abdominal AorDevice: Endur Primary Safety
Dysport® TreatCONTENT1 Terminated Has Results Urinary Incont Biological: Bo Mean Change F
An Efficacy and Safety Proo Terminated Has Results Lymphoma, Man Drug: Daratu Overall Respon
A RandomizedRESHAPE-HFTerminated
St No Results Ava
CardiovasculaDevice: MitraCHierarchical c
Randomized StSAA-G-CSF Terminated No Results Ava
Aplastic Anae Drug: G-CSF|Dr Failure free s
Repair of ChalStAR Terminated Has Results Hernia|Surgic Device: Stratt Hernia Occurr
An Evaluation Of The Effect Terminated Has Results Candidiasis|F Drug: Active aPercentage of
TNF Blockade With Remicade Terminated No Results Ava
Lupus ErythemDrug: inflixim Comparison of
Docetaxel in Combination WiTerminated No Results Ava
Prostate CancBiological: Im Survival|Time
Acute Defibrillation Study Terminated Has Results Ventricular Ar Device: DefibriDefibrillation
Evaluating theRELIEF-1 Terminated No Results Ava
Asthma Device: Targe Freedom from d
Hydroxychloroquine in OutpaTerminated No Results Ava
Coronavirus InDrug: HydroxyChange from ba
An Investigational Study to Terminated Has Results Lupus NephritiDrug: BMS-986 The Number of
A Study of BarSLE-BRAVE-XTerminated Has Results Systemic LupuDrug: Baricitin Percentage of
A Study of BarSLE-BRAVE I Terminated Has Results Systemic LupuDrug: Baricitin Percentage of
ALEctinib for ALERT-lung Terminated No Results Ava
Non-small CellDrug: AlectinibBest overall re
The AdAPT Tria AdAPT Terminated Has Results Adenovirus Other: StandarTime-averaged
QUantum Genom QUID-HF Terminated No Results Ava
Heart Failure Drug: QGC001| Relative decre
A Safety and Efficacy Study Terminated Has Results Lymphoma, NoDrug: Ibrutini Part 1: Area U
Efficacy and SSPINET Terminated Has Results NeuroendocrinDrug: LanreotiMedian Progres
Comparison ofMAGNETIC-V Terminated No Results Ava
Tachycardia, VDevice: cathetfreedom from a
A Study of ASP SOLAR Terminated Has Results Non-small Cel Drug: naquotiniProgression Fr
Study of Radium-223 DichlorTerminated Has Results Breast NeoplaDrug: Radium-2 Symptomatic Sk
Efficacy and Safety Study o Withdrawn No Results Ava
GlomerulonephDrug: BelimumIncidence of r
Evaluation of VICTORY-AF Terminated Has Results Persistent AtriaDevice: Medtr Number of Part
A Phase Ib/II Study of BYL7 Terminated Has Results Recurrent HeaDrug: BYL719 Phase a Ib Arms
Trial Evaluating Dovitinib Terminated Has Results Metastatic BreDrug: DovitinibProgression Fr
Ascending Dose CADENCE 215Terminated Has Results Atrial Fibrillat Drug: OPC-108 Part 1: Maximu
ChonDux for Filling Full Thi Terminated No Results Ava
Cartilage DefeDevice: Chon Defect fill at
Smith & Nephew's EuropeanTerminated
T No Results Ava
Defect of ArticDevice: Trufit Percent change
A Degarelix Trial in Patients Terminated Has Results Prostate CancDrug: DegareliHazard Ratio o
Efficacy, Saf CLARITY-AF Terminated No Results Ava
Atrial Fibrillati Device: RadiofFreedom from d
Study is Designed to Assess Terminated Has Results Cancer|AdvancDrug: AZD454Number of Pati
A Study of OcrSCRIPT Terminated Has Results Rheumatoid Art Drug: LeflunomPercentage of
[S,S]-Reboxetine Add-On TriTerminated No Results Ava
Pain Drug: [S,S]-ReThe numerical
Radiation Therapy, Mitomycin, Terminated No Results Ava
Anal Cancer Drug: cisplatinResponse as me
Temozolomide With or Without Terminated No Results Ava
Melanoma (SkiDrug: temozolomide|Radiation
Right Versus LRIVELA Terminated No Results Ava
BradyarrhythmDevice: ImplanReduction in LV
Study to Test the Safety an Terminated No Results Ava
Carcinoma, NoDrug: Radium-Number of part
Mesalamine foMesaCAPP Terminated No Results Ava
Colorectal CanDrug: mesalamReduction in t
Glyaderm Clinical EvaluationTerminated No Results Ava
Full-thickness Procedure: Gl scar quality|p
ABSORB PHYSIOLOGY Clinica Terminated No Results Ava
Coronary ArterDevice: Bioab Coronary arter
International SeluDex Terminated No Results Ava
Acute Lymphobl Drug: SelumetPhase I: The o
Reduced Dose- REDUCE Terminated No Results Ava
Bone Giant CeDrug: Denosum Progression fr
A Eurosarc St MEMOS Terminated Has Results OsteosarcomaDrug: MifamurtBiological Res
Repeat Dose Study of GSK377 Terminated Has Results Asthma Drug: GSK3772 Percent Change
Obeticholic AciCARE Terminated No Results Ava
Biliary Atresia Drug: OCA 0. Safety and tol
A Dose FindingEMPATHY Terminated Has Results COVID-19 Drug: ensovib Part A: Time-W
Treatment of MASCEND Terminated No Results Ava
Mitral RegurgitDevice: HARPO Percentage of
Assessment ofBIO|PULSE Terminated No Results Ava
Heart Failure Device: BIOT Rate of patien
A Dose Titration Study to As Terminated Has Results Microvascular Drug: SAR4078 Change From Ba
Efficacy and Safety of HumanTerminated Has Results Antibody-media Drug: C1-esterPercent of Par
PDR001 in Combination WithTerminated No Results Ava
Non-small Cel Drug: PDR001|D Dose Limiting
Safety and EffHATCY Terminated Has Results Acute Myeloid Biological: AT Graft-versus-h
Trabectedin Maintenance Post Terminated No Results Ava
Sarcoma, SoftDrug: Trabecteprogression-fr
PREclinical MuPRECARDIA Terminated No Results Ava
Dilated Cardi Drug: perindopChange in left
Efficacy, Safe CloSed1 Terminated No Results Ava
Sedation in In Drug: ClonidinSedation failu
A Safety and Efficacy Study Terminated No Results Ava
Non-Small CelDrug: INC280 P s hase Ib: Freq
Rabbit Anti-th RISE Terminated Has Results MyelodysplastBiological: Th Number of Part
Eurartesim® in Patients Wit Terminated No Results Ava
Malaria, Vivax Drug: EurartesUncorrected ad
Myfortic - Treatment for Ext Terminated No Results Ava
Graft vs Host Drug: Myfortic To test whethe
Efficacy of F BOS2 Terminated No Results Ava
Colorectal CanDrug: FOLFOX6 Progression fre
An Explorative Trial to Eva Terminated Has Results GastroesophagDrug: SPD557|Change From Ba
A Study of Olaratumab (IMC-3 Terminated Has Results Gastrointestin Biological: Ol Percentage of
A Study of RoActemra/Actemr Terminated Has Results Rheumatoid Art Drug: tocilizu Percentage of
Efficacy and SEMBARC-RF Terminated Has Results Bladder NeoplaBiological: EN Comparison of
Efficacy StudyACCEPTANCETerminated Has Results Neurogenic Ove Device: InterSFunctional Bla
Stage IV SurgeSTG4SURG Terminated No Results Ava
Stage IV ReseProcedure: SurOverall surviva
A(f)MAZE-CABAFMAZE-CABTerminated No Results Ava
Coronary ArteriDevice: HIFU A Freedom from A
Trial of Nelarabine, Etoposi Terminated Has Results Relapsed T-CeDrug: NelarabiTo Determine t
Study to Investigate the Perf Terminated Has Results Cervical DegenDevice: DISCOOverall Patien
MOnitoring REMORE-CARE Terminated Has Results Heart Failure Device: Medtr Phase 1: Media
A Study of the Safety and Pr Terminated Has Results Acute Myeloid Drug: midostauMaximum Tolera
A Study To Evaluate The Safe Terminated Has Results Invasive Asperg Drug: VoriconaNumber of Part
Evaluation of Safety and Eff Terminated No Results Ava
HypercholesteDrug: AVE5530 Percent change
Evaluation of Safety and Eff Terminated No Results Ava
HypercholesteDrug: 25 mg/dPercent change
Study to Demon OLMEBNP Terminated No Results Ava
Chronic Heart Drug: olmesartAbsolute BNP c
A Study of R1507 in Particip Terminated Has Results Sarcoma Drug: RG1507Percentage of
A Study to Assess the EfficacTerminated Has Results Asthma Other: PlaceboChange From Ba
Zalutumumab in CombinationTerminated Has Results Head and Neck Drug: zalutumuAdverse Event
Artificial Valv AVERT Terminated Has Results Aortic Valve DDevice: Artific Incidence of P
Hyperthermia Treatment in CTerminated No Results Ava
Urinary BladdeDevice: Syner Recurrence fre
Study Of CP-751,871 In ComTerminated Has Results Breast NeoplaDrug: CP-751,Progression-Fr
A Study of PatASSET-3 Terminated No Results Ava
Pulmonary HypeDrug: BosentaChange from ba
Low-risk Fever and NeutropeniTerminated No Results Ava
Fever|NeutropDrug: ciproflo Safety: No seri
Efficacy and SASSET-2 Terminated No Results Ava
Pulmonary HypDrug: bosentaChange from Ba
Efficacy and Safety of BosenTerminated No Results Ava
Pulmonary HypDrug: BosentaChange from Ba
Extracorporeal PhotoimmuneTerminated No Results Ava
Acute Graft-veDrug: MethoxsTo compare the
Comparison ofCAESAR Terminated No Results Ava
Aortic Aneury Procedure: EVA all cause morta
Ultraviolet Light Therapy Us Terminated No Results Ava
Lymphoma Drug: bexaroteOverall respon
Radiation Therapy With or WiTerminated No Results Ava
Head and NecBiological: epoetin alfa|Radia
Surgery With or Without ComTerminated No Results Ava
Gastric CanceDrug: cisplatin|Drug: fluorou
Adjuvant Radiation Therapy iTerminated No Results Ava
Metastatic CanProcedure: adjuSurvival with
Academisch Me All 18 Years and older
Phase (Adult,
4 Older Adult) 1 Other Interventional
Leiden UniversAll 18 Years and older
Not Applicable
(Adult, Older Adult) 1 Other Interventional
Sint MaartenskAll 18 Years and older
Not Applicable
Hiddo LambersAll 45 Years to 80Phase
Years 2 (Adult, Older Adult)9 Other|IndustryInterventional
Radboud UniverAll 16 Years and older
Not Applicable
(Child, Adult, Older 27
Adult)
Other Interventional
Maastricht Univ
All 18 Years and older
Not Applicable
Not Applicable
(Older Adult) 76 Other Interventional
Not Applicable
(Older Adult) 0 Other Interventional
Rijnstate HospiAll 18 Years and older
Phase (Adult,
UMC Utrecht|ZAll 18 Years to 110Phase
Years4 (Adult, Older Adult)
25 Other Interventional
Not Applicable
Boehringer IngMale 18 Years to 65Phase
Years 1 (Adult, Older Adult)7 Industry Interventional
University Me Female Child, Adult, OPhase 1 8 Other|IndustryInterventional
Not Applicable
(Adult, Older Adult)328 Other Interventional
Phase (Adult,
Leiden UniversAll up to 8 WeeksNot
(Child)
Applicable 15 Other Interventional
UMC Utrecht Female 50 Years and older
Phase (Adult,
Catharina Zie All 18 Years to 75Not
Years
Applicable
Maastricht UniAll 8 Years to 12 Years
Not Applicable
(Child) 52 Other Interventional
Not Applicable
Rijnstate HospiAll 18 Years to 100Not
Years
Applicable
(Adult, Older Adult)
Not Applicable
(Adult, Older Adult) 13 Other|IndustryInterventional
Richard van HiAll 18 Years and older
Phase (Adult,
Maastricht UniAll 18 Years and older
Not Applicable
UMC Utrecht All 18 Years and older
Not Applicable
The NetherlandFemale 18 Years to 50Not
Years
Applicable
(Adult) 4 Other Interventional
Academisch ZiAll 18 Years to 75Not
Years
Applicable
Diagram B.V. All 18 Years to 85Phase
Years 2 (Adult, Older Adult)9 Other Interventional
UMC Utrecht All 18 Years to 100Phase
Phase (Adult,
1|PhaseOlder Adult) 21 Other Interventional
Maastricht UniAll Child, Adult, ONot Applicable 7 Other Interventional
University MedAll 18 Years and older
Not Applicable
Maastricht RadAll 18 Years and older
Phase (Adult,
Netherlands InAll 18 Years and older
Phase (Adult,
Medtronic BR All 18 Years and older
Not Applicable
(Adult, Older Adult) 4 Industry Interventional
GGZ Centraal|UAll 18 Years to 65Not
Years
Applicable
Phase (Adult,
Maastricht UniAll 18 Years to 65Not
Years
Applicable
Stimwave TechAll 18 Years and older
Not Applicable
(Adult, Older Adult) 45 Industry|OtherInterventional
Wageningen Un All 18 Years to 65Not
Years
Applicable
Maxima Medica All 18 Years and older
Not Applicable
Maastricht UniMale 18 Years to 30Not
Years
Applicable
(Adult) 5 Other Interventional
Maastricht Un Female 18 Years and older
Phase (Adult,
3 Older Adult) 9 Other|IndustryInterventional
Canisius-WilheAll 18 Years to 80Not
Years
Applicable
St. Antonius HoAll 18 Years and older
Phase (Adult,
Rijnstate HospiMale 18 Years and older
Not Applicable
Maastricht RadFemale 18 Years and older
Phase (Adult,
Catharina Zie All 18 Years and older
Phase (Adult,
Radboud Univer All 18 Years and older
Phase (Adult,
Medical CenteAll 18 Years and older
Phase (Adult,
Phase (Adult,
Not Applicable
Not Applicable
Not Applicable
University MedFemale 45 Years to 75Not
Years
Applicable
Maastricht UniAll 40 Years to 65Phase
Years 4 (Adult, Older Adult)
University of All 18 Years to 65Not
Years
Applicable
Not Applicable
Maastricht UniAll 12 Years to 18Not
Years
Applicable
(Child, Adult) 14 Other Interventional
Prof. Dr. J. W All 18 Years and older
Not Applicable
Maastricht UniAll 40 Years to 75Phase
Radboud Univer All 18 Years to 85Phase
Phase (Adult,
Astellas PharmFemale 35 Years to 65Phase
Amsterdam UMC All 18 Years to 75Not
Years
Applicable
(Adult, Older Adult)3 Other|IndustryInterventional
Elisabeth-TweAll 18 Years and older
Phase (Adult,
Not Applicable
Medisch SpectAll 18 Years to 70Not
Years
Applicable
Phase (Adult,
Medisch SpectAll 18 Years and older
Not Applicable
Dianet Dialysi All 18 Years to 75Phase
Phase (Adult,
Catharina Zie All 18 Years and older
Not Applicable
Martini Hospit All 18 Years and older
Phase (Adult,
Not Applicable
Sanofi All 18 Years and older
Phase (Adult,
4 Older Adult) 52 Industry Interventional
Princess AmaliaAll 1 Year to 4 Years
Phase
(Child)
4 7 Other Interventional
European OrgaAll 18 Years to 120
Phase
Phase (Adult,
Bart CJM FausFemale 18 Years to 39Phase
Years 4 (Adult) 617 Other Interventional
Bart CJM FausFemale 18 Years to 37Phase
Radboud UniveAll 18 Years to 65Phase
Maastricht UniMale 40 Years to 70Not
Years
Applicable
Medtronic BakAll 18 Years and older
Not Applicable
Amsterdam UMC All 18 Years and older
Phase (Adult,
Eli Lilly and All 13 Years to 17Phase
Years 4 (Child) 7 Industry Interventional
The NetherlandFemale Child, Adult, OPhase 2|Phase 10 Other Interventional
Atos Medical AAll Child, Adult, ONot Applicable 26 Industry|OtherInterventional
Rijnstate HospAll 18 Years and older
Phase (Adult,
Not Applicable
Not Applicable
(Child, Adult, Older 98
Adult)
Phase (Adult,
Phase (Adult,
3 Older Adult)
AM-Pharma All 18 Years to 70Phase
Years 1|Phase
(Adult, Older Adult)0 Industry Interventional
Erasmus Medic All 18 Years and older
Phase (Adult,
Phase (Adult,
4 Older Adult)
335 Industry Interventional
Phase (Adult,
Hoffmann-La All 18 Years to 80Phase
Isala All 40 Years to 80Not
Years
Applicable
UMC Utrecht All 18 Years to 65Not
Years
Applicable
AstraZeneca All 18 Years to 65Phase
Radboud UniveAll 40 Years and older
Not Applicable
Cordis CorporaAll 30 Years and older
Phase (Adult,
Utrecht Instit All 21 Years to 50Phase
Years 4 (Adult) 22 Other|IndustryInterventional
Erasmus Medic Male 18 Years and older
Phase (Adult,
3 Older Adult)
Sanquin Resear All Child, Adult, OPhase 4 0 Other Interventional
Phase (Adult,
Phase (Adult,
University Me All 18 Years to 75Not
Years
Applicable
(Adult, Older Adult)0 Other|IndustryInterventional
Cochlear All 18 Years and older
Not Applicable
Phase (Adult,
Not Applicable
Amsterdam UMC All Child, Adult, OPhase 4 22 Other Interventional
Academic MS F Cemale 18 Years and older
Phase (Adult,
Phase (Adult,
3 Older Adult)
212 Other|IndustryInterventional
Phase (Adult,
UMC Utrecht|VAll 18 Years and older
Phase (Adult,
Phase (Adult,
Years 1|Phase
Phase (Adult,
2|PhaseOlder Adult)
Not Applicable
PharmaceuticaAll 3 Months to 17Phase
Years3 (Child) 2 Industry|OtherInterventional
RWTH AachenAll U 50 Years and older
Phase (Adult,
European OrgaAll 18 Years to 65Phase
UMC Utrecht|FrFemale 18 Years to 36Phase
University HosAll 18 Years and older
Phase (Adult,
The NetherlandAll 18 Years and older
Not Applicable
Erasmus MedicaAll 18 Years and older
Phase (Adult,
Phase (Adult,
UMC Utrecht|MAll 18 Years and older
Phase (Adult,
Erasmus Medic All up to 28 Days Phase
(Child)1 91 Other Interventional
Ipsen Male Child, Adult, OPhase 2 6 Industry Interventional
Rijnstate HospAll 18 Years and older
Not Applicable
Phase (Adult,
Radboud UniverAll Child, Adult, ONot Applicable 320 Other Interventional
Phase (Adult,
MJM Bonten|Zo Female 18 Years and older
Phase (Adult,
The NetherlanAll 18 Years and older
Phase (Adult,
Vascular DynamAll 18 Years to 70Not
Years
Applicable
Phase (Adult,
Phase (Adult,
UMC Utrecht|LeAll 18 Years to 75Not
Years
Applicable
Erasmus Medic All 18 Years and older
Not Applicable
Maastricht UniMale 18 Years and older
Not Applicable
Maastricht RadAll 18 Years to 100Phase
5 Other|NIH Interventional
Erasmus Medic All 12 Years to 18Phase
Years 2|Phase
(Child, Adult) 41 Other Interventional
Phase (Adult,
Phase (Adult,
European OrgaAll up to 75 YearsPhase
(Child,
2 Adult, Older Adult)
UMC Utrecht All 18 Years to 70Phase
Evasc MedicalAll 19 Years and older
Not Applicable
(Adult, Older Adult) 20 Industry|OtherInterventional
European OrganAll 18 Years and older
Phase (Adult,
The NetherlanAll 18 Years and older
Phase (Adult,
Phase (Adult,
Chantal Blok| All 18 Years and older
Phase (Adult,
Tibotec BVBA All 18 Years to 65Phase
Zimmer, GmbHAll 18 Years and older
Not Applicable
Ludwig-MaximilAll 18 Years and older
Phase (Adult,
3 Older Adult)
Not Applicable
Abbott MedicalAll 65 Years and older
Not Applicable
(Older Adult) 59 Industry Interventional
GlaxoSmithKli All 18 Years and older
Phase (Adult,
Phase (Adult,
The Netherlands
Female 51 Years and older
Not Applicable
Phase (Adult,
Not Applicable
(Child, Adult, Older193
Adult)
Phase (Adult,
Phase (Adult,
Not Applicable
Netherlands WAll 18 Years and older
Phase (Adult,
Maastricht UniFemale 18 Years and older
Not Applicable
UMC Utrecht|ZAll 18 Years and older
Not Applicable
Radboud UniveAll 18 Years to 65Phase
Jeroen Bosch All 18 Years and older
Phase (Adult,
M.J.W. KoelemAll 18 Years and older
Not Applicable
Jozef BartunekAll 20 Years to 75Not
Years
Applicable
Phase (Adult,
Not Applicable
Ipsen Male 18 Years and older
Phase (Adult,
Erasmus MedicaAll 18 Years and older
Phase (Adult,
2 Older Adult)
European OrgaAll 18 Years and older
Phase (Adult,
Sanofi|RegeneAll 50 Years and older
Phase (Adult,
3 Older Adult)
Gynesonics Female 28 Years and older
Not Applicable
Eli Lilly and All 18 Years and older
Phase (Adult,
3 Older Adult)
12092 Industry|OtherInterventional
Ironwood PharmAll 18 Years and older
Phase (Adult,
GE HealthcareAll 18 Years and older
Phase (Adult,
3 Older Adult)
Intercept PharAll 18 Years and older
Phase (Adult,
4 Older Adult)
Not Applicable
Sanofi|RegeneAll 50 Years and older
Phase (Adult,
Phase (Adult,
Vifor Pharma| All 18 Years and older
Phase (Adult,
3 Older Adult) 35 Industry|OtherInterventional
Novartis PharmAll 18 Years and older
Phase (Adult,
2 Older Adult)
Solvay PharmaAll 18 Years to 75Phase
Phase (Adult,
Not Applicable
Phase (Adult,
3 Older Adult)
InspireMD All 18 Years and older
Not Applicable
Cyberonics, InAll 16 Years and older
Phase (Child,
4 Adult, Older122
Adult)
Industry Interventional
MedtronicNeurAll 18 Years and older
Not Applicable
Phase (Adult,
Takeda All 18 Years and older
Phase (Adult,
Phase (Adult,
3 Older Adult)
Grünenthal G All 18 Years and older
Phase (Adult,
3 Older Adult)
Phase (Adult,
3 Older Adult)
Ipsen Female 18 Years to 75Phase
European OrganFemale Child, Adult, OPhase 3 26 Other Interventional
Phase (Adult,
Bristol-Myers All 18 Years and older
Phase (Adult,
2 Older Adult)
Edwards Lifes All 65 Years and older
Not Applicable
(Older Adult) 2 Industry Interventional
European OrgaAll up to 80 YearsPhase
(Child,
Medtronic CardAll 18 Years and older
Not Applicable
Ipsen All 18 Years to 80Phase
Janssen Resea All 18 Years and older
Phase (Adult,
Abbott MedicalAll 18 Years to 90Not
Years
Applicable
European SocieAll Child, Adult, OPhase 3 205 Other Interventional
LifeCell All 18 Years and older
Phase (Adult,
Pfizer All 16 Years and older
Phase (Child,
3 Adult, Older 41
Adult)
Medical UniverAll 18 Years and older
Phase (Adult,
Cell Genesys Male 18 Years and older
Phase (Adult,
3 Older Adult)
Medtronic CardAll 18 Years and older
Not Applicable
Nuvaira, Inc. All 21 Years to 65Not
Years
Applicable
Sanofi All 18 Years to 80Phase
Bristol-Myers All 18 Years to 75Phase
Phase (Adult,
3 Older Adult)
Phase (Adult,
3 Older Adult)
ETOP IBCSG AllPa 18 Years and older
Phase (Adult,
Chimerix All 2 Months to 25Phase
Years2 (Child, Adult) 29 Industry Interventional
Quantum GenoAll 18 Years and older
Phase (Adult,
Janssen Resea All 1 Year to 30 Years
Phase (Child,
3 Adult) 72 Industry Interventional
Ipsen All 18 Years and older
Phase (Adult,
Stereotaxis All 18 Years and older
Not Applicable
Astellas PharmAll 18 Years and older
Phase (Adult,
3 Older Adult)
Bayer Female 18 Years and older
Phase (Adult,
GlaxoSmithKli All 18 Years to 75Phase
Medtronic CardAll 18 Years to 75Not
Years
Applicable
Phase (Adult,
1|PhaseOlder Adult)
Novartis PharmFemale 18 Years and older
Phase (Adult,
Otsuka Pharma All 18 Years to 85Phase
Zimmer BiomeAll 18 Years to 55Not
Years
Applicable
(Adult) 21 Industry Interventional
Smith & NepheAll 18 Years and older
Not Applicable
Ferring PharmaMale 18 Years and older
Phase (Adult,
3 Older Adult)
Biosense WebstAll 18 Years and older
Phase (Adult,
Genentech, InAll 18 Years and older
Phase (Adult,
3 Older Adult)
Pfizer All 18 Years and older
Phase (Adult,
2 Older Adult)
Years 2|Phase
Phase (Adult,
Haran Burri, MAll 18 Years and older
Not Applicable
(Adult, Older Adult) 36 Other|IndustryInterventional
Bayer|Merck All 18 Years and older
Phase (Adult,
Christoph Gasc All 25 Years and older
Phase (Adult,
Euro Tissue B All 18 Years and older
Phase (Adult,
Not Applicable
University of All Child, Adult, OPhase 1|Phase 12 Other|IndustryInterventional
Phase (Adult,
University of All 16 Years to 65Phase
Years 2 (Child, Adult, Older8Adult)
Other|IndustryInterventional
GlaxoSmithKli All 18 Years and older
Phase (Adult,
Intercept PharAll 2 Years to 17 Years
Phase 2(Child) 7 Industry Interventional
Novartis Pharm All 18 Years and older
Phase (Adult,
2|Phase Older Adult)
Edwards Lifes All 18 Years and older
Not Applicable
Biotronik SE &All 18 Years and older
Not Applicable
Phase (Adult,
CSL Behring All 18 Years and older
Phase (Adult,
Phase (Adult,
1 Older Adult)
Kiadis PharmaAll 18 Years to 70Phase
Phase (Adult,
Institut Natio All 18 Years to 60Phase
University of All up to 18 YearsPhase
(Child,
3 Adult) 28 Other Interventional
Phase (Adult,
Genzyme, a Sa All 18 Years to 70Phase
Alfasigma S.p.All 18 Years and older
Phase (Adult,
European Socie All 18 Years to 60Phase
Years 3 (Adult) 34 Other|IndustryInterventional
Shire|Takeda All 18 Years to 70Phase
Phase (Adult,
Hoffmann-La All 18 Years and older
Phase (Adult,
Bioniche Life SAll 18 Years and older
Phase (Adult,
MedtronicNeurAll 18 Years and older
Not Applicable
Saint John's CAll 18 Years and older
Phase (Adult,
Not Applicable
Therapeutic A All 1 Year to 21 Years
Phase (Child,
1|Phase Adult) 23 Other|IndustryInterventional
DePuy InternatAll 18 Years to 65Phase
Not Applicable
Novartis Pharm All 3 Months to 18Phase
Years1|Phase
(Child, Adult) 22 Industry Interventional
Pfizer All 2 Years to 17 Years
Phase 3(Child) 31 Industry Interventional
Phase (Adult,
3 Older Adult)
Phase (Adult,
3 Older Adult)
Daiichi SankyoAll 18 Years to 85Phase
Hoffmann-La Ro All 2 Years and older
Phase
(Child,
2 Adult, Older 317
Adult)
Industry|OtherInterventional
MedImmune LLC All 18 Years to 80Phase
Genmab All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult) 30 Industry Interventional
Abbott MedicalAll Child, Adult, ONot Applicable 807 Industry|OtherInterventional
Medical EnterpAll 18 Years and older
Phase (Adult,
3 Older Adult)
Pfizer Female 18 Years and older
Phase (Adult,
2 Older Adult)
Actelion|Natio All 16 Years and older
Phase (Child,
3 Adult, Older236
Adult)
Industry|NIH Interventional
Swiss Pediatr All 1 Year to 18 Years
Phase (Child,
3 Adult) 70 Other|IndustryInterventional
Actelion All 12 Years and older
Phase (Child,
3 Adult, Older 12
Adult)
Actelion All 12 Years and older
Phase (Child,
3 Adult, Older 14
Adult)
Mallinckrodt|P All 18 Years and older
Phase (Adult,
University Of All 50 Years to 80Phase
European Organ All 18 Years to 75Phase
Phase (Adult,
3 Older Adult)
Allocation: Ra NL77673.018. ### April 22, 2022 April 22, 2022 ###
Allocation: N/ P19.032 ### ### ### April 20, 2022
Allocation: N/ 993_Pes_equinApril 1, 2022 May 1, 2024 May 1, 2024 ###
Allocation: Ra 2021/1001|202 ### ### ### ###
Allocation: Ra 112814 ### ### ### ###
Allocation: Ra METC 21-013 April 22, 2021 ### ### April 14, 2021
Allocation: Ra 2020-6884|645 April 1, 2021 ### ### ###
Allocation: Ra NL72116.058. ### ### ### ###
Allocation: N/ 2019-1432 May 12, 2020 ### ### June 9, 2020
Allocation: Ra NL73529.041.2April 14, 2020 June 8, 2020 June 8, 2020 April 24, 2020
Allocation: N/ NL52657.091. May 15, 2017 ### ### ###
Allocation: No 1399-0013|201 ### April 2, 2020 April 2, 2020 ### ###
Allocation: N/ OLIVIA-UMCG- ### ### ### ###
Allocation: Ra P18.127 ### ### ### ###
Allocation: No 2014_078#B20 May 2014 March 2017 March 2017 ###
Allocation: Ra COCkPIT|NL66 ### ### ### ###
Allocation: N/ NL63209 041 ### ### ### ###
Allocation: N/ Resistance S ### July 1, 2019 July 1, 2019 ###
Allocation: Ra NL61033.000. ### ### ### ###
Allocation: N/ NL38948.091. January 2017 ### ### ###
Allocation: No NL61884.091. ### May 11, 2020 May 11, 2020 July 12, 2017
Allocation: Ra AiRDRoP ### ### ### July 7, 2017
Allocation: N/ NL58258.041.1 ### April 23, 2018 April 23, 2018 May 12, 2017
Allocation: Ra RCT DVO ### ### ### ###
Allocation: N/ NL54535.041. ### ### ### ###
Allocation: N/ N16PRB|NL595 ### ### ### ###
Allocation: N/ SFN-SCS|NL53 July 1, 2018 ### ### ###
Allocation: No 9218 ### May 4, 2020 May 4, 2020 ###
Allocation: N/ NL55770.041. June 2016 April 2020 April 2020 ###
Allocation: N/ AMC-TIBOHC May 2016 ### April 2020 July 19, 2016
Allocation: Ra Tryptophan dep ### ### ### ###
Allocation: Ra 2015/383 ### June 2016 June 2016 ###
Allocation: N/ NL50833.068 May 2016 May 2017 May 2017 ###
Allocation: Ra NL49394.018. June 2015 January 2016 January 2016 ###
Allocation: Ra SCS-PAF ### ### ### ###
Allocation: Ra DBS for TD June 2015 May 2, 2017 ### ###
Allocation: Ra LIPMAT ### May 30, 2018 May 30, 2018 July 13, 2015
Allocation: Ra METC 14-3-05 ### ### ### ###
Allocation: No 05-1971 October 2016 ### ### ###
Allocation: Ra NL46674.081. ### ### ### ###
Allocation: Ra 24-SMI-2014 ### July 2017 October 2017 ###
Allocation: N/ NL47945.068. June 2014 April 2015 ###
Allocation: Ra METC 13-2-03 ### June 2016 June 2016 ###
Allocation: N/ 2013/498 ### January 2017 January 2017 ###
Allocation: Ra NL45370.100. ### April 26, 2018 April 26, 2018 ###
Allocation: Ra NL46979.091. July 2014 January 2021 January 2021 ###
Allocation: N/ 11-36-14/12 ### May 2018 May 2018 ###
Allocation: N/ EPICSCZE14 August 2014 April 2017 April 2017 ###
Allocation: Ra ABILITY August 2014 ### ### July 10, 2014
Allocation: Ra NL46719.029. ### ### ### June 2, 2014
Allocation: N/ 47955 June 2015 June 2016 April 10, 2014
Allocation: N/ 1335-1812-int ### ### ### ###
Allocation: N/ Apple study 2 ### May 2016 ###
Allocation: Ra NL43116.041. ### May 2016 May 2017 ###
Allocation: Ra MIDRF|NL3663 July 2011 ### ### ###
Allocation: Ra 133031 October 2013 ### ### ###
Allocation: N/ NL41466.042. August 2015 ### ### ###
Allocation: N/ NL44048.018. July 2013 January 2018 January 2018 ###
Allocation: Ra METC 13-2-0 January 2014 October 2014 October 2014 ###
Allocation: Ra NL nr.: 40730. August 2012 October 2014 October 2014 July 31, 2012
Allocation: Ra METC 12-2-03October 2012 ### ### July 11, 2012
Allocation: N/ CMO 2011/345| March 2012 ### ### April 13, 2012
Allocation: N/ CHLOROQUINE May 2014 July 2017 July 2017 April 11, 2012
Allocation: No 905-EC-010 March 2012 June 2012 June 2012 ###
Allocation: Ra AAA-PET/CT v ### ### ### ###
Allocation: Ra 15378 ### March 2009 June 2009 ###
Allocation: Ra NL36977.091. October 2013 June 2015 June 2015 June 7, 2011
Allocation: Ra NL35192.044. May 2011 May 2013 May 2014 May 26, 2011
Allocation: No MFX468 May 2011 June 2015 August 2016 April 5, 2011
Allocation: Ra NL32865.044.10 ### ### ### ###
Allocation: Ra NOCTX-2|2009 ### July 2012 July 2012 ###
Allocation: Ra UMCNONCO20 January 2011 April 2012 October 2012 ###
Allocation: N/ Nitroglycerin ### ### March 2017 ###
Allocation: No NL26963.060. August 2010 April 2012 April 2012 ###
Allocation: Ra PDinCHF|2009 April 2010 ### ### May 17, 2010
Allocation: Ra NL 28041.018.January 2010 ### ### April 20, 2010
Allocation: Ra APIDR_L_0471January 2010 July 2012 July 2012 ###
Allocation: Ra NL26689.075. May 2010 January 2012 January 2012 ###
Allocation: No EORTC-08061| ### July 2010 ### ###
Allocation: Ra NL24375.041. May 2009 ### ### ###
Allocation: Ra CETRO Trial| ### October 2012 October 2012 ### ###
Allocation: Ra MOSTrial|CCMOctober 2008 January 2011 January 2011 ###
Allocation: Ra HOADO March 2009 ###
Allocation: Ra STW6041 January 2009 June 2009 ### ###
Allocation: Ra BRC-CS ### August 2015 ### ### May 16, 2017
Allocation: Ra ROSEL October 2008 ### ### June 2, 2008
Allocation: N/ 12382|B4Z-UT ### June 2009 June 2009 June 2, 2008 ###
Allocation: Ra N07MAN|Eudra April 2008 May 2012 May 2013 May 26, 2008
Allocation: N/ UD736 March 2008 March 2009 March 2009 April 18, 2008 ###
Allocation: N/ LTC-499-301107 August 2011 August 2011 ###
Allocation: Ra LTC-510-1001 March 2008 July 2017 July 2017 ###
Allocation: Ra LTC-502-1412 July 2008 ### ### ###
Allocation: Ra ICHYPDEL/00 ### May 2008 May 2008 ###
Allocation: N/ 06-02-117|TA October 2008 June 2009 ###
Allocation: Ra AMP SSTI 01- ### July 2009 October 2009 ###
Allocation: Ra CERL080ANL0 July 2007 August 2009 August 2009 July 19, 2007
Allocation: Ra 20061016-V2 March 2007 January 2011 January 2011 May 30, 2007 ###
Allocation: Ra p06-108a April 2007 March 2008 May 2008 ###
Allocation: No WA19078 January 2006 June 2010 June 2010 ### July 16, 2014
Allocation: Ra NL11494.075. October 2006 October 2007 October 2007 ###
Allocation: No 06-125 October 2006 October 2007 October 2007 ###
Allocation: Ra D1449C00008 June 2006 ### ### ###
Allocation: Ra 945-16-104 March 2006 June 2008 ###
Allocation: Ra EE04-01NL ### June 2008 June 2008 ###
Allocation: No 04/089-E ### ### January 2008 ###
Allocation: Ra 2004-165 October 2005 ### ###
Allocation: Ra 01-021 July 2002 July 2005 ###
Allocation: No FLT-PET CRCJanuary 2005 ### ### ###
Allocation: Ra 05IAT0061|200 ### January 2007 January 2007 ###
Allocation: N/ 201700599|20 May 22, 2019 May 1, 2022 May 1, 2022 ###
Allocation: N/ CEL5684 ### ### ### ###
Allocation: Ra REMINDRA April 21, 2017 ### ### ###
Allocation: Ra NL512830291 May 2015 May 2017 May 2017 April 6, 2016
Allocation: Ra NL40128.029. May 2013 January 2018 January 2018 ###
Allocation: Ra EMR200109_63 ### ### ### ###
Allocation: Ra MEC06-2-003 July 2006 ### July 2012 ###
Allocation: Ra 10/157 August 2010 January 2015 ### June 7, 2012
Allocation: Ra 12-046 April 1, 2012 June 1, 2016 July 1, 2016 April 24, 2012
Allocation: N/ AMCmedonc010 October 2010 April 2015 April 2015 ###
Allocation: No NL22553.000. June 2009 April 2016 April 2016 ###
Allocation: Ra P06.108 April 2007 May 2009 ###
Allocation: N/ METc2011.08 ### October 2016 October 2016 April 4, 2013
Allocation: Ra 2014-004851- ### May 31, 2019 ### ###
Allocation: Ra 12-027|111/13 August 2014 ### ### ###
Primary PurpoEORTC-20963 March 1997 ### ###
Allocation: Ra LITE study|C January 2009 October 2010 October 2010 ### ###
Allocation: Ra EPLERAF-01|V March 2008 ### ### ###
Allocation: N/ M19CCR ### April 1, 2023 April 1, 2023 ###
Allocation: Ra NL61630.078. ### July 5, 2022 July 5, 2022 ###
Allocation: N/ NL50488.042. ### ### May 1, 2018 April 19, 2016
Allocation: N/ CC-TT-IMA-14 April 2016 ### ### ###
Allocation: N/ 20132312|201 July 2014 ### ### ###
Allocation: Ra A-95-52014-19 March 2012 July 2013 July 2013 ###
Allocation: Ra LTC 625-2306 January 2010 April 2011 May 2011 July 17, 2009
Allocation: N/ D4200C00085| May 2009 August 2010 August 2010 ###
Allocation: Ra CP MM 19-08-January 2008 March 2010 March 2010 ###
Allocation: Ra UMCN-AKF 16 April 1, 2018 ### ### ###
Allocation: Ra NL75841.041. ### ### ### ###
Allocation: N/ M17GEL ### May 1, 2022 July 1, 2022 May 10, 2017
Allocation: Ra CRD0339 ### ### July 21, 2021 ###
Allocation: N/ 201500776 August 2016 May 30, 2018 May 30, 2018 ###
Allocation: Ra NL44622.029. ### ### ### May 17, 2013
Allocation: Ra NL39851.041.1 ### ### ### ###
Allocation: Ra CRESCENT-1 July 2011 August 2014 August 2014 July 13, 2011
Allocation: Ra NL36322.068. June 2011 June 2017 June 2017 April 13, 2011
Allocation: No Chloroquine IV ### June 2016 June 2016 ###
Allocation: Ra MEC-2013-460October 2014 April 2020 April 2020 ###
Allocation: N/ UMCN-AKF 14 August 2015 ### ### ###
Allocation: Ra P08.185 ### May 2015 July 2015 April 29, 2009
Primary PurpoEORTC-22971October 1998 July 2001 April 9, 2004
Allocation: No D1690C00049|July 12, 2017 ### ### May 12, 2017 May 28, 2021
Allocation: Ra NL46653 July 2014 May 2019 May 2019 ###
Allocation: N/ CT-15-009 April 1, 2016 ### ### ###
Allocation: Ra EORTC-26021 ### ### ###
Allocation: N/ M18TEO ### May 17, 2021 May 17, 2021 ###
Allocation: Ra IMPROVE-II ### May 11, 2021 May 11, 2021 ###
Allocation: Ra TIS2012 August 2012 ### ### ###
Allocation: Ra CR017992|TM June 2011 ### ### July 11, 2011
Allocation: N/ CSE2017-01K ### ### ### ### ###
Allocation: Ra TRE-1486--010 ### July 28, 2022 July 28, 2022 ###
Allocation: Ra NL45994.091. May 2015 ### ### April 3, 2015
Allocation: Ra AF-10-023-ND July 2011 ### March 2016 ###
Allocation: Ra 115393 ### ### ### ###
Allocation: N/ NordDutchCML April 2013 April 8, 2016 May 1, 2016 May 31, 2013
Allocation: Ra M15PAP|NL538 ### ### ### ###
Allocation: Ra NL73547.091. April 17, 2020 May 25, 2021 May 25, 2021 April 6, 2020
Allocation: No UMCN-AKF-18 ### May 2, 2019 May 2, 2019 ###
Allocation: Ra NL62110.068. June 4, 2018 ### ### ###
Allocation: Ra NVALT 18 ### April 2019 April 2019 May 17, 2016
Allocation: Ra M15CRH ### ### ### April 20, 2015
Allocation: N/ M14REP ### ### ### April 13, 2015
Allocation: Ra BOOG 2013-0 June 2014 March 2018 March 2018 April 14, 2014
Allocation: Ra AIPOP ### ### ### ###
Allocation: No AKF UMCN 12 May 2013 ### ### April 26, 2013
Allocation: Ra BOOG 2010-0 ### January 2014 January 2014 July 12, 2011
Allocation: Ra 171102025;Z ### May 2016 May 2016 ###
Allocation: Ra SELECT-AMI ### ### ### ###
Allocation: Ra NL20963.091. October 2009 May 1, 2017 May 1, 2018 ###
Allocation: Ra MOBILE-AF July 29, 2016 ### ### July 24, 2015
Allocation: Ra I-48-52014-14 ### ### June 2008 ###
Allocation: Ra NL51318.078. April 30, 2015 April 30, 2020 April 30, 2020 ###
Allocation: Ra EORTC-BTG-1 ### ### ### ###
Allocation: Ra EFC15160|201 ### May 19, 2021 May 19, 2021 July 26, 2018 ###
Allocation: N/ CL02413 January 2011 March 2014 March 2014 ###
Allocation: Ra 11949|I1V-MCOctober 2012 March 2016 July 2016 ### May 16, 2018
Allocation: Ra ICP-112-201 October 2012 ### March 2014 ###
Allocation: Ra GE-122-020|2 ### May 4, 2018 May 4, 2018 ### May 22, 2019
Allocation: Ra 747-302 ### ### ### ### ###
Allocation: Ra CR-13-006-ID ### May 30, 2021 May 30, 2021 ### May 17, 2023
Allocation: Ra EFC15068|201 ### ### ### July 26, 2018 ###
Allocation: Ra EudraCT nr: 2 August 2010 July 2014 July 2014 July 16, 2010
Allocation: Ra FER-CARS-03 ### October 2009 January 2011 ###
Allocation: Ra CLIK066B2204July 25, 2017 June 6, 2018 June 6, 2018 May 15, 2017 ###
Allocation: Ra C LF23-0121 0 June 2006 ### ### ###
Allocation: Ra HepBurn|2012October 2013 October 2016 ### ###
Allocation: Ra PLATA August 2013 April 2017 April 2017 ###
Allocation: Ra EORTC-08972 ### March 2003 ###
Primary PurpoEORTC-08981 April 2001 October 2002 ###
Allocation: Ra IMD-10 June 2013 August 2015 August 2015 June 5, 2013
Allocation: Ra E-100 ### July 2008 July 2008 ### May 17, 2010
Allocation: Ra 1.02.7007 ### ### ### ### ###
Allocation: R EORTC-40004 May 2002 June 2007 ###
Allocation: N/ COEB071X2101 ### April 2014 April 2014 July 26, 2011
Allocation: No BY1023/NL51 March 2007 October 2007 ### ###
Allocation: R EORTC-08021| May 2004 July 2008 ###
Allocation: N/ 835093|2009- ### ### January 2011 ### ###
Allocation: Ra EORTC-20971January 2001 March 2009 ###
Allocation: Ra Y-79-52120-12 ### June 2009 ### ###
Allocation: Ra EORTC-10974October 2001 ### ###
Allocation: Ra CACZ885V2201 ### April 20, 2022 ### May 30, 2019 July 3, 2023
Allocation: Ra CA209-9UT|20 ### ### ### May 8, 2018 June 1, 2023
Allocation: N/ CIP-3102-01 June 2015 August 2015 August 2015 ###
Allocation: Ra EORTC-30004 May 2002 May 2004 ###
Allocation: N/ 10173339DOC May 2015 ### ### June 3, 2015
Allocation: Ra D-FR-52120-2 March 2016 ### ### ### ###
Allocation: N/ CR106660|547 ### June 1, 2017 June 1, 2017 April 10, 2015 ###
Allocation: Ra 12-513 April 2013 ### January 2015 ###
Allocation: Ra Flagship AA tr March 2001 June 2008 ### July 16, 2010
Allocation: Ra LFC2009.01.0 March 2010 June 2012 June 2012 ### ###
Allocation: Ra A8851022 April 2009 June 2012 June 2012 ### ###
Allocation: Ra TRIAL V|Eudra ### June 2009 June 2009 ###
Allocation: Ra G-0034|VITAL July 2005 August 2008 June 2009 ###
Allocation: N/ ASD Study ### October 2015 ### ### ###
Allocation: N/ D0384 ### April 6, 2020 April 6, 2020 ###
Allocation: Ra EFC16855|202April 12, 2020 May 26, 2020 May 26, 2020 April 3, 2020
Allocation: Ra IM011-073|201July 15, 2019 ### ### May 9, 2019 ###
Allocation: Ra 16832|I4V-MC ### April 1, 2022 April 1, 2022 ### May 16, 2023
Allocation: Ra 16676|I4V-MC ### ### ### ### ###
Allocation: N/ ETOP 12-17|2 ### ### ### ###
Allocation: Ra CMX001-999 ### May 10, 2019 May 10, 2019 ### ###
Allocation: Ra QUID-HF_v5.0 June 2016 ### ### May 23, 2016
Allocation: Ra CR108134|541 July 1, 2016 ### ### ### ###
Allocation: Ra A-US-52030-3 ### ### ### ### ###
Allocation: Ra CLIN-021 January 2016 ### ### ###
Allocation: Ra 8273-CL-0302 ### ### ### ### ###
Allocation: Ra 16298|2014-0 ### ### ### ### ###
Allocation: Ra 114674 April 2013 January 2014 January 2014 ###
Allocation: N/ VICTORY AF ### ### ### ### ###
Allocation: Ra CBYL719X2104 ### ### ### May 18, 2012 May 21, 2018
Allocation: Ra CTKI258A2210 April 2012 April 2015 April 2015 ### July 11, 2016
Allocation: Ra 269-11-215 ### October 2015 October 2015 ### April 10, 2017
Allocation: Ra CCS-08 July 2010 ### ### April 26, 2010
Allocation: Ra CSA-2005-02 April 15, 2008 ### ### ###
Allocation: No FE200486 CS3October 2010 ### January 2012 ### June 3, 2015
Allocation: Ra BWI130 April 2010 ### ### May 5, 2010
Allocation: N/ D2610C00001 ### ### ### ### ###
Allocation: Ra ACT3986g|WA2 May 15, 2007 ### May 14, 2018 May 22, 2007 ###
Allocation: Ra A6061021 ### ### ### June 8, 2006
Allocation: Ra EORTC-22011 July 2003 ### ###
Allocation: Ra EORTC-18981 April 2001 May 2003 ###
Allocation: Ra CRM-CH-Riv0 January 2012 May 2016 May 2016 ###
Allocation: Ra 19781|2018-0 ### April 14, 2021 ### ###
Allocation: Ra MesaCAPP ### April 10, 2019 April 10, 2019 ###
Allocation: Ra 2010/363|B67 ### ### ### ###
Allocation: Ra 10-390 ### April 2013 April 2013 ###
Allocation: No RG_16-186|20May 18, 2018 May 3, 2023 May 3, 2023 ###
Allocation: N/ EORTC 1762-S ### July 30, 2020 July 30, 2020 ###
Allocation: Ra OCTO_039 October 2014 ### ### May 12, 2015 ###
Allocation: Ra 207972|2017- April 18, 2018 ### ### ### ###
Allocation: No 747-206 July 1, 2015 ### ### April 11, 2022
Allocation: Ra MP0420-CP302 May 10, 2021 ### ### April 1, 2021 ###
Allocation: N/ 2018-22 ### ### ### May 11, 2020
Allocation: N/ CR022 ### ### July 6, 2018 ###
Allocation: Ra ACT14656|201 ### July 23, 2018 July 23, 2018 ### July 11, 2019
Allocation: Ra CSL842_3001| ### ### ### July 19, 2017 ###
Allocation: No CPDR001C2101 May 24, 2017 July 28, 2021 July 28, 2021 ###
Allocation: Ra CR-AIR-009|2 ### ### ### ### May 24, 2022
Allocation: Ra EORTC-1447-S ### June 5, 2020 June 5, 2020 ###
Allocation: Ra C10-44|2010- ### January 2014 January 2014 April 23, 2012
Allocation: Ra CLON01|2014- May 2016 October 2018 ### July 28, 2015
Allocation: No CINC280B2201 ### ### ### ###
Allocation: No ThymoHEM0120 October 2007 May 2009 July 2009 ### April 27, 2010
Allocation: N/ ST3073-ST307 ### ### April 30, 2017 April 10, 2014
Allocation: Ra EudraCT 2005 ### ### ### ###
Allocation: Ra EORTC-40091| June 2013 ### ### ###
Allocation: Ra SPD557-202|2 ### May 29, 2012 May 29, 2012 ### June 7, 2013
Allocation: No 14244|CP15-1 August 2011 May 2012 ### ### ###
Allocation: Ra MA25522|2010 May 2011 August 2012 August 2012 ### ###
Allocation: Ra EN3348-303 ### April 2013 ### ### ###
Allocation: Ra 1.02.7004 ### June 2012 June 2012 ### ###
Allocation: Ra MORD-STG4SU ### ### ### ###
Allocation: Ra AF07004AF July 2009 August 2012 August 2012 ###
Allocation: No T2008-002 June 2010 ### July 18, 2016 ### ###
Allocation: Ra CT 05/25 May 2008 May 2010 May 2010 ### ###
Allocation: Ra MDT-MORE-C June 2009 ### January 2016 April 22, 2009 April 4, 2017
Allocation: No CPKC412A2114 ### ### ### ### ###
Allocation: N A1501080|200 May 2009 May 2013 May 2013 ### ###
Allocation: Ra EFC10841|EudOctober 2008 April 2009 June 2009 ###
Allocation: Ra EFC6910|Eudr July 2008 June 2009 June 2009 ###
Allocation: Ra DSE-866-45|2 June 2008 ### ### May 16, 2008
Allocation: No NO21157|SARC ### ### ### ### ###
Allocation: Ra CAT-354-0603January 2008 July 2008 July 2008 ### ###
Allocation: No Hx-EGFr-203 ### October 2010 October 2010 ### ###
Allocation: Ra 979 July 1998 ### ### ### ###
Allocation: Ra 102.1 ### ### ### ###
Allocation: Ra A4021004|200 ### ### June 2014 ### July 28, 2015
Primary PurpoAC-052-371 March 2006 August 2007 ### ###
Allocation: Ra SPOG 2003 FN|January 2004 ### ### April 5, 2005
Allocation: Ra AC-052-369|A April 2006 August 2007 August 2007 April 12, 2006
Allocation: Ra AC-052-368|A March 2006 August 2007 August 2007 April 5, 2006
Allocation: Ra Acute GvHD-1January 2006 June 2007 ###
Allocation: Ra 384/03 ### May 2010 ### July 11, 2005
Allocation: Ra EORTC-21011|January 2003 May 2010 June 2011 ###
Allocation: R EORTC-22996 March 2001 April 2003 ###
Allocation: R EORTC-40954 July 1999 ### ###
Allocation: Ra EORTC-22952 ### ### ###
### Amsterdam UMC, location AM https://ClinicalTrials.gov/show/NCT05735756
### Leiden University Medical Cehttps://ClinicalTrials.gov/show/NCT05338125
### Netherlands, Nijmegen, Geldhttps://ClinicalTrials.gov/show/NCT05279222
### UMCG, Groningen, Netherla https://ClinicalTrials.gov/show/NCT05268926
### Radboud university medical chttps://ClinicalTrials.gov/show/NCT05194176
### Maastricht University Medicahttps://ClinicalTrials.gov/show/NCT04844346
### Radboudumc, Nijmegen, Geld https://ClinicalTrials.gov/show/NCT04733898
### M.V. Koning, Arnhem, M, Nethttps://ClinicalTrials.gov/show/NCT04420455
### UMCU, Utrecht, Netherlandshttps://ClinicalTrials.gov/show/NCT04362332
### Radboudumc, Nijmegen, Nethttps://ClinicalTrials.gov/show/NCT04311047
June 1, 2022 PRA Health Sc"Study Protocohttps://ClinicalTrials.gov/show/NCT04267276
### UMCG, Groningen, Netherla https://ClinicalTrials.gov/show/NCT04163094
### Academic Medical Center, A https://ClinicalTrials.gov/show/NCT04051853
June 9, 2020 Leiden University Medical Cehttps://ClinicalTrials.gov/show/NCT03877198
### UMC Utrecht, Utrecht, Nethehttps://ClinicalTrials.gov/show/NCT03863301
July 16, 2020 Catharina Hospital, Eindhovehttps://ClinicalTrials.gov/show/NCT03439150
### Rijnstate, Arnhem, Gelderlanhttps://ClinicalTrials.gov/show/NCT03326219
July 20, 2020 Rijnstate Hospital, Arnhem, https://ClinicalTrials.gov/show/NCT03214809
### Academisch Medisch Centrum https://ClinicalTrials.gov/show/NCT03211494
April 17, 2019 University Medical Center Utrhttps://ClinicalTrials.gov/show/NCT03150628
April 8, 2022 Maastricht university medicalhttps://ClinicalTrials.gov/show/NCT03026049
### University Medical Center Utrhttps://ClinicalTrials.gov/show/NCT02975739
### Netherlands Cancer Institut https://ClinicalTrials.gov/show/NCT02941835
May 6, 2020 A. Elvan, Zwolle, Overijssel, https://ClinicalTrials.gov/show/NCT02856373
### UMC Utrecht, Utrecht, Nethehttps://ClinicalTrials.gov/show/NCT02853162
### Academic Medical Center, Inhttps://ClinicalTrials.gov/show/NCT02836340
June 9, 2016 University Medical Center G https://ClinicalTrials.gov/show/NCT02629055
### MAASTRO Clinic, Maastricht,https://ClinicalTrials.gov/show/NCT02584400
### Netherlands Institute for Pi https://ClinicalTrials.gov/show/NCT02548533
April 6, 2016 Medisch Spectrum Twente (M https://ClinicalTrials.gov/show/NCT02530203
May 23, 2017 Zon en Schild, Amersfoort, Uhttps://ClinicalTrials.gov/show/NCT02524886
### Amphia Ziekenhuis, Oosterhohttps://ClinicalTrials.gov/show/NCT02403518
### Gelderse Vallei Hospital, Ed https://ClinicalTrials.gov/show/NCT02361957
### Máxima Medisch Centrum, Eihttps://ClinicalTrials.gov/show/NCT02349659
### Maastricht University, Maastrhttps://ClinicalTrials.gov/show/NCT02333916
### Canisuis Wilhelmina Hospitalhttps://ClinicalTrials.gov/show/NCT02319733
May 10, 2019 St Antonius hospital, Nieuwe https://ClinicalTrials.gov/show/NCT02299947
### Rijnstate Hospital, Arnhem, https://ClinicalTrials.gov/show/NCT02295163
### MAASTRO clinic, Maastricht,https://ClinicalTrials.gov/show/NCT02233387
April 5, 2017 Catharina Hospital, Eindhovehttps://ClinicalTrials.gov/show/NCT02210949
### Radboudumc, Nijmegen, Nethttps://ClinicalTrials.gov/show/NCT02185937
July 31, 2018 Medical Center Alkmaar, Alk https://ClinicalTrials.gov/show/NCT02152930
### University Medical Center G https://ClinicalTrials.gov/show/NCT02110316
### Maastricht Radiation Oncolo https://ClinicalTrials.gov/show/NCT02062372
June 1, 2016 University Medical Center G https://ClinicalTrials.gov/show/NCT02029781
### University Medical Centre G https://ClinicalTrials.gov/show/NCT01921062
### Maastricht University, Maastrhttps://ClinicalTrials.gov/show/NCT01887119
### University Medical Centre G https://ClinicalTrials.gov/show/NCT01886625
### Academic Medical Center, A https://ClinicalTrials.gov/show/NCT01882660
April 1, 2015 Radboud University Nijmegenhttps://ClinicalTrials.gov/show/NCT01654328
### Radboud University Nijmegenhttps://ClinicalTrials.gov/show/NCT01577212
July 18, 2017 MAASTRO clinic, Maastricht,https://ClinicalTrials.gov/show/NCT01575782
### VU University Medical Cente https://ClinicalTrials.gov/show/NCT01425242
### St Elisabeth Hospital, Tilbur https://ClinicalTrials.gov/show/NCT01407614
July 7, 2016 Medisch Spectrum Twente, En https://ClinicalTrials.gov/show/NCT01360918
### University Medical Center G https://ClinicalTrials.gov/show/NCT01329250
July 7, 2016 Medisch Spectrum Twente, Ehttps://ClinicalTrials.gov/show/NCT01319747
May 11, 2012 University Medical Centre Ni https://ClinicalTrials.gov/show/NCT01262183
### MAASTRO clinic, Maastricht,https://ClinicalTrials.gov/show/NCT01210378
### Catharina Ziekenhuis, Eindh https://ClinicalTrials.gov/show/NCT01193712
### Martini Hospital, Groningen, https://ClinicalTrials.gov/show/NCT01124227
### Academic Medical Center, Unhttps://ClinicalTrials.gov/show/NCT01107184
May 29, 2013 Sanofi-Aventis Administrativ https://ClinicalTrials.gov/show/NCT01079364
### Princess Amalia Children's Clhttps://ClinicalTrials.gov/show/NCT00962299
July 26, 2018 Vrije Universiteit Medisch C https://ClinicalTrials.gov/show/NCT00953459
April 21, 2015 University Medical Center, U https://ClinicalTrials.gov/show/NCT00922844
July 22, 2013 University Medical Center Utrhttps://ClinicalTrials.gov/show/NCT00866008
May 16, 2017 Isala Klinieken, Zwolle, Neth https://ClinicalTrials.gov/show/NCT00703157
### VU University Medical Cente https://ClinicalTrials.gov/show/NCT00687986
### For additional information r https://ClinicalTrials.gov/show/NCT00687609
### NKI-AVL, Amsterdam, Netherhttps://ClinicalTrials.gov/show/NCT00684216
### Netherlands Cancer Institut https://ClinicalTrials.gov/show/NCT00661570
### Alysis Rijnstate Hospital, A https://ClinicalTrials.gov/show/NCT00631267
### University Medical Center, U https://ClinicalTrials.gov/show/NCT00599287
### Maastricht Radiation Oncolo https://ClinicalTrials.gov/show/NCT00522639
May 28, 2014 UMC St. Radboud, Nijmegen,https://ClinicalTrials.gov/show/NCT00509847
### Erasmus MC, Rotterdam, Nethttps://ClinicalTrials.gov/show/NCT00504244
### Medtronic Bakken Research https://ClinicalTrials.gov/show/NCT00480077
C
### LUMC, Leiden, Netherlands https://ClinicalTrials.gov/show/NCT00452166
July 16, 2014 Amsterdam, Netherlands https://ClinicalTrials.gov/show/NCT00422942
### Isala Klinieken, Zwolle, Overihttps://ClinicalTrials.gov/show/NCT00413543
June 3, 2015 University Medical Center Utrhttps://ClinicalTrials.gov/show/NCT00371579
### Research Site, Utrecht, Nethhttps://ClinicalTrials.gov/show/NCT00302770
### AMC, Amsterdam, Netherlanhttps://ClinicalTrials.gov/show/NCT00289055
April 15, 2008 Utrecht Institute for Pharmachttps://ClinicalTrials.gov/show/NCT00223587
### Erasmus MC-Daniel den Hoed https://ClinicalTrials.gov/show/NCT00215631
June 2, 2015 Sanquin Blood Bank South Whttps://ClinicalTrials.gov/show/NCT00202371
### Radboud University, Nijmegehttps://ClinicalTrials.gov/show/NCT00145665
### HIV Outpatient Clinic, Acad https://ClinicalTrials.gov/show/NCT00128908
May 15, 2023 VU University Medical Cente https://ClinicalTrials.gov/show/NCT03850028
### Department of Otorhinolarynghttps://ClinicalTrials.gov/show/NCT03026829
April 29, 2019 Reumazorg Zuidwest Nederlan https://ClinicalTrials.gov/show/NCT02935387
May 20, 2019 Netherlands Cancer Institut https://ClinicalTrials.gov/show/NCT02729558
### Academic Medical Center, Am https://ClinicalTrials.gov/show/NCT02473562
### Canisius Wilhelmina Ziekenhhttps://ClinicalTrials.gov/show/NCT02096133
### Atrium Medical Center Parksthttps://ClinicalTrials.gov/show/NCT01820962
### Academic Medical Centre Ams https://ClinicalTrials.gov/show/NCT01613235
May 3, 2021 VUmc, Amsterdam, Netherlan https://ClinicalTrials.gov/show/NCT01583881
April 22, 2015 Academic Medical Center, Am https://ClinicalTrials.gov/show/NCT01178151
### Medisch Centrum Haaglanden, https://ClinicalTrials.gov/show/NCT00169923
May 4, 2018 University Medical Center Grhttps://ClinicalTrials.gov/show/NCT01823809
### Universitaets klinikum Erla https://ClinicalTrials.gov/show/NCT02722603
April 12, 2017 Department of Internal Medichttps://ClinicalTrials.gov/show/NCT02077309
July 2, 2012 Academisch Ziekenhuis Utrechttps://ClinicalTrials.gov/show/NCT00003152
### UZ Brussel, Brussel, Belgiumhttps://ClinicalTrials.gov/show/NCT00823472
### Universitätsklinikum des Saahttps://ClinicalTrials.gov/show/NCT00647192
May 24, 2023 Netherlands Cancer Institut https://ClinicalTrials.gov/show/NCT03984019
### HagaZiekenhuis, Den Haag, https://ClinicalTrials.gov/show/NCT03846570
N
### University Medical Center Grhttps://ClinicalTrials.gov/show/NCT02743975
### Meander Medical Center, Amer https://ClinicalTrials.gov/show/NCT02685046
### VU Medical Center, Amsterdahttps://ClinicalTrials.gov/show/NCT02040909
### St. Antonius Hospital, Nieu https://ClinicalTrials.gov/show/NCT01562522
### Ziekenhuis Rijnstate, Arnhemhttps://ClinicalTrials.gov/show/NCT00940979
### Research site, Amsterdam, Ne https://ClinicalTrials.gov/show/NCT00807170
July 7, 2010 Radboud University Nijmegenhttps://ClinicalTrials.gov/show/NCT00512655
### University of Bonn, Germany,https://ClinicalTrials.gov/show/NCT03389061
### Medisch Centrum Heuvelrug,https://ClinicalTrials.gov/show/NCT05254808
D
July 19, 2022 Antoni van Leeuwenhoek, Ams https://ClinicalTrials.gov/show/NCT03147040
April 26, 2023 HagaZiekenhuis, The Hague,https://ClinicalTrials.gov/show/NCT02804087
July 26, 2018 Dutch Cancer Institute/ A v https://ClinicalTrials.gov/show/NCT02621515
### Academic Medical Center, Am https://ClinicalTrials.gov/show/NCT01856738
### Leiden University Medical C https://ClinicalTrials.gov/show/NCT01708265
### MC Haaglanden, Leidschenda https://ClinicalTrials.gov/show/NCT01393028
### Academic Medical Centre Amst https://ClinicalTrials.gov/show/NCT01334775
### NKI/AvL, Amsterdam, Netherla https://ClinicalTrials.gov/show/NCT00969306
April 14, 2020 University Hospital Leuven, https://ClinicalTrials.gov/show/NCT02256124
### University of Bonn, Bonn, Gehttps://ClinicalTrials.gov/show/NCT02566707
### University hospital Gent, Ge https://ClinicalTrials.gov/show/NCT00889590
### Institut Bergonie, Bordeaux, https://ClinicalTrials.gov/show/NCT00003642
May 28, 2021 Research Site,"Study Protocohttps://ClinicalTrials.gov/show/NCT03152084
### ZNA, Antwerp, Belgium|Univer https://ClinicalTrials.gov/show/NCT02949232
### Aarhus Universitetshospital, https://ClinicalTrials.gov/show/NCT02607501
### University Hospital Schleswi https://ClinicalTrials.gov/show/NCT00104936
### Maastricht UMC+, Maastrichthttps://ClinicalTrials.gov/show/NCT03784599
May 13, 2022 Jeroen Bosch Hospital, 's-Hehttps://ClinicalTrials.gov/show/NCT03655821
### Centrum Oosterwal, Alkmaar,https://ClinicalTrials.gov/show/NCT02360358
### Zuidlaren, Netherlands|Krak https://ClinicalTrials.gov/show/NCT01391117
### HELIOS Klinike"Study Protocohttps://ClinicalTrials.gov/show/NCT03275246
### Insitute for Stroke and Demehttps://ClinicalTrials.gov/show/NCT03082014
May 13, 2022 Radiotherapiegroep Arnhem,https://ClinicalTrials.gov/show/NCT02407795
### Elkerliek Hospital, Helmond https://ClinicalTrials.gov/show/NCT01276093
### GSK Investigational Site, Le https://ClinicalTrials.gov/show/NCT01658605
### Aarhus University Hospital, https://ClinicalTrials.gov/show/NCT01866553
### Institut Curie, Saint-Cloud, https://ClinicalTrials.gov/show/NCT02913729
### Jeroen Bosch Ziekenhuis, 's https://ClinicalTrials.gov/show/NCT04335786
### Radboudumc, Nijmegen, Gelde https://ClinicalTrials.gov/show/NCT03728855
### Envida - De Wi"Study Protocohttps://ClinicalTrials.gov/show/NCT03616639
April 30, 2019 VUmc Medical Center, Amster https://ClinicalTrials.gov/show/NCT02775006
### Medisch Spectrum Twente, En https://ClinicalTrials.gov/show/NCT02421458
### The Netherlands Cancer Instihttps://ClinicalTrials.gov/show/NCT02414750
May 9, 2018 Maastricht University Medicahttps://ClinicalTrials.gov/show/NCT02112682
June 8, 2023 University Health Network T https://ClinicalTrials.gov/show/NCT04506372
### Academic Medical Centre Ams https://ClinicalTrials.gov/show/NCT01841502
### Medisch Centrum Alkmaar, Alk https://ClinicalTrials.gov/show/NCT01392586
### Flevoziekenhuis, Almere, Ne https://ClinicalTrials.gov/show/NCT01385774
April 22, 2015 OLVZ Aalst, Aalst, Belgium|Chttps://ClinicalTrials.gov/show/NCT00529932
May 31, 2017 NKI/AvL, Amsterdam, Netherla https://ClinicalTrials.gov/show/NCT00989820
### Regionshospitalet Midtjyllan https://ClinicalTrials.gov/show/NCT02507986
### Vrije Universiteit Medisch https://ClinicalTrials.gov/show/NCT00444639
### UH Antwerp, Antwerp, Belgiuhttps://ClinicalTrials.gov/show/NCT02470533
### Princess Alexandra Hospital https://ClinicalTrials.gov/show/NCT03763422
### Investigationa "Study Protocohttps://ClinicalTrials.gov/show/NCT03600818
April 2, 2015 Universidad Autonoma de Nue https://ClinicalTrials.gov/show/NCT01226290
### https://ClinicalTrials.gov/show/NCT01687998
### AZ Sint-Lucas Brugge, Brugghttps://ClinicalTrials.gov/show/NCT01712412
May 22, 2019 Vascular Biolo"Study Protocohttps://ClinicalTrials.gov/show/NCT02656329
### Mayo Clinic Ar"Study Protocohttps://ClinicalTrials.gov/show/NCT02308111
May 17, 2023 Heart Center R"Study Protocohttps://ClinicalTrials.gov/show/NCT02006069
### George Washington University https://ClinicalTrials.gov/show/NCT01164046
June 3, 2015 Research Site, Copenhagen https://ClinicalTrials.gov/show/NCT00821717
S,
### Novartis Invest"Study Protocohttps://ClinicalTrials.gov/show/NCT03152552
### Site105, Pula, Croatia|Site1 https://ClinicalTrials.gov/show/NCT00361868
### St Vincent's Hospital, Melbo https://ClinicalTrials.gov/show/NCT01773083
### Massachusetts General Hospit https://ClinicalTrials.gov/show/NCT01626755
July 18, 2012 Algemeen Ziekenhuis Middelh https://ClinicalTrials.gov/show/NCT00003803
July 18, 2012 Algemeen Ziekenhuis Middelhe https://ClinicalTrials.gov/show/NCT00021112
### Yale University School of Mehttps://ClinicalTrials.gov/show/NCT01869738
### ULB-Hôpital Erasme, Centre https://ClinicalTrials.gov/show/NCT00522418
d
### Hunter Pain Clinic, Broadmeahttps://ClinicalTrials.gov/show/NCT01711619
### Allgemeines Krankenhaus - Un https://ClinicalTrials.gov/show/NCT00043004
### City of Hope National Medicalhttps://ClinicalTrials.gov/show/NCT01402440
May 7, 2012 Altana Pharma/Nycomed, BThttps://ClinicalTrials.gov/show/NCT00449813
O
July 16, 2012 Ziekenhuis Netwerk Antwerpen https://ClinicalTrials.gov/show/NCT00091156
### BE004, Brugge, Belgium|BE00 https://ClinicalTrials.gov/show/NCT00986258
July 16, 2012 U.Z. Gasthuisberg, Leuven, Bhttps://ClinicalTrials.gov/show/NCT00014326
### ULB Hôpital Erasme, Brussels https://ClinicalTrials.gov/show/NCT00578097
July 18, 2012 Centre Hospitalier Etterbeek https://ClinicalTrials.gov/show/NCT00028704
July 3, 2023 UCLA Oncology H Protocohttps://ClinicalTrials.gov/show/NCT03968419
"Study
June 1, 2023 Local Instituti "Study Protocohttps://ClinicalTrials.gov/show/NCT03519256
### Rigshospitalet University Ho https://ClinicalTrials.gov/show/NCT02478008
### Academisch Ziekenhuis der Vr https://ClinicalTrials.gov/show/NCT00042887
### Krankenhaus Hietzing, Viennhttps://ClinicalTrials.gov/show/NCT02461524
### UAB School of"Study Protocohttps://ClinicalTrials.gov/show/NCT02660138
### Duarte, Califo "Study Protocohttps://ClinicalTrials.gov/show/NCT02413489
### Allgemein öffentliches Krank https://ClinicalTrials.gov/show/NCT01772108
April 3, 2015 University Hospital, Pilsen, https://ClinicalTrials.gov/show/NCT01163942
### CHU Amiens Hopital Nord, Am https://ClinicalTrials.gov/show/NCT01083472
### Pfizer Investigational Site, https://ClinicalTrials.gov/show/NCT00805740
### Departments of Rheumatology, https://ClinicalTrials.gov/show/NCT00368264
### Alaska Clinical Research Cenhttps://ClinicalTrials.gov/show/NCT00133224
### Prince of Wales Hospital, Sh https://ClinicalTrials.gov/show/NCT02227121
April 12, 2022 CHU de Grenoble, Grenoble,https://ClinicalTrials.gov/show/NCT02872298
April 25, 2022 Investigational Site Number https://ClinicalTrials.gov/show/NCT04333654
### University of "Study Protocohttps://ClinicalTrials.gov/show/NCT03943147
May 16, 2023 Achieve Clinic "Study Protocohttps://ClinicalTrials.gov/show/NCT03843125
### Achieve Clinic "Study Protocohttps://ClinicalTrials.gov/show/NCT03616912
### Institut Jules Bordet, Brusse https://ClinicalTrials.gov/show/NCT03445000
### Children's Hos"Study Protocohttps://ClinicalTrials.gov/show/NCT03339401
### Hospital of Fridek-Mistek P. https://ClinicalTrials.gov/show/NCT02780180
### Los Angeles, C"Study Protocohttps://ClinicalTrials.gov/show/NCT02703272
July 6, 2022 Arizona Oncolo"Study Protocohttps://ClinicalTrials.gov/show/NCT02683941
### Florida Hospital, Orlando, F https://ClinicalTrials.gov/show/NCT02637947
### Site US10029,"Study Protocohttps://ClinicalTrials.gov/show/NCT02588261
### Bakersfield, C "Statistical A https://ClinicalTrials.gov/show/NCT02258464
### GSK Investigational Site, Sa https://ClinicalTrials.gov/show/NCT01762852
### Phoenix Cardio"Study Protocohttps://ClinicalTrials.gov/show/NCT01693120
### Novartis Investigative Site, https://ClinicalTrials.gov/show/NCT01602315
July 11, 2016 Ironwood Cancer and Research https://ClinicalTrials.gov/show/NCT01528345
April 10, 2017 Otsuka Investigational Site, https://ClinicalTrials.gov/show/NCT01483183
July 7, 2017 Medalp, Imst, Austria|Ortho https://ClinicalTrials.gov/show/NCT01110070
April 1, 2021 Karl Brabants, MD, Antwerp, https://ClinicalTrials.gov/show/NCT01246635
June 3, 2015 University of Colorado Schoohttps://ClinicalTrials.gov/show/NCT01242748
### A.Z. Middelheim, Antwerpen,https://ClinicalTrials.gov/show/NCT01116557
### Research Site, Stanford, Cal https://ClinicalTrials.gov/show/NCT00979134
### Pinnacle Research Group; Llc https://ClinicalTrials.gov/show/NCT00476996
### Pfizer Investigational Site, https://ClinicalTrials.gov/show/NCT00334685
### Ziekenhuis Netwerk Antwerpen https://ClinicalTrials.gov/show/NCT00068744
### Krankenhaus der Elisabethine https://ClinicalTrials.gov/show/NCT00020839
May 13, 2016 Cardiovascular Research Insti https://ClinicalTrials.gov/show/NCT01535404
### Ccare San Marcos Cancer Cent https://ClinicalTrials.gov/show/NCT03996473
April 18, 2019 Department of Surgery, Medic https://ClinicalTrials.gov/show/NCT03070574
### Hospital Network Antwerp - shttps://ClinicalTrials.gov/show/NCT01616043
May 7, 2013 Austin Health, Heidelberg, V https://ClinicalTrials.gov/show/NCT01308346
May 11, 2023 Rigshospitalet, Copenhagen,https://ClinicalTrials.gov/show/NCT03705507
### IRCCS Istituto Ortopedico Rizhttps://ClinicalTrials.gov/show/NCT03620149
### Pediatric Hematology and Onc https://ClinicalTrials.gov/show/NCT02441309
### GSK Investigat"Study Protocohttps://ClinicalTrials.gov/show/NCT03393806
### Clinques University Saint-Lu https://ClinicalTrials.gov/show/NCT05321524
### Jasper Summit"Study Protocohttps://ClinicalTrials.gov/show/NCT04828161
### Kepler Universitätsklinikum https://ClinicalTrials.gov/show/NCT04382612
### Institute for Clinical and https://ClinicalTrials.gov/show/NCT03314675
July 29, 2022 University of "Study Protocohttps://ClinicalTrials.gov/show/NCT03221842
### Highlands Oncology Group, Fay https://ClinicalTrials.gov/show/NCT03064854
May 24, 2022 City of Hope N"Study Protocohttps://ClinicalTrials.gov/show/NCT02999854
### Institut Bergonie, Bordeaux, https://ClinicalTrials.gov/show/NCT02929394
### Skejby University Hospital S https://ClinicalTrials.gov/show/NCT01583114
### Univerzita Karlova v Praze, https://ClinicalTrials.gov/show/NCT02509273
### Los Angeles Hematology/Oncolo https://ClinicalTrials.gov/show/NCT02468661
April 3, 2015 Hopital Avicenne/University https://ClinicalTrials.gov/show/NCT00542828
### Hôpital St André-CHU, Médeci https://ClinicalTrials.gov/show/NCT02110784
April 3, 2015 Hopital St. Louis, Paris, Fra https://ClinicalTrials.gov/show/NCT00298324
### Allgemeines Krankenhaus der https://ClinicalTrials.gov/show/NCT01508000
### CUB Hôpital Erasme, Brussels https://ClinicalTrials.gov/show/NCT01370863
### ImClone Investigational Site https://ClinicalTrials.gov/show/NCT01316263
### Huntsville, Alabama, United https://ClinicalTrials.gov/show/NCT01283971
### Alaska Clinical Research Cenhttps://ClinicalTrials.gov/show/NCT01200992
### Universitair Ziekenhuis Gent https://ClinicalTrials.gov/show/NCT01023269
### UC Davis Medical Center, Sac https://ClinicalTrials.gov/show/NCT01013623
### Queen Elisabeth II Health S https://ClinicalTrials.gov/show/NCT00735722
### Childrens Hospital Los Angele https://ClinicalTrials.gov/show/NCT00981799
### Westmead Private Hospital, S https://ClinicalTrials.gov/show/NCT00700739
April 4, 2017 Institut Klinicke a Experimen https://ClinicalTrials.gov/show/NCT00885677
### Seattle Children's Hospital C https://ClinicalTrials.gov/show/NCT00866281
### Childrens Hospital Los Angelhttps://ClinicalTrials.gov/show/NCT00836875
May 16, 2016 Sanofi-Aventis Administrativehttps://ClinicalTrials.gov/show/NCT00766688
May 16, 2016 Sanofi-Aventis Administrativ https://ClinicalTrials.gov/show/NCT00729027
### Bron, France|Cedex, France|https://ClinicalTrials.gov/show/NCT00679484
### City of Hope National Medicahttps://ClinicalTrials.gov/show/NCT00642941
### St. Vincents Hospital, Thora https://ClinicalTrials.gov/show/NCT00640016
### Oregon Health Sciences Cente https://ClinicalTrials.gov/show/NCT00401401
### Florida Heart Group, Orlandohttps://ClinicalTrials.gov/show/NCT00590889
### University Hospital - AKH Viehttps://ClinicalTrials.gov/show/NCT00384891
### UCSD Medical Center - La Jol https://ClinicalTrials.gov/show/NCT00372996
### University of Alabama, Birmi https://ClinicalTrials.gov/show/NCT00360087
### Pediatric Hematology/Oncolog https://ClinicalTrials.gov/show/NCT00107081
### University of Florida, Gaine https://ClinicalTrials.gov/show/NCT00282503
### Vitkovice Hospital Ostrava anhttps://ClinicalTrials.gov/show/NCT00118573
July 9, 2018 Karl-Franzens-University Grahttps://ClinicalTrials.gov/show/NCT00056056
### Newcastle Mater Misericordiahttps://ClinicalTrials.gov/show/NCT00017277
### Institut Jules Bordet, Bruss https://ClinicalTrials.gov/show/NCT00004099
July 2, 2012 Academisch Ziekenhuis der Vr https://ClinicalTrials.gov/show/NCT00002899
1 Terminated (The clinical trial has ended prematurely due to low 1 NCT05735756
1 Terminated (too busy for recruitment) 2 NCT05338125
1 Withdrawn (No participants were enrolled in the study within an 3 NCT05279222
1 Terminated (Inclusion rate too low.) 7 NCT05194176
1 Terminated (Recruitment was dependent on finding participants 13 NCT04844346
1 Terminated (Aimed sample size could not be reached within the 17 NCT04733898
1 Terminated (Currently almost no patients admitted to Dutch hos 23 NCT04362332
1 Terminated (Due to the COVID-19 pandemic the recruitment of 26 NCT04267276
1 Terminated (Despite the extension of the original recruitment pe 33 NCT04163094
1 Terminated (stopped prematurely due to too low inclusion rate) 34 NCT04132791
1 Terminated (As a result of a slower inclusion rate than expect 43 NCT03877198
1 Withdrawn (no participants enrolled) 44 NCT03863301
1 Terminated (slow enrolment) 58 NCT03439150
1 Terminated (Inclusion rate not reached and due to the COVID- 59 NCT03435575
1 Withdrawn (Difficulty finding eligible patients) 64 NCT03326219
1 Terminated (Slow inclusion rate (partly due to Covid-19)) 68 NCT03214809
1 Terminated (Unexpected low recruitment rate) 69 NCT03211494
1 Terminated (Conflicting recruitment with PERISCOPE II stud 70 NCT03150628
1 Terminated (it was not possible to recruit the required amount 75 NCT03026049
1 Terminated (slow inclusion rate) 79 NCT02941835
1 Terminated (Low enrollment number) 83 NCT02856373
1 Terminated (Insufficient recruitment during the predefined time 96 NCT02629055
1 Terminated (patients did not want to participate) 100 NCT02584400
1 Terminated (Not enough patients eligible for recruitment.) 101 NCT02548533
1 Terminated (Due to a change in medication guidelines it became 103 NCT02530203
1 Terminated (It was not possible to recruit and include a suffici 106 NCT02524886
1 Suspended (We recruited 25 of the 40 participants from inte 111 NCT02361957
1 Terminated (Sponsor withdrawn due to low inclusion rate) 112 NCT02349659
1 Terminated (Recruitment target could not be met) 113 NCT02333916
1 Withdrawn (no participants) 118 NCT02295163
1 Terminated (patients did not want to participate) 123 NCT02233387
1 Terminated (Low inclusion rate) 126 NCT02210949
1 Withdrawn (no eligible patients; study stopped without inclusio 130 NCT02110316
1 Terminated (Delayed/poor inclusion rate.) 134 NCT02029781
1 Terminated (slow enrollment study device unavailable ( CoreVa 138 NCT01982032
1 Terminated (Severe difficulties with recruiting participants) 140 NCT01921062
1 Terminated (Failure to recruit sufficient participants) 141 NCT01887119
1 Terminated (It was decided to discontinue the study due to insu 159 NCT01540786
1 Terminated (patient enrollment too slow) 163 NCT01407614
1 Terminated (Inclusion rate insufficiënt) 167 NCT01360918
1 Terminated (slow enrolment of patients and new insights) 171 NCT01329250
1 Terminated (Inclusion rate insufficient) 172 NCT01319747
1 Terminated (low recruitment numbers) 176 NCT01262183
1 Withdrawn (too limited number of eligible patients) 179 NCT01193712
1 Terminated (Slow recruitment) 183 NCT01079364
1 Terminated (recruitment was unsuccesfull only 7 patient have b 188 NCT00962299
1 Terminated (poorly recruiting) 189 NCT00953459
1 Terminated (too slow recruitment; lack of funding) 190 NCT00922844
1 Terminated (Due to a very slow inclusion rate.) 194 NCT00866008
1 Terminated (Recruitment faillure. Similar study published by o 196 NCT00856817
1 Withdrawn (Suitable subjects could not be recruited within the 200 NCT00826566
1 Terminated (Enrollments slowed down significantly despite seve 205 NCT00703157
1 Terminated (Poor recruitment) 206 NCT00687986
1 Terminated (The study was discontinued early owing to difficult 207 NCT00687609
1 Terminated (Unable to recruit enough patients) 212 NCT00637624
1 Terminated (Inclusion rate too low due to a lack of eligible pati 214 NCT00599287
1 Withdrawn (conduct (recruitment) not feasible within timeframe 218 NCT00509847
1 Terminated (Low enrollment rates) 222 NCT00480077
1 Terminated (it was not possible to recruit new patients anymor 223 NCT00452166
1 Terminated (Study was terminated after enrollment of 3 participa 227 NCT00422942
1 Terminated (enrollment insufficient 228 NCT00413543
1 Withdrawn (no actual patients recruited within year 1 after eth 232 NCT00371579
1 Terminated (This study was terminated due to poor enrollment 235 NCT00302770
1 Terminated (recruitment of patients did not reach sufficient nu 237 NCT00294905
1 Terminated (lack of enrollment) 238 NCT00289055
1 Terminated (slow recruitment rate) 240 NCT00223587
1 Terminated (Did not recruit) 255 NCT00128908
1 Terminated (Number of subjects could not be achieved due to 263 NCT03026829
1 Terminated (low recruitment rate) 265 NCT02935387
1 Terminated (insufficient patient enrollment insufficient funds fo 268 NCT02473562
1 Terminated (Because the inclusion rate was lower than expect 273 NCT01820962
1 Terminated (As advised by the DSMB the study was stopped du 275 NCT01613235
1 Withdrawn (No patients) 279 NCT01178151
1 Withdrawn (it was not possible to recruit any patient in the stud 285 NCT00169923
1 Terminated (The study was early terminated due to insufficient 295 NCT02722603
1 Terminated (bad recruitment of suitable participants just 4 pati 297 NCT02077309
1 Terminated (Inclusion rate too low. Recruitment of further study 305 NCT00647192
1 Terminated (Insufficient inclusion rate (due to COVID-19 pand 308 NCT03846570
1 Terminated (Low accrual rate) 312 NCT02685046
1 Terminated (Poor enrolment; only 6 subjects enrolled and they w 317 NCT01562522
1 Terminated (Very slow recruitment) 320 NCT00807170
1 Terminated (Extremely difficult recruitment. Preliminary analysi 322 NCT00512655
1 Terminated (Due to the rigorous nature of the trial and enroll 330 NCT02804087
1 Terminated (In the Netherlands we wanted to add pilimumab to 331 NCT02621515
1 Terminated (enrollment to slow insufficient funds) 332 NCT01856738
1 Terminated (low inclusion rate) 334 NCT01708265
1 Terminated (due to introduction of another integrase inhibitor 346 NCT02566707
1 Terminated (low recruitment with registration denosumab) 351 NCT00889590
1 Terminated (Poor recruitment.) 356 NCT03152084
1 Terminated (Difficulties with recruitment) 358 NCT02949232
1 Terminated (Insufficient accrual rate) 359 NCT02607501
1 Terminated (The clinical study was stopped due to very low en 375 NCT03275246
1 Terminated (completed for the primary study group of sporadic 386 NCT03082014
1 Terminated (DSMB recommendation; enrollment too slow) 392 NCT01276093
1 Withdrawn (Study CCX115383 has been terminated prior to enrol 396 NCT01658605
1 Terminated (insufficient enrollment) 399 NCT01866553
1 Terminated (Enrollment was stopped to facilitate successful 405 NCT04335786
1 Terminated (Difficult recruitment despite several interventions.) 406 NCT03728855
1 Terminated (recruiting rate was to low) 414 NCT02421458
1 Terminated (slow accrual rate) 420 NCT02112682
1 Suspended (slow recruitment rate) 421 NCT04506372
1 Terminated (due to low accrual rate) 427 NCT01392586
1 Terminated (Recruitment problems patients refused to participa 433 NCT00989820
1 Terminated (no personnel for recruitment) 434 NCT02507986
1 Terminated (Poorly recruiting) 448 NCT03763422
1 Terminated (Protracted recruitment timeline exacerbated by 454 NCT03600818
1 Terminated (Investigational device changes; adequate enrollm 462 NCT01226290
1 Terminated (Sponsor discretion (low recruitment rate)) 474 NCT02656329
1 Terminated (The DMC made the recommendation to not pursue fur 481 NCT02308111
1 Terminated (The steering committee had decided to discontinue 490 NCT02006069
1 Terminated (Protracted recruitment timeline exacerbated by 499 NCT03600805
1 Terminated (Positive FAIR-HF study data are available this st 503 NCT00821717
1 Terminated (This study terminated prematurely because of slo 510 NCT03152552
1 Terminated (The study was discontinued prematurely at the en 522 NCT00361868
1 Terminated (insufficient recruitment of patients and high costs 527 NCT01773083
1 Terminated (Lack of funding and recruitment.) 537 NCT01626755
1 Terminated (low enrollment rate) 545 NCT01869738
1 Terminated (Challenges to recruit qualified participants) 549 NCT01711619
1 Terminated (Study terminated due to enrolment challenges and a 553 NCT01402440
1 Terminated (This clinical trial was terminated early due to slo 564 NCT00986258
1 Terminated (The study was terminated early due to poor recrui 572 NCT00578097
1 Terminated (Study early terminated due to low enrollment compa 590 NCT03968419
1 Terminated (Insufficient Enrollment) 599 NCT03519256
1 Terminated (Edwards acquired CardiAQ and opted to terminate th604 NCT02478008
1 Terminated (This study terminated enrollment due to device fail 613 NCT02461524
1 Terminated (Low recruitment of patients) 614 NCT02660138
1 Terminated (DLBCL and FL cohorts met the pre-specified futili 617 NCT02413489
1 Terminated (As recruitment rate was lower than anticipated) 628 NCT01772108
1 Terminated (Ceased production of the study drug Lymphoglobulin 642 NCT01163942
1 Terminated (Surgical practice evolution changed acceptable sta 645 NCT01083472
1 Terminated (The study was terminated prematurely on May 18 2 652 NCT00805740
1 Terminated (Failure to recruit patients with membranous lupus n 666 NCT00368264
1 Terminated (Sufficient enrollments under current protocol for 671 NCT02227121
1 Terminated (Rate of enrollment too slow to allow completion i 678 NCT04333654
1 Terminated (terminated due to low enrollment rate) 704 NCT03339401
1 Terminated (insufficient recruitment) 718 NCT02780180
1 Terminated (IDMC recommended that enrolment be stoped as the720 NCT02703272
1 Terminated (National Comprehensive Cancer Network & European722 NCT02683941
1 Terminated (In the post-market environment the RCT design di 724 NCT02637947
1 Terminated (Following recommendation by SOLAR Study IDMC 728 NCT02588261
1 Terminated (Due to lower than expected recruitment since the s 740 NCT02258464
1 Withdrawn (Withdrawn due to difficulties in to recruiting due to 749 NCT01762852
1 Terminated (The study was stopped solely based on lower than 751 NCT01693120
1 Terminated (early termination due to Sponsor decision (slow re 754 NCT01602315
1 Terminated (Slow and low enrollment) 755 NCT01528345
1 Terminated (Enrollment Difficulty) 758 NCT01483183
1 Terminated (Enrollment suspended; follow up continue) 762 NCT01110070
1 Terminated (The study was terminated early due to slow and insu 763 NCT01246635
1 Terminated (Inadequate recruitment resulting in a too low patien 764 NCT01242748
1 Terminated (Biosense stopped Study enrollment following public 766 NCT01116557
1 Terminated (Termination of study enrolment to Part C Cohort 771 NCT00979134
1 Terminated (Recruitment was fully completed for this study; h 781 NCT00476996
1 Terminated (LPLV reached on 30Jan2023. Study was closed early794 NCT03996473
1 Terminated (Due to poor patient recruitment and insufficient fin 796 NCT03070574
1 Terminated (delay in recruitment lack of additional funding) 804 NCT01616043
1 Terminated (Poor recruitment due to a change in the standard of 810 NCT03705507
1 Terminated (Failed to recruit sufficient numbers of patients in 814 NCT02441309
1 Terminated (Recruitment was terminated early before meeting tar 815 NCT03393806
1 Terminated (After extensive efforts to improve recruitment it 820 NCT05321524
1 Terminated (Phase 2 completed as planned. Due to the evolving 824 NCT04828161
1 Terminated (Unsuccessful enrollment) 852 NCT03314675
1 Terminated ((Recruitment was early terminated due to slow recr 855 NCT03236311
1 Terminated (The study was terminated early due to futility of e 857 NCT03221842
1 Terminated (Recruitment halted prematurely due to competitive 865 NCT03064854
1 Terminated (recruitement problem) 888 NCT01583114
1 Terminated (lack of recruitment) 893 NCT02509273
1 Terminated (Major challenge for enrollment of participants.) 896 NCT02468661
1 Terminated (Study terminated due to slow enrollment.) 906 NCT00542828
1 Terminated (This study was terminated early due to recruitment 947 NCT01370863
1 Terminated (The study was closed due to the slow enrollment r 953 NCT01283971
1 Terminated (Lack of Recruitment) 957 NCT01200992
1 Terminated (difficulty in the enrolment) 965 NCT01023269
1 Terminated (Slow accrual rate) 969 NCT00981799
1 Terminated (study progress and recruitment rate too low) 972 NCT00700739
1 Terminated (Low enrollment rate) 976 NCT00885677
1 Terminated (Despite considerable efforts to boost recruitment d 978 NCT00866281
1 Terminated (This protocol terminated prematurely on July 8 20 979 NCT00836875
1 Terminated (Lack of subject recruitment) 986 NCT00679484
1 Terminated (The study was closed to further enrollment due to 987 NCT00642941
1 Terminated (The study was terminated prematurely by the spon 988 NCT00640016
1 Terminated (MTD was established and patients completed 16 mon990 NCT00401401
1 Terminated (A post-PMA begun in 1998; enrollment halted in 20 991 NCT00590889
1 Terminated (This study was closed to enrollment as of 13 May 1005 NCT00372996
1 Terminated (lower than anticipated events;slow recruitment;lar 1023 NCT00118573
0 Terminated (Due to a delayed start-up and delayed patient inclus 4 NCT05268926
0 Withdrawn (Pending further development) 5 NCT05242926
0 Withdrawn (Study canceled) 6 NCT05217472
0 Terminated (Due to occurrence of eye related adverse events.) 8 NCT05156034
0 Withdrawn (Pending further development) 9 NCT05084456
0 Withdrawn (Alternative study was set up) 10 NCT05060653
0 Terminated (Lack of financial support) 11 NCT05056103
0 Terminated (The study was terminated based on new safety da 12 NCT04940949
0 Terminated (Approx. half of all samples withdrawn are readily av 14 NCT04833075
0 Withdrawn (Program terminated prior to enrolling subjects) 15 NCT04782661
0 Terminated (Too few patients) 16 NCT04746430
0 Withdrawn (Lack of inclusion / COVID-19 regulations) 18 NCT04648436
0 Terminated (Development of compound has been stopped) 19 NCT04575818
0 Withdrawn (Medigene transfered all rights to a new Sponsor) 20 NCT04464889
0 Terminated (A limited number of inclusions due to the Covid-p 21 NCT04420455
0 Terminated (Safety concerns) 22 NCT04415463
0 Terminated (We decided to stop inclusions and start analysis af 24 NCT04311047
0 Suspended (Study temporary on hold due to safety event for the 25 NCT04307992
0 Terminated (Some subjects could not complete the second cross 27 NCT04240158
0 Terminated (Due to covid-19 pandemic) 28 NCT04239482
0 Terminated (COVID-19 pandemic impacted the BE assessment of the 29 NCT04236453
0 Terminated (Not possible due to COVID-19) 30 NCT04234009
0 Terminated (Cessation of main trial of which this study was a 31 NCT04222426
0 Terminated (new safety data from another study) 32 NCT04199585
0 Terminated (Interim analysis showed positive results it was diff 35 NCT04081480
0 Terminated (Slow accrual.) 36 NCT04051853
0 Terminated (Based on available data UCB has decided to stop 37 NCT04039919
0 Terminated (no availability of IMP for this study) 38 NCT03993613
0 Terminated (Study discontinued - testing of highest dose obsol 39 NCT03979820
0 Terminated (COVID-19 pandemic.) 40 NCT03977974
0 Terminated (Continuation of the trial cannot serve a scientific 41 NCT03953456
0 Terminated (Mild infusion reactions were observed in two healt 42 NCT03879278
0 Terminated (study is merged with CONTESSA study) 45 NCT03852979
0 Terminated (COVID-19 crisis.) 46 NCT03846102
0 Terminated (Subject withdrawals after temporal suspension of the 47 NCT03813108
0 Terminated (Due to company decision.) 48 NCT03780725
0 Terminated (Interim results showed high futility to continue) 49 NCT03764644
0 Terminated (The pandemic caused a rising tide phenomenon on o 50 NCT03735940
0 Terminated (The pandemic caused a rising tide phenomenon on o 51 NCT03735927
0 Terminated (safety issues) 52 NCT03729297
0 Withdrawn (Strategic decision) 53 NCT03710044
0 Terminated (Interim analysis showed primary outcome was not 54 NCT03658200
0 Terminated (injection site reaction burden) 55 NCT03590860
0 Terminated (Dose-escalation was finished but no clear correl 56 NCT03558724
0 Withdrawn (No study drug available. Same concept with new s 57 NCT03470350
0 Terminated (The sponsor decided to stop further dosing of healt 60 NCT03399435
0 Withdrawn (No response to EC questions were given) 61 NCT03397927
0 Terminated (Lack of effect in interim analysis) 62 NCT03334240
0 Terminated (Adverse change in the risk/benefit) 63 NCT03329885
0 Terminated (Concluded study following COVID19 outbreak and i 65 NCT03310034
0 Terminated (Arthrex stopped manufacturing the device) 66 NCT03303690
0 Terminated (Negative clinical outcomes) 67 NCT03238469
0 Terminated (The Philips Minicare has been taken off the market 71 NCT03115190
0 Terminated (Reaching total sample size was not feasible within 72 NCT03111758
0 Terminated (Side effects) 73 NCT03085641
0 Terminated (Interim analysis showed no differences between g 74 NCT03051698
0 Terminated (Futility) 76 NCT03022019
0 Terminated 77 NCT03008031
0 Terminated (Slow accrual) 78 NCT02975739
0 Terminated (Mobile-bearing insert dislocation) 80 NCT02924961
0 Terminated (After an interim analysis of the data it became clea 81 NCT02922283
0 Terminated (Only 1 inclusion in 2 5 years) 82 NCT02905396
0 Withdrawn 85 NCT02844140
0 Terminated (Inclusion of patients slow) 86 NCT02836340
0 Terminated (technical difficulties) 88 NCT02808806
0 Terminated (Hydrotherapy pool has closed.) 89 NCT02757157
0 Withdrawn (Not yet submitted unclear timelines) 91 NCT02735850
0 Terminated (No effect of carnitine on lipid induced insulin resi 92 NCT02722902
0 Terminated (Due to the very low inlcusion rate and the curre 93 NCT02700763
0 Terminated ( Insufficient rates of participant accrual Effects i 95 NCT02632279
0 Withdrawn (Ethical concerns with efficacy of technique.) 97 NCT02625077
0 Withdrawn (no approval) 98 NCT02621190
0 Withdrawn (never started) 99 NCT02599857
0 Terminated (low detection of the SN in patients included so far 102 NCT02540551
0 Terminated (All Parkinson's disease patients have finished tra 105 NCT02525367
0 Terminated (Minimal to no inclusion.) 108 NCT02469506
0 Terminated (The study was terminated after the second cohort 109 NCT02432664
0 Terminated (Insufficient number of participants.) 114 NCT02329171
0 Terminated (insufficient eligable subjects and new data on BVS 116 NCT02319733
0 Withdrawn (Difficulty including patients) 119 NCT02290717
0 Withdrawn (Problems with availability of study medicine in clini 121 NCT02243059
0 Withdrawn (Lack of funding) 122 NCT02238574
0 Withdrawn (No financial agreement) 124 NCT02216669
0 Terminated (Lack of efficacy / adverse events) 125 NCT02214706
0 Terminated (inclusion was too slow) 127 NCT02185937
0 Terminated (Data from LC1033 study of same product indicated 128 NCT02183727
0 Terminated (Expectation that within the set time period insuffic 132 NCT02062372
0 Terminated (GSK has elected to terminate development principall 135 NCT02000453
0 Terminated (Problems with product performance) 136 NCT01994863
0 Terminated (Device failure) 137 NCT01982266
0 Withdrawn (No local inclusions) 142 NCT01886625
0 Terminated (Inclusion of patients was slow. Could not reach the 143 NCT01882660
0 Terminated (The study was terminated based on an included sto 144 NCT01833338
0 Terminated (Insufficient number of participants) 145 NCT01796340
0 Withdrawn (No funding) 146 NCT01783340
0 Terminated (The results were disappointing.) 148 NCT01753492
0 Terminated (guideline developed) 149 NCT01727908
0 Withdrawn (Main investigators (Pieters/van Zundert) changed in 151 NCT01691963
0 Terminated (1 Indication for further investigations (brain ultras 152 NCT01655212
0 Terminated (Terminated because of insufficient number of subj 154 NCT01638260
0 Withdrawn (No funding from the sponsor) 155 NCT01622764
0 Terminated (Manufacturer recently halted production of gadofo 156 NCT01609920
0 Terminated (The study was terminated because Cell Genesys st 160 NCT01510288
0 Terminated (New study protocol started including targeted biop 161 NCT01481441
0 Terminated (Insufficient number of participants) 162 NCT01425242
0 Withdrawn (study never started) 164 NCT01401387
0 Terminated (Proof of principle established with completed SAD 165 NCT01374503
0 Terminated (only 1 inclusion in 1.5 years due to strict exclusion 166 NCT01367405
0 Withdrawn (logistic and financial accounting reasons) 170 NCT01347528
0 Terminated (insufficient patients enrolled) 173 NCT01276834
0 Terminated (Futility and limited feasibility) 174 NCT01275976
0 Withdrawn (Because of safety issues/support concerning the mu 177 NCT01230190
0 Terminated (Accrual stopped) 178 NCT01210378
0 Terminated (Financial and organisational reasons) 180 NCT01187680
0 Terminated (Due to very specific inclusion criteria the antici 181 NCT01124227
0 Terminated (Interim analysis indicated that endpoints can not b 184 NCT01074749
0 Withdrawn (No MEC approval) 185 NCT00987818
0 Withdrawn (Difficulty in enrolling participants) 186 NCT00982241
0 Withdrawn (internal decision) 187 NCT00979771
0 Withdrawn (strategic decision) 191 NCT00908414
0 Terminated (Due to limited rate of patient inclusion) 193 NCT00866034
0 Terminated (Study was terminated after unplanned interim analy 195 NCT00857597
0 Terminated (Our RCT recently started. The RCT is similar to the f 197 NCT00841633
0 Terminated (Abnormality prevalence revealed to be much lowe 198 NCT00830401
0 Terminated (Experimental treatment not feasible due to high ra 199 NCT00827671
0 Withdrawn (Research question was integrated in other study pr 201 NCT00807521
0 Withdrawn (No EC approval obtained) 202 NCT00774059
0 Terminated (SB-656933 is no longer being developed for ulcerati 203 NCT00748410
0 Withdrawn (financial constraints) 204 NCT00705796
0 Terminated (acrual too slow) 208 NCT00684216
0 Terminated (Primary endpoint reached slow accrual leakage a 209 NCT00661570
0 Withdrawn (A paper on the same topic came out just before we 210 NCT00653679
0 Terminated (Due to poor patient accrual) 213 NCT00631267
0 Terminated (Study terminated due to toxicity) 215 NCT00531076
0 Withdrawn (Patient population not available) 219 NCT00509834
0 Terminated (Activation of a similar multicenter study for same 224 NCT00448266
0 Withdrawn (new insights have let us to expect marginal annexi 225 NCT00441714
0 Withdrawn (Strategic company decision) 226 NCT00430469
0 Terminated (Data from the C08 study and Avant study) 229 NCT00394992
0 Terminated (End of research time time-resources) 233 NCT00332670
0 Terminated (Interim analysis has shown that the objectives of 234 NCT00306332
0 Terminated (Number included has been reached) 236 NCT00298454
0 Terminated (Required number of subjects to be included could 239 NCT00282165
0 Terminated (On of the liners has been taken from the market) 242 NCT00214760
0 Terminated (Change in formulation) 243 NCT00205920
0 Suspended 244 NCT00205621
0 Withdrawn (Too few inclusions) 245 NCT00202371
0 Terminated (Analysis was frustrated by inadequate PhD's....) 250 NCT00184925
0 Terminated (problems with including patients and a large multice 253 NCT00160004
0 Terminated (no accrual achieved) 254 NCT00145665
0 Terminated (Lack of patients) 256 NCT00125801
0 Terminated (Funding stopped) 257 NCT05508893
0 Terminated (Due to the decline of COVID-19 patients on Dutch I 258 NCT04794088
0 Terminated (due to COVID-19 and lack of financial means to c 259 NCT04194983
0 Withdrawn (Due to the termination of the collaboration of ApiFi 260 NCT04003233
0 Terminated (Participants no longer receiving intervention) 261 NCT03963973
0 Withdrawn (Closed prematurely because the accrual was not a 262 NCT03850028
0 Terminated (Needle production stopped) 264 NCT02975128
0 Terminated (Investigator changed jobs) 266 NCT02823275
0 Terminated (Too limited accrual) 267 NCT02729558
0 Terminated (Difficulties with including patients) 269 NCT02110251
0 Terminated (difficulties with inclusion) 270 NCT02096133
0 Terminated (Disapointing randomization rate) 272 NCT01975272
0 Terminated (bad taste of Caphosol - early stop of intake by pat 274 NCT01809756
0 Terminated (In consequence of termination of ALTITUDE. A num 277 NCT01302899
0 Terminated (The study was terminated due to safety reasons) 280 NCT01065623
0 Terminated (Efficacy seen in the solid tumour patient populati 283 NCT00497731
0 Withdrawn (lack of data) 284 NCT00456313
0 Terminated (The Sponsor decided to terminate this study in fa 287 NCT03375606
0 Terminated (Terminated) 288 NCT03320265
0 Suspended (The decision to discontinue the study was made afte 289 NCT05510843
0 Terminated (Sponsor election) 290 NCT02002637
0 Terminated (Problems with inclusion >80% of patients included 291 NCT01823809
0 Terminated (The study was terminated under the political pres 292 NCT01319188
0 Terminated (Completion of follow-up period) 293 NCT01299727
0 Terminated (Issues with development and supply of infusion syst 296 NCT02269436
0 Terminated (Issues with development and supply of infusion syst 298 NCT01999803
0 Terminated (Not enough study subjects) 299 NCT01880307
0 Terminated (Lack of budget) 301 NCT01592656
0 Terminated (Inclusion of the study didn't go as fast as expecte 304 NCT00823472
0 Terminated (Slow accrual due to COVID-19 and lower accrual 306 NCT03984019
0 Withdrawn (project stopped by the sponsor) 307 NCT03964025
0 Terminated (Halted prematurely) 309 NCT03696836
0 Terminated (Not enough eligble patient can be found too many 310 NCT02826512
0 Terminated (Insufficient tumor-to-background ratios in the first 311 NCT02743975
0 Terminated (Primary endpoint could no longer be reached.) 313 NCT02117466
0 Terminated (interim results concluded no added value of additio 314 NCT02040909
0 Terminated (Termination due to high current screen rate fail 315 NCT01933022
0 Terminated (Interim analyses showed insufficient result. Termina 319 NCT00940979
0 Withdrawn (Unavailability of investigational product) 321 NCT00640497
0 Terminated (stopping rule) 323 NCT02575066
0 Withdrawn (Lack of patients who are eligible for inclusion 324 NCT03389061
0 Terminated (Expected futility in reaching the primary endpoint) 325 NCT02173470
0 Terminated (Insufficient participating sites and insufficient p 326 NCT05254808
0 Withdrawn (Withdrawn) 327 NCT05077085
0 Withdrawn (Withdrawal of MacroGenics (pharmaceutical comp 328 NCT05063123
0 Terminated (At interim analysis insufficient benefit was observe 329 NCT03147040
0 Terminated (Insufficient funds) 335 NCT01393028
0 Terminated (Inclusion speed too slow no longer relevant and t 336 NCT01334775
0 Suspended (in preparation for an amendment) 339 NCT00738777
0 Terminated (The study was terminated under the political pres 340 NCT01436123
0 Terminated (The NEVO™ stent will not be commercialized. Cordis341 NCT01202058
0 Terminated (Due to our experience the small number of new in 342 NCT02256124
0 Terminated (Due to change in Sanofi's development strategy 343 NCT03757351
0 Terminated (Decision to discontinue patient follow-up at 2 year 347 NCT01732341
0 Terminated (Too few participants) 349 NCT01336075
0 Terminated (Interim results of another trial showed inferior acti 352 NCT00447421
0 Terminated (No difference in protein excretion at 6&12 months. 354 NCT00130312
0 Terminated (Results interim-analysis) 357 NCT03173053
0 Terminated (Futility at the interim analysis.) 360 NCT02565147
0 Terminated (See termination reason in detailed description.) 362 NCT00936559
0 Terminated (Failure to achieve one of the primary endpoints.) 363 NCT00487552
0 Terminated (insufficient effectiveness) 365 NCT03784599
0 Terminated (81 patients included difficult inclusion and full inc 366 NCT03655821
0 Terminated (interim analysis showed incorrect use of simple ru 368 NCT02218502
0 Terminated (Superiority was no longer attainable) 369 NCT01740947
0 Terminated (during anticipated study duration trial power was n 370 NCT01145937
0 Terminated (Preliminary efficacy seen to date following treat 371 NCT03287804
0 Withdrawn (Due to the COVID-19 pandemic the financial sponsor 372 NCT04720742
0 Terminated (Antiviral activity was considered insufficient to w 373 NCT01391117
0 Terminated (Low implant success rate(46%). For the successfull 374 NCT02301429
0 Terminated (NIH decision) 376 NCT03169530
0 Terminated (Company have withdrawn the product) 377 NCT02793349
0 Terminated (Company decision to terminate the trial) 378 NCT02363946
0 Terminated (Contractual and financial issues.) 380 NCT03785067
0 Terminated (Further internal evaluation of the device was requi 382 NCT01140555
0 Terminated (Terminated due to lagging follow-up) 383 NCT00958347
0 Terminated (The study was terminated because of immunogenic 387 NCT02291614
0 Terminated (Inability to meet protocol objectives) 388 NCT00948389
0 Terminated (Protocol updates resulted in new protocol/study) 389 NCT02960139
0 Terminated (Not enough participants were included) 390 NCT02510508
0 Terminated (very slow inclusion) 391 NCT02407795
0 Terminated (The study is prematurely terminated due to a safet 393 NCT00704301
0 Withdrawn (Project No Longer in Development) 395 NCT02274896
0 Terminated (Interim analysis did not show sufficient immunoge 397 NCT02888756
0 Terminated (Sponsor decision) 398 NCT03604445
0 Terminated (vaccination uptake 80% in the target population/ 400 NCT04589949
0 Suspended (Because the COVID pandemic became less severe 402 NCT04743232
0 Terminated (new insights into COVID19 pathogenesis) 403 NCT04342182
0 Terminated (Regulatory approval was not obtained for drisaper 404 NCT02958202
0 Terminated (Insufficient inclusion of subjects) 407 NCT03616639
0 Terminated (The study was stopped because of futility of bein 408 NCT03628391
0 Withdrawn (Due to new insights) 409 NCT03532087
0 Terminated (Advised by DSMB based on interim-analysis highly 411 NCT03212352
0 Terminated (COVID-19 pandemic has changed routine diagnostic 4w12 NCT03360851
0 Terminated (accrual to slow target not achievable) 413 NCT02775006
0 Terminated (Slow accrual and changing treatment landscape) 415 NCT02414750
0 Terminated (Interim analysis showed no added value of secon 416 NCT02328664
0 Terminated (Results of interim analysis) 417 NCT02277132
0 Terminated (Unable to achieve accrural within anticipated time 418 NCT02353000
0 Terminated (not enough data collected) 419 NCT01405417
0 Terminated (Budget exceeded) 422 NCT02032654
0 Terminated (Telaprevir will not be used in NL no more inclusio 424 NCT01841502
0 Terminated (Sponsor election) 426 NCT02343705
0 Terminated (Study terminated after 240 patients because of slo 428 NCT01385774
0 Terminated (Company decision taken in light of demands by cert 429 NCT00678483
0 Terminated (Study was terminated due to Sponsor decision (all 430 NCT01986348
0 Terminated (Publication of data from a similar study made the 432 NCT01080768
0 Terminated (Due to the arrival of DAAs replacing standard of c 436 NCT00662220
0 Terminated (wothdrawal of sponsor) 438 NCT00377780
0 Terminated (Business objectives have changed) 440 NCT03281122
0 Terminated (Limited efficacy upon blinded review) 441 NCT05039359
0 Terminated ((Sponsor decision)) 442 NCT04410445
0 Withdrawn (Business objectives have changed) 444 NCT04495010
0 Terminated (The Data Monitoring Committee (DMC) concluded tha445 NCT04411472
0 Terminated (Due to lack of availability of study participants t 446 NCT01127646
0 Terminated (Based on recommendations by an external IDMC Spons 447 NCT03840902
0 Terminated (Study terminated due to business decision) 449 NCT03521934
0 Terminated (Unfavourable benefit 450 NCT03345407
0 Terminated (Company financial insolvency not due to safety or 451 NCT03190473
0 Terminated (The benefit-risk profile no longer supports continu 452 NCT03733444
0 Terminated (The study was stopped for futility based on efficac 453 NCT03071692
0 Terminated (Independent Data Monitoring Committee recomme 455 NCT03033511
0 Terminated (Change of marketing authorisation holder) 456 NCT04326764
0 Terminated (Investigational device changes) 457 NCT01539187
0 Terminated (The study was terminated based on the results of a 460 NCT02718417
0 Terminated (COVID-19 Pandemic) 461 NCT03864328
0 Terminated (Study terminated by Sponsor following a recomme 463 NCT02641392
0 Terminated (study terminated due to business decision) 464 NCT03315143
0 Terminated (Sponsor decision to discontinue the SHP647 (ontam 466 NCT03259334
0 Terminated (See Detailed Description) 467 NCT01975389
0 Terminated (See Detailed Description) 468 NCT01975376
0 Withdrawn (Due to unexpected operational issues outside of Lil 470 NCT01870284
0 Terminated (Study termination due to insufficient efficacy.) 471 NCT01687998
0 Terminated (An independent assessment concluded the trial was n472 NCT02783573
0 Terminated (Novartis decided not to pursue further developmen 475 NCT01633060
0 Terminated (The study was stopped after the first Interim Analysi 477 NCT01798485
0 Terminated (Sponsor decided to terminate the study early becau 478 NCT02450331
0 Withdrawn (Study withdrawn due to company decision) 479 NCT04661917
0 Terminated (Study redesign) 480 NCT03559387
0 Suspended (The quality of study was seriously affected by the C 482 NCT04520412
0 Terminated (due to futility) 485 NCT02195310
0 Terminated (This study was terminated due to the lack of eff 487 NCT01316939
0 Terminated (Lack of efficacy) 488 NCT01130246
0 Terminated (Terminated early in agreement with Health Authoriti 489 NCT01259297
0 Terminated (The ASCEND Study did not achieve statistical sign 491 NCT01416181
0 Terminated (Terminated 492 NCT01077154
0 Terminated (Early termination was approved due to compelling e 494 NCT01035255
0 Suspended (Data Safety Monitoring Board recommendation) 495 NCT01273779
0 Terminated (The study was terminated for reasons pertaining to 496 NCT03709706
0 Terminated (devices malfunctioned) 497 NCT03379233
0 Terminated (Study is terminated as per Sponsor's Decision.) 498 NCT01190839
0 Terminated (Due to slow inclusion of patients) 500 NCT01164046
0 Terminated (Study terminated early (date of study termination 504 NCT03376321
0 Terminated (This study was terminated due to benefit/risk analy 506 NCT03273153
0 Terminated (The study was terminated on August 6 2012 becaus 507 NCT00676143
0 Terminated (Recommendation of DMC) 508 NCT00766779
0 Terminated (Majority of patients (62%) had been treated with ne 509 NCT00748189
0 Terminated (early discontinuation based on strategic sponsor d 511 NCT00580216
0 Terminated (Lack of benefit and safety concern) 512 NCT00549757
0 Terminated (early efficacy review by the Independent Data Moni 515 NCT00626548
0 Terminated (Overall profile of the compound does not offer signi 516 NCT00532558
0 Terminated (The extension study was terminated early after the 517 NCT00731692
0 Terminated (Results of step1 518 NCT01189253
0 Terminated (Study did not meet the predefined primary surrogat 520 NCT02704403
0 Terminated (Study was terminated for business reasons; not due 523 NCT02574637
0 Terminated (Change in benefit-risk profile for individuals with 524 NCT02569398
0 Terminated (See termination reason in detailed description) 525 NCT00348712
0 Terminated (sufficient POC to switch development from bovin 526 NCT00511186
0 Terminated (Based on preliminary parent study results) 528 NCT00490568
0 Terminated (The development program has been terminated) 529 NCT00252876
0 Terminated (See detailed description for reason.) 530 NCT00239681
0 Terminated (The development program has been terminated) 532 NCT00214591
0 Terminated (FDA has placed the trial on full clinical hold.) 535 NCT00879970
0 Terminated (Melagatran/ximelagatran was withdrawn from the ma536 NCT00206089
0 Withdrawn (Due to preliminary efficacy results from an influenza 541 NCT01992276
0 Terminated (Interim analysis-DSMB stated good safety profile bu 544 NCT01870609
0 Terminated (The study was terminated following assessment of 548 NCT00480025
0 Terminated (Amgen Administrative Decision - termination of L 552 NCT01493505
0 Terminated (See Termination Reason in Detailed Description) 554 NCT00254904
0 Terminated (Inclusion-rate does not seem feasible anymore to ob 555 NCT00449813
0 Terminated (Sponsor decision to prematurely stop the study not 556 NCT01252355
0 Terminated (Planned independent DMC Interim review 557 NCT01231347
0 Terminated (Animal Safety Data) 558 NCT00335660
0 Terminated (The result of a pre-planned interim futility analysis 565 NCT00893867
0 Terminated (The primary endpoint at 15 months was not met.) 570 NCT00723411
0 Terminated (Protocol was cancelled by company based on overa 573 NCT00488774
0 Terminated (The study was discontinued due to unfavorable int 574 NCT00484536
0 Terminated (imbalance of gastrointestinal and the lipase event 576 NCT00396955
0 Terminated (The sponsor decided to terminate the study.) 577 NCT04955990
0 Terminated (The study met the protocol defined stopping bound 578 NCT04934670
0 Terminated (Strategic considerations) 579 NCT04853368
0 Terminated (Business decision) 580 NCT04848220
0 Terminated (The study was early terminated due to lack of effi 582 NCT04578548
0 Terminated (High-level results from the MESSINA Phase III tria 583 NCT04543409
0 Terminated (See Termination Reason in Detailed Description) 584 NCT00254891
0 Terminated (The study was terminated based on the review by 585 NCT04478266
0 Terminated (Study was terminated due to a strategic decision 587 NCT04210843
0 Terminated (The sponsor has decided to close the study due to 588 NCT04197986
0 Terminated (Sponsor decision to terminate due to the lack of 589 NCT04139317
0 Terminated (This study was terminated due to a lack of efficacy 591 NCT00090532
0 Terminated (A decision was made to stop the study early when 592 NCT03756285
0 Terminated (Administrative reasons) 593 NCT03710291
0 Terminated (The study was early terminated due to the lack of 594 NCT03626545
0 Terminated (desired primary endpoint was not met) 595 NCT03577899
0 Terminated (Study was stopped because of safety concerns.) 596 NCT03573505
0 Terminated (Interim analysis for futility of the Stage 1 of th 598 NCT03523728
0 Withdrawn (sponsor decision) 600 NCT03502694
0 Terminated (Sponsor's decision) 601 NCT03469050
0 Terminated (Sponsor terminated open-label extension) 602 NCT03398837
0 Terminated (Based on interim Analysis outcome being futile fo 603 NCT03381196
0 Terminated (Due to a change in the development program the 606 NCT03240523
0 Terminated (Occurrence of objective responses in multiple indi 607 NCT03192345
0 Terminated (The study was terminated after the episodic cluster 608 NCT03107052
0 Terminated (The study got discontinued due to lack of efficacy) 609 NCT02994953
0 Terminated (Futility analysis revealed that the primary endpoin 610 NCT02964338
0 Terminated (Study was terminated as a result of a pre-specified f 611 NCT02945046
0 Terminated (Strategic Business Decision) 612 NCT02712905
0 Terminated (Imbalance in the efficacy and safety endpoints be 615 NCT02556203
0 Terminated (GSK decision to return rights to sirukumab to Jans 616 NCT02531633
0 Terminated (Lack of efficacy in combination.) 618 NCT02393209
0 Terminated (Sponsor discontinued development of CO-1686 f 619 NCT02322281
0 Terminated (The safety committee found no safety issues but rec 623 NCT02119663
0 Terminated (Study has been suspended due to clinical hold.) 625 NCT01969136
0 Terminated (The study was terminated due to futility.) 627 NCT01905592
0 Terminated (The study crossed the prospective futility boundar 629 NCT01767857
0 Terminated (The Initial Phase 3 Study (NCTO1281189) did not m 630 NCT01622088
0 Terminated (Evidence of very low probability to success. No sa 631 NCT01538251
0 Terminated (5 years follow up completed in October 2018 long- 635 NCT01368666
0 Terminated (Futility of Primary Efficacy Endpoint) 637 NCT01303718
0 Withdrawn (Study canceled based on results of different study w 638 NCT01266811
0 Terminated (Sponsor decision due to the protocol-defined stopp 639 NCT01244191
0 Terminated (Clinical development program terminated due to fai 640 NCT01209689
0 Terminated (based on IDMC decision) 641 NCT01208064
0 Terminated (The study was terminated early based on an imbal 643 NCT01150890
0 Terminated (Study was terminated as per sponsor's decision) 644 NCT01126749
0 Terminated (More possibly treatment-related deaths on tasisu 647 NCT01006252
0 Terminated (EMD Serono voluntarily decided to terminate this t 649 NCT00853762
0 Terminated (Criterion according study protocol to end study pre 650 NCT00811382
0 Terminated (study did not meet pre-specified criteria for continua 653 NCT00738699
0 Terminated (Sponsor voluntarily decided to terminate trial due 655 NCT00642902
0 Terminated (Study was terminated for futility following the plan 656 NCT00625833
0 Terminated (Ofatumumab IV trials in RA were prematurely ter 659 NCT00603525
0 Terminated (Sponsor Decision) 663 NCT00406653
0 Terminated (Myriad has discontinued the development of Fluriz 667 NCT00322036
0 Terminated (Accrual and treatment with CG1940/CG8711 sto 670 NCT00133224
0 Terminated (Independent Data Monitoring Committee recommenda 672 NCT03174522
0 Terminated (Study has been prematurely terminated as the Interim674 NCT04988308
0 Terminated (A lack of efficacy was seen with RO7049665 in a stud676 NCT04790916
0 Terminated (general circumstances around COVID-19 and current677 NCT04776044
0 Terminated (Discontinuation of zandelisib program) 679 NCT04745832
0 Terminated (The study was terminated by Sponsor as the futilit 680 NCT04594707
0 Terminated (Study terminated for meeting protocol specified futil 682 NCT04145700
0 Terminated (A safety signal has emerged in Phase 2 studies o 684 NCT04096560
0 Terminated (Sponsor's Decision) 685 NCT03993379
0 Terminated (Core terminated due to lack of efficacy) 686 NCT03948334
0 Terminated (The decision was made to discontinue the 547674 688 NCT03871829
0 Terminated (Study was terminated based on Sponsor decision. 689 NCT03866577
0 Terminated (Study terminated due to insufficient evidence to su 690 NCT03843125
0 Terminated (Due to lower antitumor activity than expected) 691 NCT03834220
0 Terminated (Livoletide did not result in a statistically signifi 692 NCT03790865
0 Terminated (Study was stopped after interim analysis for all 4 coh 693 NCT03769181
0 Terminated (BeiGene and Celgene Corporation terminated the pa 694 NCT03745222
0 Terminated (The study did not demonstrate efficacy on the pri 695 NCT03689244
0 Terminated (Study terminated due to insufficient evidence to su 697 NCT03616912
0 Terminated (strategic reasons (not due to lack of efficacy or sa 698 NCT03138083
0 Terminated (The reason for terminating study early was inconclu 699 NCT03459443
0 Terminated (Lack of Efficacy) 700 NCT03445533
0 Terminated (The study was terminated because clinical develop 702 NCT03419403
0 Terminated (Study BAY1128688/17472 (AKRENDO 1) was termina 703 NCT03373422
0 Terminated (Sponsor decision to close study early; not due to 705 NCT03339336
0 Terminated (Study discontinued considering the limited clinica 706 NCT02984683
0 Terminated (As per sponsor) 707 NCT03294200
0 Terminated (Study was terminated during Open Label Extension p708 NCT03289143
0 Terminated (Post Market Study terminated early due to the lau 709 NCT03187522
0 Terminated (The study was terminated due to safety issues.) 710 NCT03131453
0 Terminated (Company Decision) 711 NCT03052517
0 Withdrawn (Sponsor decision not to start trial) 712 NCT02974322
0 Terminated (sponsor decision) 713 NCT02935673
0 Terminated (Intepirdine did not meet its primary efficacy endpo 714 NCT02928445
0 Terminated (The results of a third interim analysis (ad hoc) indica 715 NCT02007252
0 Terminated (Interim analysis concluded to futility) 716 NCT02814019
0 Terminated (Exceed of pre-specified number of failures in the 717 NCT02808247
0 Terminated (Company decision) 719 NCT02703571
0 Terminated (Business reasons) 725 NCT02608268
0 Terminated (Trial was cancelled due to availability of clinical su 727 NCT02593851
0 Terminated (Following a pre-scheduled interim analysis performe 729 NCT02547220
0 Terminated (The study was stopped for futility based on efficac 730 NCT02545283
0 Terminated (Amgen prioritization decision) 731 NCT02520427
0 Terminated (Study was discontinued based on futility analysis 732 NCT02484547
0 Terminated (Cystic Fibrosis (CF) data from the double-blind 733 NCT02456103
0 Terminated (At 75% patient completion overall mortality was mu 734 NCT02392689
0 Terminated (Study terminated for business reasons not related 735 NCT02341625
0 Terminated (The Sponsor discontinued the manufacturing and deve 736 NCT02340221
0 Terminated (This study was terminated due to the efficacy re 737 NCT02336425
0 Terminated (The VITAL study was terminated due to futility ana 738 NCT02312206
0 Terminated (The required number of endpoints will be obtained w 739 NCT02275260
0 Terminated (There was an unexpected toxicology finding obse 742 NCT02240355
0 Terminated (Sponsor discontinued development of CO-1686 f 744 NCT02147990
0 Terminated (The study is being terminated for lack of efficacy) 748 NCT01865084
0 Terminated (focus resources in the allogeneic platform and prov 750 NCT01756326
0 Terminated (An interim analysis was conducted in May-2014. Up 752 NCT01646125
0 Terminated (This trial was terminated based on an interim ana 753 NCT01628913
0 Terminated (The study was stopped after the interim analysis b 756 NCT01513317
0 Terminated (The study was formally terminated given that GSK 759 NCT01480245
0 Terminated (company decision) 760 NCT01474122
0 Terminated (Preliminary data from study NCT00994214 do not 767 NCT01018953
0 Terminated (Sponsor terminated RRMS studies as sufficient long 769 NCT00988052
0 Terminated (Logistic reasons associated with the FDA-imposed c 772 NCT00964990
0 Terminated (Failure to meet primary objective) 773 NCT00911027
0 Terminated (The study was terminated early because of a relate 775 NCT00845832
0 Terminated (The study was terminated early following assessmen 776 NCT00796445
0 Suspended (Company ended operations January 2011) 778 NCT00787293
0 Terminated (A 300 patient safety analysis by the Data Monitor 779 NCT00742482
0 Terminated (This study was terminated at the recommendation 782 NCT00430716
0 Terminated (The Data Monitoring Committee terminated the study784 o NCT00334685
0 Terminated (Based on the results of the interim analysis it was 786 NCT00300885
0 Terminated (DMC recommendation no efficacy) 787 NCT00279422
0 Terminated (Based on futility analysis showing <30% chance o 790 NCT00089856
0 Terminated (The combination part of the study was terminated 797 NCT02601378
0 Terminated (We have discontinued development of FPA008 in 798 NCT01962337
0 Terminated (Terminated as the active treatment was associate 801 NCT00696631
0 Terminated (1st two cohorts provided the required data there 802 NCT03292653
0 Terminated (Due to a challenging protocol inclusion/ exclusion c 805 NCT01308346
0 Terminated (Company decision taken in light of demands by cert 806 NCT00228176
0 Withdrawn (Nellix stent cannot be placed in patients yet.) 809 NCT03763812
0 Terminated (After the investigators and experts in the field impu 812 NCT01378390
0 Terminated (Data don't support further development) 813 NCT04568174
0 Terminated (The results of the interim analysis showed that the e 816 NCT02982694
0 Suspended (Roche announced a decision to discontinue most of 817 NCT05552157
0 Suspended (for safety analysis) 818 NCT04958239
0 Terminated (The DMC recommended the trial be discontinued due819 NCT05442775
0 Withdrawn (Akari has decided to discontinue AK802 study due to 821 NCT05061771
0 Terminated (Terminated by sponsor) 822 NCT05024058
0 Terminated (The DMC recommended the trial be discontinued due823 NCT04944784
0 Terminated (Business priorities) 825 NCT04167618
0 Terminated (LTS15823 (long-term extension of the EFC15392 stu826 NCT04705051
0 Terminated (Based on tolerability findings at the low dose level 827 NCT04033159
0 Terminated (A recently conducted Interim analysis of IMR-SCD-3 828 NCT04474314
0 Terminated (IMR-BTL-201demonstrated that while IMR-687 was ge 829 NCT04411082
0 Terminated (Decision to terminate development of Gantenerumab831 NCT04374253
0 Terminated (BI's decision to terminate the development of speso 832 NCT04362254
0 Terminated (Study was terminated early due to low blinded event 834 NCT04308395
0 Terminated (There was no evidence of benefit across efficacy e 835 NCT04288856
0 Terminated (The IDMC recommended the study be discontinued d836 NCT04248465
0 Terminated (A strategic decision was made to discontinue the 838 NCT04056611
0 Terminated (The study was terminated based on the primary effic 839 NCT04025632
0 Terminated (Due to agreement to transfer rights for IPN01087 t 840 NCT03525392
0 Terminated (This was an open label extension for patients c 841 NCT03948178
0 Terminated (The trial was stopped based on the assessment of c 842 NCT03893565
0 Terminated (Study was prematurely stopped due to sponsor decis843 NCT03860844
0 Terminated (Arimoclomal did not meet it's primary and secondary 844 NCT03836716
0 Terminated (Study was terminated by sponsor due to increased in845 NCT03810313
0 Terminated (This was a sponsor decision and was not a conse 846 NCT03742349
0 Terminated (The 6-month efficacy analysis did not show any si 847 NCT03715166
0 Terminated (Study was stopped after interim analysis for 4 coh 848 NCT03637764
0 Terminated (Trial was terminated early to analyze the accumula 850 NCT03442985
0 Terminated (The Sponsor terminated the study due to futility. 851 NCT03439514
0 Terminated (The study terminated early due to business reasons 853 NCT03281304
0 Terminated (Terminated (Decision by the Sponsor. The study w 854 NCT03276728
0 Terminated (The top-line results from the Part 1 did not meet 856 NCT03222973
0 Terminated (Study was terminated early by sponsor due to th 858 NCT03219164
0 Terminated (Sponsor's decision) 860 NCT03172936
0 Suspended (The Sponsor has been notified of an interruption in 861 NCT03165292
0 Terminated (program has been put on hold by the sponsor) 863 NCT03123055
0 Terminated (The company determined that continued exposure of 864 NCT03068130
0 Terminated (This study was terminated early due to lack of effi 866 NCT03053050
0 Terminated (Insufficient efficacy terminated by Sponsor) 867 NCT02999854
0 Terminated (the results of the interim analysis are clear with a 868 NCT01887522
0 Terminated (Takeda has determined that the benefit/risk profile 870 NCT02895945
0 Terminated (Data Monitoring Committee discontinued the trial d 871 NCT02895100
0 Terminated (The study was terminated at the time of interim a 873 NCT02480010
0 Terminated (The trial was terminated for scientific reasons.) 874 NCT01801358
0 Terminated (Lack of efficacy of test drug) 876 NCT02764229
0 Terminated (Company no longer operational) 877 NCT02749071
0 Terminated (Trial stopped for futility) 879 NCT02725372
0 Terminated (Completion of follow-up period) 881 NCT02350816
0 Terminated (The overall benefit risk profile of ocrelizumab was 882 NCT02720120
0 Terminated (The Sponsor voluntarily recalled SD-101 and termin 883 NCT02670330
0 Terminated (Exposure of these high-risk patients to clinic or i 884 NCT02657356
0 Terminated (Based on available data UCB has decided to stop d 885 NCT02625090
0 Terminated (following a recommendation from the data safety a 886 NCT02618577
0 Terminated (Study terminated by Sponsor as a result of a busi 887 NCT02616146
0 Terminated (Sponsor decision to terminate because limited inve 890 NCT02541604
0 Terminated (Study terminated early at a time point when suffic 891 NCT02527343
0 Terminated (Terminated due to futility) 894 NCT02508649
0 Terminated (This study served its purpose in providing conside 895 NCT02494778
0 Terminated (Sponsor's discretion to terminate study prematurely 899 NCT02351063
0 Terminated (This study has been terminated for administrative 902 NCT02245568
0 Terminated (The study was terminated at median 46-48 months l 903 NCT01897714
0 Terminated (The study was terminated prior to a planned interim 904 NCT02227108
0 Terminated (RCT/Roll-in completed. CAS/21mm/Nested Registry t905 NCT02202434
0 Terminated (Study was terminated after completion of Part 1 b 908 NCT02170025
0 Terminated (AZ decision to discontinue fostamatinib developmen 910 NCT02092961
0 Terminated (FDA approval of supplementation to IDE/protocol 911 NCT02059057
0 Terminated (Study has been suspended due to clinical hold.) 912 NCT02004392
0 Terminated (Substance discontinued) 913 NCT01955733
0 Terminated (Sponsor is bankrupt) 914 NCT01950871
0 Withdrawn (Sangart ceased operations) 915 NCT01925001
0 Terminated (EMA/PDCO acknowledged that available results from920 NCT01853228
0 Terminated (The Sponsor decided to halt the development of G 921 NCT01823835
0 Terminated (study team decision because of IP supply issue 922 NCT01809340
0 Terminated (Study was withdrawn due to scientific and busines 923 NCT01777776
0 Terminated (Unable to reach sample size to satisfy the primary 924 NCT01475175
0 Terminated (Due to slow accrual) 925 NCT00298324
0 Terminated (substance discontinued) 926 NCT01682512
0 Terminated (Study terminated based on evaluation of safety da 927 NCT01650805
0 Terminated (FDA approval of supplementation to IDE to termina 929 NCT01608490
0 Terminated (Business reasons) 930 NCT01606566
0 Terminated (Interim analysis suggested that size of benefit ant 931 NCT01589237
0 Terminated (Study terminated due to abnormal liver biochemical 932 NCT01561430
0 Terminated (Company closed) 933 NCT01286116
0 Terminated (due to sponsor decision) 935 NCT01545050
0 Terminated (For futility reasons and potential "loss of chance 937 NCT01532453
0 Terminated (Low or poor accrual) 938 NCT01508000
0 Terminated (Amgen decided to terminate the study early to be a 941 NCT01439867
0 Terminated (The study treatment failed to demonstrate effica 942 NCT01433354
0 Terminated (Did not achieve statistical significance for primary 943 NCT01399593
0 Terminated (It became unlikely to achieve the study objective 944 NCT01376700
0 Terminated (Company Decision) 945 NCT01376310
0 Terminated (The study was stopped for not meeting the primar 946 NCT01374451
0 Terminated (Lack of new studies contributing subjects to this s 948 NCT01369433
0 Terminated (Trial terminated strategically due to poor accrual.) 951 NCT01316263
0 Terminated (AZ decision to discontinue fostamatinib developmen 954 NCT01264770
0 Terminated (Trial has failed to meet primary - and major seco 955 NCT01230827
0 Terminated (The study was terminated early based on an imbal 958 NCT01199302
0 Terminated (The study was stopped because of safety concern 960 NCT01151137
0 Terminated (Lack of benefit on efficacy) 961 NCT01118728
0 Terminated (Novartis discontinued the development of imatinib 962 NCT01117987
0 Terminated (No difference in outcome between the two groups 963 NCT01092312
0 Terminated (Interim analysis showed statistically significant res 964 NCT00822159
0 Terminated (Lack of accrual lack of continued funding.) 966 NCT01013623
0 Terminated (Preliminary data from this study does not support 967 NCT00994214
0 Terminated (Based on lack of efficacy in PAI2003 sponsor made 970 NCT00973024
0 Terminated (Due to a single unexpected serious event the trial 973 NCT00941707
0 Terminated (Lack of efficacy data from the Phase 3 clinical 974 NCT00940095
0 Terminated (recommendation by Data Monitoring Committee) 975 NCT00886769
0 Terminated (Negative efficacy results of the MAESTRO-01 trial 977 NCT00870155
0 Terminated (This trial was prematurely terminated on Dec 9 201 980 NCT00811018
0 Terminated (it is unethical to continue a study with deactivati 981 NCT00776087
0 Terminated (AVE5530 in hypercholesterolemia was stopped due t983 NCT00766688
0 Terminated (AVE5530 in hypercholesterolemia was stopped due t984 NCT00729027
0 Terminated (The study was terminated on 21 June 2010 due to r 989 NCT00634933
0 Terminated (Futility on primary endpoint.Study confounded by st 992 NCT00562016
0 Terminated (Lack of efficacy with respect to skin-related lesion 994 NCT00534313
0 Terminated (Data required further pilot work to be undertaken.) 996 NCT00496067
0 Terminated (Due to considerations regarding the appropriate th 997 NCT00460551
0 Terminated (This study was stopped by the sponsor based on a 998 NCT00452478
0 Terminated (Study was terminated based on the results of ana 999 NCT00433017
0 Terminated (Company decision has been taken in light of recen 1000 NCT00412698
0 Terminated (EMEA recommendation to suspend Acomplia marke1002 NCT00405808
0 Terminated (Nephrotoxicity) 1003 NCT00401947
0 Terminated (Study was terminated based on the interim results of1006 NCT00366080
0 Terminated (NINDS/NIH-DSMB recommended halting trial due to1008 NCT00359424
0 Terminated (Preliminary data showed no survival benefit in t 1009 NCT00358566
0 Terminated (Accrual goal for interventional part not achievable 1011 NCT00107081
0 Terminated (company decision based on other studies) 1016 NCT00279435
0 Terminated (Company decision taken in light of demands by cert1017 NCT00263042
0 Terminated (Sponsor's decision not to pursue development of uP1022 NCT00123266
0 Terminated (poor accrual) 1027 NCT00056056
0
Lack Of RecruRecruitment Status Rank NCT Number
Effect of Citalopram on Terminated Functional Chest Pain Drug: Citalop
Electrophysiology of th Terminated Pituitary Adenoma|Pituitary Tumor|Diabetes InsiProcedure: Mi
Window of Trainability i Withdrawn Stroke Other: Gait ada
The Effect of Virtual R Terminated Blunt Chest Trauma Device: Virtual
Plant Stanol Esters an Terminated Overweight and Obesity Dietary Supple
Social Health Games: TTerminated Loneliness Other: SamenS
Chloroquine, HydroxychTerminated COVID-19 Drug: Chloroqu
A Study in Healthy MenTerminated Healthy Volunteers Drug: Part 1:
Ovarian Cancer TreatmTerminated Ovarian Cancer Drug: W_ova1
TIME ASPIRIN: Chronoth Terminated Cardiovascular Diseases Other: placebo
Comparison of Oxygen T Cerminated Premature Infant|Respiratory Insufficiency|HypoDevice: Automa
MRI-guided Single DoseWithdrawn Breast Cancer Radiation: MR-
Resistance STEMI StudTerminated STEMI|Acute Myocardial Infarction Diagnostic Tes
BOOSTH: Serious Gaming Terminated Physical Activity|Serious Game|Childhood ObesiDevice: Boost
Endoveneous HistologicWithdrawn Varicose Veins Procedure: Cla
The Use of a Point-of-c Terminated Dyspnea|Coma|Hypotension and Shock Diagnostic Tes
Does Automated Closed- Terminated ARDS Device: INTELL
Cytoreductive Surgery aTerminated Gastric Cancer|Peritoneal Carcinomatosis|HIPEDrug: Perioper
Stent Versus ConservatTerminated Deep-Venous Thrombosis|Deep Venous Stenting| Device: deep v
Preoperative Breast IrraTerminated Breast Cancer Radiation: pre-
Renal Nerve StimulationTerminated Arrhythmias, Cardiac Procedure: R
Respiratory EMG for NIV Terminated Chronic Obstructive Pulmonary Disease (COPDOther: Respir
Tumor Hypoxia With HXTerminated Prostatic Neoplasms|Esophageal Neoplasms|Neo Drug: Injection
Fractional Laser Assist Terminated Cicatrix Device: AFXL|
Spinal Cord StimulationTerminated
t Atrial Fibrillation Device: Spina
Deep Brain Stimulation Terminated Tardive Dyskinesia|Tardive Dystonia Device: GPi DB
Clinical Outcomes of t Terminated Chronic Low Back Pain|Pain in Leg, UnspecifiedDevice: Freed
The Effect of the Multis Suspended Ulcerative Colitis Dietary Supple
A Multi-Centre RCT of tTerminated Chronic Inguinal Pain Refractory to Previous SuDevice: Implan
Effect of Exercise and Terminated Overfeeding and Exercise Other: overfeed
Stellate Ganglion Block Withdrawn Prostate Cancer Procedure: Ste
PET CT With HX4 in CeTerminated Cervix Cancer Other: injecti
Pre-operative TreatmentTerminated Heart; Dysfunction Postoperative, Cardiac SurgeDrug: Erythrop
The Effects of Fish Oil Terminated Intermittent Claudication Drug: Omega-3
Bioavailability of Vorico Withdrawn Voriconazole|Bioavailability|Critically Ill Other: Dosage
The Laparoscopic Append Terminated Appendicitis Procedure: LA
Edwards SAPIEN-3 Perip Terminated Periprosthetic Aortic Valve Regurgitation After Procedure: Tra
Motor Imagery in Rehabil Terminated Distal Radius Fracture Behavioral: Mo
Aldosterone AntagonismTerminated Abdominal Obesity Metabolic Syndrome|Insulin Drug: Eplereno
An Exploratory Study t Terminated Healthy Subjects|Overactive Bladder Procedure: Hi
The Tilburg VasospasmTerminated Brain Ischemia|Intracranial Vasospasm Procedure: ext
Concomitant Epicardial Terminated
P Atrial Fibrillation Device: Epicar
Pharmacokinetics and Sa Terminated Tuberculosis Drug: Moxiflox
Video-Assisted Thoracosc Terminated Atrial Fibrillation Procedure: PV
Radio-chemotherapy Wit Terminated Irresectable Squamous Cell or AdenocarcinomaDrug: CRT + P
Endocardial Pacing in Withdrawn Heart Failure Procedure: tem
Remote Ischemic Conditi Terminated Atrial Fibrillation Procedure: Re
Better Acceptance of SiTerminated Diabetes Mellitus, Type 2 Drug: Insulin g
Effectiveness of Inhale Terminated Wheezing|Dyspnea Drug: Beclome
Sunitinib Malate in Tre Terminated Lung Cancer Drug: sunitini
The Effect of Sevoflura Terminated Hypotension Drug: Sevoflur
A Study of the Effects oTerminated In Vitro Fertilization Drug: Ovarian
Heme Oxygenase (HO)Terminated
Ac Atherosclerotic Cardiovascular Disease Drug: L-argini
Anti-inflammatory EffecWithdrawn Chronic Obstructive Pulmonary Disease Dietary Supple
Surgical or Catheter AblaTerminated Atrial Fibrillation Procedure: Cat
Trial of Either Surgery Terminated Lung Cancer Radiation: ste
Pilot Evaluation of Ato Terminated Attention Deficit Hyperactivity Disorder|Cannab Drug: Atomoxe
N-AcetylCysteine vs. P Terminated Carcinoma, Non-Small-Cell Lung|Carcinoma, Sm Drug: N-Acetyl
Methylphenidate, RivastTerminated Delirium Drug: Haloperi
A Study on the TolerabilWithdrawn Staphylococcal Infections|Bacteremia Drug: human la
Myfortic Versus Azathi Terminated Systemic Lupus Erythematosus Drug: switch to
Diagnostic Outcome Tria Terminated Heart Failure Device: Progr
Rosiglitazone and InsulTerminated Chronic Kidney Disease|Insulin Resistance Drug: rosiglita
A Pharmacokinetic and Terminated Rheumatoid Arthritis Drug: rituxima
Pulmonary Rehabilitati Terminated Chronic Obstructive Pulmonary Disease Other: early pu
Rosuvastatin for HepatitWithdrawn Hepatitis C Drug: rosuvast
Efficacy of Quetiapine i Terminated Social Anxiety Disorder Drug: quetiapi
Implementation of an E Terminated COPD Behavioral: Im
The Study to Compare tTerminated Arterial Occlusive Diseases Device: stent|
Seasonal Allergic RhinitiTerminated Seasonal Allergic Rhinitis Other: 1 week
Can Tadalafil Maintain Terminated Prostate Cancer|Erectile Dysfunction Drug: tadalafil
Sequential HIV TherapyTerminated HIV Infections Drug: Standard
Sound Therapy for TinniTerminated Tinnitus, Hearing Loss, Cochlear Implant Users Device: CART
REMission INDuction inTerminated Arthritis, Rheumatoid Other: Taper
Varenicline Treatment fTerminated Parkinson's Disease Drug: Varenicli
Concentrated Citrate LoTerminated Hematological Malignancies|Bacteremia|ThrombProcedure: hep
Induced Hypertension f Terminated Cerebral Ischemia|Subarachnoid Hemorrhage Other: Induced
Study of Everolimus in Withdrawn Peutz-Jeghers Syndrome|Neoplastic ProcessesDrug: Everoli
Anti-Inflammatory EffecWithdrawn Chronic Kidney Disease|Inflammation Drug: rosiglita
Study to Compare Gabap Terminated Chronic Pain Drug: gabapent
Effect of Linagliptin on Terminated Diabetes Mellitus Type 2 (T2DM)|Vascular Infl Drug: Linaglip
EPLERAF-Study: Eplereno Terminated Atrial Fibrillation Drug: Epleren
Formoterol-beclomethaso Terminated Bronchiectasis Drug: Formote
Imatinib as Pre-operati Terminated Colonic Neoplasms Drug: Imatinib
Evaluation of the Effec Terminated Prostate Cancer Other: Psychol
Investigate the Maximu Terminated Non-small Cell Lung Cancer (NSCLC) Drug: ZD6474
Trial to Reduce Falls In Terminated Accidental Falls Behavioral: Fa
Controlling And Loweri Terminated Hypertension Device: Mobiu
Nivo/Ipi Combination T Terminated Melanoma|Brain Metastasis Drug: Nivolum
Cholinesterase Inhibito Terminated Parkinson's Disease Drug: Rivastig
The Dutch Asymptomatic Terminated Heart; Disease, Mitral(Valve)|Diseases of Mitral Other: Watchful
Pharmacokinetics of At Terminated HIV-1 Infection Drug: Atazanav
Adjuvant Zoledronic AciTerminated Giant Cell Tumor of Bone|Osteoclastoma Drug: Zoledron
The Study Will EvaluateTerminated Diabetes Mellitus, Type 2|Kidney Function TestsDrug: Dapaglif
Prednisolone Addition f Terminated Schizophrenia|Schizoaffective Disorder|SchizopDrug: Predniso
European eCLIPS™ Safet Terminated Saccular Aneurysm|Intracranial Aneurysm Device: Implan
Establish Implant Accu Terminated Knee Osteoarthritis|Post-traumatic Osteoarthriti Device: X-PSI
Effects of Amlodipine a Terminated Cerebral Small Vessel Diseases Drug: Amlodipi
Pulmonary Vein Ablation Terminated Atrial Fibrillation Procedure: PVI
A Study to Investigate t Withdrawn Colitis, Ulcerative Drug: GSK1605
Nilotinib Plus Pegylate Terminated Chronic Myeloid Leukemia Drug: Nilotinib
Valsartan for Preventio Terminated Acute Respiratory Distress Syndrome|SARS-C Drug: Valsarta
Effects of Self-administ Terminated Medication Safety|Patient Safety|Patient Empo Behavioral: Se
Comparing Two Palliati Terminated Head and Neck Neoplasms Radiation: 6 x
Omitting Completion AxiTerminated Breast Neoplasms Procedure: Com
Management of Angiotens Suspended Surgery|Angiotensin Hypertension|PerioperativeDrug: Perioper
Systemic Therapy With Terminated
o Metastatic Breast Cancer Procedure: upf
A Trial Using CD133 Enr Terminated Acute Myocardial Infarction Other: CD133+
Efficacy of Hyperbaric Terminated Osteoradionecrosis Drug: hyperbar
Mobile Phones in Cryptog Terminated Atrial Fibrillation|Ischemic Stroke|Transient Isc Device: Single
Study to Assess the NoTerminated Prostate Cancer Drug: Triptore
Trial in Low Grade Glio Terminated Low-grade Glioma|Temozolomide|Phase III|WaitDrug: Temozol
Evaluation of the Effic Terminated Polymyalgia Rheumatica Drug: Sarilum
Fibroid Ablation Study Terminated Leiomyoma|Uterine Fibroids|Menorrhagia Device: VizAb
Phase 2a Study of IW-9Terminated Dyspepsia|Functional Gastrointestinal DisordersDrug: IW-9179
International Study to Terminated Heart Failure Drug: Iobenguan
Phase 4 Study of Obetich Terminated Liver Cirrhosis, Biliary Drug: Obeticho
MOre REsponse on Cardi Terminated Heart Failure Device: MPP
Evaluation of Efficacy Terminated Giant Cell Arteritis Drug: Sarilum
EFfect of Ferric CarboxTerminated Chronic Heart Failure|Iron Deficiency|Iron Def Drug: Ferinjec
A Dose Finding Study toTerminated Diabetes Mellitus and Heart Failure Drug: LIK066|D
Fenofibrate and Metfor Terminated Dyslipidemia|Glucose Metabolism Disorder Drug: fenofibr
Trial of Nebulized HepaTerminated Inhalation Injury|Burn Injury Drug: unfracti
Prevention of Phantom T Lerminated Phantom Limb Pain|Chronic Pain|Prevention Procedure: Sci
MGuard™ Prime Stent Sys Terminated ST Elevation Myocardial Infarction Device: MGuar
Study Comparing Best Me Terminated Epilepsy|Partial Epilepsy Device: Vagal
SubQStim: A Post-marke Terminated Failed Back Surgery Syndrome Device: subcu
Study of AEB071 (a ProtTerminated Diffuse Large B-Cell Lymphoma Drug: AEB071
Evaluation of Effective Terminated Pain|Chronic Pain|Low Back Pain|Neuropathic PDrug: Tapenta
Efficacy and Safety StuTerminated Overactive Bladder Biological: Bo
This Study Will Evalua Terminated Non-small Cell Lung Cancer Drug: Canakin
A Study of Nivolumab oTerminated Urinary Bladder Neoplasms Biological: Ni
A Clinical Study of th Terminated Mitral Insufficiency|Heart Valve Disease|Cardio Device: Cardi
Endurant Evo Internation Terminated Abdominal Aortic Aneurysm|AAA Device: Endur
Dysport® Treatment of U Terminated Urinary Incontinence|Overactive Bladder Biological: Bo
An Efficacy and Safety Terminated Lymphoma, Mantle-Cell|Lymphoma, Large B-Cell, Drug: Daratu
A Randomized Study ofTerminated
th Cardiovascular Diseases Device: MitraC
Randomized Study In Se Terminated Aplastic Anaemia Drug: G-CSF|Dr
Repair of Challenging ATerminated Hernia|Surgical Wound Dehiscence Device: Stratt
An Evaluation Of The ETerminated Candidiasis|Fungemia Drug: Active a
TNF Blockade With Remi Terminated Lupus Erythematosus, Systemic|Lupus NephritisDrug: inflixim
Acute Defibrillation Stu Terminated Ventricular Arrhythmias Device: Defibri
Evaluating the Safety a Terminated Asthma Device: Targe
Hydroxychloroquine in Terminated Coronavirus Infection Drug: Hydroxy
An Investigational Stud Terminated Lupus Nephritis Drug: BMS-986
ALEctinib for the Trea Terminated Non-small Cell Lung Cancer|Non-small Cell LunDrug: Alectinib
The AdAPT Trial; Adenov Terminated Adenovirus Other: Standar
QUantum Genomics Incre Terminated Heart Failure Drug: QGC001|
A Safety and Efficacy STerminated Lymphoma, Non-Hodgkin Drug: Ibrutini
Efficacy and Safety of Terminated Neuroendocrine Tumors in Lung Drug: Lanreoti
Comparison of VT AblaTerminated Tachycardia, Ventricular Device: cathet
A Study of ASP8273 vs.Terminated Non-small Cell Lung Cancer (NSCLC) Drug: naquotini
Study of Radium-223 DiTerminated Breast Neoplasms Drug: Radium-2
Efficacy and Safety St Withdrawn Glomerulonephritis, Membranous Drug: Belimum
Evaluation of the Phas Terminated Persistent Atrial Fibrillation Device: Medtr
A Phase Ib/II Study of Terminated Recurrent Head and Neck Squamous Cell CarciDrug: BYL719 a
Trial Evaluating Dovit Terminated Metastatic Breast Cancer Drug: Dovitinib
Ascending Dose Study of Terminated Atrial Fibrillation|Paroxysmal Atrial Fibrillation|Per
Drug: OPC-108
ChonDux for Filling Ful Terminated Cartilage Defect Device: Chon
Smith & Nephew's Europ Terminated Defect of Articular Cartilage Device: Trufit
A Degarelix Trial in Pat Terminated Prostate Cancer Drug: Degareli
Efficacy, Safety and E Terminated Atrial Fibrillation Device: Radiof
Study is Designed to AsTerminated Cancer|Advanced Solid Malignancies Drug: AZD454
A Study of OcrelizumabTerminated Rheumatoid Arthritis Drug: Leflunom
Right Versus Left ApicaTerminated Bradyarrhythmia Device: Implan
Study to Test the Safe Terminated Carcinoma, Non-Small-Cell Lung Drug: Radium-
Mesalamine for ColorecTerminated Colorectal Cancer Drug: mesalam
Glyaderm Clinical EvaluTerminated Full-thickness Skin Loss Due to Burn, UnspecifieProcedure: Gl
International Trial of Terminated Acute Lymphoblastic Leukemia|Acute Lymphoblas Drug: Selumet
A Eurosarc Study of M Terminated Osteosarcoma Drug: Mifamurt
Repeat Dose Study of GTerminated Asthma Drug: GSK3772
Obeticholic Acid in PediaTerminated Biliary Atresia Drug: OCA 0.
A Dose Finding, Effica Terminated COVID-19 Drug: ensovib
Treatment of Mitral Re Terminated Mitral Regurgitation Device: HARPO
Assessment of Pacing STerminated Heart Failure Device: BIOT
A Dose Titration Study Terminated Microvascular Coronary Artery Disease Drug: SAR4078
Efficacy and Safety of Terminated Antibody-mediated Rejection Drug: C1-ester
PDR001 in CombinationTerminated Non-small Cell Lung Cancer Drug: PDR001|D
PREclinical Mutation C Terminated Dilated Cardiomyopathy Drug: perindop
Efficacy, Safety and PhTerminated Sedation in Intensive Care Drug: Clonidin
A Safety and Efficacy Terminated Non-Small Cell Lung Cancer Drug: INC280 s
Rabbit Anti-thymocyte GTerminated Myelodysplastic Syndrome (MDS) Biological: Th
Eurartesim® in Patient Terminated Malaria, Vivax Drug: Eurartes
An Explorative Trial t Terminated Gastroesophageal Reflux Disease Drug: SPD557|
A Study of RoActemra/ATerminated Rheumatoid Arthritis Drug: tocilizu
Efficacy and Safety Ev Terminated Bladder Neoplasm|Neoplasm Recurrence, Local|T Biological: EN
Efficacy Study of PudenTerminated Neurogenic Overactive Bladder|Urinary IncontinDevice: InterS
A(f)MAZE-CABG StudyTerminated Coronary Arteriosclerosis|Atrial Fibrillation|Cor Device: HIFU A
Trial of Nelarabine, Et Terminated Relapsed T-Cell Acute Lymphoblastic LeukemiaDrug: Nelarabi
Study to Investigate th Terminated Cervical Degenerative Disc Disease Device: DISCO
MOnitoring REsynchroniTerminated Heart Failure Device: Medtr
A Study of the Safety a Terminated Acute Myeloid Leukemia|Acute Lymphoblastic Drug: midostau
A Study To Evaluate The Terminated Invasive Aspergillosis Drug: Voricona
Study to Demonstrate thTerminated Chronic Heart Failure|High Blood B-type (or BraiDrug: olmesart
A Study of R1507 in ParTerminated Sarcoma Drug: RG1507
A Study to Assess the ETerminated Asthma Other: Placebo
Zalutumumab in CombinTerminated Head and Neck Cancer|Squamous Cell Cancer Drug: zalutumu
Artificial Valve EndocardTerminated Aortic Valve Disease|Mitral Valve Disease|EndocDevice: Artific
Study Of CP-751,871 I Terminated Breast Neoplasms Drug: CP-751,
A Study of Patients Ha Terminated Pulmonary Hypertension|Sickle Cell Anemia Drug: Bosenta
Efficacy and Safety of Terminated Pulmonary Hypertension Drug: bosenta
Efficacy and Safety of Terminated Pulmonary Hypertension Drug: Bosenta
Extracorporeal PhotoimTerminated Acute Graft-versus-Host Disease Drug: Methoxs
Comparison of SurveillaTerminated Aortic Aneurysm, Abdominal|Endovascular Procedure: EVA
TreatIng MicroalbuminuTerminated Albuminuria Drug: Dapaglif
Absorption and ExcretioWithdrawn Solid Tumor, Adult Drug: ModraDo
An Efficacy and Safety Withdrawn Sjogren's Syndrome (SS) Drug: Ravagli
A Multiple Dose Study tTerminated Healthy Participants Drug: SRK-001
Oral Docetaxel in Patie Withdrawn Solid Tumor, Adult|Impaired Liver Function Drug: ModraDo
Stereotactic Body RadioWithdrawn Spinal Neoplasms|Neoplasm Metastasis|Radiosu Other: SBRT fol
Automated Secretion ReTerminated Mechanical Ventilation Complication Device: Trach
A Study to Evaluate Lu Terminated Healthy Drug: Lu AF90
Real World Pharmacokin Terminated Cancer Other: blood s
A Study of JNJ-70075200 Withdrawn Healthy Drug: JNJ-700
COVID-19 Primary CareTerminated Covid19|Corona Virus Infection Drug: Dexame
Evaluation of Surgery Withdrawn Intracranial Hemorrhages|Surgery Other: Early n
A Study in Healthy MaleTerminated Healthy Drug: GLPG405
HA-1H TCR T Cell for Re Withdrawn Acute Myeloid Leukemia|Acute Lymphoid Leukem Drug: MDG1021
The Effects of EnoximoTerminated COPD Exacerbation|Enoximone|Phosphodiesteras Drug: Enoximo
Esophageal Multisegmen Terminated Oesophageal Cancer|Esophageal Stent StenosiDevice: Multis
Preoperative Detection Terminated Pancreatic Cancer|Periampullary Cancer Diagnostic Te
AneuFix - Prophylactic S Suspended Abdominal Aortic Aneurysm|Endoleak Device: Prophyl
IW-6463 Safety Study inTerminated Other Drug: IW-6463
Nutritional Supplementat Terminated Nitric Oxide|Insulin Sensitivity|Vascular Function|Dietary Supple
A Study in Healthy PartTerminated Healthy Drug: Darunavi
Lifestyle and Brain Vas Terminated Healthy Lifestyle|Physical Exercise|Healthy Di Other: Healthy
89Zr-atezolizumab PETTerminated Lobular Metastatic Breast Cancer Other: 89Zr-a
Safety and Tolerability Terminated Healthy Drug: Lu AF95
Pharmacokinetics of Vala Terminated Herpes Simplex Virus Infection|Varicella Zoster V Drug: Valacycl
Sorafenib PK in Patien Terminated BCLC Stage C HCC|CP-B Liver Cirrhosis Drug: Sorafeni
A Study to Test the PhaTerminated Healthy Participants Drug: Padsevon
Apotransferrin in Patie Terminated β-thalassemia Intermedia Biological: hu
A Study in Healthy Peo Terminated Healthy Drug: BI 14673
A Study of LY3526318 in Terminated Healthy Drug: LY35263
Study to Evaluate the EfTerminated Non-Alcoholic Fatty Liver Drug: elafibra
Multiple Ascending Dose Terminated Amyloidosis Drug: NPT189
Neo-Adjuvant Chemothera Terminated Cervical Cancer Drug: Paclitax
MORphine Use in the Fa Terminated Humans|Anesthetics, Local|Morphine|Pain Manag Drug: Levobupi
Safety and Efficacy of Terminated Malaria,Falciparum|Controlled Human Malaria Inf Biological: CP
This Study Tests How BTerminated Carcinoma, Non-Small-Cell Lung|Head and NecDrug: BI 75411
Web-based Attention Bia Terminated Anxiety Disorder|Anxiety Disorder of Childhood| Behavioral:
Clinical Evaluation Pro Terminated Delirium Other: Spot mo
Clinical Evaluation Pro Terminated Delirium Other: Spot mo
Cabozantinib in AdvancTerminated Salivary Gland Cancer Drug: Cabozant
Investigation of Flare a Withdrawn Atopic Dermatitis Drug: Cyclospo
Fully Automated Scan TTerminated Pulmonary Disease Other: FAST st
A Study of LY3322207 in Terminated Hypertension Drug: LY33222
Fluorescence EndoscopTerminated Esophageal Cancer Drug: Bevaciz
Galunisertib and CapeciWithdrawn Colorectal Cancer Metastatic Drug: Galunise
A Study in Healthy MaleTerminated Anesthesia|Anesthesia, Local|Analgesia Combination Pr
The Improved Ballet Sho Withdrawn Ballet Dancers Device: orthos
ICVT in HPV-induced GTerminated HPV-Induced Genital Lesions Drug: CLS003|
A Study of ExperimentalTerminated Rheumatoid Arthritis|Psoriasis|Ankylosing SpondDrug: BMS-986
NAD Supplementation STerminated Aging|Mitochondrial Function Dietary Supple
AS: Ankle Spacer for TaTerminated Osteochondral Defect of Talus Procedure: An
Microwave Ablation in Mi Terminated Hidradenitis Suppurativa|Acne Inversa Device: Microw
Improving the Referral Terminated Acute Coronary Syndrome|Myocardial InfarctionDiagnostic Tes
Flow Augmentation StudTerminated Postthrombotic Syndrome Device: Flow
Treatment of Central SlTerminated Central Sleep Apnea|Cheyne-Stokes Respiratio Device: Nasal
C1-inhibitor in Allergic Terminated Asthma Drug: C1-inhibi
ReNovaCell in Non-segme Terminated Non-segmental Vitiligo|Vitiligo Device: ReNov
Reduced Contrast AdmiTerminated Breast Neoplasm|Contrast-enhanced Spectral Procedure: CES
Feasibility of Holmium Terminated Radioisotopes|Head and Neck Neoplasms Device: Holmiu
Fluoroscopic and RSA Ev Terminated Complications; Arthroplasty, Mechanical|Asepti Device: Triath
IL2 Imaging in Metasta Terminated Melanoma Device: IL2-PE
Spinal Cord StimulationTerminated Small Fiber Neuropathy Device: Spinal
Ablative tReatment of Terminated Renal Cell Carcinoma Radiation: AR
DE-CT in Lung Cancer Withdrawn Non Small Cell Lung Cancer Procedure: DE
TIBOHCA: Safety, Tolera Terminated Cardiac Arrest|Hypoxic Ischemic Brain Injury Drug: 2-Iminob
Difference in Pain Perc Withdrawn Prostate Biopsy Other: ultrasou
A Reduction in Time WitTerminated Acute Ischemic Stroke|Stroke Other: real-ti
Comparison of Walking Terminated Pulmonary Disease, Chronic Obstructive Behavioral: Wa
Roll Over Study to ProviTerminated Lymphoid Malignancies Drug: Idelalisib
Combination of SABR an Withdrawn NSCLC Stage IV|Limited Metastatic Disease Drug: L19-IL2|
Carnitine Infusion and I Terminated Glucose Intolerance Drug: Carnitor
[18F]Dabrafenib MolecuTerminated Melanoma Other: [18F]da
Targeted Vessel AblatioTerminated Uterine Fibroid Device: Magnet
Tryptophan Depletion i Terminated Parkinson's Disease Dietary Supple
Valvuloplasty as Altern Withdrawn Gastroesophageal Reflux|Hernia, Hiatal Procedure: Lap
Cabazitaxel in mCRPC W P ithdrawn Prostatic Neoplasms Drug: cabazita
The Effects of a CONC Withdrawn Congenital Heart Disease|Smartphone ApplicatioDevice: CONCO
Sentinel Node Detectio Terminated Ovarian Neoplasms|Sentinel Node Procedure: Inje
A Comparative Study o Terminated Arthroplasty, Replacement, Hip Device: Triden
Online Cognitive Traini Terminated Idiopathic Parkinson's Disease|Multiple Sclerosi Behavioral: Onl
The LIPMAT Study: LipoTerminated Renal Dialysis|Hemodynamics|Vascular RemodeDrug: PEG-lip
Neuromuscular ElectricaTerminated Immobilization|Muscle Disuse Atrophy Device: Neurom
Safety, Tolerability, P Terminated Healthy Drug: ODM-108
Imiquimod Treatment ofTerminated Cervical Intraepithelial Neoplasia Drug: Imiquim
A Study to Investigate Terminated Healthy Volunteer Drug: Placebo
Plaque Stabilization an Terminated Vulnerable Plaque Device: Biores
Bloodtranfusions After ATerminated Hemorrhage|Thoracic Aneurysm Drug: Haemoco
Fractional Laser in ComWithdrawn Vitiligo Device: Fracti
A Randomised Pilot Stud Terminated Chronic Pain Device: Treat
Magnetic Resonance Ima Withdrawn Ovarian Neoplasms Drug: Gadofosv
Diagnostics for the Tre Withdrawn Chromosomal Instability|Low Grade Dysplasia Ora Procedure: sur
Trial to Determine OptimWithdrawn Solid Tumors|Head and Neck Neoplasms Drug: DTP348
Treatment of Port Wine Terminated Port-Wine Stain Drug: Sirolimu
Influence of an Acidic Terminated Gastrointestinal Stromal Tumor|Major Gastrect Dietary Supple
L-C Ligament Versus Ha Terminated Acute Ruptures of the Anterior Cruciate LigamenDevice: L-C Li
Phase II Study of Sunit Terminated Metastatic Renal Cell Carcinoma Drug: Sunitinib
Spatial Analysis and VaTerminated Glioblastoma Device: 7 T MR
Cell Savers and Blood Q Terminated Coronary Artery Bypass, Off-Pump Device: Xtra®,
Safety and Tolerability Terminated Colitis, Ulcerative Drug: GSK258
Safety and PerformanceTerminated Ileostomy - Stoma Device: Colopl
A Prospective, MulticenTerminated Degenerative Joint Disease of the Hip Device: GRADI
First-time-in-man, to A Terminated Healthy Male Volunteers Drug: BP1.537
Single-port ThoracoscoWithdrawn Complex Regional Pain Syndrome Type I of the Procedure: uni
Pre-operative DecitabinTerminated Colon Cancer Drug: Decitabi
Non-invasive and InvasiTerminated Non ST Elevation Myocardial Infarction Device: Imagi
Cue Exposure Training Terminated Overweight|Obesity Behavioral: Fo
Immunization With PlasWithdrawn Malaria, Falciparum Drug: Azithrom
Effect of MethylphenidaWithdrawn Attention Deficit Hyperactivity Disorder Drug: Methylph
Trabeculectomy With OTerminated Glaucoma Device: Ologe
Screening for Familial GTerminated Malignant Neoplasm of Stomach|Carcinoma, DiffOther: Endosco
Research Into the EffectTerminated Acute Ischemic Stroke Drug: M5|Drug:
Epiglottic Downfolding Withdrawn Intubation Complication|Injury of Epiglottis Device: C-MAC®
Congenital Cytomegalovi Terminated Congenital Cytomegalovirus Infection|SensorineDrug: Valganci
Oral Versus Intravenou Terminated Radiographic Contrast Agent Nephropathy Drug: Sodium ch
GLP-1 and Non-exercise Terminated Type 2 Diabetes Mellitus Drug: Liraglut
89Zr-RO5323441 PET Im Withdrawn Glioblastoma Radiation: Mo
Nodal Staging in Breas Terminated Breast Neoplasms Drug: Gadofos
Individualized Dose Pr Terminated Stage III Non-small Cell Lung Cancer|Individual Radiation: Indi
Chloroquine as an Anti-Terminated Small Cell Lung Cancer Drug: Chloroq
Phase 1 Trial of Ipilim Terminated Prostate Cancer Drug: GVAX an
Quantification of Contr Terminated Prostate Cancer Drug: SonoVu
Study on Anti-inflammatTerminated Hypertension|Abdominal Aortic Aneurysm Drug: Aliskire
Pancreatic Enzyme Supp Withdrawn Adenocarcinoma of the Pancreas|Normal Pancrea Other: Timing
First in Man Study of Terminated Healthy Volunteers Biological: AL
Comparing Surgical DecTerminated Central Spinal Cord Syndrome Procedure: Sur
A Study in Patients Wit Terminated Chronic Obstructive Pulmonary Disease Drug: Foster®
Multiple Ascending DosTerminated Hypercholesterolemia Drug: SPC5001
Improving MEDication Withdrawn Heart Failure Behavioral: M
Comparison of Immunosup Terminated Renal Transplantation Drug: everolim
Effect of C1-esterase I Terminated Trauma|Inflammation|Sepsis|Multiple Organ Dy Drug: C1-ester
Cediranib as Palliative Terminated Malignant Ascites|Malignant Pleural Effusion Drug: immediat
Management of EczemaWithdrawn
b Eczema|Atopic Dermatitis Dietary Supple
Nitroglycerin in Non-smTerminated Non Small Cell Lung Cancer (NSCLC) Drug: Nitroglyc
Efficacy of Sprayable PTerminated Postoperative Adhesion|Peritoneal Adhesion, N Device: Sprayg
Peritoneal Dialysis in C Terminated Congestive Heart Failure Drug: icodextri
Optimal Sensing in Atri Terminated Sick Sinus Syndrome|Paroxysmal Atrial FibrillatiDevice: Accen
Procalcitonin Guided VeWithdrawn Sepsis|Intensive Care Other: Procalc
Overactive Bladder (OAWithdrawn Overactive Bladder Syndrome Dietary Supple
A Study to Investigate t Withdrawn Arthritis, Rheumatoid Drug: GSK7067
PEPI-TiDP23-C104 is aWithdrawn HIV Infections Drug: TMC589
Safety and Efficacy StuTerminated Heart Failure|Kidney Failure Drug: Aliskire
Cetrotide Treatment OptTerminated In Vitro Fertilization|Intracytoplasmic Sperm InjeDrug: Cetrotide
Endoscopic FundoplicatTerminated Gastroesophageal Reflux Disease (GERD) Procedure: Tra
Induced Hypertension f Terminated Cerebral Ischemia|Subarachnoid Hemorrhage Drug: Induced
The Impact of Treating Terminated Minor Intra-uterine Abnormalities Procedure: Tre
Study of Combination oTerminated Resectable Esophageal Cancer Drug: cetuxima
Steroid-induced ReductiWithdrawn Coronary Artery Stenosis|Coronary Artery BypasDrug: Dexamet
Evaluation of Safety an Withdrawn Breast Ptosis Device: Breast
Study to Evaluate the PTerminated Colitis, Ulcerative Drug: SB-6569
Influence of AdministratWithdrawn Hypogonadism Drug: MPP10, t
Second-line Endocrine Terminated Breast Cancer Drug: capecita
Long-term Clinical FeasTerminated Total Laryngectomy Device: Provox
Exercise and Muscle Pro Withdrawn Muscle Protein Synthesis Other: exercis
Stenting of HaemodialysTerminated Outflow Stenosis Device: Viabahn stent-graft
CoNCReTe-trial: CollesTerminated Colles' Fracture Procedure: Man
Safety Study of BevacizTerminated Toxicity Biological: be
Changes in Myocardial Terminated
Pe Atrial Fibrillation Device: HIS bu
Predictive Value of FD Terminated Lung Cancer|SCLC|NSCLC Other: 18F-de
A Study on the TolerabiWithdrawn Candidaemia Drug: hLF1-11
Value of Urodynamics Pr Terminated Stress Urinary Incontinence Procedure: Ur
Intensified IAA With P Terminated Breast Cancer Drug: Intensif
Effect of Ischemic Post Withdrawn Cardiovascular Disease|Ischemia-reperfusion InjProcedure: rep
Safety of hLF1-11 for t Withdrawn Fungal Infection|Bacterial Infection Drug: human la
Adjuvant Xeloda Plus Elo Terminated Colorectal Cancer|Liver Metastases Drug: oxalipla
Anti-Oxidant Therapy InTerminated Chronic Kidney Disease Drug: pravasta
Effect Study of a Theor Terminated Sexual Risk Behavior for HIV-Infection Behavioral: Cog
Light Therapy for Elder Terminated Major Depressive Disorder Procedure: 10.
T-cell and B-cell Deplet Terminated Leukemia, Myeloid|Leukemia, Lymphocytic|MyeProcedure: T-ce
Forced Diuresis Versus Terminated
O Renal Failure|Critically Ill Drug: Furosem
Efficacy of a Triptan i Terminated Psychotic Disorders|Antisocial Personality DisorDrug: naratrip
Polymethyl Methacryla Terminated Osteoarthritis Device: PGET
Netherlands 10 mL BronTerminated Pulmonary Emphysema Biological: BL
Positron Emission TomoSuspended Alzheimer's Disease Device: Posit
Transfusion Effects in MWithdrawn Myelodysplastic Syndromes Procedure: Red
Effects of Gabapentin i Terminated Chronic Neuropathic Pain Drug: gabapen
Effects of Amitriptyline Terminated Chronic Neuropathic Pain Drug: amitripty
Women Abuse and the Terminated
Ro Improved Recognition of Partner Abuse|Gender Behavioral: a t
Opioid Receptors InflueSuspended Ischemia-Reperfusion Injury Drug: morphine
Ventilator Associated Terminated Pneumonia Procedure: Tra
Adenosine Receptors InSuspended Ischemia-Reperfusion Injury Drug: acetylch
Comparative Effects of Terminated Healthy Drug: Rupatad
The Effect of Intensive Terminated Amyotrophic Lateral Sclerosis Behavioral: In
The Role of FluorothymiTerminated Colorectal Neoplasms|Liver Neoplasms Procedure: FL
The Pain Pen for BreakTerminated Neoplasms|Pain Drug: Subcuta
Screening for CoronaryTerminated Coronary Artery Disease (CAD)|Coronary ArteryRadiation:
C CT
Intravenous Imatinib in Terminated ARDS|Acute Respiratory Distress Syndrome|Cov Drug: Imatinib
The Effect of Fish Oils Terminated Ageing|Mitochondrial Function|Physical FunctionDietary Supplem
Limited-efficacy Testin Withdrawn Early-Onset Scoliosis Deformity of Spine (Disorde
Device: SDS|D
A 28 Day Parallel GroupTerminated Healthy Drug: RDN-929
Molecular Imaging UsinWithdrawn Diffuse Large B-Cell Lymphoma, Not Otherwise Other: 89Zr-a
Minimal Invasive Breas Terminated Breastcancer Device: BLES
Post Operative Quality Terminated Ankle Fractures Other: Function
Local Radiotherapy FollTerminated Brain Neoplasms Radiation: loc
Exercise Therapy With R Terminated Peripheral Arterial Disease, Rutherford 4 and 5 W
Behavioral: Su
Vitamin D3 and the StreTerminated Multiple Sclerosis Drug: Cholecal
Safety, Pharmacokineti Terminated Healthy Volunteers|Multiple Sclerosis Drug: 2B3-201|
The Use of Iron TherapyTerminated Postoperative Anaemia Drug: Ferinjec
The Effect of Caphosol Terminated Small Cell Lung Cancer|Non Small Cell Lung CaOther: Caphos
Denervation of the renATerminated Diastolic Heart Failure|Hypertension Procedure: ren
To Study the Effects of Terminated Non-diabetic Nephropathy Drug: Aliskire
Targeted Therapy Select Terminated Advanced Solid Tumors|Inoperable|Metastasis Drug: desatinib
Clinical Study to Eval Terminated Neoplasms Drug: BAY79-
Messenger Ribonucleic Terminated Uveal Melanoma Biological: au
Pharmacokinetic Study T oerminated Tumor Drug: aprepit
AZD1152 in Patients WiTerminated Solid Tumors Drug: AZD115
No Resistance After L Withdrawn Asthma Drug: FLIXOT
Modification Of Disea Terminated Chronic Obstructive Pulmonary Disease Drug: fluticas
Assessing the Safety anTerminated Healthy Biological: CS
Phosphorylcholine PC-mA Terminated Arterial Inflammation|Cardiovascular Diseases Drug: PC-mAb|
A Study to Evaluate THB Suspended Chronic Cold Urticaria Drug: THB001
Feasibility of the Latel Terminated Osteoarthritis Device: Latell
Non-invasive and InvasTerminated Coronary Artery Disease Device: adeno
Ranibizumab and the RiTerminated Age-related Macular Degeneration|Coronary ArtDrug: 0.5 mg o
Extension of Study HGTTerminated Sanfilippo Syndrome Biological: rh
A Study of DCR-PH1 in Terminated Primary Hyperoxaluria Type 1 Drug: DCR-PH1
A follow-on Study to AsTerminated Amyotrophic Lateral Sclerosis Drug: sNN0029
A Safety Study of sNN00 Terminated Amyotrophic Lateral Sclerosis Drug: sNN0029
Infliximab Top-down in Terminated Crohn's Disease Drug: Azathiop
A Dose Escalation Study Suspended Cancer Drug: E7107
Long-term Effects of NoTerminated Chronic Obstructive Pulmonary Disease Radiation: Fun
Chemotherapy Plus Inter Terminated Lymphoma Biological: filgrastim|Biologica
Vitrification Versus S Terminated Infertility Other: embryo v
Trial Comparing Start STerminated in Vitro Fertilization|Ovulation Induction Drug: Mild stim
Cardiac Changes After Terminated Lung Cancer Stage I|Lung Cancer Stage II|Lun Diagnostic Tes
Clinical Investigation t Withdrawn Atrial Fibrillation Device: Wearin
AIR (Artificial Implant Terminated Meniscectomy|Osteo Arthritis Knee Device: Tramm
A Feasibility Study of Terminated Breast Cancer Drug: Nirapari
Near-infrared Image GuTerminated Pancreatic Cancer|Pancreatic Adenocarcinoma Drug: Bevaci
Image Guided Treatment Terminated Metastatic Colorectal Cancer Drug: Dose esc
Optimizing Propofol DosTerminated Anesthesia Intubation Complication|Premature BDrug: Propofol
A Study in Patients Wit Terminated Metastatic Prostate Cancer Drug: Eligard
CPCT-05 Biopsy Protoco Terminated Solid Tumors|Metastatic Disease Procedure: His
Targeted Disc Decompre Terminated Lumbar Spine Disc Herniation Procedure: Ta
Trial Using Integuseal aTerminated Arterial Obstructive Diseases Procedure: App
Anti-CD3 & Anti-CD7 RiWithdrawn Acute Graft Versus Host Disease Biological: IT
Clinical Study of Concu Terminated Sarcoma|Soft Tissue Sarcomas Radiation: ext
Bioequivalence Study oWithdrawn HCV Drug: sofosbuvi
Chest CT With IterativeTerminated Cardiac Defects|Disorder; Heart, Functional, Po Other: CT sca
EXtended Use of FOsfomy Terminated Urinary Tract Infections Drug: Fosfomyc
Bezlotoxumab Versus FM Withdrawn Clostridium Infections|Clostridioides Difficile| Drug: Bezlotox
Study to Assess an Int Withdrawn AML Drug: Flotetu
AssessinG Efficacy of Terminated Breast Cancer Drug: Carbopla
Santeon-CAP; DexametTerminated Community-acquired Pneumonia Drug: Dexamet
Computed TomographyTerminated
Ve Angina Pectoris|Chest Pain Other: Cardiac
Comparison of Self-adhTerminated Inguinal Hernia Procedure: Ope
Chloroquine as an Anti Terminated Small Cell Lung Cancer Drug: Chloroq
The Treatment of CoronTerminated Coronary Artery Disease Device: PRO-Ki
Pre-operative HormonalSuspended Breast Cancer Drug: Anastroz
Plasmonic PhotothermalTerminated Coronary Artery Disease|Atherosclerosis Other: Stenting
An Observational SafetyTerminated Atherosclerotic Coronary Artery Disease Device: NEVO™
Effect of Lamotrigine o Terminated Neurofibromatosis Type 1 Drug: Lamotrig
Study to Evaluate DNL74 Terminated Amyotrophic Lateral Sclerosis Drug: DNL747|
Safety and Efficacy of Terminated Neurogenic Urinary Bladder|Neurogenic BladderDrug: SAF312|
Multicenter Study of MaTerminated Bone Metastasis Device: MR-HIF
Stentys Coronary Stent Terminated
S Acute Myocardial Infarction Device: STENTY
Gemcitabine and Doceta Terminated Metastatic Colorectal Adenocarcinoma Drug: Gemcitab
Atrial Fibrillation: Abla Terminated Paroxysmal Atrial Fibrillation. Procedure: Per
Glivec Phase II PediatriTerminated Cancer Drug: Glivec|D
A Study to Treat Small Terminated Small Cell Lung Cancer|Carcinoma, Small Cell Drug: pemetrex
ELB139 Given Orally toTerminated Panic Disorder Drug: ELB139
Effect of Sulodexide in Terminated Diabetic Nephropathy Drug: Sulodexi
Radiation Therapy and C Terminated Bladder Cancer Drug: cisplatin|Drug: fluorour
S. Aureus DecolonizatioTerminated Staphylococcus Aureus|Motility Disorder Drug: Doxycycl
Bivalirudin Infusion for Terminated Acute Myocardial Infarction Procedure: PPC
Radiotherapy or RadiosTerminated Brain and Central Nervous System Tumors Procedure: adju
Study Evaluating Safet Terminated Rotator Cuff Tear Biological: BM
Magnetic Anastomosis De Terminated Gastric Outlet Obstruction Device: Cook
Lumbar Interbody Fusi Terminated Low Back Pain|Spondylolisthesis|Spinal StenosisDevice: Lumbar
T-DM1 and Osimertinib Terminated Carcinoma, Non-Small-Cell Lung Drug: Trastuz
Dose Individualization Terminated Non Small Cell Lung Cancer|Mesothelioma Drug: Pemetre
Autologous Skin SubstitTerminated Varicose Ulcer Drug: Tiscover
Study Into a New Diagno Terminated Ovarian Carcinoma|Ovarian Cancer|Ovarian Mas Other: Ultraso
Does Administration of Terminated Colorectal Cancer Drug: Selective
PENTACON Trial: Partial Terminated Keratoconus Procedure: PE
APRIL CAR T Cells (AUT Terminated Multiple Myeloma Biological: A
Immune Therapy and Anal Withdrawn HIV Infection Drug: Analytic
TMC649128HPC1002 -Terminated
a Tr Hepatitis C Virus Drug: placebo
Model 20105 Lead StudTerminated Sick Sinus Node Syndrome Device: Model
Moderate Alcohol and Ca Terminated Cardiovascular Diseases|Diabetes Other: Alcohol
The ABSORB Bioresorba Terminated Ischemia|Peripheral Arterial Disease (PTA|Arter Device: Absorb
A Study of ARC-AAT in Terminated
H Alpha-1 Antitrypsin Deficiency Drug: ARC-AAT
Phase 1 Study of LOP628 Terminated cKIT-positive Solid Tumors|AML Drug: LOP628
Triple Therapy PreventiTerminated Cognitive Decline|Intracerebral Hemorrhage|De Drug: telmisar
Postoperative Patient-cTerminated Injury of Foot, Shoulder or Knee|Perineural AnalOther: Remote
A Pilot Study to DetermTerminated Uterine Fibroids Device: GY
Omnifit Hydroxylapatit Terminated Arthroplasty, Replacement, Hip Device: Omnifi
A Phase 1/2 Study of ETerminated Advanced Solid Tumors Drug: Epofolat
A Phase I Study of BMSTerminated Cancer Drug: Oral Ta
A Phase 1 Study of AMG Terminated GI Adenocarcinoma Drug: AMG 21
Study of CCNU (Lomusti Terminated Glioblastoma Drug: Dasatini
A Clinical Study CompaTerminated Colorectal and Ileorectal Anastomosis Device: Test-
Group Version of CRAFT Terminated Addiction|Substance Use Disorder|Alcohol Use Behavioral: Gr
Conventional With StereTerminated Spinal Metastases Radiation: conv
Rivastigmine for IntensiTerminated Delirium Drug: Rivastig
Implitapide in Patients Terminated Familial Hypercholesterolemia Drug: Implitapide
Bayston Multicenter AntWithdrawn End Stage Renal Disease (ESRD) Device: PD Ca
iHIVARNA Clinical Trial Terminated HIV Infections Biological: iHI
This Study Aims to FindTerminated Neoplasms Drug: BI 9056
Early Convalescent PlasTerminated Covid19 Biological: Co
Pre- Versus Postoperativ Terminated Breast Cancer|Cancer of the Breast|Neoplasms,Radiation: parti
COVID-19 ResuscitationSuspended Covid19|Cardiac Arrest Other: Decision
Convalescent Plasma aTerminated COVID-19 Biological: Co
Extension Study of BM Terminated Duchenne Muscular Dystrophy Drug: BMN 044
Neurotoxic Adverse EffeTerminated Pain|Terminal Illness|Renal Impairment Drug: Oxycodo
Haloperidol for DeliriumTerminated
i Delirium|Critical Illness|Intensive Care Psychos Drug: Haloperi
Study to Identify the Withdrawn Breast Neoplasms Drug: Denosu
Open Label, Extension Terminated Duchenne Muscular Dystrophy Drug: PRO044
Comparing Two MedicalTerminated Early Pregnancy Failure Drug: Mifepris
DiagNostic Study of Lo Terminated Community-acquired Pneumonia Diagnostic Tes
Docetaxel Versus Inter Terminated Carcinoma, Non-small Cell Lung Drug: Docetaxe
Vemurafenib Plus Cobim Terminated Metastatic Melanoma Drug: Vemurafe
SCar-biopsies After MalTerminated Colorectal Cancer Procedure: Fle
The Dutch STRIDER (Sild Terminated Fetal Growth Restriction Drug: Sildenaf
Whole Brain RadiotheraTerminated Neoplasm Metastasis Radiation: Ste
Endoscopic Peroral MyoTerminated Achalasia Procedure: En
Duration of ANtibiotic ThTerminated Cellulitis|Erysipelas Drug: Flucloxaci
Iressa Re-challenge i Terminated Lung Cancer Drug: Gefitini
Interaction Between ParTerminated Hepatitis C Infection|Depression Drug: Paroxeti
Efficacy of Clean IntermTerminated Bladder Dysfunction|Multiple Sclerosis Device: CIC us
Evaluation of the Latell Terminated Osteoarthritis Device: Latell
SUPER Study; SUPERvised Terminated Intermittent Claudication|Peripheral Arterial Dis Procedure: Per
Long-Term Effect of 10 Terminated Obesity|Weight Loss Drug: rimonab
Study Evaluating the EfTerminated Glioblastoma|Glioma Drug: Selinexo
Assessment of Aliskire Terminated Hypertension|Ankle Edema Drug: Aliskire
Adjuvant Breast CancerTerminated High-Risk Breast Cancer Procedure: ste
High-dose Ribavirin in Terminated Chronic Hepatitis C Drug: ribavirin
Liposomal Doxorubicin,Terminated Breast Cancer|Neoplasm Metastasis Drug: Non pegy
Prevention of Relapses Terminated Vasculitis Drug: azathiop
A Study of BMS-986224Terminated
i Heart Failure Drug: Placebo
Flecainide Acetate InhalTerminated Paroxysmal Atrial Fibrillation Drug: Placebo
Study to Compare AdjuvTerminated Melanoma|Melanoma Stage III|Melanoma StageBiological: Be
Transarterial Chemoembo Terminated Liver Neoplasms Radiation: Rad
Neoadjuvant Nivolumab+ Withdrawn Melanoma Biological: Niv
(Revival) Study to Inve Terminated Acute Kidney Injury Due to Sepsis Biological: Re
A Study in Attention DefTerminated Attention Deficit Hyperactivity Disorder Drug: Atomoxet
M7824 With cCRT in Unr Terminated Non-small Cell Lung Cancer Drug: M7824|Dr
Effect of Sotagliflozin Terminated Heart Failure|Type 2 Diabetes Mellitus Drug: Sotaglif
Dose Finding Study of Terminated Pulmonary Disease, Chronic Obstructive Drug: Placebo
OPTIMIZE IDE for the Terminated Acute Coronary Syndrome Device: DES
A Clinical Study to Tes Terminated Idiopathic Pulmonary Fibrosis Drug: GLPG169
Pemafibrate to Reduce Terminated Type2 Diabetes|Dyslipidemia Drug: K-877|D
A Study of Rovalpituzu Terminated Small Cell Lung Cancer Drug: Placebo
Panobinostat Maintena Terminated Acute Myeloid Leukaemia (AML)|Myelodysplast Drug: Panobino
Fibroid Ablation Study -Terminated Leiomyoma|Uterine Fibroids|Menorrhagia Device: VizAb
Efficacy and Safety StuTerminated Crohn Disease Drug: GED-030
To Evaluate The Effica Terminated Active Rheumatoid Arthritis Drug: Treatmen
Avelumab in PreviouslyTerminated Ovarian Cancer Drug: carbopla
A Phase 2b Study of InhTerminated Persistent Cough in IPF|Chronic Cough|IPF Drug: RVT-160
A Long-term Active Tre Terminated Crohn's Disease Drug: GED-030
Effect of Sotagliflozin Terminated Heart Failure|Type 2 Diabetes Mellitus|Chronic Drug: Sotaglif
Thrombolysis or Antico Terminated Sinus Thrombosis, Intracranial Drug: Endovasc
Efficacy and Safety StuTerminated Ulcerative Colitis Drug: Ontamal
The Evaluation of BocoTerminated Cardiovascular Disease Drug: bocociz
The Evaluation of BocoTerminated Cardiovascular Disease Drug: bocociz
A Study to Evaluate Eff Withdrawn Giant Cell Arteritis Drug: Abatacep
Study of Ixekizumab in PWithdrawn Spondylitis, Ankylosing Drug: Ixekizu
A Study of Evacetrapib Terminated Cardiovascular Diseases Drug: Evacetra
A Study of LanabecestatTerminated Alzheimer's Disease Drug: Lanabec
A Phase III Study of B Terminated Metastatic Breast Cancer Drug: Fulvest
Study of Zevalin Versu Terminated Diffuse Large B-cell Lymphoma|Follicle Center Drug: Zevalin|
A Phase 3 Study of GanTerminated Non-Small-Cell Lung Adenocarcinoma|Non-small Drug: Docetax
A Study of AtezolizumabTerminated Carcinoma, Transitional Cell Drug: Atezoli
A Trial to Learn More Withdrawn Chronic Kidney Disease|Diabetic Kidney DiseasDrug: BAY2327
Randomized Phase 2, DTerminated Chemotherapy-induced Neutropenia Drug: ANF-RH
A Study of Sodium OligoSuspended Alzheimer Disease Drug: GV-971|
Implitapide in Patients Terminated Hypertriglyceridemia Drug: implitapide
Study of the Safety andTerminated Coronary Artery Disease Drug: Apaden
The Use of PrevenaTM Terminated
on Surgical Site Occurences After Sternotomy|Woun Device: Preve
An Active Treatment St Terminated Crohn's Disease Drug: GSK160
GSK1605786A in the Mai Terminated Crohn's Disease Drug: GSK1605
VISTA-16 Trial: EvaluatTerminated Acute Coronary Syndrome Drug: A-002, v
A Randomized Controlled Terminated Cardiovascular Events Drug: Aliskire
A Clinical Study of the Terminated Secondary Progressive Multiple Sclerosis Drug: natalizu
Study of Denosumab asTerminated Breast Cancer Drug: Placebo
Ofatumumab Maintenance Terminated Leukaemia, Lymphocytic, Chronic Biological: Of
This Study Will Evaluat Terminated Heart Failure With Reduced Ejection Fraction Drug: LCZ696
Safety and Efficacy of TSuspended Severe Sepsis Drug: Talactofe
Pilot Immunotherapy StTerminated Neoplasms Drug: Lete-ce
A Randomized Study toTerminated Chronic Obstructive Pulmonary Disease Combination Pr
A Multicenter Trial ComTerminated Crohn's Disease Biological: Inf
Long-term Treatment foTerminated Venous Thromboembolism|Neoplasms Drug: low mole
Phase III Acute CoronaTerminated Acute Coronary Syndrome Drug: Apixaba
A Study to Assess the STerminated Atopic Dermatitis Drug: Placebo
A Study to Evaluate theTerminated Influenza A Drug: Pimodiv
Open-Label, Long-TermTerminated
T Subjective Tinnitus Drug: Neramex
A Study of Cobimetinib Terminated Advanced BRAFV600 Wild-type Melanoma Drug: Cobimet
Study Evaluating the SaTerminated Alzheimer Disease Drug: bapineu
HCT Versus CT in EldeTerminated Acute Myeloid Leukemia Procedure: hem
Ofatumumab + Chlorambu Terminated Leukaemia, Lymphocytic, Chronic Drug: chloramb
Evaluation of Weekly IdTerminated Atrial Fibrillation Drug: Idrabiota
Aliskiren Trial in Type Terminated Type 2 Diabetes Mellitus|Cardiovascular DiseasDrug: Aliskire
Study Evaluating The ETerminated Alzheimer Disease Drug: bapineu
Evaluation of Thoraflex Withdrawn Aortic Aneurysm, Thoracic|Penetrating Aortic U Device: Thorac
A Phase III Trial of ZD Terminated Prostate Cancer Drug: ZD4054|
Efficacy of Lapaquistat Terminated Hypercholesterolemia Drug: Lapaquis
This Was an Open-labelTerminated Primary Progressive Multiple Sclerosis Drug: FTY720|
Doxorubicin HydrochloriTerminated Sarcoma Drug: doxorubi
A Study of PEGylated RTerminated Pancreatic Ductal Carcinoma Other: Biolog
Phase 3 Study to Evalua Terminated Nonalcoholic Steatohepatitis (NASH) With FibrosDrug: Elafibra
ASA404 or Placebo in Co Terminated Non-Small Cell Lung Cancer Drug: ASA404|D
Evaluation of Efficacy Terminated Crohn's Disease Drug: Brazikum
An Efficacy and Safety Terminated Asymptomatic Amyloid-positive Drug: Atabeces
Efficacy and Safety of Terminated Diabetes|Diabetes Mellitus, Type 2 Drug: rosiglit
A Study in Sepsis PatieTerminated Sepsis|Bacterial Infections and Mycoses Drug: Placebo
Open-Label Extension STerminated Alzheimer's Disease Drug: Rosiglit
GALLEX 1 - Long TermTerminated
E Type 2 Diabetes Drug: tesaglita
JUPITER - Crestor 20mg Terminated Elevated High-sensitivity C-Reactive Protein (h Drug: Rosuvast
Long-term, Open-label Terminated Atrial Fibrillation|Stroke Drug: dabigatra
GALLANT 5 TesaglitazaTerminated Diabetes Mellitus, Type 2 Drug: GALIDA
Efficacy and Safety of Terminated Atherosclerosis|Heterozygous Familial HyperchoDrug: Pactimib
A Study Examining Torce Terminated Coronary Disease|Diabetes Mellitus Drug: torcetrap
Thiazolidinedione Inter Terminated Diabetes Mellitus, Type 2 Drug: pioglita
Melagatran/XimelagatraTerminated Thromboembolism Drug: EXANTA
Pembrolizumab With TaTerminated Melanoma Drug: Talimog
Chemotherapy Plus Radia Terminated Lung Cancer Drug: cisplatin|Drug: gemcita
Natalizumab (Tysabri) ReTerminated Relapsing-Remitting Multiple Sclerosis Drug: Nataliz
Assessment of Efficacy Withdrawn Influenza Biological: CR
Placebo Controlled DosTerminated Pain Drug: PD-217,
Combination Chemothera Terminated Lung Cancer Drug: cisplatin|Drug: etoposid
Placebo Controlled StudTerminated Malignant Pleural Mesothelioma Drug: defactin
Pacritinib Versus Best ATerminated Primary Myelofibrosis|Post-polycythemia Vera MDrug: Pacritin
GSK1572932A Antigen-Sp Terminated Lung Cancer, Non-Small Cell Biological: GS
P3 Study Brodalumab inTerminated Moderate to Severe Plaque Psoriasis Drug: 210 mg
Chemotherapy and Bevac Terminated Colorectal Cancer|Metastatic Cancer Biological: be
TRINOVA-3: A Study ofTerminated Fallopian Tube Cancer|Ovarian Cancer|PeritoneDrug: AMG 386
Randomized Trial of GeTerminated Carcinoma, Non-Small-Cell Lung Drug: Cisplati
The CONQUEST-Study.Terminated
E Gastroesophageal Reflux Disease|Non-erosive Drug: Pantopr
Efficacy and Safety of TTerminated Multiple Sclerosis Relapse Drug: Terifluno
QUILT-2.014: GemcitabiTerminated Adenocarcinoma of the Pancreas|Advanced SoliDrug: AMG 479
Safety and Efficacy of ATerminated Overactive Bladder Syndrome Drug: AV608
Gefitinib After ChemothTerminated Lung Cancer Drug: gefitinib
KRN7000 in Treating PaWithdrawn Lung Cancer|Unspecified Adult Solid Tumor, Prot Drug: KRN7000
Monoclonal Antibody ThWithdrawn Myelodysplastic Syndromes Biological: lintuzumab
BIBX 1382 in Treating PSuspended Unspecified Adult Solid Tumor, Protocol SpecificDrug: BIBX 1382
A Long-Term Safety And Terminated Alzheimer Disease Drug: Bapineu
Efficacy and Safety StuTerminated Acute Ischemic Stroke Drug: DP-b99|
Anemia Treatment for Terminated Non-Small Cell Lung Cancer|Anemia|Cancer|LuDrug: Darbepoe
Efficacy and Safety of Terminated Ovarian Cancer Drug: Farletu
Involved-Field Radiatio Terminated Lymphoma Radiation: radi
CHS 828 in Treating PatWithdrawn Unspecified Adult Solid Tumor, Protocol SpecificDrug: CHS 828
A Phase III Study to In Terminated Type 1 Diabetes Mellitus Drug: rhGAD65
Tiotropium/Salmeterol Terminated Pulmonary Disease, Chronic Obstructive Drug: Tiotropi
An Efficacy and Safety STerminated Colitis, Ulcerative Other: Placeb
Placebo Controlled StudTerminated Multiple Sclerosis Drug: CDP323|
A 14-Month Study On Th Terminated Obesity Drug: CP-945,5
A Study Comparing 4 Do Terminated Osteoarthritis Drug: PLA-695
A Study of Real-world CTerminated Pulmonary Arterial Hypertension Drug: PAH The
A Study to Compare T-G Terminated Steroid-Refractory Acute Graft Versus Host Dis Drug: T-Guard|
Study to Evaluate AdverTerminated Cystic Fibrosis (CF) Drug: ABBV-57
A Study Evaluating the Terminated Microvascular Obstruction Drug: Temanog
A Study to Test WhetheTerminated Acute Respiratory Distress Syndrome Drug: Alteplas
A Study to Evaluate th Terminated Autosomal Dominant Polycystic Kidney DiseaseDrug: Placebo
A Study of Benralizumab Terminated Eosinophilic Esophagitis Biological: Be
Trial of Paclitaxel/Car Terminated Carcinoma, Non-Small-Cell Lung Drug: PF-35126
Amcenestrant (SAR43985 Terminated Breast Cancer Drug: Amcenest
Breast-Conserving TherTerminated Breast Cancer Procedure: conventional surg
Study of Efficacy and STerminated Chronic Spontaneous Urticaria Drug: Ligelizu
Study of Oral Infigrati Terminated Upper Tract Urothelial Carcinomas|Urothelial B Drug: Infigrati
Safety and Efficacy of Terminated Non-small Cell Lung Cancer (NSCLC) Drug: Capmatin
A Study Of The Safety Terminated Age-Related Macular Degeneration Drug: AG-013,
Safety and Tolerability Terminated Heart Failure Drug: AZD4831
Evaluation of Effect of Terminated Metabolic Acidosis|Chronic Kidney Disease Drug: TRC101|
Phase III Study EvaluatTerminated Non-Small-Cell Lung Drug: Canakin
Efficacy and Safety Tri Terminated Neovascular Age-related Macular Degeneration Biological: 0.5
An Efficacy and Safety Terminated Idiopathic Pulmonary Fibrosis Drug: BG00011
Efficacy and Safety St Terminated Crohn's Disease Biological: On
A Medical Research StuTerminated Polycystic Kidney, Autosomal Dominant Drug: Venglust
Antiviral Activity, Cli Withdrawn Metapneumovirus Drug: Lumicita
Rifaximin Delayed Releas Terminated Diverticulitis Drug: Rifaximi
Trial to Evaluate Effic Terminated Diffuse Cutaneous Systemic Sclerosis Drug: Lenabas
A Study to Evaluate theTerminated Influenza A Drug: Pimodiv
Chemotherapy With or W Terminated Bladder Cancer Drug: mitomycin C|Procedure
Assess Safety and Effica Terminated Uterine Fibroids Drug: Vilapri
A First-in-human Study Terminated Malignant Solid Tumor Biological: S
A Study to Explore the Terminated Cluster Headache Drug: Freman
A Phase Ib Study to EvaTerminated Advanced Solid Tumors Drug: Aveluma
A Study Comparing the Terminated Chronic Cluster Headache Drug: Fremane
A Study to Evaluate th Terminated Episodic Cluster Headache Drug: Fremane
An Open-Label, Dose-Es Terminated Solid Tumors and Hematologic Malignancy Drug: INCB0598
Global Study ComparingTerminated Transcatheter Aortic Valve Replacement Drug: Rivaroxa
Efficacy and Safety StudTerminated Giant Cell Arteritis Drug: Sirukuma
Docetaxel With or With Terminated Non-small Cell Lung Cancer Drug: Docetax
TIGER-3: Open Label, M Terminated Non-small Cell Lung Cancer Drug: Rocileti
Effect of Eleclazine (G Terminated Hypertrophic Cardiomyopathy Drug: Eleclazi
A Study Investigating t Terminated Geographic Atrophy Drug: Lampali
Efficacy and Safety of Terminated Critical Limb Ischemia Biological: HG
A Study of Ruxolitinib i Terminated Pancreatic Cancer Drug: Ruxoliti
Study to Assess EfficacWithdrawn Cystic Fibrosis Drug: AZD1236
Study of the Safety andTerminated Alzheimer's Disease|Dementia Drug: Drug: E
Nintedanib (BIBF 1120)Terminated Mesothelioma Drug: Nintedan
A Phase III Trial of Ni Terminated Neoplasms, Breast|Carcinoma of Breast|HumanDrug: nirapari
A Phase III Study of Xi Terminated Metastatic Colorectal Cancer Drug: Xilonix|
Phase 3 Extension StudTerminated Amyotrophic Lateral Sclerosis Drug: Dexpram
Efficacy, Safety and TolTerminated Ulcerative Colitis Drug: Propiony
Efficacy and Safety StuTerminated Arrhythmias, Cardiac|Heart Diseases|Cardiovascu Drug: Azimilid
Dabigatran Etexilate in Terminated Heart Valve Diseases Drug: warfarin
Safety and Efficacy St Terminated Urinary Bladder Neoplasms Biological: re
Safety and EffectivenesTerminated Aortic Valve Replacement Device: Percev
LUX-Head&Neck 2: A Pha Terminated Head and Neck Neoplasms Drug: Placebo|
INcrease Of VAgal Ton Terminated Left Ventricular Dysfunction|Heart Failure Device: Cardio
A Phase 3 Study of Sil Withdrawn Multiple Myeloma Drug: Placebo
Tivantinib Plus Erlotin Terminated Non Squamous, Non-small-cell Lung Cancer Drug: Tivantini
A Study of Tocilizumab Terminated Spondylitis, Ankylosing Drug: Tocilizu
Pazopanib HydrochloridTerminated Lung Cancer Drug: pazopani
Brodalumab (AMG 827)Terminated
i Crohn's Disease Biological: Br
Eribulin Mesylate AdminTerminated Bladder Cancer Drug: Gemcitab
Efficacy and Tolerabili Terminated Hepatocellular Carcinoma Non-resectable|HepatDrug: ABT-869
A Study of Tasisulam-s Terminated Melanoma Drug: Tasisula
Study Evaluating SafetyTerminated Hemophilia A Drug: moroctoc
Atacicept in Multiple ScTerminated Relapsing Multiple Sclerosis Drug: Atacicep
Clinical effecT of Heart Terminated Heart Failure (HF)|Atrial Fibrillation Device: Home Mo
Long-Term Analgesic EfTerminated Osteoarthritis|Arthritis Drug: NSAID|B
An Efficacy and Safety Terminated Ovarian Cancer Drug: MORAb-00
Tiotropium/Salmeterol Terminated Pulmonary Disease, Chronic Obstructive Drug: Tiotropi
A Phase 2 Study of AtacTerminated Relapsing Multiple Sclerosis Drug: Atacicep
A Trial Of [S,S]-ReboxetTerminated Diabetic Neuropathies Drug: Placebo|
BAY79-4980 ComparedTerminated
to Hemophilia A Biological: rF
Long-term OL Study of [Terminated Fibromyalgia Drug: [S,S]-re
Investigating Clinical Terminated Arthritis, Rheumatoid Drug: Ofatumu
A Phase IIa Study Of MTerminated Fracture Healing Drug: SB-7516
Safety And Efficacy Of Terminated Pulmonary Disease, Chronic Obstructive Drug: UK-432,
Prospective, Open-Label Terminated Cushing's Syndrome Drug: Mifepris
A Study of Abatacept inTerminated Crohn's Disease Drug: abatacep
Study of Epratuzumab iTerminated Systemic Lupus Erythematosus Drug: Epratuz
Study of Epratuzumab iWithdrawn Systemic Lupus Erythematosus Drug: Epratuz
Global Efficacy Study oTerminated Alzheimer Disease|Dementia Drug: MPC-78
Assessment of Safety, Terminated Rheumatoid Arthritis (RA) Drug: SMP-11
Carotid B-mode Ultrasou Terminated Mixed Hyperlipidemia Drug: torcetrap
Docetaxel in Combinati Terminated Prostate Cancer Biological: Im
The Efficacy and SafetyTerminated Peripheral Arterial Disease (PAD)|Diabetes MelliDrug: REX-001
A Study of BermekimabTerminated
f Hidradenitis Suppurativa Drug: Bermeki
Efficacy and Safety of Terminated Hypertriglyceridemia Drug: evinacu
Effect of RO7049665 onTerminated Autoimmune Hepatitis|Autoimmune Chronic Hepa Drug: RO70496
Clinical Trial to Evalua Terminated COVID-19 Drug: ATR-002
Phase 3 Study of ZandeTerminated Follicular Lymphoma (FL)|Non Hodgkin Lymph Drug: Zandeli
A Study to Evaluate LonTerminated Idiopathic Pulmonary Fibrosis Drug: PRM-151
A Clinical Study Evalua Withdrawn Carcinoma, Non-small Cell Lung Cancer Biological: niv
CAMPFIRE: A Study of Terminated Synovial Sarcoma Drug: Ramucir
Study of AMG 199 in Sub Terminated MUC17-positive Solid Tumors Drug: AMG 19
A Study of TAK-994 in Terminated Narcolepsy Type 1 (NT1)|Narcolepsy Type 2 (N Drug: TAK-994
PROCLAIM: CX-072-002: Terminated Solid Tumor|Unresectable or Metastatic Melan Drug: CX-072|
A Study to Assess the STerminated Atopic Dermatitis Drug: ZPL389
Daratumumab Retreatmen Terminated Multiple Myeloma Drug: Carfilz
Safety and Tolerability Terminated Immune Thrombocytopenic Purpura (ITP) Biological: Bi
A Study of Baricitinib Terminated Systemic Lupus Erythematosus Drug: Baricitin
Basket Trial in Solid T Terminated Solid Tumor Drug: Debio 1
Effects of Livoletide ( Terminated Prader-Willi Syndrome|Hyperphagia Drug: Livoleti
A Study of Isatuximab- Terminated Lymphoma Drug: isatuxi
A Study of Tislelizuma Terminated Carcinoma, Non-Small-Cell Lung Drug: Tisleliz
A Study to Find Out if Terminated Chronic Thromboembolic Pulmonary HypertensiDrug: Selexipa
Efficacy and Safety St Terminated Crohn's Disease Drug: Ontamal
A Study of Baricitinib Terminated Systemic Lupus Erythematosus Drug: Baricitin
OMO-1 in Solid MalignaTerminated Neoplasms Drug: OMO-1
A Proof of Concept Stu Terminated C3 Glomerulonephritis|C3 Glomerulopathy|ImmuDrug: Danicop
A Study of Tilsotolimod Terminated Metastatic Melanoma Drug: Ipilimum
UNITE Study: UnderstaTerminated Glioblastoma Multiforme Drug: Steroid
A Study to Test WhetheTerminated Endometriosis Drug: BAY1128
Efficacy and Safety StuTerminated Small Fiber Neuropathy|Diabetes Mellitus Drug: BIIB074
Study Evaluating Effica Terminated Triple Negative Breast Cancer Drug: SAR566
Clinical Trial Evaluati Terminated Tricuspid Regurgitation Device: TriCin
A Study to Evaluate theTerminated Alzheimer's Disease Drug: Semorin
An European Union (EU) Terminated Aortic Aneurysm, Abdominal Device: TREO
A Study of CNP520 Versu Terminated Alzheimers Disease Drug: CNP520
Study of Safety of QAWTerminated Asthma Drug: QAW039
A Study of Efficacy andWithdrawn Crohn Disease Drug: GED-030
Study to Evaluate the AnTerminated Respiratory Syncytial Viruses Drug: lumicita
Long-Term Extension StTerminated Dementia With Lewy Bodies Drug: RVT-101
ACZ885 for the TreatmeTerminated Abdominal Aortic Aneurysm (AAA) Drug: ACZ885|
A Phase III Double-bli Terminated Duchenne Muscular Dystrophy (DMD) Drug: Idebenon
Ph II Nintedanib vs. If Terminated Sarcoma, Soft Tissue Drug: Nintedan
Study of Safety and Eff Terminated Solid Tumors for Phase Ib|Pancreatic Cancer forDrug: ribocicli
CER-001 Therapy as a T Nerminated Familial Hypoalphalipoproteinemia Drug: CER-001
Perceval Sutureless Im Terminated Aortic Valve Disease|Aortic Stenosis Device: Perceva
Phase I-Ib/II Study of Terminated Advanced Malignancies Drug: MBG453|
Phase I Study of LXH25Terminated NSCLC|Ovarian Cancer|Melanoma|Other Solid Drug: LXH254
A Study to Assess the PTerminated Respiratory Syncytial Virus Infections|Virus Dis Drug: JNJ-537
A Multicenter Study to Terminated Acute Antibody-Mediated Rejection (AMR) Biological: Ci
A Study of Idasanutlin Terminated Leukemia, Myeloid, Acute Drug: Cytarabi
A Phase 1 Study of AMG Terminated Relapsed/Refractory AML|Minimal Residual Dis Drug: AMG 33
221AD302 Phase 3 Study Terminated Alzheimer's Disease Drug: Aducanu
Extension Study of AtalTerminated Cystic Fibrosis Drug: Ataluren
Improve Management ofTerminated Heart Failure|Infection Other: Procalci
A Study of BMS-986148Terminated Advanced Cancer Drug: BMS-986
A Study of Taselisib + Terminated Breast Cancer Drug: Taselisi
Efficacy and Safety of Terminated Asthma Drug: QGE031|
The VITAL Amyloidosis Terminated Primary Systemic (AL) Amyloidosis Drug: NEOD001
Reduction of AF Ablati Terminated Paroxysmal Atrial Fibrillation Device: Cerebr
A Study Investigating t Terminated Geographic Atrophy Drug: Lampali
A Study of RO6885247 Terminated
i Muscular Atrophy, Spinal Drug: RO68852
Flotetuzumab in PrimaryTerminated AML Biological: Fl
Multicenter Study of RoTerminated Non-small Cell Lung Cancer Drug: Rociletin
OnabotulinumtoxinA forTerminated Urinary Incontinence|Urinary Bladder|OveractiveBiological: B
Pacritinib Versus Best Terminated Primary Myelofibrosis|Post-polycythemia Vera MDrug: Pacritin
Safety and Efficacy of Terminated c-MET Inhibitor; PI3K Inhibitor, PTEN Mutatio Drug: INC280|D
A Study of Tadalafil fo Terminated Muscular Dystrophy, Duchenne Drug: Tadalafi
Study on Autologous Ost Terminated Long Bone Non-Union Drug: PREOB®
An Open-label, Randomi Terminated Advanced Non Small Cell Lung Cancer (NSCLCDrug: AUY922|
Efficacy and Safety of Terminated Pancreatic Neuroendocrine Tumors (pNET) Drug: BEZ235|
A Study Comparing SiltuTerminated Myelodysplastic Syndrome Drug: Siltuxim
Follow on Study From Terminated Thromboembolism|Heart Valve Prosthesis Drug: dabigatr
Open Label Study of G Terminated Muscular Dystrophies Drug: GSK240
Macitentan for the TreatTerminated Digital Ulcers Drug: Maciten
Safety and Efficacy StuWithdrawn Hepatitis C Virus (HCV) Biological: Peg
A Long Term Study To E Terminated Psoriasis Drug: CP-690,
Study to Assess the EffTerminated Carcinoid Syndrome Drug: BIM 23A
A Long-Term Safety And Terminated Alzheimer Disease Drug: Bapineu
A Study To Evaluate theTerminated Relapsing Multiple Sclerosis Drug: Laquini
Study to Evaluate Effic Terminated Premature Ejaculation Drug: Tramado
A Study to Evaluate theTerminated Pain|Neuralgia, Postherpetic|Neuralgia|MononeuDrug: JNJ-421
SonoVue Guided ProstaTerminated Prostate Cancer Drug: Contrast
Study of Dasatinib in I Withdrawn Chronic Myeloid Leukemia|Acute LymphoblasticDrug: Dasatini
A Study of CombinationTerminated Rheumatoid Arthritis Drug: Placebo|
A Phase III Study to Te Terminated Melanoma Drug: GSK 213
An Exploratory Study toTerminated Cystic Fibrosis|Allergic Bronchopulmonary Asperg Drug: Omalizu
Study of Safety and EffiSuspended Heart Failure|Mitral Regurgitation Device: PTMA (
Efficacy and Safety of Terminated Acute Lung Injury|Acute Respiratory Distress S Drug: HL 10
Echocardiography GuidTerminated Heart Failure|Ventricular Dyssynchrony Device: Implan
To Assess The EfficacyTerminated Pulmonary Arterial Hypertension Drug: Sildenafil
Study of BMS-275183 inTerminated Non-small Cell Lung Cancer Drug: BMS-275
[S,S]-Reboxetine Add-OTerminated Pain Drug: [S,S]-Re
Efficacy and Safety of Terminated Blood Loss, Surgical|Postoperative HemorrhageDrug: Trasylol
A Randomized Controlled Terminated Carcinoma, Non-Small Cell Lung Drug: Nexavar
A Study of Visilizumab iTerminated Ulcerative Colitis Drug: visilizumab
Study Comparing BloodWithdrawn Hemophilia A Drug: ReFacto
Study of BMS-275183 inTerminated Non-small Cell Lung Cancer Drug: BMS-275183
GVAX® Vaccine for Pros Terminated Prostate Cancer Biological: Im
Radiation Therapy, MitoTerminated Anal Cancer Drug: cisplatin
Temozolomide With or Wi Terminated Melanoma (Skin)|Metastatic Cancer Drug: temozolomide|Radiatio
An Investigation of TA Terminated Advanced Solid Tumors Drug: TAS-119
A Phase I Study of LXSTerminated Uveal Melanoma Drug: LXS196
Phase 1 Single and MultTerminated Healthy|Rheumatoid Arthritis Drug: FPA008|
A Phase I/II Study of Terminated Duchenne Muscular Dystrophy Drug: Regimen
Phase IIb Study of PROTerminated Duchenne Muscular Dystrophy Drug: PRO045,
European Trial of DroneTerminated Congestive Heart Failure Drug: Droneda
Safety, Tolerability an Terminated Cardiac Failure Aggravated Drug: Sotaglif
Thoratec Corporation HTerminated Cardiogenic Shock Device: Heart
ABSORB PHYSIOLOGY Terminated
Cli Coronary Artery Disease Device: Bioab
Atherosclerosis Underl Terminated Carotid Artery Plaque|Arteriosclerosis|Obesity| Drug: Rimonab
Empiric Quinidine for Withdrawn Arrhythmia Drug: quinidin
Implitapide in Patient Terminated Familial Hypercholesterolemia Drug: Implitapide
Post Implant SyndromeWithdrawn Abdominal Aortic Aneurysm|Inflammatory Resp Procedure: En
Reduced Dose-density Terminated Bone Giant Cell Tumor Drug: Denosum
Safety and Efficacy of Terminated Complex Perianal Fistula|Crohn Disease Drug: Expanded
First in Human Study toTerminated Anti-MAG Neuropathy Drug: PPSGG|D
Study With AtezolizumaTerminated MSI|ColoRectal Cancer|Chemotherapy|Resista Drug: Atezoli
A Study of Potential Di Suspended Alzheimers Disease|Dementia|Alzheimers Diseas Drug: Gantene
A Study to Test Differe Suspended Neoplasms Drug: BI 7651
A Phase 3, Open-LabelTerminated Amyotrophic Lateral Sclerosis Drug: Reldese
Nomacopan Therapy in Withdrawn
A Bullous Pemphigoid Drug: nomacop
Study of Efficacy and STerminated Chronic Inducible Urticaria Drug: Ligelizu
A Study to Evaluate theTerminated Amyotrophic Lateral Sclerosis Drug: Reldese
177Lu-DTPA-Omburtamab Terminated Medulloblastoma, Childhood Drug: 177Lu-
Long-term Treatment ofTerminated Congenital Cystic Kidney Disease Drug: Venglus
Early Phase Human Drug Terminated Centronuclear Myopathy Drug: DYN101
A Study of IMR-687 in STerminated Sickle Cell Disease Drug: IMR-687
A Study of IMR-687 in Terminated β Thalassemia Drug: IMR-687
A Study to Evaluate theTerminated Alzheimer Disease Drug: Ganten
A Study to Test Long-teTerminated Crohn Disease Drug: Spesoli
A Study to Evaluate theTerminated Alzheimer Disease Drug: Ganten
Extension Study of PatiTerminated Basal Cell Nevus Syndrome Drug: Patidegi
Study to Assess the SafTerminated Amyotrophic Lateral Sclerosis Drug: BIIB078
An Efficacy and Safety Terminated Amyotrophic Lateral Sclerosis|ALS Drug: Placebo|
Efficacy and Safety of Terminated Glomerulonephritis, Membranous Drug: LNP023|
Effects of JNJ-53718678 Terminated Respiratory Syncytial Virus Infections Drug: JNJ-537
Safety and Efficacy StuTerminated Immune Mediated Necrotizing Myopathy Drug: zilucopl
Study to Evaluate the STerminated Pancreatic Ductal Adenocarcinoma|Colorectal Drug: 177Lu-3
Effects of Oral LevosimTerminated Amyotrophic Lateral Sclerosis Drug: Levosim
Safety, Tolerability, E Terminated Colitis, Ulcerative Drug: GSK2831
Isatuximab in CombinatTerminated Acute Lymphoblastic Leukemia|Acute Myeloid Drug: Monteluk
Arimoclomol in Amyotrop Terminated Amyotrophic Lateral Sclerosis Drug: Arimocl
Assessing the Efficacy Terminated Central Retinal Vein Occlusion Drug: Broluciz
Study of Safety and Eff Terminated Triple Negative Breast Cancer (TNBC) Biological: sp
Efficacy and Safety of Terminated Autism Spectrum Disorder (ASD) Drug: Bumetani
Safety, Preliminary Eff Terminated Neoplasm Drug: Isatuxi
Safety and Efficacy StuTerminated Alzheimer Disease Drug: Gantene
An Efficacy and Safety Terminated Exostoses, Multiple Hereditary Drug: Palovaro
A Study of ARRY-371797 Terminated Dilated Cardiomyopathy|Lamin A/C Gene MutatiDrug: ARRY-37
A Study of Tofacitinib i Terminated Ulcerative Colitis Drug: CP-690,
Study to Evaluate the STerminated Heart Failure|Healthy Volunteer Drug: AMG 986
Efficacy and Safety of Terminated Multiple Sclerosis Drug: BIIB033
Study of Aztreonam for Terminated Pseudomonas Aeruginosa Respiratory Tract Infec Drug: AZLI|Dru
A Phase 2 Study of NI Terminated NSCLC, Non Small Cell Lung Cancer|RCC, Renal Drug: NIR178|
Study of the Safety an Terminated Solid Tumors and Lymphomas Drug: MIW815|
Evaluation of 2 Intensi Suspended Very High Risk Neuroblastoma Radiation: mIB
Safety and Efficacy of Terminated Epidermolysis Bullosa Simplex Drug: diacerei
A Study of B-701 in Com Terminated Locally Advanced or Metastatic Urothelial Cell Drug: B-701|D
Extended Access Progra Terminated Pulmonary Hypertension Drug: Bardoxo
Safety and Efficacy of STerminated Nonalcoholic Steatohepatitis Drug: SEL|Dru
Safety and Efficacy of Terminated Acute Myeloid Leukemia|Acute Lymphoblastic LBiological: AT
Study of Vinblastine in Terminated Refractory Low-grade Gliomas|Recurrent Low-gDrug: Vinblasti
Trabectedin Maintenance Terminated Sarcoma, Soft Tissue Drug: Trabecte
BAX 802 in CHA With InTerminated Hemophilia A Biological: An
Safety and Efficacy StuTerminated Ulcerative Colitis Drug: PTG-100
To Investigate the Pha Terminated Contraception Drug: BAY1007
A Study of Pertuzumab Terminated
i Prostate Cancer Drug: Pertuzu
A Phase Ib/II Study of Terminated Uveal Melanoma Drug: AEB071
Study of Safety and Eff Terminated Non-alcoholic Steatohepatitis (NASH) Drug: Tropifex
Open-label Extension StTerminated Colitis, Ulcerative Drug: LYC-30
An Investigation of the Terminated Gastroesophageal Reflux Disease (GERD)|RefluProcedure: Lap
Long-Term Safety of LaTerminated Geographic Atrophy Drug: Lampali
Clinical Study of Pulse Terminated Pulmonary Arterial Hypertension Drug: Inhaled
CardiAQ-Edwards™ Tran Withdrawn Mitral Valve Regurgitation Device: Transc
An Extension Study to DTerminated Sanfilippo Syndrome|Mucopolysaccharidosis (MDrug: HGT-14
A Study of OcrelizumabTerminated Rheumatoid Arthritis Drug: Ocreliz
Open Label Extension St Terminated Epidermolysis Bullosa Drug: SD-101-
Bardoxolone Methyl in Terminated Connective Tissue Disease-Associated Pulmonar Drug: Placebo
An Open-label Extension Terminated Highly Drug-resistant Focal Epilepsy Drug: UCB094
Non-vitamin K Antagonis Terminated Atrial High Rate Episodes Drug: Edoxaba
Efficacy and Safety of Terminated Contraception Drug: ENG-E2
A Study of CAD106 andTerminated
C Alzheimers Disease Biological: C
A Study to Evaluate theTerminated Solid Tumor Drug: Atezoli
The BROADEN Study: A Terminated
S Familial Partial Lipodystrophy Drug: volanes
Safety and Efficacy of Terminated Ulcerative Colitis Biological: An
Selepressin Evaluation Terminated Septic Shock Drug: selepres
A Study Evaluating if PrTerminated Huntington's Disease Drug: Pridopid
BG00012 and Delay of Di Terminated Multiple Sclerosis, Secondary Progressive Drug: dimethyl
An Extension Study to ETerminated Alzheimer Disease Drug: JNJ-548
HF Assessment With BNP Terminated Heart Failure Drug: Changes
Effect of Eleclazine on Terminated Long QT Syndrome Type 3 Drug: Eleclazi
TINN2: Treat Infection Withdrawn Bronchopulmonary Dysplasia Drug: Azithrom
Open-Label Study of LeTerminated Alzheimer's Disease|Behavioral Variant Fronto Drug: LMTM
Safety and Efficacy of Terminated Relapsed and/or Relapsed-refractory Multiple Drug: Melfluf
Study in Pediatrics Wi Terminated B-Cell Pediatric ALL Drug: Moxetu
Safety and Efficacy StuTerminated Aortic Stenosis Device: Lotus
Study of the Efficacy Terminated Post-polio Syndrome Biological: F
Early Signs of Efficacy Terminated Cystic Fibrosis Drug: Riocigu
Randomised Double-Blin Terminated Rheumatoid Arthritis Drug: Fostamat
LVRC IDE Crossover StTerminated Emphysema Device: LVRC
Study of the Safety an Terminated Alzheimer's Disease|Dementia Drug: EVP-61
Safety and Efficacy of Terminated Arthritis, Rheumatoid Drug: BI 6955
Prostate Guided BiopsyTerminated Prostate Cancer Device: Prosta
Phase 2 Study of MP4CO Withdrawn Anemia, Sickle Cell|Sickle Cell Anemia|Sickle Drug: MP4CO|D
BMN 701 Phase 3 in rhTerminated Late-onset Pompe Disease Drug: BMN 70
Study of the Efficacy anTerminated Cushings Disease Drug: Pasireoti
A Open Label Study to Terminated Hypertension Drug: Ambrise
Ambrisentan for Inoper Terminated Hypertension Drug: Ambrise
A Study of Decitabine Terminated Acute Myeloid Leukemia Drug: Phase1 a
A Study of GDC-0810 SiTerminated Breast Cancer Drug: GDC-081
The Effect of Minocycl Terminated Depressive Disorder Drug: Minocycl
Safety and Efficacy of Terminated Locally Advanced Metastatic BRAF Mutant Mel Drug: LEE011
Adaptive Cardiac ResynTerminated Heart Failure Device: CRT pa
Myfortic - Treatment fo Terminated Graft vs Host Disease Drug: Myfortic
Efficacy, PharmacokinetTerminated Arthritis, Rheumatoid Drug: BI 6955
Ponatinib in Newly Dia Terminated Chronic Myeloid Leukemia Drug: ponatinib
Global Study Looking aTerminated Hepatocellular Carcinoma Drug: RAD001|
Lung Volume ReductionTerminated Emphysema Device: RePne
A Study to Evaluate th Terminated Recurrent Head and Neck Cancer|Carcinoma, SDrug: Amphine
Extension to a RandomiTerminated Familial Chylomicronemia Syndrome (FCS) (HLP Drug: LCQ908
Study of LY2886721 in M Terminated Alzheimer's Disease Drug: LY28867
A Multinational Trial T Terminated Heart Failure|Myocardial Infarction Device: Parach
A Study to Evaluate theTerminated Epilepsy Drug: Zonisami
Dose Ranging Study of Terminated Crohn's Disease Biological: Pl
Gemcitabine HydrochlorTerminated Stage I Uterine Sarcoma AJCC v7|Uterine Cor Other: Clinica
Prevention of UV-induc Terminated Actinic Keratoses|Squamous Cell Carcinomas Device: MD-35
Efficacy of FOLFOX Al Terminated Colorectal Cancer Metastatic|Liver Metastases Drug: FOLFOX6
The Cooling And SurvivTerminated Septic Shock Procedure: Mi
Study of the AeriSeal Terminated Pulmonary Emphysema Device: Treatm
Safety & Tolerability o Terminated Chronic Kidney Disease|Hyperparathyroidism, Drug: Cinacalc
Long-term, Safety and TTerminated Fragile X Syndrome Drug: AFQ056
Safety & Efficacy of Ec Terminated Antibody Mediated Rejection Drug: Eculizu
Early Prophylaxis ImmuTerminated Hemophilia A Biological: Re
GSK1120212 Rollover STerminated Cancer Drug: GSK1120
Efficacy of Everolimus Terminated Islet Cell Tumor Drug: Everolim
A Rollover Protocol to Terminated Solid Tumors Drug: Tivozani
Comparative Trial Of MaTerminated HIV-1 Drug: Maraviroc
Treatment Of Adult Grow Terminated Brain Injuries|Growth Hormone Deficiency Drug: Genotrop
A Study of Olaratumab (Terminated Gastrointestinal Stromal Tumor (GIST) Biological: Ol
Open-Label Extension St Terminated Eosinophilic Asthma Drug: Reslizu
Evaluation of Efficacy Terminated Rheumatoid Arthritis Drug: Fostamat
A Study of the Safety a Terminated Juvenile Idiopathic Arthritis Drug: CNTO 14
Dose-reduced Versus STerminated Myelodysplastic Syndromes|Secondary Acute MOther: Reduced
Long-term Safety StudyTerminated Crohn's Disease Biological: Br
Multiple-Dose Study ApiTerminated Venous Thromboembolism Drug: Apixaba
Permanent Atrial fibri Terminated Atrial Fibrillation Drug: Droneda
Extension Study for Lo Terminated Ankylosing Spondylitis Drug: Sarilum
Extension to QTI571A230 Terminated Pulmonary Arterial Hypertension Drug: Imatinib
Signature Personalised Terminated Arthroplasty, Replacement, Knee Procedure: Va
Influence of Bone Stre Terminated Femoral Fractures|Hip Fractures|Osteoporosis| Device: Densi
Stage IV Surgery VersuTerminated Stage IV Resectable Melanoma Procedure: Sur
Study to Assess the EffTerminated Acromegaly Drug: BIM 23A
A Dose-ranging Study oTerminated Low Back Pain|Low Back Pain, Recurrent Drug: JNJ-421
Efficacy and Safety of Terminated Myeloid Leukemia|Lymphoblastic Leukemia|Lymp Biological: Don
An Efficacy and Safety Terminated Rheumatoid Arthritis Drug: JNJ 385
Clazosentan in Aneury Terminated Aneurysmal Subarachnoid Hemorrhage Drug: Clazose
Single-dose Study to AsTerminated Systemic Juvenile Idiopathic Arthritis Drug: Canakin
A Study for Patients WitTerminated Secondary Progressive Multiple Sclerosis Drug: dirucotid
A Long-Term, Open-Label Terminated Pulmonary Arterial Hypertension Drug: Sitaxsen
European Health Econom Terminated Ventricular Fibrillation|Tachycardia, Ventricular|VDevice: Home
(ARTEMIS-IPF) Randomiz Terminated Idiopathic Pulmonary Fibrosis Drug: Ambrise
Evaluation of Safety an Terminated Hypercholesterolemia Drug: AVE5530
Evaluation of Safety an Terminated Hypercholesterolemia Drug: 25 mg/d
Evaluation of AVE5026 Terminated
i Venous Thromboembolism Drug: Semulop
Study Evaluating 2 DosTerminated Arthritis, Rheumatoid Drug: TRU-015
Protect II, A Prospectiv Terminated Coronary Artery Disease Device: IMPLEL
Phase II Study to EvaluTerminated Pancreatic Cancer Drug: RP101|D
Safety and Efficacy of ATerminated Psoriatic Arthritis Drug: Abatace
Efficacy and Safety of Terminated Rheumatoid Arthritis Drug: ACZ885
Uterine Artery OcclusionTerminated Menorrhagia|Uterine Fibroids Device: Dopple
Zalutumumab in Combina Terminated Non Small Cell Lung Cancer Biological: Za
Conversion From Standa Terminated Kidney Diseases Drug: Lanthan
Verteporfin PhotodynamTerminated Macular Degeneration|Choroidal NeovascularizaDrug: Vertepo
European Trial About ETerminated Obesity|Dyslipidemias Drug: rimonab
Comparative Study of Fle Terminated Atrial Fibrillation Drug: Flecaini
Rimonabant in Abdomina Terminated Obesity Drug: Rimonab
A Study to Investigate t Terminated HCV Infection Drug: ACH-01
Hyperthermia TreatmentTerminated Urinary Bladder Diseases|Urinary Bladder NeopDevice: Syner
Effectiveness Of The D Terminated Narcolepsy Drug: GSK189
Interventional Managemen Terminated Stroke Drug: IV rt-PA
GV1001 and Gemcitabine Terminated Advanced Unresectable Pancreatic Cancer Biological: G
A Clinical Trial Compa Terminated Diabetes Mellitus, Type 1 Drug: Inhaled
Low-risk Fever and Neutr Terminated Fever|Neutropenia|Cancer Drug: ciproflo
A Study To Evaluate T Terminated Growth Hormone Deficiency Drug: PHA-79
Study of Visilizumab VerTerminated Ulcerative Colitis Drug: visilizumab
Comprehensive Rimonab Terminated Cardiovascular Disease Drug: Rimonab
Atrial Fibrillation Clop Terminated Atrial Fibrillation|Vascular Risk Drug: clopido
An Evaluation of the M Terminated Gastroesophageal Reflux Disease Device: Gatek
Evaluation of Recombina Terminated Acquired Bleeding Disorder|Trauma Drug: eptacog
Ancrod (Viprinex™) for Terminated Stroke|Cerebral Ischemia|Brain Infarction Drug: Ancrod (
Intra-arterial Microplas Terminated Stroke Drug: Micropl
Study of Epratuzumab iTerminated Systemic Lupus Erythematosus Drug: epratuz
GW873140 In Combinatio Terminated Infection, Human Immunodeficiency Virus I|HIV IDrug: GW873140
Study Evaluating of CalTerminated Liver Transplantation Drug: Sirolimu
Ultraviolet Light Thera Terminated Lymphoma Drug: bexarote
Radiation Therapy WithTerminated Head and Neck Cancer Biological: epoetin alfa|Radia
Surgery With or WithouTerminated Gastric Cancer Drug: cisplatin|Drug: fluorour
Adjuvant Radiation TherTerminated Metastatic Cancer Procedure: adju
YM598 Added to Mitoxan Terminated Hormone-Refractory Prostate Cancer|Prostatic Drug: YM598
Title Status Conditions Interventions

Global assessment of patient reAcademisch Me All 18 Years and older
Phase (Adult,
4 Older Adult)
Electrophysiological properties| Leiden UniversAll 18 Years and older
Not Applicable
Emory Functional Ambulation Pro Sint MaartenskAll 18 Years and older
Not Applicable
Inspiration volume, mean change Radboud Univer All 16 Years and older
Not Applicable
(Child, Adult, Older Adult)
Vaccine specific antibody titer Maastricht Univ All 18 Years and older
Not Applicable
Loneliness indirect|Loneliness dRadboud Univer All 65 Years and older
Not Applicable
(Older Adult)
Composite endpoint with disease UMC Utrecht|ZAll 18 Years to 110Phase
Part 1: Mass Balance Recovery Boehringer
o IngMale 18 Years to 65Phase
Change from baseline W_ova1 vacc University Me Female Child, Adult, OPhase 1
Incidence rate of major adverse Leiden UniversAll 18 Years and older
Not Applicable
Proportion of time with SpO2 spLeiden UniversAll up to 8 WeeksNot
(Child)
Applicable
Pathologic complete response (pC UMC Utrecht Female 50 Years and older
Phase (Adult,
2 Older Adult)
Primary endpoint - changes in mi Catharina Zie All 18 Years to 75Not
Years
Applicable
change in moderate to vigorous Maastricht UniAll 8 Years to 12 Years
Not Applicable
(Child)
Occlusion of the with Clarivein Rijnstate HospiAll 18 Years and older
Not Applicable
Concordance between MET diagnosi Rijnstate HospiAll 18 Years to 100Not
Years
Applicable
Transpulmonary driving pressurAcademisch Me All 18 Years and older
Not Applicable
Morbidity|Mortality|Survival|Rec Richard van HiAll 18 Years and older
Phase (Adult,
2 Older Adult)
Quality of Life score Maastricht UniAll 18 Years and older
Not Applicable
Postoperative surgical complicaThe Netherland Female 18 Years to 50Not
Years
Applicable
(Adult)
Induction of ventricular arrhyth Diagram B.V. All 18 Years to 85Phase
Nocturnal gas exchange (PCO2University
(k MedAll 18 Years and older
Not Applicable
Visualization of tumor hypoxia Maastricht RadAll 18 Years and older
Phase (Adult,
2 Older Adult)
Pain, as scored on a VAS from 0- Netherlands InAll 18 Years and older
Phase (Adult,
4 Older Adult)
Atrial fibrillation|Medication| Medtronic BR All 18 Years and older
Not Applicable
DBS efficacy as measured as thGGZ Centraal|U All 18 Years to 65Not
Years
Applicable
Percentage of pain relief experi Stimwave TechAll 18 Years and older
Not Applicable
Intestinal permeability measuredWageningen Un All 18 Years to 65Not
Years
Applicable
Percentage of subjects experienMaxima Medica All 18 Years and older
Not Applicable
Change in 24-hour fat balance wi Maastricht UniMale 18 Years to 30Not
Years
Applicable
(Adult)
Hot flush score Rijnstate HospiMale 18 Years and older
Not Applicable
Visualisation of tumor hypoxia Maastricht RadFemale 18 Years and older
Phase (Adult,
2 Older Adult)
The number of patients who rece Catharina Zie All 18 Years and older
Phase (Adult,
4 Older Adult)
Maximal walking distance with stMedical CenteAll 18 Years and older
Phase (Adult,
3 Older Adult)
The bioavailability of voriconazolUniversity MedAll 18 Years and older
Phase (Adult,
4 Older Adult)
Negative appendectomy|MissedUniversity MedAll 18 Years and older
Not Applicable
PAR (expressed as regurgitant vUMC Utrecht All 18 Years and older
Not Applicable
Hand function University MedFemale 45 Years to 75Not
Years
Applicable
Change in capillary recruitment Maastricht UniAll 40 Years to 65Phase
Identify objective parameters t Astellas PharmFemale 35 Years to 65Phase
Clinical signs of delayed cereb Elisabeth-TweAll 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Recurrence of atrial fibrillation| Medisch SpectAll 18 Years to 70Not
Years
Applicable
Bound area under the plasma con University MedAll 18 Years and older
Phase (Adult,
4 Older Adult)
Recurrence of AF|Treatment imMedisch SpectAll 18 Years and older
Not Applicable
1-year overall survival|toxici Radboud Univer All 18 Years to 70Phase
change in acute hemodynamic re Catharina Zie All 18 Years and older
Not Applicable
Post-operative atrial fibrillatio Academisch Me All 18 Years and older
Not Applicable
Glycosylated Haemoglobin (HbA1 Sanofi All 18 Years and older
Phase (Adult,
4 Older Adult)
Number of unscheduled doctor vPrincess Amalia All 1 Year to 4 Years
Phase
(Child)
4
Disease control rate (percentageEuropean OrgaAll 18 Years to 120Phase
Total amount of the vasopressorUMC Utrecht All 18 Years and older
Phase (Adult,
4 Older Adult)
Proportion of chromosomally abBart CJM FausFemale 18 Years to 37Phase
Years 4 (Adult)
Adenosine induced vasodilationRadboud Unive All 18 Years to 65Phase
Plasma concentrations of C-reacMaastricht UniMale 40 Years to 70Not
Years
Applicable
Change in AF Burden After AblaMedtronic BakAll 18 Years and older
Not Applicable
local and regional control|OveralAmsterdam UMC All 18 Years and older
Phase (Adult,
3 Older Adult)
Attention Deficit Hyperactivit Eli Lilly and All 13 Years to 17Phase
Years 4 (Child)
The occurrence of peripheral neu Rijnstate HospiAll 18 Years and older
Not Applicable
duration of delirium|duration of UMC Utrecht All 18 Years and older
Phase (Adult,
3 Older Adult)
Haematology, biochemistry, andAM-Pharma
m All 18 Years to 70Phase
Years 1|Phase
SLEDAI|BILAG|renal function|Pred Erasmus Medic All 18 Years and older
Phase (Adult,
3 Older Adult)
Number of Participants With Comb Medtronic BakAll 18 Years and older
Phase (Adult,
4 Older Adult)
Insulin sensitivity|inflammation| Leiden UniversAll 18 Years and older
Phase (Adult,
3 Older Adult)
Change From Baseline in Absolu Hoffmann-La All 18 Years to 80Phase
Exercise tolerance in meters|Exa Isala All 40 Years to 80Not
Years
Applicable
occurrence of serious side effe UMC Utrecht All 18 Years to 65Not
Years
Applicable
Change on Lebowitz Social Anxie AstraZeneca All 18 Years to 65Phase
Primary outcome measures will R b adboud Unive All 40 Years and older
Not Applicable
Primary patency.|Technical succCordis CorporaAll 30 Years and older
Phase (Adult,
4 Older Adult)
Driving test: Standard DeviationUtrecht Instit All 21 Years to 50Phase
Years 4 (Adult)
To assess the efficacy, and safeErasmus Medic Male 18 Years and older
Phase (Adult,
3 Older Adult)
Changes in plasma HIV-1 RNA lo Academisch Me All 18 Years and older
Phase (Adult,
4 Older Adult)
Quantification of Cochlear Implan Cochlear All 18 Years and older
Not Applicable
proportion of patients in sustai UMC Utrecht All 18 Years and older
Phase (Adult,
4 Older Adult)
Daytime sleepiness|Sleep qualitAmsterdam UMC All Child, Adult, OPhase 4
central venous catheter-related Maastricht UniAll 18 Years and older
Phase (Adult,
3 Older Adult)
The main outcome measurement Academisch
wil Me
Phase (Adult,
3 Older Adult)
To determine the response rate Academisch Me All 18 Years and older
Phase (Adult,
2 Older Adult)
intima media thickness|carotid arLeiden UniversAll 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Pain score|Percentage of responPharmaceuticaAll 3 Months to 17Phase
Years3 (Child)
Effect of linagliptin on vascular RWTH AachenAll U 50 Years and older
Phase (Adult,
3 Older Adult)
Atrial fibrillation recurrence aft University HosAll 18 Years and older
Phase (Adult,
2 Older Adult)
Clinical effect on coughing|QualErasmus Medica All 18 Years and older
Phase (Adult,
3 Older Adult)
Effects of treatment on the mes UMC Utrecht|MAll 18 Years and older
Phase (Adult,
2 Older Adult)
Sufficient interest in participa Ipsen Male Child, Adult, OPhase 2
To investigate the maximum toleSanofi All 18 Years and older
Phase (Adult,
1 Older Adult)
Falls incidence rate|Burden for Radboud Univer All Child, Adult, ONot Applicable
The difference in the change in Vascular Dynam All 18 Years to 70Not
Years
Applicable
The best overall response rate University MedAll 18 Years and older
Phase (Adult,
2 Older Adult)
time to start with antipsychoti Amsterdam UMC All 40 Years and older
Phase (Adult,
4 Older Adult)
Composite endpoint: cardiovascul UMC Utrecht|LeAll 18 Years to 75Not
Years
Applicable
Area under the plasma concentra Radboud UniverAll 18 Years and older
Phase (Adult,
2 Older Adult)
Determine if adjuvant zoledroni Leiden UniversAll 18 Years and older
Phase (Adult,
2 Older Adult)
Change in 24-hour Sodium Excre AstraZeneca All 18 Years to 80Phase
Change in symptom severity|ImpUMC Utrecht All 18 Years to 70Phase
Safety End Point: absence of a Evasc MedicalAll 19 Years and older
Not Applicable
Mechanical Leg Alignment|Cost-e Zimmer, GmbHAll 18 Years and older
Not Applicable
Change from Baseline Cerebrovas Ludwig-MaximilAll 18 Years and older
Phase (Adult,
3 Older Adult)
Recurrence of episodes of AF, atyAbbott MedicalAll 65 Years and older
Not Applicable
(Older Adult)
Efficacy of GSK1605786 at week GlaxoSmithKli All 18 Years and older
Phase (Adult,
2 Older Adult)
the proportion of patients achi Amsterdam UMC All 18 Years and older
Phase (Adult,
2 Older Adult)
first occurrence of intensive ca Radboud UniverAll 18 Years and older
Phase (Adult,
4 Older Adult)
Proportion of medication administRadboud Unive All 16 Years and older
Not Applicable
time to loco-regional progressio The NetherlandAll 18 Years and older
Not Applicable
Regional recurrence rate Maastricht UniFemale 18 Years and older
Not Applicable
Postoperative acute kidney injurUMC Utrecht|ZAll 18 Years and older
Not Applicable
Survival|Quality of Life|Two yea Jeroen Bosch All 18 Years and older
Phase (Adult,
3 Older Adult)
PRIMARY SAFETY ENDPOINTJozef Compar
BartunekAll 20 Years to 75Not
Years
Applicable
absence of exposed bone, fistula Radboud UniverAll 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Percentage of detected atrial fibLeiden UniversAll 18 Years and older
Not Applicable
Percentage of patients achievingIpsen Male 18 Years and older
Phase (Adult,
2 Older Adult)
Next intervention free survival European OrgaAll 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants Achi Sanofi|RegeneAll 50 Years and older
Phase (Adult,
3 Older Adult)
Mean percentage change in targe Gynesonics Female 28 Years and older
Not Applicable
Rate of treatment-emergent adve Ironwood PharmAll 18 Years and older
Phase (Adult,
2 Older Adult)
All-cause Mortality|Percentage GE HealthcareAll 18 Years and older
Phase (Adult,
3 Older Adult)
Time to the First Occurrence Intercept PharAll 18 Years and older
Phase (Adult,
4 Older Adult)
Percentage of Non-responder Pa Abbott MedicalAll 18 Years and older
Not Applicable
Percentage of Participants WhoSanofi|RegeneAll 50 Years and older
Phase (Adult,
3 Older Adult)
The distance covered in six-minVifor Pharma| All 18 Years and older
Phase (Adult,
3 Older Adult)
Change From Baseline in N-term Novartis PharmAll 18 Years and older
Phase (Adult,
2 Older Adult)
HbA1c/TG|Lipid and glycemic p Solvay PharmaAll 18 Years to 75Phase
Number of ventilator-free days Academisch Me All 18 Years and older
Phase (Adult,
3 Older Adult)
Point prevalence of chronic phaAcademisch Me All 18 Years and older
Not Applicable
rate of complete ST-segment resInspireMD All 18 Years and older
Not Applicable
Overall Quality of Life in Epi Cyberonics, InAll 16 Years and older
Phase (Child,
Effectiveness of Treatment on MedtronicNeurAll 18 Years and older
Not Applicable
Frequency of Dose Limiting ToxNovartis Pharm All 18 Years and older
Phase (Adult,
1 Older Adult)
Number of Participants That ReGrünenthal G All 18 Years and older
Phase (Adult,
3 Older Adult)
Number of episodes of urgency Ipsen
an Female 18 Years to 75Phase
Major Pathological Response ( Novartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Participants With Ad Bristol-Myers All 18 Years and older
Phase (Adult,
2 Older Adult)
Composite Major Adverse EventEdwards Lifes All 65 Years and older
Not Applicable
(Older Adult)
Primary Safety Endpoint assesse Medtronic CardAll 18 Years and older
Not Applicable
Mean Change From Baseline in Ipsen All 18 Years to 80Phase
Overall Response Rate (ORR)|Du Janssen Resea All 18 Years and older
Phase (Adult,
2 Older Adult)
Hierarchical composite of all-c Abbott MedicalAll 18 Years to 90Not
Years
Applicable
Failure free survival|Haematolo European SocieAll Child, Adult, OPhase 3
Hernia Occurrence LifeCell All 18 Years and older
Phase (Adult,
4 Older Adult)
Percentage of Participants WithPfizer All 16 Years and older
Phase (Child,
Comparison of time needed to redMedical UniverAll 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Defibrillation Outcome Medtronic CardAll 18 Years and older
Not Applicable
Freedom from device related theNuvaira, Inc. All 21 Years to 65Not
Years
Applicable
Change from baseline to Day 3 inSanofi All 18 Years to 80Phase
The Number of Participants Expe Bristol-Myers All 18 Years to 75Phase
Best overall response|Best overaETOP IBCSG AllPa 18 Years and older
Phase (Adult,
2 Older Adult)
Time-averaged Area Under the Chimerix All 2 Months to 25Phase
Years2 (Child, Adult)
Relative decrease in NT-proBNP| Quantum GenoAll 18 Years and older
Phase (Adult,
2 Older Adult)
Part 1: Area Under the Plasma C Janssen Resea All 1 Year to 30 Years
Phase (Child,
3 Adult)
Median Progression-Free SurvivIpsen All 18 Years and older
Phase (Adult,
3 Older Adult)
freedom from any VT in the overStereotaxis All 18 Years and older
Not Applicable
Progression Free Survival (PFSAstellas PharmAll 18 Years and older
Phase (Adult,
3 Older Adult)
Symptomatic Skeletal Event FreBayer Female 18 Years and older
Phase (Adult,
2 Older Adult)
Incidence of remission (completGlaxoSmithKli All 18 Years to 75Phase
Number of Participants With Pr Medtronic CardAll 18 Years to 75Not
Years
Applicable
Phase Ib Arms A: Probability T Novartis Pharm All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Progression Free Survival (PFSNovartis Pharm Female 18 Years and older
Phase (Adult,
2 Older Adult)
Part 1: Maximum (Peak) PlasmaOtsuka
C Pharma
All 18 Years to 85Phase
Defect fill at 6 months determ Zimmer BiomeAll 18 Years to 55Not
Years
Applicable
(Adult)
Percent change in the Knee injurSmith & NepheAll 18 Years and older
Not Applicable
Hazard Ratio of Prostate-specif Ferring PharmaMale 18 Years and older
Phase (Adult,
3 Older Adult)
Freedom from documented AF/AT Biosense WebstAll 18 Years and older
Phase (Adult,
4 Older Adult)
Number of Patients Who ExperieAstraZeneca All 25 Years to 149Phase
Percentage of Participants Wit Genentech, InAll 18 Years and older
Phase (Adult,
3 Older Adult)
Reduction in LVEF|Change in left Haran Burri, MAll 18 Years and older
Not Applicable
Number of participants with advBayer|Merck All 18 Years and older
Phase (Adult,
1 Older Adult)
Reduction in the occurrence of aChristoph Gasc All 25 Years and older
Phase (Adult,
2 Older Adult)
scar quality|percentage of Glya Euro Tissue BAll 18 Years and older
Phase (Adult,
3 Older Adult)
Phase I: The occurrence/non-occ University of All Child, Adult, OPhase 1|Phase
Biological Response Data BasedUniversity of All 16 Years to 65Phase
Years 2 (Child, Adult, Older Adult)
Percent Change From Baseline GlaxoSmithKli
i All 18 Years and older
Phase (Adult,
2 Older Adult)
Safety and tolerability as asse Intercept PharAll 2 Years to 17 Years
Phase 2(Child)
Part A: Time-Weighted Change N Fovartis PharmAll 18 Years and older
Phase (Adult,
Percentage of Subject's With FrEdwards Lifes All 18 Years and older
Not Applicable
Rate of patients with LV latenc Biotronik SE &All 18 Years and older
Not Applicable
Change From Baseline in UncorrSanofi All 18 Years and older
Phase (Adult,
2 Older Adult)
Percent of Participants With Lo CSL Behring All 18 Years and older
Phase (Adult,
3 Older Adult)
Dose Limiting Toxicities (DLTs) Novartis Pharm All 18 Years and older
Phase (Adult,
1 Older Adult)
Change in left ventricle diamet Institut Natio All 18 Years to 60Phase
Years 3 (Adult)
Sedation failure|Pharmacokinet University of All up to 18 YearsPhase
(Child,3 Adult)
Phase Ib: Frequency and charact Novartis PharmAll 18 Years and older
Phase (Adult,
1 Older Adult)
Number of Participants Who AchGenzyme, a Sa All 18 Years to 70Phase
Uncorrected adequate clinical aAlfasigma S.p.All 18 Years and older
Phase (Adult,
2 Older Adult)
Change From Baseline in the NuShire|Takeda All 18 Years to 70Phase
Percentage of Participants Wit Hoffmann-La All 18 Years and older
Phase (Adult,
4 Older Adult)
Comparison of Event-free Survi Bioniche Life SAll 18 Years and older
Phase (Adult,
3 Older Adult)
Functional Bladder Capacity MedtronicNeurAll 18 Years and older
Not Applicable
Freedom from Atrial ArrhythmiasAbbott MedicalAll 18 Years and older
Not Applicable
To Determine the Presence of DTherapeutic A All 1 Year to 21 Years
Phase (Child,
1|Phase Adult)
Overall Patient Success|ChangeDePuy InternatAll 18 Years to 65Phase
Phase 1: Median Time BetweenMedtronic
E BakAll 18 Years and older
Not Applicable
Maximum Tolerated Dose (MTD)Novartiso PharmAll 3 Months to 18Phase
Years1|Phase
(Child, Adult)
Number of Participants With AdvPfizer All 2 Years to 17 Years
Phase 3(Child)
Absolute BNP change from week Daiichi
0 SankyoAll 18 Years to 85Phase
Percentage of Participants WithHoffmann-La Ro All 2 Years and older
Phase (Child,
Change From Baseline in DoubliMedImmune LLC All 18 Years to 80Phase
Adverse Events|Overall ResponGenmab All 18 Years and older
Phase (Adult,
Incidence of Prosthetic Valve Abbott MedicalAll Child, Adult, ONot Applicable
Progression-Free Survival (PFSPfizer Female 18 Years and older
Phase (Adult,
2 Older Adult)
Change from baseline to all assActelion|Natio All 16 Years and older
Phase (Child,
Change from Baseline to End ofActelion
S All 12 Years and older
Phase (Child,
Change from Baseline to End ofActelion
S All 12 Years and older
Phase (Child,
To compare the safety and efficaMallinckrodt|P All 18 Years and older
Phase (Adult,
3 Older Adult)
all cause mortality at 3 years|a University Of All 50 Years to 80Phase
urinary albumin/creatinine rati Hiddo LambersAll 45 Years to 80Phase
The absorption of oral docetaxelModra Pharmac All 18 Years and older
Phase (Adult,
1 Older Adult)
Change From Baseline in EULAR AbbVie All 18 Years to 75Phase
Number of Participants with OneSarkana Pharm All 18 Years to 65Phase
The AUC of docetaxel (area under Modra Pharmac All 18 Years and older
Phase (Adult,
1 Older Adult)
Pain response|Duration of pain rUMC Utrecht All 18 Years and older
Not Applicable
proportion of successful TrachFlAcademisch Me All 18 Years and older
Not Applicable
Number of Participants With Tr H. Lundbeck AMale 18 Years to 65Phase
Real-world pharmacokinetic para Radboud UniverAll 18 Years and older
Not Applicable
Percentage of Participants with Janssen Resea All 18 Years to 55Phase
Years 1 (Adult)
Hospitalization/death|Recovery General PractiAll 18 Years and older
Phase (Adult,
4 Older Adult)
Glasgow Outcome Scale Exten Leiden UniversAll 65 Years and older
Not Applicable
(Older Adult)
Frequency and severity of trea Galapagos NVMale 18 Years to 54Phase
Years 1 (Adult)
Safety and tolerability of HA-1 Medigene AG All 18 Years and older
Phase (Adult,
1 Older Adult)
PEEP|Lung compliance|Airway rRijnstate HospiAll 18 Years and older
Phase (Adult,
4 Older Adult)
Adverse events|Technical succes Radboud Unive All 18 Years and older
Not Applicable
Accuracy of USPIO MRI on a reRadboud Univer All 18 Years and older
Not Applicable
Technical Success|Clinical Succe TripleMed B.V.All 18 Years and older
Not Applicable
Change From Baseline in Cerebr Cyclerion TherAll 65 Years and older
Phase (Older
1 Adult)
Change in insulin sensitivity|Ch Maastricht UniAll 50 Years to 70Not
Years
Applicable
Maximum Observed Analyte Concen Janssen Pharm All 18 Years to 55Phase
Years 1 (Adult)
Brain vascular function|Cognit Maastricht UniAll 55 Years to 70Not
Years
Applicable
Change in tumor uptake between University MedFemale 18 Years and older
Not Applicable
Number of participants with tr H. Lundbeck AMale 18 Years to 45Phase
Years 1 (Adult)
Area under the curve|Cmax|TmaRadboud Univer All 2 Years to 12 Years
Not Applicable
(Child)
Sorafenib exposure (AUC).|Soraf Academisch Me All 18 Years and older
Phase (Adult,
2 Older Adult)
Percentage of Smooth Pursuit Ey UCB BiopharmAll 18 Years to 55Phase
Years 1 (Adult)
Erythropoiesis|Change from base Prothya BiosolAll 18 Years and older
Phase (Adult,
2 Older Adult)
Tyramine Sensitivity Factor (TS Boehringer IngAll 18 Years to 45Phase
Years 1 (Adult)
Number of Participants with On Eli Lilly and All 18 Years to 65Phase
Change in relative amount of satGenfit All 40 Years to 75Phase
Adverse event assessment in subj Proclara BioscAll 18 Years to 65Phase
efficacy of neo-adjuvant chemoth The NetherlandFemale 18 Years to 40Phase
Years 2 (Adult)
Mean morphine consumption in Zuyderland
mi MeAll 18 Years and older
Phase (Adult,
4 Older Adult)
Frequency of Adverse Events ARadboud Univer All 18 Years to 35Not
Years
Applicable
(Adult)
Standardized uptake values (SUV Boehringer IngAll 18 Years and older
Phase (Adult,
1 Older Adult)
Anxiety disorder status|Number Erasmus Medic All 8 Years to 16 Years
Not Applicable
(Child)
Delirium detection rate|Length oUMC Utrecht|CAll 18 Years and older
Not Applicable
Delirium detection rate|Length oUMC Utrecht|CAll 70 Years and older
Not Applicable
(Older Adult)
overall response rate|progressi Radboud Univer All 18 Years and older
Phase (Adult,
2 Older Adult)
Time to flare* in subjects with LEO Pharma All 18 Years and older
Phase (Adult,
4 Older Adult)
Intravascular enhancement|Enhan Maastricht UniAll 18 Years and older
Not Applicable
Number of Participants with On Eli Lilly and All 18 Years to 65Phase
Discrimination of tumorous and University MedAll 18 Years and older
Phase (Adult,
1 Older Adult)
Phase I: The recommended phase The2NetherlandAll 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Occurrence of dose limiting evenGrünenthal G Male 18 Years to 55Phase
Years 1 (Adult)
VAS-score|lower extremities mus Maastricht UniFemale 12 Years to 18Not
Years
Applicable
(Child, Adult)
Lesion (vulvar HSIL or wart) siz Maruho Co., LtAll 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Participants That ExpBristol-Myers All 18 Years to 70Phase
Years 1|Phase
Ex vivo mitochondrial respiratio Maastricht Univ
All 65 Years to 75Not
Years
Applicable
(Older Adult)
NRS during walking/weightbeariAcademisch Me All 18 Years to 80Not
Years
Applicable
Hidradenitis Suppurativa Clinic M.B.A. van DoAll 18 Years to 80Not
Years
Applicable
Suspected diagnosis|Major adveVieCuri MedicaAll 18 Years and older
Not Applicable
Time Averaged Maximum Flow V Maastricht UniAll 18 Years and older
Not Applicable
Reduction of apnea/hypopnea ind University MedAll 18 Years and older
Not Applicable
Influx of inflammatory cells in T. van der Pol All 18 Years to 45Phase
Years 4 (Adult)
degree of repigmentation Netherlands InAll 18 Years and older
Not Applicable
Accuracy of maximum tumor size Maastricht UniFemale 18 Years and older
Not Applicable
Total amount of activity leakageUMC Utrecht All 18 Years and older
Not Applicable
Migration, measured by means of Leiden UniversAll 18 Years and older
Not Applicable
Biodistribution and kinetics of University MedAll 18 Years and older
Not Applicable
Pain relief|Pain reduction|Activ Academisch ZiAll 18 Years to 75Not
Years
Applicable
Number of participants with treaUMC Utrecht All 18 Years to 100Phase
Dose distribution on the CTV (mMaastricht RadAll 18 Years and older
Not Applicable
Number of patients with treatmeAcademisch Me All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
NRS score|age of patient|PrevioRijnstate HospiMale 40 Years to 85Not
Years
Applicable
total system delay (TSD) to intr Leiden UniversAll 18 Years and older
Not Applicable
Breath-by-breath oxygen consum European RespiAll 18 Years and older
Not Applicable
Number of Participants Experie Gilead Scienc All 18 Years and older
Phase (Adult,
4 Older Adult)
Improved progression free survivMaastricht RadAll 18 Years and older
Phase (Adult,
2 Older Adult)
Whole body insulin sensitivity|MeMaastricht UniMale 18 Years to 40Not
Years
Applicable
(Adult)
Absolute uptake of [18F]dabrafeUniversity MedAll 18 Years and older
Not Applicable
Time to peak|Regional Blood voUMC Utrecht Female 18 Years to 100Not
Years
Applicable
Mood|Motor scores|Impulsivity| Maastricht UniAll Child, Adult, ONot Applicable
Success rate, objective|SuccessMeander Medic All 18 Years and older
Not Applicable
Prostate specific antigen (PSA) Erasmus Medic Male 18 Years and older
Phase (Adult,
2 Older Adult)
Composite of arrhythmia and hear Academisch Me All 18 Years and older
Not Applicable
Number of patients (%) in whichMaastricht UniFemale 18 Years to 85Phase
To Compare Wear of the Polyeth Stryker Europ All 18 Years to 75Not
Years
Applicable
Feasibility|Trail Making Task|C Amsterdam UMC All 30 Years to 70Not
Years
Applicable
Cephalic vein diameter|Radial arLeiden UniversAll 18 Years and older
Phase (Adult,
2 Older Adult)
Percentage change in calf muscle Maastricht UniAll 18 Years to 65Not
Years
Applicable
Number of participants with adveOrion CorporaMale 18 Years to 55Phase
Years 1 (Adult)
Treatment efficacy: histological Maastricht Un Female 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants Wi Hoffmann-La All 18 Years to 60Phase
Years 1 (Adult)
change in plaque cumulative scoCanisius-WilheAll 18 Years to 80Not
Years
Applicable
Number of transfused blood prod St. Antonius HoAll 18 Years and older
Phase (Adult,
4 Older Adult)
Repigmentation % with sheets|GNetherlands InAll 18 Years and older
Not Applicable
Specificity of Stimulation Induc Abbott MedicalAll 18 Years to 75Not
Years
Applicable
Feasibility of MRI in depicting Maastricht UniFemale 18 Years and older
Phase (Adult,
4 Older Adult)
Number of patients (CIN negative Maastricht UniAll 18 Years and older
Not Applicable
The maximum-tolerated dose (MT Maastricht RadAll 18 Years and older
Phase (Adult,
1 Older Adult)
Percentage clearance assessedErasmus
c Medic
Not Applicable
imatinib area under the curve|n Radboud Univer All 18 Years and older
Phase (Adult,
1 Older Adult)
Graft Failure|Physical Knee Fu Soft Tissue ReAll 18 Years to 45Phase
Years 2|Phase
(Adult)
Progression free survival|Clinic Amsterdam UM All 18 Years and older
Phase (Adult,
2 Older Adult)
The co-localisation of the Gros Maastricht RadAll 18 Years and older
Not Applicable
quality of the washed red blood University MedAll 18 Years and older
Not Applicable
Safety and Tolerability of twic GlaxoSmithKli All 18 Years to 75Phase
Leakage Coloplast A/S All 18 Years and older
Phase (Adult,
2 Older Adult)
Adverse events Biomimedica, IAll 18 Years and older
Not Applicable
Single Ascending Dose - safety B a ioprojet Male 18 Years to 45Phase
Years 1 (Adult)
Change in perceived pain measur University of All 18 Years to 65Not
Years
Applicable
Wnt target gene expression (APAcademisch Me All 18 Years and older
Not Applicable
Accuracy of detection of thrombUniversity MedAll 18 Years and older
Not Applicable
Eating in the absence of hunger|Maastricht UniAll 12 Years to 18Not
Years
Applicable
(Child, Adult)
Volunteers falciparum positive Radboud Univer All 18 Years to 35Phase
Years 1|Phase
(Adult)
The difference in functional co Iris Sommer|NMale 18 Years to 40Phase
Years 4 (Adult)
Postoperative intraocular press Maastricht UniAll 18 Years and older
Not Applicable
The percentage of increasementRadboud
o Univer
Not Applicable
Changes to vital signs, routine sTSI, LLC Male 18 Years to 35Early
YearsPhase
(Adult)
1
The Cormack and Lehane grade| Catharina Zie All 18 Years and older
Not Applicable
Hearing assessment|Child develDr. Ann C.T.M.All 3 Weeks to 12Phase
Weeks3 (Child)
The primary endpoint will be chaProf. Dr. J. W All 18 Years and older
Not Applicable
Change in HbA1c from baselineMaastricht
a UniAll 40 Years to 75Phase
Assess the penetration of RO53University MedAll 18 Years and older
Phase (Adult,
2 Older Adult)
The diagnostic performance (sens Maastricht UniFemale 18 Years and older
Not Applicable
Pulmonary toxicity grade 2-4|EsopRadboud Univer All 18 Years to 85Phase
Number of Participants with Adve Maastricht RadAll 18 Years and older
Phase (Adult,
1 Older Adult)
Number of patients with adverseAmsterdam UMC Male 18 Years to 80Phase
Quantification prediction comparAcademisch Me Male 18 Years and older
Not Applicable
Change in aneurysmal vessel wa Amsterdam UMC All 18 Years to 75Not
Years
Applicable
To evaluate if prescribing pancreFoundation forAll 18 Years and older
Phase (Adult,
4 Older Adult)
Number of treatment emergent aAblynx, a San Male 18 Years to 55Phase
Years 1 (Adult)
Dutch translation of mJOA|DASRadboud Univer All 18 Years and older
Not Applicable
Change from baseline to end of Chiesi Farmace All 40 Years and older
Phase (Adult,
3 Older Adult)
Safety and Tolerability|Peak P Santaris Phar All 18 Years to 65Phase
Change in medication adherence| Tilburg Univer All 50 Years and older
Not Applicable
change in coronary artery calcifiDianet Dialysi All 18 Years to 75Phase
Delta Interleukine-6|Cytokines UMC Utrecht|Pr All 18 Years to 80Phase
puncture free survival Radboud Univer All 18 Years and older
Phase (Adult,
2 Older Adult)
decrease in severity of atopic d Agentschap NAll 1 Day to 15 Months
Phase 3 (Child)
Increase of 2 year overall surv Maastricht RadAll 18 Years and older
Phase (Adult,
2 Older Adult)
successful adhesion prevention Radboud Unive Female 18 Years to 40Phase
Years 4 (Adult)
Number of patients in NYHA class Martini
I Hospit All 18 Years and older
Phase (Adult,
3 Older Adult)
Number of undersensing of paroAbbott MedicalAll 18 Years and older
Not Applicable
duration of antibiotic therapy|28 Rijnstate HospiAll 18 Years and older
Not Applicable
urine osmolality|PPIUS urge-sc Radboud Univer All 18 Years to 75Not
Years
Applicable
Maintenance of clinical remissi GlaxoSmithKli All 18 Years and older
Phase (Adult,
2 Older Adult)
The trial objectives are to det Tibotec Pharma All 18 Years to 55Phase
Years 1 (Adult)
Change in renal blood flow as asUniversity MedAll 18 Years and older
Phase (Adult,
2 Older Adult)
Live Birth Rate Per Started Cyc Bart CJM FausFemale 18 Years to 39Phase
Years 4 (Adult)
GERD symptoms|PPI usage|Lower University of PAll 18 Years to 75Phase
The main study parameter will be UMC Utrecht|Ne All 18 Years and older
Phase (Adult,
3 Older Adult)
Cumulative implantation rate|CuUMC Utrecht| Female up to 36 YearsPhase
(Child,
2 Adult)
pathological complete remission|P.O. Wittevee All 18 Years and older
Phase (Adult,
2 Older Adult)
Expression of p38 in cultured c Amsterdam UM All 18 Years to 75Not
Years
Applicable
Result after using the breast lif Maastricht UniFemale 30 Years to 50Not
Years
Applicable
(Adult)
Change From Baseline at 1 andGlaxoSmithKli All Child, Adult, OPhase 2
The main study parameter is theAcerus Pharma Male 50 Years to 80Phase
Quality of life during the study The Netherland Female Child, Adult, OPhase 2|Phase
Device Life Time|Voice Quality| Atos Medical AAll Child, Adult, ONot Applicable
The difference in phosphorylation Maastricht UniMale 18 Years to 28Not
Years
Applicable
(Adult)
vice: Viabahn stent-graft Rijnstate HospAll 18 Years and older
Phase (Adult,
2 Older Adult)
To determine the difference in sRijnstate HospiAll 16 Years and older
Not Applicable
To establish the safety and tole Amsterdam UM All Child, Adult, OPhase 1
Difference in size of myocardia R&D CardiologAll 18 Years and older
Not Applicable
Tumour response, measured with Maastricht RadAll 18 Years and older
Phase (Adult,
3 Older Adult)
m All 18 Years to 70Phase
Years 1|Phase
Non inferiority among the two grRadboud Unive Female Child, Adult, ONot Applicable
Percentage of tumors with HRDThe (p Netherland Female 18 Years to 59Phase
Years 2|Phase
(Adult)
Annexin A 5 targeting in the nonRadboud Univer Male 18 Years to 50Not
Years
Applicable
(Adult)
Safety and tolerability as measurAM-Pharma All 18 Years and older
Phase (Adult,
3-year disease free survival, defDutch ColorecAll 18 Years and older
Phase (Adult,
3 Older Adult)
Common carotid artery intima me Amsterdam UMC All 18 Years to 80Phase
Scores on the practice of safe sePublic Health Male Child, Adult, ONot Applicable
Hamilton Depression Rating Scal GGZ BuitenamstAll 60 Years and older
Phase (Adult,
2|PhaseOlder Adult)
relapse|event-free survival|surviRadboud Univer All 18 Years to 65Phase
Creatinin clearance|length of staMedical Centr All 18 Years and older
Phase (Adult,
3 Older Adult)
number of aggressive incidents|UMC Utrecht|FMale 18 Years to 65Phase
Alignment|Complications|Pain|FBiomet NederlAll 18 Years to 75Phase
Include: Product-related life-t Aeris TherapeuAll 18 Years and older
Phase (Adult,
2 Older Adult)
quantification of amyloid bindingAmsterdam UM Male 60 Years to 80Phase
fatigue|Health related Quality o Sanquin Resear All Child, Adult, OPhase 4
driving test parameters|laboratoUMC Utrecht|Ut All 30 Years to 60Phase
Years 4 (Adult)
driving parameters|laboratory UMC Utrecht|Ut All 30 Years to 60Phase
Years 4 (Adult)
number of reported cases whereRadboud Univer Female 18 Years and older
Not Applicable
Percentual difference in AnnexinRadboud Univer Male 18 Years to 50Not
Years
Applicable
(Adult)
Clinical Pulmonary Infection ScoRadboud Univer All 18 Years and older
Not Applicable
Percentual increase in forearm bRadboud Univer All 18 Years to 50Not
Years
Applicable
(Adult)
Actual driving performance|DaytJ. Uriach and All 21 Years to 35Phase
Years 4 (Adult)
Cardiorespiratory fitness meas Radboud Univer All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
correlation FLT-uptake in coloreRadboud Univer All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Pain intensity difference (PID) aErasmus Medic All 18 Years and older
Phase (Adult,
3 Older Adult)
Determine the prevalence and se UMC Utrecht|CeAll 40 Years and older
Not Applicable
Change in extravascular lung waDr. Jurjan Am All 18 Years and older
Phase (Adult,
2 Older Adult)
Mitochondrial respiration|PhysicMaastricht UniAll 65 Years and older
Not Applicable
(Older Adult)
Limited-efficacy of SDS and MIDUMC Utrecht|Ap All 6 Years to 12 Years
Not Applicable
(Child)
Number of subjects with advers Alkermes, Inc.All 55 Years to 85Phase
Biodistribution of 89Zr-atezol University Me All 18 Years to 75Not
Years
Applicable
Frequency of successful complete Radboud UniverFemale 19 Years and older
Not Applicable
pain|Pain medication used Rijnstate HospAll 18 Years to 65Not
Years
Applicable
local control rate|Decrease in n Amsterdam UMC All 18 Years and older
Not Applicable
Mobility|Quality of life|Mortality Catharina Zie All Child, Adult, ONot Applicable
The area under the curve (AUC)Academic
o MS F
Cemale 18 Years and older
Phase (Adult,
2 Older Adult)
Number of subjects with adverseBBB-Therapeut All 18 Years to 65Phase
Hemoglobin|Serum Ferritin|Ser Maastricht UniFemale 18 Years and older
Phase (Adult,
4 Older Adult)
number of patients with esopha Amphia HospitAll 18 Years and older
Not Applicable
Change from baseline E/E' at 12UMC Utrecht|VAll 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Effect of Aliskiren on Albumin Novartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
The clinical benefit rate (CBR) oAmsterdam UMC All 18 Years and older
Not Applicable
Adverse Event reporting|PharmaBayer All 18 Years and older
Phase (Adult,
1 Older Adult)
immunological response|clinical Radboud Univer All 18 Years to 75Phase
Years 1|Phase
plasma concentrations of etopo Radboud Unive All 18 Years to 75Phase
Safety and Tolerability|Pharmaco AstraZeneca All 18 Years and older
Phase (Adult,
1 Older Adult)
Mean change in neutrophil primGlaxoSmithKli All 18 Years to 50Phase
Years 4 (Adult)
Inflammation: localisation, numbLeiden UniversAll 45 Years to 75Phase
Percentage of subjects with advCSL Behring All 20 Years to 55Phase
Years 1 (Adult)
Monocyte function|Arterial infl Athera BiotechAll 50 Years and older
Phase (Adult,
2 Older Adult)
Safety as assessed by the incidThird HarmonicAll 18 Years to 75Phase
Freedom from unanticipated seriCotera, Inc. All 30 Years to 65Not
Years
Applicable
Diagnostic accuracy to detect i University MedAll 18 Years and older
Not Applicable
Arterial thromboembolic events Ural State MedAll 50 Years to 90Phase
Number of Participants With Tr Shire|Takeda All 3 Years and older
Phase
(Child,
1|Phase
Adult, Older Adult)
The safety of DCR-PH1 evaluated Dicerna Pharma All 12 Years and older
Phase (Child,
Number Patients with Adverse Ev Newron SwedeAll 18 Years to 75Phase
Number of Adverse Events (AEs) Newron SwedeAll 18 Years to 75Phase
Clinical remission without need Erasmus Medica All 3 Years to 17 Years
Phase 4(Child)
To determine MTD of E7107. Safet Eisai Limited|EAll 18 Years and older
Phase (Adult,
1 Older Adult)
Changes in the distribution of t FLUIDDA nv All 40 Years and older
Phase (Adult,
2 Older Adult)
ological: filgrastim|Biological: recombinant European OrgaAll 18 Years to 65Phase
The percent change of the ongoiUMC Utrecht|Vr All 18 Years to 35Not
Years
Applicable
(Adult)
Proportion of Top Embryos Pe UMC Utrecht|Fr Female 18 Years to 36Phase
Years 4 (Adult)
Percentage of patients with a c The Netherland All 18 Years and older
Not Applicable
Sensitivity, specificity, positi Institut de RecAll 18 Years and older
Not Applicable
Knee injury and Osteoarthritis ATRO MedicalAll 30 Years to 65Not
Years
Applicable
Progression free survival|ObjectThe Netherland All 18 Years and older
Phase (Adult,
2 Older Adult)
Tracer accumulation in tumor ti University MedAll 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Uptake (SUV) of 89Zr-cetuximabAmsterdam UMC All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
adequate propofol dose|DetermiErasmus Medic All up to 28 Days Phase
(Child)1
Changes from baseline of TestoAstellas PharmMale 18 Years and older
Phase (Adult,
4 Older Adult)
Percentage of screened patientsP.O. WitteveenAll 18 Years and older
Not Applicable
Primary end point is pain after Rijnstate HospAll 18 Years to 65Not
Years
Applicable
Postoperative wound infections|C Rijnstate HospAll 18 Years and older
Not Applicable
The acute GVHD response rate Henogen
on All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
pathological near complete remiThe Netherland All 18 Years and older
Phase (Adult,
2 Older Adult)
AUC|Cmax|Adverse events Radboud Univer All 18 Years and older
Phase (Adult,
4 Older Adult)
Postoperative stroke|Altered su UMC Utrecht|ZAll 18 Years and older
Not Applicable
Time to recovery|Clinical failu MJM Bonten|Zo Female 18 Years and older
Phase (Adult,
3 Older Adult)
Global cure of the treatment str Leiden Univer All 18 Years to 90Phase
Rate of CR/CRi without MRD defStichting Hem All 18 Years and older
Phase (Adult,
2 Older Adult)
Number of patients free of prog The NetherlanAll 18 Years and older
Phase (Adult,
2 Older Adult)
Length of hospital stay|Mortalit St. Antonius HAll 18 Years and older
Phase (Adult,
4 Older Adult)
Chest pain|Class IA RevasculariErasmus Medic All 18 Years and older
Not Applicable
Difference in early postoperativ Maastricht UniMale 18 Years and older
Not Applicable
To determine the toxicity of ad Maastricht RadAll 18 Years to 100
Phase
In-stent late lumen loss Biotronik AG All 18 Years and older
Not Applicable
Decrease in tumor cell prolifer The Netherland All Child, Adult, OPhase 2
Total atheroma volume|Composite Ural State MedAll 45 Years to 65Phase
Twelve month composite clinicalCordis CorporaAll 18 Years and older
Phase (Adult,
3 Older Adult)
Performance intelligence quotienErasmus Medic All 12 Years to 18Phase
Years 2|Phase
(Child, Adult)
Number of Subjects with TreatmSanofi|Denali All 21 Years to 80Phase
Maximum cystometric capacity (MC Novartis PharmAll 18 Years to 65Phase
Pain response to therapy|Total nPhilips Health All 18 Years and older
Not Applicable
Target Vessel Failure|Acute SteStentys All 18 Years and older
Phase (Adult,
3 Older Adult)
Response Rate|Progression-freeSidney KimmelAll 18 Years and older
Phase (Adult,
2 Older Adult)
Freedom from atrial fibrillation Aalborg UniverAll 18 Years to 75Not
Years
Applicable
- Tumour Response|Progression-f Gustave RoussAll 6 Months to 21Phase
Phase 1: Maximum Tolerated Dos Eli Lilly and All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
degree of subjective anxiety as elbion AG All 18 Years to 65Phase
Time to doubling of the serum cKeryx Biopharm All 18 Years and older
Phase (Adult,
4 Older Adult)
ug: cisplatin|Drug: fluorouracil|Radiation: ra European OrgaAll up to 75 YearsPhase
(Child,
Proportion of patients totally e Radboud Unive All 18 Years and older
Not Applicable
CMR Assessment Of Infarct Size The Medicine All 18 Years and older
Phase (Adult,
3 Older Adult)
Progression-free survival|QualityEuropean Organ All 18 Years and older
Phase (Adult,
3 Older Adult)
Abnormal X-rays, MRIs, CT scans, Pfizer All 25 Years to 75Phase
Success Rate Associated With tCook Group InAll 18 Years and older
Not Applicable
Acquired fusion|Clinical outcom Medtronic SpinAll 18 Years to 70Phase
Safety (intensity and incidence The NetherlanAll 18 Years and older
Phase (Adult,
2 Older Adult)
Exposure (AUC)|The fraction (peRadboud Unive All 18 Years and older
Phase (Adult,
4 Older Adult)
Proportion of subjects with com Chantal Blok| All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Sensitivity and specificity|Likel Maastricht UniFemale 18 Years and older
Not Applicable
anastomotic leakage and/or absc H. Jaap BonjeAll Child, Adult, OPhase 4
Peroperative corneal perforationUMC Utrecht|Dr All 18 Years and older
Not Applicable
Phase I - Number of Subjects WiAutolus Limite All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Time to reappearance of HIV-1 vIrsiCaixa All 18 Years to 65Phase
Change in the steady-state plasTibotec BVBA All 18 Years to 65Phase
All Implant Procedure and Lead Medtronic BR All 18 Years and older
Not Applicable
Cardiovascular Disease or DeatBeth Israel DeAll 50 Years and older
Not Applicable
Angiographic patency|TechnicalThe Universit All 18 Years and older
Not Applicable
Number of Participants With Tr Arrowhead Pha All 18 Years to 70Phase
Incident rate of dose limiting Novartis PharmAll 18 Years and older
Phase (Adult,
1 Older Adult)
Memory as measured by the Camb The George InsAll 18 Years and older
Phase (Adult,
3 Older Adult)
Time between the patient's call University Hosp All 18 Years and older
Not Applicable
Optimal procedural steps|FibroidEthicon, Inc. Female 25 Years to 55Not
Years
Applicable
(Adult)
Patients Will be Evaluated for PaStryker OrthopAll 18 Years and older
Not Applicable
To determine the Maximum Toler Bristol-Myers All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
To assess the safety of taking NBristol-Myers All 18 Years and older
Phase (Adult,
1 Older Adult)
Number of Participants With DosAmgen|MedImAll 18 Years and older
Phase (Adult,
1 Older Adult)
Number of Participants With AdvBristol-Myers All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
A comparison of the incidence ofCohera Medical All 22 Years and older
Not Applicable
Concerned Significant Other (CSIrisZorg All 18 Years and older
Not Applicable
Pain reduction measured by theRadboud
D Univer
Not Applicable
Duration of delirium|Severity of UMC Utrecht|ZAll 18 Years and older
Phase (Adult,
4 Older Adult)
ug: Implitapide Medical Resear All 18 Years to 70Phase
Number of Adverse events Medical CompAll 18 Years to 65Not
Years
Applicable
Number of Participants With Tr Rob Gruters|InAll 18 Years and older
Phase (Adult,
2 Older Adult)
Maximum tolerated dose (MTD)Boehringer
of IngAll 18 Years and older
Phase (Adult,
1 Older Adult)
Highest disease status|PercentaErasmus Medica All 50 Years and older
Phase (Adult,
3 Older Adult)
Cosmetic outcome|tumor respons The NetherlandsFemale 51 Years and older
Not Applicable
ICU-admissions|Mortality|HealthErasmus
c MedicAll 18 Years and older
Not Applicable
Overall mortality until dischar Erasmus Medica All 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Number of subjects with 1 or m BioMarin PharMale 5 Years and older
Phase
(Child,
Occurrence of delirium|OccurrenMaastricht UniAll 18 Years and older
Phase (Adult,
4 Older Adult)
delirium- and coma-free days|Cog Erasmus Medic All 18 Years and older
Phase (Adult,
3 Older Adult)
Change in intratumoral T-cell ( Borstkanker OFemale 18 Years and older
Phase (Adult,
2 Older Adult)
Efficacy of PRO044 (composite BioMarin PharMale 9 Years to 20 Years
Phase 2(Child, Adult)
Complete evacuation|patient satis Radboud Univer Female 16 Years and older
Phase (Child,
Days of therapy of broad-spectruMJM Bonten|BiAll 18 Years and older
Not Applicable
progression free survival|quanti The Netherland All 18 Years and older
Phase (Adult,
3 Older Adult)
Progression Free survival (PFS Netherlands WAll 18 Years and older
Phase (Adult,
2 Older Adult)
Sensitivity of biopsies for resi Dr. Frank ter All 18 Years and older
Not Applicable
Intact neonatal survival until Academisch Me Female 18 Years to 50Phase
Years 2|Phase
(Adult)
Quality of life in patients with Maastricht RadAll 18 Years and older
Not Applicable
Eckhard symptom score at 3 moUniversitätsk All 18 Years and older
Not Applicable
Part 1/2: Resolution...|Part 2/2: Academisch Me All 18 Years and older
Phase (Adult,
4 Older Adult)
Disease control rate Amsterdam UM All 18 Years and older
Phase (Adult,
2 Older Adult)
paroxetine area under the curv Radboud Unive All 18 Years to 65Phase
Percent Change From Baseline Wellspect
i HeaAll 18 Years and older
Not Applicable
Primary Endpoint: Efficacy asseCotera, Inc. All 30 Years to 70Not
Years
Applicable
Disease specific Quality of Lif M.J.W. KoelemAll 18 Years and older
Not Applicable
The primary endpoint is the chanSanofi All 18 Years and older
Phase (Adult,
3 Older Adult)
6-Month Progression-Free SurviKaryopharm Th All 18 Years and older
Phase (Adult,
2 Older Adult)
Change in the Ankle Foot Volu Novartis Pharm All 18 Years to 75Phase
Maximum degree of non-hematologi University MedFemale 18 Years to 50Phase
Years 2 (Adult)
HCV-RNA negativity by qualitatiFoundation fo All 18 Years to 70Phase
Cardiotoxicity (definite or prob Laurence J.C. All 18 Years and older
Phase (Adult,
2 Older Adult)
disease free survival|cumulativ University MedAll 18 Years and older
Phase (Adult,
4 Older Adult)
Number of Serious Adverse Event Bristol-Myers All 18 Years to 55Phase
Years 1 (Adult)
Assessment of proportion of patInCarda Therap All 18 Years to 85Phase
Recurrence-free Survival (RFS) Nektar Therape All 12 Years and older
Phase (Child,
Time to progression|Time to localErasmus MedicaAll 18 Years and older
Phase (Adult,
2 Older Adult)
Event-free survival (EFS)|RecurrBristol-Myers All 12 Years and older
Phase (Child,
28-day all-cause mortality|To in AM-Pharma All 18 Years and older
Phase (Adult,
3 Older Adult)
Daily Parent Report of Evening Eli Lilly and All 6 Years to 16 Years
Phase 4(Child)
Progression-free Survival (PFS)EMD Serono Re All 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Total Occurrences ofLexicon Pharma All 18 Years to 85Phase
Change From Baseline in Clinic GlaxoSmithKli All 40 Years to 80Phase
Target Lesion Failure (TLF)|Ta Svelte MedicalAll 18 Years and older
Not Applicable
Annual Rate of Decline in Forc Galapagos NVAll 40 Years and older
Phase (Adult,
3 Older Adult)
Number of patients with first oc Kowa Research All 18 Years and older
Phase (Adult,
3 Older Adult)
Overall Survival (OS) in Parti AbbVie All 18 Years and older
Phase (Adult,
3 Older Adult)
Overall survival (OS)|Event-fre Goethe Univers All 18 Years to 70Phase
Mean percentage change in targe Gynesonics Female 28 Years and older
Not Applicable
The Percentage of Participants Celgene All 18 Years and older
Phase (Adult,
3 Older Adult)
Good/Moderate European Leagu Sun PharmaceutAll 18 Years to 90Phase
Progression-Free Survival (PFSPfizer Female 18 Years and older
Phase (Adult,
3 Older Adult)
Change in 24-hour average coug Respivant Sci All 40 Years to 89Phase
Number of Participants With T Celgene All 12 Years and older
Phase (Child,
Number of Total Occurrences ofLexicon Pharma All 18 Years and older
Phase (Adult,
3 Older Adult)
Favorable clinical outcome (modJan Stam, MD,All 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Number of Participants With ReShire|Takeda All 16 Years to 80Phase
Event Rate Per 100 Participant-Pfizer All 18 Years and older
Phase (Adult,
3 Older Adult)
Event Rate Per 100 Participant-Pfizer All 18 Years and older
Phase (Adult,
3 Older Adult)
Patients in sustained remission Bristol-Myers All 50 Years and older
Phase (Adult,
3 Older Adult)
Efficacy of Ixekizumab in Parti Eli Lilly and All 18 Years and older
Phase (Adult,
3 Older Adult)
Number of Participants With Com Eli Lilly and All 18 Years and older
Phase (Adult,
3 Older Adult)
Change From Baseline in AlzheiAstraZeneca|ElAll 55 Years to 85Phase
Progression Free Survival (PFS)Novartis Pharm Female 18 Years and older
Phase (Adult,
3 Older Adult)
Overall Survival (OS) for Living Spectrum PharAll 60 Years and older
Phase (Adult,
3 Older Adult)
Overall Survival as of 19 Octo Synta PharmacAll 18 Years and older
Phase (Adult,
3 Older Adult)
Disease-Free Survival (DFS), a Hoffmann-La All 18 Years and older
Phase (Adult,
3 Older Adult)
Change from baseline in urine aBayer All 45 Years and older
Phase (Adult,
2 Older Adult)
Duration of neutropenia grade 1Prolong PharmFemale 18 Years and older
Phase (Adult,
2 Older Adult)
Change from baseline in the ADGreen Valley (All 50 Years to 85Phase
ug: implitapide Medical ResearAll 8 Years to 70 Years
Phase 2(Child, Adult, Older Adult)
Presence of myocardial perfusi Forest Labora All 18 Years and older
Phase (Adult,
3 Older Adult)
Surgical Site Infection (SSI) R 3M|KCI EuropeAll 18 Years and older
Not Applicable
Percentage of Participants Ach GlaxoSmithKli All 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants in C GlaxoSmithKli All 18 Years and older
Phase (Adult,
3 Older Adult)
Primary Objective of the Study| Anthera PharmAll 40 Years and older
Phase (Adult,
3 Older Adult)
Number of Participants With Com Novartis PharmAll 65 Years and older
Phase (Older
3 Adult)
Part 1: Percentage of Particip Biogen All 18 Years to 58Phase
Years 3 (Adult)
Bone Metastasis-free Survival ( Amgen|DaiichiFemale 18 Years and older
Phase (Adult,
3 Older Adult)
Progression-free Survival, as Novartis Pharm All Child, Adult, OPhase 3
Number of Participants That HadNovartis Pharm All 18 Years and older
Phase (Adult,
3 Older Adult)
All Cause Mortality|Assess SafetAgennix All 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Number of participants with advGlaxoSmithKli All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Change in Participant's On-timeNovartis Pharm All 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants WithJanssen BiotecAll 18 Years to 99Phase
Symptomatic recurrent VTE, i.e.University MedAll 18 Years and older
Phase (Adult,
3 Older Adult)
Event Rate of Cardiovascular DeBristol-Myers SAll 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of IGA Responders Novartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Participants With HosJanssen Resea All 13 Years to 85Phase
Descriptive analyses of TBF-12 M( erz PharmacAll 18 Years to 75Phase
Progression Free Survival (PFSHoffmann-La All 18 Years and older
Phase (Adult,
3 Older Adult)
Change From Baseline in AlzheiPfizer All 50 Years to 88Phase
To evaluate Leukaemia Free Surv European SociAll 60 Years to 75Phase
Progression-Free Survival (PFSNovartis Pharm All 18 Years and older
Phase (Adult,
3 Older Adult)
Composite of all fatal or non-f Sanofi All 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants WithNovartis Pharm All 35 Years and older
Phase (Adult,
3 Older Adult)
The Change From Baseline in thPfizer All 50 Years to 89Phase
Successful aneurysm/PAU treatmenVascutek Ltd. All 18 Years and older
Not Applicable
Overall Survival|Progression Fr AstraZeneca Male 18 Years and older
Phase (Adult,
3 Older Adult)
Change from Baseline in fastingTakeda All 18 Years and older
Phase (Adult,
3 Older Adult)
Kaplan-Meier Estimate of the R Novartis Pharm All 25 Years to 65Phase
Progression-free survival as asse
European OrganAll 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Overall Survival|Progression-Fr Halozyme TherAll 18 Years and older
Phase (Adult,
3 Older Adult)
Number of Elafibranor-treated PGenfit All 18 Years to 75Phase
Overall survival rate|Overall s Novartis PharmAll 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants Wit AstraZeneca All 18 Years to 80Phase
Change From Baseline in PrecliJanssen Resea All 60 Years to 85Phase
Years 2|Phase
Treatment difference in HbA1c| Novo Nordisk All 18 Years and older
Phase (Adult,
3 Older Adult)
mi All 18 Years to 80Phase
Number of Participants With An GlaxoSmithKli All 51 Years to 91Phase
Adverse events, laboratory variab
AstraZeneca All 18 Years and older
Phase (Adult,
3 Older Adult)
Time to Major Cardiac Event (CaAstraZeneca All 50 Years and older
Phase (Adult,
3 Older Adult)
Yearly Event Rate for CompositeBoehringer IngAll 18 Years and older
Phase (Adult,
2 Older Adult)
Absolute change from baseline toAstraZeneca All 18 Years and older
Phase (Adult,
3 Older Adult)
To demonstrate the effect of pacDaiichi Sankyo,All 40 Years to 75Phase
Years 2|Phase
The time to first occurrence of Pfizer All 45 Years to 75Phase
Number of Participants With theGlaxoSmithKlinAll 50 Years and older
Phase (Adult,
4 Older Adult)
Non-inferiority for the preventi AstraZeneca All 18 Years and older
Phase (Adult,
3 Older Adult)
Phase 1b: Number of ParticipanAmgen|Merck All 18 Years to 95Phase
ug: cisplatin|Drug: gemcitabine hydrochloride European OrgaAll 18 Years and older
Phase (Adult,
3 Older Adult)
Time to 24-week Confirmed ExpBiogen All 18 Years and older
Phase (Adult,
3 Older Adult)
Rate of decline in quantitative v Crucell Hollan All 18 Years and older
Phase (Adult,
2 Older Adult)
To characterise the effectivenesPfizer All 18 Years and older
Phase (Adult,
2 Older Adult)
ug: cisplatin|Drug: etoposide|Procedure: conEuropean OrgaAll 18 Years to 75Phase
Compare the overall survival (OVerastem, Inc.All 18 Years and older
Phase (Adult,
2 Older Adult)
Spleen Volume Reduction|TotalCTI BioPharm All 18 Years and older
Phase (Adult,
3 Older Adult)
Person Year Rate (PYAR) as Reg GlaxoSmithKli All 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants WithBausch HealthAll 18 Years to 75Phase
Survival rate as measured by KaEuropean OrgaAll 18 Years to 80Phase
Progression free survival|OveraAmgen Female 18 Years and older
Phase (Adult,
3 Older Adult)
Overall Survival|Patient Report Pfizer All 18 Years and older
Phase (Adult,
3 Older Adult)
Rate of misclassification on da Takeda All 18 Years and older
Phase (Adult,
4 Older Adult)
Annualized Relapse Rate (ARR)Sanofi All 18 Years to 55Phase
Years 3 (Adult)
To determine if AMG 479 in comb NantCell, Inc. All 18 Years and older
Phase (Adult,
3 Older Adult)
Comparison between treatment Averagr Pharmac Female 18 Years to 65Phase
Overall survival|Progression-fre European OrgaAll 18 Years and older
Phase (Adult,
3 Older Adult)
ug: KRN7000 European OrgaAll 18 Years and older
Phase (Adult,
1 Older Adult)
ological: lintuzumab European OrgaAll 18 Years and older
Phase (Adult,
2 Older Adult)
ug: BIBX 1382 European OrgaAll 18 Years and older
Phase (Adult,
1 Older Adult)
Number of Participants Reporti Pfizer All 51 Years to 90Phase
Modified Rankin Scale (mRS) cat D-Pharm Ltd. All 18 Years to 85Phase
Overall Survival (OS)|Progressi Amgen All 18 Years and older
Phase (Adult,
3 Older Adult)
Progression-free Survival (PFS)Morphotek|Eisa Female 18 Years and older
Phase (Adult,
3 Older Adult)
Disease-free survival|Overall s European OrgaAll 18 Years and older
Phase (Adult,
3 Older Adult)
ug: CHS 828 European OrgaAll 18 Years and older
Phase (Adult,
1 Older Adult)
Meal stimulated C-peptide (areaDiamyd TherapAll 10 Years to 20Phase
Years 3 (Child, Adult)
Trough FEV1 response|FEV1AUC Boehringer
0 IngAll 40 Years and older
Phase (Adult,
3 Older Adult)
Number of Participants With Cli Janssen Resea All 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
The cumulative number of newlyUCB Pharma|BAll 18 Years to 55Phase
Years 2 (Adult)
Percent weight regained during Pfizer All 18 Years to 70Phase
WOMAC VAS walking pain (questio Wyeth is now aAll 50 Years to 75Phase
Time to all Cause Death|Time t Actelion All 18 Years and older
Phase (Adult,
4 Older Adult)
Complete Response (CR)|Overall Xenikos|NationAll 18 Years and older
Phase (Adult,
3 Older Adult)
Cohorts 1 and 2: Absolute ChanAbbVie All 18 Years and older
Phase (Adult,
2 Older Adult)
Change in Index of Microcircul Arena Pharmac All 30 Years to 80Phase
Time to clinical improvement or Boehringer IngAll 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Mean Percent Change From Basel Galapagos NVAll 18 Years to 50Phase
Years 2 (Adult)
Proportion of patients with a h AstraZeneca All 12 Years to 65Phase
Overall Survival|Overall Object Pfizer All 18 Years and older
Phase (Adult,
3 Older Adult)
Progression-free survival|OveraSanofi All 18 Years and older
Phase (Adult,
3 Older Adult)
ocedure: conventional surgery|Radiation: radEuropean OrganFemale Child, Adult, OPhase 3
The proportion of subjects with Novartis Pharm All 12 Years and older
Phase (Child,
Centrally determine disease-fre QED Therapeuti All 18 Years and older
Phase (Adult,
3 Older Adult)
Progression-free survival (PFS Novartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
To evaluate the ocular and systePfizer All 55 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Change From Baseline in MPO AstraZeneca
Sp All 45 Years to 85Phase
Progression of chronic kidney d Tricida, Inc. All 18 Years to 85Phase
Safety run-in Part: Percentage Novartis Pharm All 18 Years and older
Phase (Adult,
3 Older Adult)
Mean change from baseline in be Chengdu Kangh All 50 Years and older
Phase (Adult,
3 Older Adult)
Change From Baseline in Forced Biogen All 40 Years and older
Phase (Adult,
2 Older Adult)
Number of Participants With Cl Shire|Takeda All 16 Years to 80Phase
Annualized Slope of Change in T Genzyme, a Sa All 18 Years to 55Phase
Years 2|Phase
(Adult)
Area Under the Concentration-TiJanssen Resea All 18 Years and older
Phase (Adult,
2 Older Adult)
Rate of patients with recurrenceAlfasigma S.p.All 18 Years to 80Phase
Years 2|Phase
Efficacy of lenabasum comparedCorbus Pharmac All 18 Years and older
Phase (Adult,
3 Older Adult)
Time to Resolution of 7 PrimaryJanssen Resea All 13 Years to 85Phase
ug: mitomycin C|Procedure: conventional suEuropean OrgaAll up to 80 YearsPhase
(Child,
Amenorrhea (yes/no)|Total volum Bayer Female 18 Years and older
Phase (Adult,
3 Older Adult)
Incidence of Dose Limiting Tox Sanofi All 18 Years and older
Phase (Adult,
1 Older Adult)
Number of Participants With AdvTeva Branded All 18 Years to 70Phase
Part A and B: Occurrence and SEMD Serono Re All 18 Years and older
Phase (Adult,
1 Older Adult)
Mean Change From Baseline in Tevat Branded All 18 Years to 70Phase
Mean Change From Baseline in Tevath Branded All 18 Years to 70Phase
Number of Participants Receiv Incyte CorporaAll 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Number of Participants With DeaBayer|JanssenAll 18 Years and older
Phase (Adult,
3 Older Adult)
Part A: Number of Participants GlaxoSmithKli All 50 Years and older
Phase (Adult,
3 Older Adult)
Number of Participants With DoMillennium PhaAll 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Progression Free Survival (PFSClovis OncologAll 18 Years and older
Phase (Adult,
3 Older Adult)
Change in Peak Oxygen UptakeGilead( Scienc All 18 Years to 65Phase
Years 2|Phase
Change From Baseline in Geogra Hoffmann-La All 50 Years and older
Phase (Adult,
3 Older Adult)
Major Amputation or RevascularAnGes USA, InAll 40 Years to 90Phase
Overall Survival (OS)|Progress Incyte CorporaAll 18 Years and older
Phase (Adult,
3 Older Adult)
Effect on biomarker levels in in AstraZeneca All 18 Years and older
Phase (Adult,
2 Older Adult)
Change from Baseline in Alzheim FORUM Pharma All 55 Years to 85Phase
Progression-Free Survival (PFSBoehringer IngAll 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Progression Free Survival (PFSTesaro, Inc.|E All 18 Years and older
Phase (Adult,
3 Older Adult)
Overall Survival (OS)|Change FJanssen Resea All 18 Years and older
Phase (Adult,
3 Older Adult)
Number of Subjects Who Reported Knopp BioscieAll 18 Years to 80Phase
Proportion of clinical/endoscop sigma-tau i.f.r.All 18 Years to 75Phase
Time to first cardiovascular evenForest LaboratAll 18 Years and older
Phase (Adult,
3 Older Adult)
Comparison of Observed and Pre Boehringer IngAll 18 Years to 75Phase
Disease Free Survival|Overall Su European AssoAll 18 Years and older
Phase (Adult,
2 Older Adult)
Evaluation of the safety: incid Corcym S.r.l All 65 Years and older
Not Applicable
(Older Adult)
Disease Free Survival (DFS)|DisBoehringer IngAll 18 Years and older
Phase (Adult,
3 Older Adult)
Number of participants reachingBioControl Med All 18 Years and older
Phase (Adult,
3 Older Adult)
Progression-free survival (PFS) Centocor, Inc. All 18 Years and older
Phase (Adult,
3 Older Adult)
Overall Survival Following Trea Daiichi SankyoAll 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of ASsessment in AHoffmann-La All 18 Years and older
Phase (Adult,
3 Older Adult)
Overall survival|Progression-fre European OrgaAll 18 Years to 120
Phase
Years2|Phase
Percentage of Participants Wh Amgen All 18 Years to 65Phase
Phase 1b: Number of ParticipantEisai Inc.|Pha All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Overall Survival|Time To Progr Abbott All 18 Years and older
Phase (Adult,
3 Older Adult)
Overall Survival (OS)|Progress Eli Lilly and All 18 Years and older
Phase (Adult,
3 Older Adult)
Number of Participants With Cli Pfizer Male 12 Years and older
Phase (Child,
Number of Subjects With TreatmEMD Serono|MAll 18 Years to 60Phase
Years 2 (Adult)
Days Lost|Heart Failure Clinic Biotronik SE &All 18 Years and older
Not Applicable
Change From Baseline in the We Pfizer All 18 Years to 99Phase
Progression-Free Survival (PFSMorphotek Female 18 Years to 99Phase
Trough FEV1 response|FEV1AUC Boehringer
0 IngAll 40 Years and older
Phase (Adult,
3 Older Adult)
Mean Number of Time ConstantEMD 1 Serono All 18 Years to 60Phase
Years 2 (Adult)
Change from baseline in weeklyPfizer All 18 Years and older
Phase (Adult,
2 Older Adult)
Percentage of Participants WithBayer Male 12 Years to 70Phase
12-lead ECG|Hematology/Biochem Pfizer All 18 Years and older
Phase (Adult,
3 Older Adult)
Number of Participants With a GlaxoSmithKli All 18 Years and older
Phase (Adult,
3 Older Adult)
Data from the study will be usedGlaxoSmithKli All 35 Years to 80Phase
Change From Baseline in Trough Pfizer All 40 Years to 80Phase
Glycemic Disorders Improved orHRA Pharma All 18 Years to 85Phase
Induction Period (IP); Number Bristol-Myers All 18 Years and older
Phase (Adult,
3 Older Adult)
Patient response variable (compUCB Pharma All 18 Years and older
Phase (Adult,
3 Older Adult)
The primary objective is to cont UCB Pharma All 18 Years and older
Phase (Adult,
3 Older Adult)
Cognition and activities of daily Myrexis Inc. All 55 Years and older
Phase (Adult,
3 Older Adult)
To compare the efficacy of SMP-Dainippon SumAll 18 Years and older
Phase (Adult,
2 Older Adult)
Change in intima media thicknesPfizer All 18 Years to 70Phase
Survival|Time to disease progresCell Genesys Male 18 Years and older
Phase (Adult,
3 Older Adult)
Complete healing of all ischemicIxaka Ltd|AndaAll 18 Years to 85Phase
Part 1: Percentage of Participa Janssen Resea All 18 Years and older
Phase (Adult,
2 Older Adult)
Proportion of patients with at Regeneron Pha All 18 Years to 80Phase
Time to Relapse for RO7049665Hoffmann-La All 18 Years to 75Phase
Clinical severity status on a 7- Atriva Therap All 18 Years and older
Phase (Adult,
2 Older Adult)
Progression Free Survival|Over MEI Pharma, In All 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants with Hoffmann-La All Child, Adult, OPhase 3
Overall Reponse Rate (ORR) usiBristol-Myers All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Progression Free Survival (PFSEli Lilly and All 12 Months to 29Phase
Years 1|Phase
(Child, Adult)
Incidence of Dose-limiting toxi Amgen All 18 Years to 99Phase
Parts A and D: Number of Parti Takeda All 18 Years to 65Phase
Overall Response Rate by RECIS CytomX Therap All 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Patients With AdversNovartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
Percentage of Participants Ach Janssen Resea All 18 Years and older
Phase (Adult,
2 Older Adult)
Number and Severity of AdverseMomenta
E Pharm
Phase (Adult,
1|PhaseOlder Adult)
Percentage of Participants Wit Eli Lilly and All 18 Years and older
Phase (Adult,
3 Older Adult)
Objective Response Rate (ORR)| Debiopharm IntAll 18 Years and older
Phase (Adult,
2 Older Adult)
Change in Hyperphagia and Food Millendo TheraAll 4 Years to 65 Years
Phase 2|Phase
Phase 1 - Dose limiting toxici Sanofi All 12 Years and older
Phase (Child,
1|PhaseAdult, Older Adult)
Progression-Free Survival (PFSCelgene|BeiG All 18 Years and older
Phase (Adult,
3 Older Adult)
Percent of baseline Pulmonary Actelion All 18 Years to 85Phase
Number of Participants With Cl Shire|Takeda All 16 Years to 80Phase
Percentage of Participants Ach Eli Lilly and All 18 Years and older
Phase (Adult,
3 Older Adult)
Incidence of treatment-emergentOctimet OncolAll 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Change From Baseline In Composi Alexion All 12 Years and older
Phase (Child,
Summary of Independent Review Idera PharmaceAll 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants WhoAbbVie All 18 Years and older
Phase (Adult,
3 Older Adult)
Absolute change in mean pain ofBayer Female 18 Years and older
Phase (Adult,
2 Older Adult)
Change from Baseline in WeeklyBiogen All 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Participants With InvSanofi Female 18 Years and older
Phase (Adult,
2 Older Adult)
All-cause mortality of the Per P 4Tech Cardio LAll 18 Years and older
Not Applicable
Change From Baseline on the CD Genentech, IncAll 50 Years to 80Phase
Aneurysm-related mortality|StroBolton MedicaAll 18 Years and older
Not Applicable
Time to Event (Diagnosis of Mi Novartis Pharm All 60 Years to 75Phase
Years 2|Phase
Number of Participants With Tr Novartis Pharm All 12 Years and older
Phase (Child,
Clinical remission defined by a Celgene All 12 Years and older
Phase (Child,
Maximum Observed Plasma Concen Janssen Resea All 18 Years and older
Phase (Adult,
2 Older Adult)
Incidence of adverse events andAxovant Scienc All 50 Years to 86Phase
Years 2|Phase
Change From Baseline in Abdom Novartis PharmAll 45 Years and older
Phase (Adult,
2 Older Adult)
Change From Baseline in Forced Santhera PharMale 10 Years and older
Phase (Child,
progression-free survival (PFS)|European OrgaAll 18 Years and older
Phase (Adult,
2 Older Adult)
Incidence of dose limiting toxic Novartis PharmAll 18 Years and older
Phase (Adult,
1 Older Adult)
Change in mmean vessel wall are Cerenis TherapAll 18 Years and older
Phase (Adult,
3 Older Adult)
Proportion of Participants Wit Corcym S.r.l All 18 Years and older
Not Applicable
Safety and tolerability of MBG Novartis Pharm All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Safety and tolerability as ass Novartis Pharm All 18 Years and older
Phase (Adult,
1 Older Adult)
Maximum Observed Plasma Concen Janssen ScienAll 1 Month to 24 Phase
Months1 (Child)
Percentage of Participants WithShire|Takeda All 18 Years to 70Phase
Overall Survival in TP53 WT PoHoffmann-La All 18 Years and older
Phase (Adult,
3 Older Adult)
Subject incidence of adverse evAmgen All 18 Years and older
Phase (Adult,
1 Older Adult)
Change From Baseline in Clinic Biogen All 50 Years to 85Phase
Number of Participants With Tr PTC TherapeutAll 6 Years and older
Phase (Child,
all cause mortality|all-cause ho Brahms AG All 18 Years and older
Not Applicable
Number of Participants With Ad Bristol-Myers All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Progression-Free Survival (PFS)Hoffmann-La Female 18 Years and older
Phase (Adult,
3 Older Adult)
QGE031 Compared to Placebo Novartis
in PharmAll 18 Years to 75Phase
Time to Composite of All-cause P Mrothena BioscAll 18 Years and older
Phase (Adult,
3 Older Adult)
Thromboembolic lesions|Neurocog Biotronik SE &All 18 Years and older
Not Applicable
Change From Baseline in Geogra Hoffmann-La All 50 Years and older
Phase (Adult,
3 Older Adult)
Safety: Incidence of adverse e Hoffmann-La All up to 55 YearsPhase
(Child,1 Adult)
Efficacy based on CR or CRh ratMacroGenics All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Objective Response Rate (ORR)Clovis OncologAll 18 Years and older
Phase (Adult,
2 Older Adult)
Change From Study Baseline inAllergan
t All 12 Years to 17Phase
Years 3 (Child)
Spleen Volume Reduction|TotalCTI BioPharm All 18 Years and older
Phase (Adult,
3 Older Adult)
Number of Patients Reporting Do Novartis PharmAll 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Change From Baseline in Six MiEli Lilly and Male 7 Years to 14 Years
Phase 3(Child)
Global Disease Evaluation as peBone Therapeu All 18 Years to 65Phase
Years 2|Phase
Progression Free Survival (PFSNovartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
Progression Free Survival (PFS)Novartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
Percentage of Participants WhoJanssen Resea All 18 Years and older
Phase (Adult,
2 Older Adult)
Percentage of Patients With AnyBoehringer IngAll 18 Years to 75Phase
Differences between the 6MWDGlaxoSmithKli
at Male 5 Years and older
Phase (Child,
Incidence Rate of New Digital Actelion All 18 Years and older
Phase (Adult,
3 Older Adult)
Efficacy of Lambda + Ribavirin Bristol-Myers All 18 Years to 70Phase
Number of Participants With Tr Pfizer All 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Patients With a Ipsen All 18 Years to 75Phase
Number of Participants Reporti Pfizer All 51 Years and older
Phase (Adult,
3 Older Adult)
Participants With Treatment-Eme Teva Branded All 18 Years to 55Phase
Years 3 (Adult)
Increase in IELT (Intravaginal e Bausch HealthMale 18 Years to 65Phase
The daily evening assessment ofJohnson & JohAll 18 Years to 80Phase
Determination of potentiality of Bracco DiagnosMale 40 Years and older
Phase (Adult,
3 Older Adult)
Incidence and severity of drug Bristol-Myers All 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Percentage of Participants Ach Hoffmann-La All 18 Years to 65Phase
Disease Free Survival (DFS)|OvGlaxoSmithKli All 18 Years and older
Phase (Adult,
3 Older Adult)
Change From Baseline, as Measu Novartis PharmAll 12 Years and older
Phase (Child,
Freedom from MACE at 30 daysViacor|Duke
po Un
Phase (Adult,
2 Older Adult)
28 days mortality|Days alive andLEO Pharma All 18 Years and older
Phase (Adult,
3 Older Adult)
Composite Primary Endpoint: Num Biotronik, Inc. All 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Change From Baseline in the ToPfizer's UpjohnAll 18 Years and older
Phase (Adult,
4 Older Adult)
To assess efficacy of BMS-27518 Bristol-Myers All 18 Years and older
Phase (Adult,
2 Older Adult)
The numerical pain intensity ra Pfizer All 18 Years and older
Phase (Adult,
2 Older Adult)
The primary criterion for effica Bayer All 18 Years and older
Phase (Adult,
3 Older Adult)
Overall Survival (OS) in Patie Bayer All 18 Years and older
Phase (Adult,
3 Older Adult)
ug: visilizumab Facet Biotech|All 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Pharmacokinetic measurement of Wyeth
a is now aMale 18 Years to 64Phase
Years 4 (Adult)
ug: BMS-275183 Bristol-Myers All 18 Years and older
Phase (Adult,
2 Older Adult)
Survival|Bone pain and bone relCell Genesys Male 18 Years and older
Phase (Adult,
3 Older Adult)
Response as measured by RECIST European OrgaAll 18 Years to 75Phase
Years 2|Phase
ug: temozolomide|Radiation: radiation theraEuropean OrgaAll 18 Years and older
Phase (Adult,
3 Older Adult)
Number of participants with tr Taiho Oncology All 18 Years and older
Phase (Adult,
1 Older Adult)
Incidence of dose limiting tox Novartis Pharm All 18 Years and older
Phase (Adult,
1 Older Adult)
Incidence of adverse events andFive Prime TheAll 21 Years to 70Phase
Change from baseline in 6 minutBioMarin PharMale 5 Years to 18 Years
Phase 1|Phase
(Child, Adult)
Change from baseline in 6 minutBioMarin PharMale 5 Years to 18 Years
Phase 1|Phase
(Child, Adult)
Death from any cause or adjudica Sanofi All 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants Wit Lexicon Pharma All 18 Years and older
Phase (Adult,
2 Older Adult)
Clinical stabilization defined Abbott MedicalAll up to 85 YearsNot
(Child,
Applicable
Adult, Older Adult)
Coronary artery endothelial res Abbott MedicalAll 18 Years and older
Not Applicable
Absolute change from baseline in Sanofi All 55 Years and older
Phase (Adult,
3 Older Adult)
Combined endpoint of all cause International All 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
ug: Implitapide Medical Resear All 8 Years to 70 Years
Phase 2(Child, Adult, Older Adult)
Change in inflammatory responsRijnstate HospiAll 50 Years and older
Not Applicable
Progression free survival (PFS) European OrgaAll 18 Years and older
Phase (Adult,
2 Older Adult)
Percentage of subjects in whomTigenix
t S.A.U.All 18 Years and older
Phase (Adult,
3 Older Adult)
Adverse Events (AEs) and Seri Polyneuron PhAll 18 Years to 80Phase
Years 1|Phase
Overall Response Rate|Immune-re Vall d'Hebron All 18 Years and older
Phase (Adult,
2 Older Adult)
Part 1: Difference in change fr Washington Uni All 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Maximum Tolerated Dose (MTD)|Nu Boehringer IngAll 18 Years and older
Phase (Adult,
1 Older Adult)
Long-term safety and tolerabilit Cytokinetics All 18 Years and older
Phase (Adult,
3 Older Adult)
Achievement of Complete Disease AKARI Therape All 18 Years to 99Phase
Change from baseline in Total FrNovartis Pharm All 12 Years and older
Phase (Child,
Effect of reldesemtiv versus pla Cytokinetics All 18 Years to 80Phase
Incidence of adverse events (AEY-mAbs Therap All 3 Years to 19 Years
Phase 1|Phase
(Child, Adult)
Percent Change in Total KidneySanofi All 18 Years and older
Phase (Adult,
3 Older Adult)
Number of Participants With Dr Dynacure All 16 Years and older
Phase (Child,
1|PhaseAdult, Older Adult)
Effect on the incidence of vaso Imara, Inc. All 18 Years to 65Phase
IMR-687 Safety and Tolerabilit Imara, Inc. All 18 Years to 65Phase
Percentage of Participants wit Hoffmann-La All Child, Adult, OPhase 3
Exposure adjusted rate of patienBoehringer IngAll 18 Years and older
Phase (Adult,
2 Older Adult)
Percentage of Participants wit Hoffmann-La All Child, Adult, OPhase 3
Incidence of treatment-emergenSol-Gel Techno All 18 Years and older
Phase (Adult,
3 Older Adult)
Number of Participants with AdvBiogen All 18 Years and older
Phase (Adult,
1 Older Adult)
Change From Baseline In Amyotr Alexion All 18 Years and older
Phase (Adult,
3 Older Adult)
Ratio between baseline Urine PrNovartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
Percentage of Participants WhoJanssen ScienAll 13 Years to 75Phase
Percentage Change From Baselin Ra PharmaceuAll 18 Years to 75Phase
Incidence of dose limiting toxi Ipsen All 18 Years and older
Phase (Adult,
1 Older Adult)
Adverse Events Recording|PulseOrion CorporatAll 18 Years to 120Phase
Number of Participants With Ad GlaxoSmithKli All 18 Years and older
Phase (Adult,
2 Older Adult)
Complete Response (CR) rate inSanofi All 28 Days to 17 Phase
Years 2(Child)
Incidence and severity of TreatmZevraDenmarkAll 18 Years and older
Phase (Adult,
3 Older Adult)
Change From Baseline in Best-cNovartis Pharm All 18 Years and older
Phase (Adult,
3 Older Adult)
Incidence of Adverse Events (A Novartis Pharm All 18 Years and older
Phase (Adult,
1 Older Adult)
Childhood Autism Rating Scale, Institut de Re All 7 Years to 17 Years
Phase 3(Child)
Number of Participants With DoSanofi All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Change From Baseline to WeekHoffmann-La
1 All 50 Years to 90Phase
Annualized Rate of New Osteoch Clementia PharAll 2 Years to 14 Years
Phase 2(Child)
Change from baseline in 6-minutPfizer All 18 Years and older
Phase (Adult,
3 Older Adult)
Number of Participants With Rem Pfizer All 18 Years and older
Phase (Adult,
4 Older Adult)
Participants With Treatment Eme Amgen All 18 Years to 85Phase
Part 1: Overall Response ScoreBiogen All 18 Years to 58Phase
Years 2 (Adult)
Percentage of Participants Wit Gilead Scienc All 3 Months to 18Phase
Part 1: Overall Response Rate (Novartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
Incidence of dose limiting toxi Novartis PharmAll 18 Years and older
Phase (Adult,
1 Older Adult)
Event Free Survival (EFS) Gustave RoussyAll Child, Adult, OPhase 2
Proportion of Subjects Who AchCastle Creek All 4 Years and older
Phase
(Child,
Number of Participants With DoRainier TherapAll 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Long-term Safety Reata PharmaceAll 18 Years to 85Phase
Percentage of Participants WhoGilead Scienc All 18 Years to 70Phase
Graft-versus-host Disease-free, Kiadis PharmaAll 18 Years to 70Phase
Progression Free Survival (PFSGustave RoussAll 6 Months to 20Phase
progression-free survival|SafetyEuropean OrgaAll 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Surgeries With a Baxalta now paMale 12 Years to 75Phase
Proportion of Subjects Receivi Protagonist ThAll 18 Years to 80Phase
Number of bleeding and spottingBayer Female 18 Years to 40Phase
Years 2 (Adult)
Percentage of Participants Wit Hoffmann-La Male 19 Years and older
Phase (Adult,
2 Older Adult)
Phase Ib: Incidence of Dose LimArray Biopharm All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Number of Nonalcoholic SteatohNovartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Subjects With TypesLycera Corp. All 18 Years to 75Phase
Rate of device and/or procedureEndoStim Inc. All 22 Years to 75Not
Years
Applicable
Percentage of Participants WithHoffmann-La All Child, Adult, OPhase 3
Change in 6-minute Walk DistanBellerophon PuAll 18 Years to 85Phase
Freedom from major adverse card Edwards Lifes All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Number of Participants With Tr Shire|Takeda All 12 Months to 48Phase
Months2 (Child)
Percentage of Participants wit Hoffmann-La All 18 Years to 80Phase
Years 1|Phase
Number Of Participants With T Scioderm, Inc.All 1 Month and older
Phase (Child,
Change From Baseline in Six-miReata Pharmace All 18 Years to 75Phase
Percentage of Participants Exp UCB BiopharmAll 18 Years and older
Phase (Adult,
2 Older Adult)
Time from randomisation to the Atrial Fibrill All 65 Years and older
Phase (Older
3 Adult)
Number of In-Treatment Pregnan Organon and Female 18 Years and older
Phase (Adult,
3 Older Adult)
Time to Event (Diagnosis of Mi Novartis Pharm All 60 Years to 75Phase
Years 2|Phase
Percentage of Participants Wit Hoffmann-La All up to 30 YearsPhase
(Child,
1|Phase
Adult)
Randomized Treatment Period: A Pkcea Therapeu All 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
For Cohort 1, Percentage of ParGilead Scienc All 18 Years to 75Phase
Years 2|Phase
Vasopressor- and Mechanical Ven Ferring Pharma All 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Percentage of Participants Wit Prilenia All 21 Years and older
Phase (Adult,
2 Older Adult)
Time to Disability Progression Biogen All 18 Years to 58Phase
Years 3 (Adult)
Number of Participants With Tr Janssen Resea All 50 Years to 85Phase
Change in BNP Alere San Die All 18 Years and older
Not Applicable
Change From Baseline in Mean Gilead
D Scienc All 18 Years to 70Phase
The proportion of surviving inf Institut Natio All 23 Weeks to 28 Phase
Weeks 3 (Child)
Number of Participants With Se TauRx Therape All Child, Adult, OPhase 3
Percentage of Patients Who AchOncopeptides All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Percentage of Participants Wit MedImmune LAll 6 Months to 18Phase
Percentage of Participants WithBoston ScientiAll Child, Adult, ONot Applicable
Change From Baseline in Physi Instituto Grifo All 18 Years to 75Phase
Years 2|Phase
Change of Sweat Chloride ContBayer|Merck All 18 Years and older
Phase (Adult,
2 Older Adult)
OMERACT RAMRIS Synovitis Scor AstraZeneca All 18 Years and older
Phase (Adult,
2 Older Adult)
Mean Change in Six Minute WalBoston ScientiAll 36 Years and older
Not Applicable
Safety of 2 fixed doses of EVP- FORUM Pharma All 55 Years to 85Phase
The Percentage of Patients Wit Boehringer IngAll 18 Years to 82Phase
Diagnostic performance of prostaAdvanced Medic Male 18 Years and older
Phase (Adult,
4 Older Adult)
Duration of hospitalization for Sangart All 16 Years and older
Phase (Child,
Percent Predicted Maximum Insp BioMarin PharAll 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Responders WithNovartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Participants With An GlaxoSmithKli All 18 Years to 80Phase
Change From Baseline in Six MiGlaxoSmithKli All 18 Years to 80Phase
Phase 1: Maximum Tolerated Dos Janssen Resea All 1 Month to 18 Phase
Years 1|Phase
(Child, Adult)
Phase Ia: Maximum Tolerated Do Genentech, IncFemale 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Proportion of patients (among r Janssen Resea All 18 Years to 80Phase
Phase Ib - Incidence of Dose Li Array BioPhar All 18 Years and older
Phase (Adult,
1|PhaseOlder Adult)
Stroke Volume at Rest|Stroke Vo Medtronic CardAll 18 Years and older
Not Applicable
To test whether the addition of European Socie All 18 Years to 60Phase
Years 3 (Adult)
Change of Disease Activity Sco Boehringer IngAll 18 Years to 80Phase
Major Molecular Response (MMR Ariad PharmaceAll 18 Years and older
Phase (Adult,
3 Older Adult)
Maximum tolerated dose of combi Novartis PharmAll 18 Years and older
Phase (Adult,
1 Older Adult)
Meters: 6 Minute Walk Test - Boston ScientiAll 35 Years and older
Not Applicable
Dose-limiting toxicities (DLT)| PCI Biotech A All 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Patients With Any AdNovartis Pharm All 18 Years and older
Phase (Adult,
3 Older Adult)
Change From Baseline to 12 Wee Eli Lilly and All 55 Years and older
Phase (Adult,
1|PhaseOlder Adult)
The successful delivery and depCardioKinetix, All 18 Years to 79Phase
Change From Baseline in CVSTEisai o Limited|EAll 65 Years and older
Phase (Older
4 Adult)
Percent of Participants With C CSL Behring All 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Participants Who ExpGynecologic OFemale 18 Years and older
Phase (Adult,
3 Older Adult)
Number of New Clinically DiagnSpirig Pharma All 40 Years and older
Phase (Adult,
3 Older Adult)
Progression free survival|PatholEuropean OrgaAll 18 Years to 75Phase
Mortality|Renal failure|Respirat Danish Procal All 50 Years to 120Phase
Years2|Phase
Forced Expiratory Volume in 1 Aeris TherapeuAll 40 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants Wit Amgen All 28 Days to 2189Phase
Days2 (Child)
Incidence and Severity of Adve Novartis Pharm All 12 Years to 18Phase
Years 2|Phase
(Child, Adult)
Treatment Failure Rate Alexion All 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Participants With SevBaxalta now paMale up to 1 Year (Child)
Phase 3
Number of Participants With Ad Novartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
Progression-free Survival (PFS Novartis Pharm All 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Subjects With Adver AVEO Pharmace All 18 Years and older
Not Applicable
Percentage of Participants Wit ViiV HealthcareAll 18 Years and older
Phase (Adult,
3 Older Adult)
Change From Baseline in the C Pfizer All 18 Years to 55Phase
Years 4 (Adult)
Percentage of Participants Wit Eli Lilly and All 18 Years and older
Phase (Adult,
2 Older Adult)
Participants With Treatment-Eme Teva Branded All 12 Years to 75Phase
DAS28-CRP Score - Change From AstraZeneca All 18 Years and older
Phase (Adult,
2 Older Adult)
Percentage of Participants Wit Janssen Resea All 2 Years to 18 Years
non-relapse mortality|organ relaEuropean Socie All 18 Years to 65Phase
Number of Participants With Tr Amgen All Child, Adult, OPhase 2
Pharmacokinetic (PK): Model-der Bristol-Myers All 12 Years to 17Phase
Years 1 (Child)
Overview of the Two Co-primarySanofi All 65 Years and older
Phase (Older
3 Adult)
Percentage of Participants Exp Sanofi|RegeneAll 18 Years and older
Phase (Adult,
2 Older Adult)
Number of Participants With Ad Novartis Pharm All 18 Years and older
Phase (Adult,
3 Older Adult)
Mechanical Axial Alignment|Cli Zimmer BiomeAll 18 Years and older
Not Applicable
Migration of the screw in relat AO Clinical In All 50 Years and older
Not Applicable
Overall survival|Time to progressSaint John's CAll 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Subjects With MeIpsen All 18 Years to 75Phase
Change from baseline in the aveJohnson & JohAll 18 Years to 80Phase
Transplant Related Mortality|IncKiadis PharmaAll 18 Years to 65Phase
Years 2|Phase
Change From Baseline in Diseas Johnson & JohAll 18 Years to 75Phase
Cerebral vasospasm-related morIdorsia PharmaAll 18 Years to 75Phase
Percentage of Patients Who Mee Novartis Pharm All 2 Years to 19 Years
To assess clinically significan Eli Lilly and All 18 Years to 65Phase
Years 2|Phase
Number of Participants With AdvPfizer All 12 Years to 75Phase
Euro spent to follow up ICD andBiotronik
C SE &All 18 Years and older
Not Applicable
Time to Death or Disease (IPF) Gilead Scienc All 40 Years to 80Phase
Percent change from baseline inSanofi All 18 Years and older
Phase (Adult,
3 Older Adult)
Percent change from baseline inSanofi All 18 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants WhoSanofi All 40 Years and older
Phase (Adult,
3 Older Adult)
Percentage of Participants Wit Pfizer|Trubion All 18 Years and older
Phase (Adult,
2 Older Adult)
Composite rate of 10 major adv Abiomed Inc. All 18 Years to 90Phase
Overall Survival|Progression F SciClone PharAll 18 Years and older
Phase (Adult,
2 Older Adult)
Long-term Period: Number of PaBristol-Myers All 18 Years and older
Phase (Adult,
2 Older Adult)
- Pharmacokinetic/total IL-1betaNovartis All 18 Years to 75Phase
Years 1|Phase
Lack of surgical re-interventio Ethicon, Inc. Female 25 Years to 50Not
Years
Applicable
(Adult)
Progression Free Survival Verif Genmab All 18 Years and older
Phase (Adult,
2 Older Adult)
Percentage of subjects achievinShire|Takeda All 18 Years and older
Phase (Adult,
4 Older Adult)
Change From Baseline in Best-co Novartis All 50 Years and older
Phase (Adult,
2|PhaseOlder Adult)
Change in HDL-C and triglyceridSanofi All 18 Years to 75Phase
Time to the first relapse after MEDA PharmaAll G 18 Years to 65Phase
Mean change in the co-primary e Sanofi All 18 Years to 75Phase
To assess the short-term safety Alexion|Achilli All 18 Years to 60Phase
Years 2 (Adult)
Recurrence free survival|ProportMedical EnterpAll 18 Years and older
Phase (Adult,
3 Older Adult)
Sleep latency (in minutes), as GlaxoSmithKli All 18 Years to 65Phase
Modified Rankin Scale (mRS) ScJoseph Broderic All 18 Years to 82Phase
Overall survival time|ProgressioPharmexa A/S|All 18 Years to 75Phase
Change From Baseline in Glycos Pfizer All 18 Years and older
Phase (Adult,
4 Older Adult)
Safety: No serious medical compli
Swiss Pediatr All 1 Year to 18 Years
Phase (Child,
3 Adult)
Responder status at visits 9 (w Pfizer All 18 Years to 65Phase
ug: visilizumab Facet Biotech|All 18 Years and older
Phase (Adult,
2|PhaseOlder Adult)
First occurrence of any of myocar
Phase (Adult,
3 Older Adult)
Primary outcome:time to the fir Sanofi|Bristol All 18 Years and older
Phase (Adult,
3 Older Adult)
Reduction in serious device andMedtronicNeurAll 18 Years and older
Not Applicable
Mortality|Morbidity|Number of DNovo Nordisk All 18 Years to 70Phase
Responder analysis based on Mod NeurobiologicaAll 18 Years and older
Phase (Adult,
3 Older Adult)
Recanalization rate|Clinical as ThromboGenicAll 18 Years to 75Phase
Patient response variable (compUCB Pharma All 18 Years and older
Phase (Adult,
3 Older Adult)
To select a GW873140 dose and ViiV
d HealthcarAll 18 Years and older
Phase (Adult,
2 Older Adult)
Change From Baseline AdjustedWyeth is now aAll 13 Years and older
Phase (Child,
Overall response rate (completeEuropean OrgaAll 18 Years to 120
Phase
ological: epoetin alfa|Radiation: radiation th European OrganAll 18 Years to 75Phase
ug: cisplatin|Drug: fluorouracil|Drug: leuco European OrgaAll 18 Years to 69Phase
Survival with a WHO performance European OrgaAll 18 Years and older
Phase (Adult,
3 Older Adult)
Astellas PharmMale 18 Years and older
Phase (Adult,
2 Older Adult)
Outcome Measures Sponsor/CollaGender Age Phases

1 Other Interventional Allocation: Ra NL77673.018. ### April 22, 2022
1 Other Interventional Allocation: N/ P19.032 ### ###
0 Other Interventional Allocation: N/ 993_Pes_equinApril 1, 2022 May 1, 2024
27 Other Interventional Allocation: Ra 112814 ### ###
48 Other Interventional Allocation: Ra METC 21-013 April 22, 2021 ###
76 Other Interventional Allocation: Ra 2020-6884|645 April 1, 2021 ###
25 Other Interventional Allocation: Ra NL73529.041.2April 14, 2020 June 8, 2020
7 Industry Interventional Allocation: No 1399-0013|201 ### April 2, 2020
8 Other|IndustryInterventional Allocation: N/ OLIVIA-UMCG- ### ###
328 Other Interventional Allocation: Ra P18.127 ### ###
15 Other Interventional Allocation: Ra COCkPIT|NL66 ### ###
0 Other Interventional Allocation: N/ NL63209 041 ### ###
5 Other Interventional Allocation: N/ Resistance S ### July 1, 2019
52 Other Interventional Allocation: Ra NL61033.000. ### ###
0 Other Interventional Allocation: N/ NL38948.091. January 2017 ###
100 Other Interventional Allocation: No NL61884.091. ### May 11, 2020
13 Other|IndustryInterventional Allocation: Ra AiRDRoP ### ###
3 Other Interventional Allocation: N/ NL58258.041.1 ### April 23, 2018
65 Other Interventional Allocation: Ra RCT DVO ### ###
4 Other Interventional Allocation: N/ N16PRB|NL595 ### ###
9 Other Interventional Allocation: No 9218 ### May 4, 2020
1 Other Interventional Allocation: Ra 2015/383 ### June 2016
1 Other Interventional Allocation: N/ NL50833.068 May 2016 May 2017
3 Other Interventional Allocation: Ra NL49394.018. June 2015 January 2016
4 Industry Interventional Allocation: Ra SCS-PAF ### ###
1 Other Interventional Allocation: Ra DBS for TD June 2015 May 2, 2017
45 Industry|OtherInterventional Allocation: No 05-1971 October 2016 ###
18 Other Interventional Allocation: Ra 24-SMI-2014 ### July 2017
5 Other Interventional Allocation: N/ NL47945.068. June 2014 April 2015
0 Other Interventional Allocation: Ra NL46979.091. July 2014 January 2021
4 Other Interventional Allocation: N/ 11-36-14/12 ### May 2018
7 Other Interventional Allocation: N/ EPICSCZE14 August 2014 April 2017
0 Other Interventional Allocation: N/ 47955 June 2015 June 2016
342 Other Interventional Allocation: N/ Apple study 2 ### May 2016
56 Other Interventional Allocation: Ra NL43116.041. ### May 2016
43 Other Interventional Allocation: Ra MIDRF|NL3663 July 2011 ###
25 Other Interventional Allocation: Ra 133031 October 2013 ###
6 Industry Interventional Allocation: No 905-EC-010 March 2012 June 2012
20 Other Interventional Allocation: Ra 15378 ### March 2009
2 Other Interventional Allocation: Ra NL35192.044. May 2011 May 2013
9 Other Interventional Allocation: No MFX468 May 2011 June 2015
77 Other Interventional Allocation: Ra NL32865.044.10 ### ###
4 Other Interventional Allocation: Ra UMCNONCO20 January 2011 April 2012
0 Other Interventional Allocation: No NL26963.060. August 2010 April 2012
191 Other Interventional Allocation: Ra NL 28041.018.January 2010 ###
52 Industry Interventional Allocation: Ra APIDR_L_0471January 2010 July 2012
7 Other Interventional Allocation: Ra NL26689.075. May 2010 January 2012
9 Other Interventional Allocation: No EORTC-08061| ### July 2010
10 Other Interventional Allocation: Ra NL24375.041. May 2009 ###
34 Other Interventional Allocation: Ra MOSTrial|CCMOctober 2008 January 2011
6 Other Interventional Allocation: Ra HOADO March 2009
0 Other Interventional Allocation: Ra STW6041 January 2009 June 2009
80 Industry Interventional Allocation: Ra BRC-CS ### August 2015
22 Other Interventional Allocation: Ra ROSEL October 2008 ###
7 Industry Interventional Allocation: N/ 12382|B4Z-UT ### June 2009
69 Other Interventional Allocation: Ra LTC-510-1001 March 2008 July 2017
80 Other Interventional Allocation: Ra ICHYPDEL/00 ### May 2008
0 Industry Interventional Allocation: Ra AMP SSTI 01- ### July 2009
12 Other|IndustryInterventional Allocation: Ra CERL080ANL0 July 2007 August 2009
335 Industry Interventional Allocation: Ra 20061016-V2 March 2007 January 2011
30 Other Interventional Allocation: Ra p06-108a April 2007 March 2008
3 Industry Interventional Allocation: No WA19078 January 2006 June 2010
17 Other Interventional Allocation: Ra NL11494.075. October 2006 October 2007
0 Other Interventional Allocation: No 06-125 October 2006 October 2007
50 Industry Interventional Allocation: Ra D1449C00008 June 2006 ###
2700 Other Interventional Allocation: Ra 945-16-104 March 2006
10 Industry Interventional Allocation: Ra EE04-01NL ### June 2008
22 Other|IndustryInterventional Allocation: No 04/089-E ### ###
100 Other Interventional Allocation: Ra 2004-165 October 2005
3 Other Interventional Allocation: Ra 05IAT0061|200 ### January 2007
32 Industry Interventional Allocation: N/ CEL5684 ### ###
53 Other Interventional Allocation: Ra REMINDRA April 21, 2017 ###
22 Other Interventional Allocation: Ra NL40128.029. May 2013 January 2018
212 Other|IndustryInterventional Allocation: Ra MEC06-2-003 July 2006 ###
26 Other Interventional Allocation: Ra 10/157 August 2010 January 2015
0 Other Interventional Allocation: N/ AMCmedonc010 October 2010 April 2015
200 Other Interventional Allocation: Ra P06.108 April 2007
2 Industry|OtherInterventional Allocation: Ra 2014-004851- ### May 31, 2019
4 Other Interventional Allocation: Ra 12-027|111/13 August 2014 ###
38 Other|IndustryInterventional Allocation: Ra EPLERAF-01|V March 2008 ###
34 Other|IndustryInterventional Allocation: Ra NL61630.078. ### July 5, 2022
5 Other Interventional Allocation: N/ CC-TT-IMA-14 April 2016 ###
6 Industry Interventional Allocation: Ra A-95-52014-19 March 2012 July 2013
5 Industry Interventional Allocation: N/ D4200C00085| May 2009 August 2010
320 Other Interventional Allocation: Ra CP MM 19-08-January 2008 March 2010
4 Industry Interventional Allocation: Ra CRD0339 ### ###
7 Other Interventional Allocation: N/ 201500776 August 2016 May 30, 2018
91 Other|IndustryInterventional Allocation: Ra NL44622.029. ### ###
12 Other Interventional Allocation: Ra NL39851.041.1 ### ###
9 Other Interventional Allocation: N/ UMCN-AKF 14 August 2015 ###
15 Other Interventional Allocation: Ra P08.185 ### May 2015
24 Industry Interventional Allocation: No D1690C00049|July 12, 2017 ###
42 Other Interventional Allocation: Ra NL46653 July 2014 May 2019
20 Industry|OtherInterventional Allocation: N/ CT-15-009 April 1, 2016 ###
8 Industry Interventional Allocation: N/ CSE2017-01K ### ###
101 Other Interventional Allocation: Ra TRE-1486--010 ### July 28, 2022
59 Industry Interventional Allocation: Ra AF-10-023-ND July 2011 ###
0 Industry Interventional Allocation: Ra 115393 ### ###
20 Other|IndustryInterventional Allocation: N/ NordDutchCML April 2013 April 8, 2016
23 Other Interventional Allocation: Ra NL73547.091. April 17, 2020 May 25, 2021
193 Other Interventional Allocation: No UMCN-AKF-18 ### May 2, 2019
36 Other Interventional Allocation: Ra M15CRH ### ###
52 Other Interventional Allocation: Ra BOOG 2013-0 June 2014 March 2018
342 Other Interventional Allocation: Ra AIPOP ### ###
10 Other Interventional Allocation: Ra BOOG 2010-0 ### January 2014
19 Other Interventional Allocation: Ra SELECT-AMI ### ###
20 Other Interventional Allocation: Ra NL20963.091. October 2009 May 1, 2017
57 Other Interventional Allocation: Ra MOBILE-AF July 29, 2016 ###
25 Industry Interventional Allocation: Ra I-48-52014-14 ### ###
19 Other Interventional Allocation: Ra EORTC-BTG-1 ### ###
118 Industry Interventional Allocation: Ra EFC15160|201 ### May 19, 2021
51 Industry Interventional Allocation: N/ CL02413 January 2011 March 2014
10 Industry Interventional Allocation: Ra ICP-112-201 October 2012 ###
395 Industry|OtherInterventional Allocation: Ra GE-122-020|2 ### May 4, 2018
334 Industry Interventional Allocation: Ra 747-302 ### ###
5850 Industry Interventional Allocation: Ra CR-13-006-ID ### May 30, 2021
83 Industry Interventional Allocation: Ra EFC15068|201 ### ###
35 Industry|OtherInterventional Allocation: Ra FER-CARS-03 ### October 2009
125 Industry Interventional Allocation: Ra CLIK066B2204July 25, 2017 June 6, 2018
88 Industry Interventional Allocation: Ra C LF23-0121 0 June 2006 ###
13 Other Interventional Allocation: Ra HepBurn|2012October 2013 October 2016
12 Other Interventional Allocation: Ra PLATA August 2013 April 2017
310 Industry Interventional Allocation: Ra IMD-10 June 2013 August 2015
122 Industry Interventional Allocation: Ra E-100 ### July 2008
162 Industry Interventional Allocation: Ra 1.02.7007 ### ###
15 Industry Interventional Allocation: N/ COEB071X2101 ### April 2014
136 Industry Interventional Allocation: N/ 835093|2009- ### ###
81 Industry Interventional Allocation: Ra Y-79-52120-12 ### June 2009
88 Industry Interventional Allocation: Ra CACZ885V2201 ### April 20, 2022
142 Industry Interventional Allocation: Ra CA209-9UT|20 ### ###
2 Industry Interventional Allocation: N/ CIP-3102-01 June 2015 August 2015
69 Industry Interventional Allocation: N/ 10173339DOC May 2015 ###
227 Industry Interventional Allocation: Ra D-FR-52120-2 March 2016 ###
36 Industry Interventional Allocation: N/ CR106660|547 ### June 1, 2017
42 Industry Interventional Allocation: Ra 12-513 April 2013 ###
205 Other Interventional Allocation: Ra Flagship AA tr March 2001 June 2008
37 Industry Interventional Allocation: Ra LFC2009.01.0 March 2010 June 2012
41 Industry Interventional Allocation: Ra A8851022 April 2009 June 2012
1 Other Interventional Allocation: Ra TRIAL V|Eudra ### June 2009
16 Industry Interventional Allocation: N/ ASD Study ### October 2015
2 Industry Interventional Allocation: N/ D0384 ### April 6, 2020
8 Industry Interventional Allocation: Ra EFC16855|202April 12, 2020 May 26, 2020
16 Industry Interventional Allocation: Ra IM011-073|201July 15, 2019 ###
14 Other|IndustryInterventional Allocation: N/ ETOP 12-17|2 ### ###
29 Industry Interventional Allocation: Ra CMX001-999 ### May 10, 2019
23 Industry Interventional Allocation: Ra QUID-HF_v5.0 June 2016 ###
72 Industry Interventional Allocation: Ra CR108134|541 July 1, 2016 ###
77 Industry Interventional Allocation: Ra A-US-52030-3 ### ###
182 Industry Interventional Allocation: Ra CLIN-021 January 2016 ###
530 Industry Interventional Allocation: Ra 8273-CL-0302 ### ###
99 Industry Interventional Allocation: Ra 16298|2014-0 ### ###
0 Industry Interventional Allocation: Ra 114674 April 2013 January 2014
199 Industry Interventional Allocation: N/ VICTORY AF ### ###
179 Industry Interventional Allocation: Ra CBYL719X2104 ### ###
97 Industry Interventional Allocation: Ra CTKI258A2210 April 2012 April 2015
40 Industry Interventional Allocation: Ra 269-11-215 ### October 2015
21 Industry Interventional Allocation: Ra CCS-08 July 2010 ###
153 Industry Interventional Allocation: Ra CSA-2005-02 April 15, 2008 ###
288 Industry Interventional Allocation: No FE200486 CS3October 2010 ###
79 Industry Interventional Allocation: Ra BWI130 April 2010 ###
95 Industry Interventional Allocation: N/ D2610C00001 ### ###
836 Industry Interventional Allocation: Ra ACT3986g|WA2 May 15, 2007 ###
36 Other|IndustryInterventional Allocation: Ra CRM-CH-Riv0 January 2012 May 2016
7 Industry Interventional Allocation: Ra 19781|2018-0 ### April 14, 2021
8 Other Interventional Allocation: Ra MesaCAPP ### April 10, 2019
40 Other Interventional Allocation: Ra 2010/363|B67 ### ###
12 Other|IndustryInterventional Allocation: No RG_16-186|20May 18, 2018 May 3, 2023
8 Other|IndustryInterventional Allocation: Ra OCTO_039 October 2014 ###
17 Industry Interventional Allocation: Ra 207972|2017- April 18, 2018 ###
7 Industry Interventional Allocation: No 747-206 July 1, 2015 ###
407 Industry Interventional Allocation: Ra MP0420-CP302 May 10, 2021 ###
42 Industry Interventional Allocation: N/ 2018-22 ### ###
16 Industry Interventional Allocation: N/ CR022 ### ###
10 Industry Interventional Allocation: Ra ACT14656|201 ### July 23, 2018
63 Industry Interventional Allocation: Ra CSL842_3001| ### ###
111 Industry Interventional Allocation: No CPDR001C2101 May 24, 2017 July 28, 2021
6 Other Interventional Allocation: Ra C10-44|2010- ### January 2014
28 Other Interventional Allocation: Ra CLON01|2014- May 2016 October 2018
23 Industry Interventional Allocation: No CINC280B2201 ### ###
16 Industry Interventional Allocation: No ThymoHEM0120 October 2007 May 2009
27 Industry Interventional Allocation: N/ ST3073-ST307 ### ###
67 Industry Interventional Allocation: Ra SPD557-202|2 ### May 29, 2012
96 Industry Interventional Allocation: Ra MA25522|2010 May 2011 August 2012
84 Industry Interventional Allocation: Ra EN3348-303 ### April 2013
17 Industry Interventional Allocation: Ra 1.02.7004 ### June 2012
188 Industry Interventional Allocation: Ra AF07004AF July 2009 August 2012
23 Other|IndustryInterventional Allocation: No T2008-002 June 2010 ###
60 Industry Interventional Allocation: Ra CT 05/25 May 2008 May 2010
918 Industry Interventional Allocation: Ra MDT-MORE-C June 2009 ###
22 Industry Interventional Allocation: No CPKC412A2114 ### ###
31 Industry Interventional Allocation: N A1501080|200 May 2009 May 2013
400 Industry Interventional Allocation: Ra DSE-866-45|2 June 2008 ###
317 Industry|OtherInterventional Allocation: No NO21157|SARC ### ###
14 Industry|OtherInterventional Allocation: Ra CAT-354-0603January 2008 July 2008
30 Industry Interventional Allocation: No Hx-EGFr-203 ### October 2010
807 Industry|OtherInterventional Allocation: Ra 979 July 1998 ###
219 Industry Interventional Allocation: Ra A4021004|200 ### ###
236 Industry|NIH Interventional Primary PurpoAC-052-371 March 2006 August 2007
12 Industry Interventional Allocation: Ra AC-052-369|A April 2006 August 2007
14 Industry Interventional Allocation: Ra AC-052-368|A March 2006 August 2007
19 Industry Interventional Allocation: Ra Acute GvHD-1January 2006 June 2007
360 Other|IndustryInterventional Allocation: Ra 384/03 ### May 2010
9 Other|IndustryInterventional Allocation: Ra 2021/1001|202 ### ###
0 Industry Interventional Allocation: N/ N16AED October 2017 April 2018
0 Industry Interventional Allocation: Ra M21-263|2019 ### April 15, 2022
16 Other Interventional Allocation: Ra SRKMD-2021|2 ### ###
0 Industry Interventional Allocation: No N16DOL July 2017 ###
0 Other Interventional Allocation: N/ NL76750.041. October 2022 October 2023
28 Other Interventional Allocation: N/ TrachFlush ### May 31, 2022
15 Industry Interventional Allocation: Ra 18907A May 26, 2021 ###
19 Other Interventional Allocation: N/ ELICIT ### May 15, 2023
0 Industry Interventional Allocation: Ra CR108971|202 ### May 9, 2022
17 Other Interventional Allocation: Ra GPRI-21001-C ### April 23, 2021
32 Industry Interventional Allocation: Ra GLPG4059-CL- ### April 8, 2021
0 Industry Interventional Allocation: N/ CD-TCR-003 July 2, 2020 July 2023
3 Other Interventional Allocation: N/ 2019-1432 May 12, 2020 ###
23 Other Interventional Allocation: N/ NL73180.091. ### ###
26 Other Interventional Allocation: N/ NL52657.091. May 15, 2017 ###
5 Industry Interventional Allocation: N/ Triplemed 003 ### ###
24 Industry Interventional Allocation: Ra C6463-102|CY ### May 22, 2020
1 Other|IndustryInterventional Allocation: Ra METC 19-085 ### ###
16 Industry Interventional Allocation: Ra CR108649|20 ### April 10, 2020
10 Other Interventional Allocation: Ra METC19-072 ### ###
1 Other Interventional Allocation: N/ 201900180 ### May 1, 2022
18 Industry Interventional Allocation: Ra 18193A ### ###
7 Other Interventional Allocation: N/ VALID2 ### May 12, 2021
5 Other Interventional Allocation: No 2014_078#B20 May 2014 March 2017
40 Industry Interventional Allocation: Ra UP0071|2019- July 17, 2019 May 22, 2020
10 Industry Interventional Allocation: N/ MD2014.01 ### ###
53 Industry Interventional Allocation: Ra 1386.16|2018- July 31, 2019 April 8, 2020
76 Industry Interventional Allocation: Ra 17426|J2D-MC ### ###
17 Industry Interventional Allocation: Ra GFT505-219-8 ### ###
8 Industry Interventional Allocation: Ra NPT189-CL00 ### ###
1 Other Interventional Allocation: N/ M17CPF ### ###
43 Other Interventional Allocation: Ra CPS135 April 1, 2019 ###
8 Industry Interventional Allocation: No 1381-0003|201 ### ###
55 Other Interventional Allocation: Ra S13-11 October 2013 ###
3630 Other|IndustryInterventional Allocation: Ra FTI-820555-De ### June 1, 2021
3907 Other|IndustryInterventional Allocation: Ra FTI-820555-De ### June 1, 2021
25 Other|IndustryInterventional Allocation: N/ MOHN14 ### ###
0 Industry Interventional Allocation: N/ EXP-1392|201 August 2019 August 2020
223 Other Interventional Allocation: Ra NL63106.068. April 5, 2018 ###
62 Industry Interventional Allocation: Ra 16771|I9K-MC July 13, 2018 ###
25 Other Interventional Allocation: No NL65856.042. ### ###
0 Other|IndustryInterventional Allocation: N/ M16TGA|2016- ### June 1, 2020
242 Industry Interventional Allocation: Ra HP7020-02|20 ### ###
0 Other Interventional Allocation: N/ 133057 ### May 2014
28 Industry Interventional Allocation: Ra CLS003-CO-P ### ###
38 Industry Interventional Allocation: Ra IM024-005|201 ### ###
2 Other Interventional Allocation: N/ GK2017AS ### ###
9 Other Interventional Allocation: Ra WAVE trial ### April 1, 2018
40 Other Interventional Allocation: No Rahel2017UrgApril 18, 2017 ###
10 Other Interventional Allocation: Ra NL59864.068. April 3, 2017 ###
6 Other Interventional Allocation: N/ 201700147 ### ###
37 Other|IndustryInterventional Allocation: Ra 2015_024 ### ###
17 Other|IndustryInterventional Allocation: Ra NL57683.018. ### May 14, 2019
11 Other Interventional Allocation: Ra 162048 January 2017 April 2020
48 Other|IndustryInterventional Allocation: Ra P07.205 April 2008 July 2011
1 Other Interventional Allocation: N/ SFN-SCS|NL53 July 1, 2018 ###
30 Other Interventional Allocation: N/ NL55770.041. June 2016 April 2020
0 Other Interventional Allocation: N/ DE-CT ### ###
21 Other Interventional Allocation: N/ AMC-TIBOHC May 2016 ###
0 Other Interventional Allocation: Ra LTC-744-040111-Roelofs|NL35454.091.11
80 Other Interventional Allocation: Ra NL 56747.058. ### ###
14 Other Interventional Allocation: Ra ERS STRTF 20October 2016 ###
3 Industry Interventional Allocation: N/ GS-US-313-21 May 4, 2016 ###
0 Other Interventional Allocation: Ra Oligometa's L1 ### ###
17 Other Interventional Allocation: Ra NL56319.068. May 2016 June 2017
1 Other Interventional Allocation: N/ 201600134 ### April 2020
6 Other Interventional Allocation: N/ 15-528 ### ###
7 Other Interventional Allocation: Ra Tryptophan dep ### ###
0 Other Interventional Allocation: Ra CHI-UPPERGIJanuary 2016 January 2019
0 Other|IndustryInterventional Allocation: No NL55865.078. ### ###
0 Other Interventional Allocation: Ra 2015-126481 ### May 1, 2017
11 Other Interventional Allocation: N/ METC152028 ### July 1, 2019
40 Industry Interventional Allocation: Ra H-S-045 October 2010 ###
28 Other Interventional Allocation: Ra CWO/15-10E March 2016 June 2017
30 Other Interventional Allocation: Ra LIPMAT ### May 30, 2018
1 Other Interventional Allocation: Ra METC 14-3-05 ### ###
85 Industry Interventional Allocation: Ra 3118001 April 14, 2015 April 22, 2016
9 Other|IndustryInterventional Allocation: Ra METC 13-2-03 ### June 2016
100 Industry Interventional Allocation: Ra NP29454|2014 ### ###
1 Other Interventional Allocation: N/ 2013/498 ### January 2017
27 Other Interventional Allocation: Ra NL45370.100. ### April 26, 2018
5 Industry Interventional Allocation: Ra 12-SMI-2014 ### ###
0 Other Interventional Allocation: Ra NL46343.068.13 January 2016
0 Other Interventional Allocation: N/ 08-2014 March 2017 June 2017
17 Other Interventional Allocation: Ra EMC14022_P July 2014 January 2016
5 Other Interventional Allocation: Ra ABILITY August 2014 ###
60 Industry Interventional Allocation: Ra LC1060 ### June 2020
5 Other Interventional Allocation: N/ 2012/259 October 2012 ###
5 Other Interventional Allocation: N/ 1335-1812-int ### ###
200 Other Interventional Allocation: Ra Cell Saver-001January 2014 ###
2 Industry|OtherInterventional Allocation: N/ 200208|2013- ### ###
23 Industry Interventional Allocation: Ra CP224 ### ###
4 Industry Interventional Allocation: N/ EP052 ### August 2014
48 Other Interventional Allocation: Ra P12-03/BP1.53October 2014 October 2014
0 Other Interventional Allocation: N/ NL41466.042. August 2015 ###
10 Other Interventional Allocation: N/ NL44048.018. July 2013 January 2018
30 Other Interventional Allocation: N/ METcUMCG 20 June 2011 May 2013
14 Other Interventional Allocation: Ra METC 13-2-0 January 2014 October 2014
0 Other Interventional Allocation: Ra MMV|NL42517. April 2013 ###
0 Other Interventional Allocation: Ra 2012-005339- April 2013 April 2015
7 Other|IndustryInterventional Allocation: N/ NL42312.068. August 2013 August 2014
79 Other Interventional Allocation: Ra Protocol ID 20 ### ###
8 Industry Interventional Allocation: Ra TS01-01|2012 ### October 2012
0 Other Interventional Allocation: Ra M12-1233|NL4 April 2013 January 2016
2 Other Interventional Allocation: Ra CMV-MM-1|201 June 2012 October 2013
256 Other Interventional Allocation: Ra NL nr.: 40730. August 2012 October 2014
22 Other Interventional Allocation: Ra METC 12-2-03October 2012 ###
0 Other Interventional Allocation: N/ BP28015|2011 ### ###
97 Other Interventional Allocation: N/ 12-2-1932 May 2012 May 2016
6 Other Interventional Allocation: N/ CMO 2011/345| March 2012 ###
5 Other Interventional Allocation: N/ CHLOROQUINE May 2014 July 2017
28 Other|IndustryInterventional Allocation: N/ G-0016 ### ###
3 Other|IndustryInterventional Allocation: Ra AAA-PET/CT v ### ###
0 Other Interventional Allocation: Ra EPC 11-01|20 October 2011 May 2013
52 Industry Interventional Allocation: Ra ALX-0651-1.1/ June 2011 January 2012
1 Other Interventional Allocation: Ra NL36977.091. October 2013 June 2015
113 Industry Interventional Allocation: Ra CCD-1007-PR- ### ###
24 Industry Interventional Allocation: Ra SPC5001-901| May 2011 October 2011
0 Other Interventional Allocation: Ra UVT MP 002 October 2011 January 2012
13 Other Interventional Allocation: Ra NOCTX-2|2009 ### July 2012
11 Other|IndustryInterventional Allocation: Ra 34932 April 2012 ###
12 Other Interventional Allocation: Ra UMCNONCO20 April 2010 ###
0 Other Interventional Allocation: Ra BAMBOO March 2011 July 2011
47 Other|IndustryInterventional Allocation: N/ Nitroglycerin ### ###
16 Other Interventional Allocation: Ra RU-RTB-0002 October 2002 April 2004
26 Other|IndustryInterventional Allocation: Ra PDinCHF|2009 April 2010 ###
111 Industry Interventional Allocation: Ra CR-09-058-ND July 2010 April 2014
0 Other Interventional Allocation: Ra 630-190809
0 Other Interventional Allocation: Ra OABdrinkstudy July 2009 ###
0 Industry Interventional Allocation: Ra 112145 ### June 2011
0 Industry Interventional Allocation: Ra CR016195|PEP May 2009 October 2009
41 Other Interventional Allocation: Ra ARIANA April 2009 July 2012
617 Other Interventional Allocation: Ra CETRO Trial| ### October 2012
60 Other|IndustryInterventional Allocation: Ra D00668-01C| March 2009 ###
15 Other Interventional Allocation: Ra 08-137 ### April 2011
700 Other Interventional Allocation: Ra TEAtrial June 2007 ###
12 Other|IndustryInterventional Allocation: No NL23124.041. March 2009 ###
0 Other Interventional Allocation: Ra 08/214 ### ###
0 Other Interventional Intervention MMEC 08-1-024
3 Industry Interventional Allocation: Ra CUC111342|20 ### ###
0 Industry Interventional Allocation: Ra Nasobol 02/2008
10 Other Interventional Allocation: Ra N07MAN|Eudra April 2008 May 2012
26 Industry|OtherInterventional Allocation: N/ UD736 March 2008 March 2009
0 Other Interventional Allocation: Ra MEC0001 ### ###
20 Other|IndustryInterventional Allocation: N/ LTC-499-301107 August 2011
98 Other Interventional Allocation: Ra LTC-502-1412 July 2008 ###
6 Other Interventional Allocation: No VUMC 2006/19October 2007 January 2010
5 Other Interventional Allocation: Ra RDC-2006-03 October 2007 July 2010
120 Other Interventional Allocation: N/ 06-02-117|TA October 2008
0 Industry Interventional Allocation: Ra AMP IC 01-01 July 2008 January 2009
290 Other Interventional Allocation: Ra NL14625.091.0 March 2007
12 Other Interventional Allocation: Ra N06IAA May 2007 ###
0 Other Interventional Allocation: Ra IPost October 2007
0 Industry Interventional Allocation: N/ AMP 02-02; S ### March 2009
79 Other|IndustryInterventional Allocation: Ra HEPATICA ### August 2013
100 Other|IndustryInterventional Allocation: Ra C97-1707 May 2001
642 Other Interventional Allocation: Ra GGD 4013 January 2003
89 Other Interventional Allocation: Ra SOW 014-91-0January 2003 June 2007
250 Other Interventional Allocation: Ra PSCT10 March 2006
72 Other Interventional Allocation: Ra 200601 ###
8 Other Interventional Allocation: Ra 05/187-E ### ###
70 Industry|OtherInterventional Allocation: Ra BMBL_2005_0 May 2005 August 2008
5 Industry Interventional Allocation: No C04-012 May 2005 ###
50 Other Interventional Allocation: No 2005/90 October 2005
0 Other Interventional Allocation: Ra 01-021 July 2002
24 Other Interventional Allocation: Ra 02/327 April 2003
24 Other Interventional Allocation: Ra 01/341-E October 2002
t Applicable Other Interventional Allocation: Ra 1,SLFW|Theia March 2003
40 Other Interventional Allocation: Ra OPIRI January 2005
120 Other Interventional Allocation: N/ CMO 2003/14 October 2003 April 2005
8 Other Interventional Allocation: Ra ACAD March 2005
20 Industry Interventional Allocation: Ra DM02RUP/IV/ May 2005
20 Other Interventional Allocation: Ra ALSICEJ1 March 2006
80 Other Interventional Allocation: No FLT-PET CRCJanuary 2005 ###
50 Other Interventional Allocation: Ra EMC 02-115 August 2005 May 2008
250 Other Interventional Allocation: No 13-693/D ### ###
67 Other|IndustryInterventional Allocation: Ra INVENT COVI ### ###
0 Other|IndustryInterventional Allocation: Ra NL63511.041. July 1, 2019 July 1, 2022
7 Industry Interventional Allocation: Ra RDN-929-103 May 16, 2019 ###
0 Other|IndustryInterventional Allocation: N/ 201700599|20 May 22, 2019 May 1, 2022
22 Other Interventional Allocation: N/ NL58040.091. ### July 31, 2019
13 Other Interventional Allocation: Ra 683-250210-NiJanuary 2012 ###
70 Other Interventional Allocation: Ra NL512830291 May 2015 May 2017
14 Other Interventional Allocation: Ra PEARL study ### August 2014
54 Other Interventional Allocation: Ra EMR200109_63 ### ###
47 Industry Interventional 2B3-201-CR-0 ### January 2015
27 Other|IndustryInterventional Allocation: Ra METC 12-2-01 ### May 17, 2018
55 Other Interventional Allocation: Ra NL41938.015. ### June 1, 2016
60 Other Interventional Allocation: Ra 12-046 April 1, 2012 June 1, 2016
8 Industry Interventional Allocation: Ra CSPP100A2260 January 2011 ###
45 Other Interventional Allocation: N/ 2010/124 August 2010 ###
2 Industry Interventional Allocation: No 12672|2009-0 April 2010 August 2010
23 Other Interventional Allocation: No NL22553.000. June 2009 April 2016
20 Other|IndustryInterventional Allocation: Ra UMCN-AKF 07. March 2008 January 2010
70 Industry Interventional Allocation: No D1531C00001 May 2005 June 2008
0 Industry Interventional Allocation: Ra SAM109352 ### ###
200 Other|IndustryInterventional Allocation: Ra SCO30001|SER April 2000
26 Industry Interventional Allocation: Ra CSL730_1001| ### ###
10 Industry Interventional Allocation: Ra ATH3G10-005 ### ###
5 Industry Interventional Allocation: No THB001-01-00 ### ###
11 Industry Interventional Allocation: N/ COT1-13-01| ### ###
120 Other Interventional Allocation: N/ METc2011.08 ### October 2016
380 Other Interventional Allocation: Ra RATE01 June 2010 October 2012
12 Industry Interventional Allocation: No HGT-SAN-067| ### April 12, 2019
41 Industry Interventional Allocation: Ra DCR-PH1-101May 13, 2016 ###
11 Industry Interventional Allocation: N/ sNN0029-004| January 2015 October 2015
15 Industry Interventional Allocation: Ra sNN0029-003| ### October 2015
13 Other Interventional Allocation: Ra NL39202.078.1January 2013 ###
40 Industry Interventional Allocation: No E7107-E044-1 May 2007 June 2009
40 Industry Interventional Allocation: No FLUI-2010-68 ### October 2013
469 Other Interventional Primary PurpoEORTC-20963 March 1997 ###
146 Other Interventional Allocation: Ra Vitrification May 2009 May 2012
147 Other Interventional Allocation: Ra LITE study|C January 2009 October 2010
10 Other Interventional Allocation: N/ M19CCR ### April 1, 2023
0 Other Interventional Allocation: N/ CL3-13001-00 July 1, 2021 ###
5 Industry Interventional Allocation: N/ AM-001 ### ###
9 Other|IndustryInterventional Allocation: N/ M14ABC May 15, 2018 July 1, 2022
85 Other Interventional Allocation: No 2013.265|2013 April 2014 January 2021
91 Other Interventional Allocation: N/ 20132312|201 July 2014 ###
1 Industry Interventional Allocation: N/ EGD-EC-005|2 August 2014 August 2015
195 Other Interventional Allocation: N/ NL.45677.041.January 2014 January 2016
9 Other Interventional Allocation: N/ LTC 760-2204 August 2011 ###
450 Other|IndustryInterventional Allocation: Ra LTC 625-2306 January 2010 April 2011
12 Industry Interventional Allocation: N/ HN019/ITC-00January 2010 January 2012
25 Other Interventional Allocation: N/ M15PAS|DSS ### ###
0 Other Interventional Allocation: Ra UMCN-AKF 16 April 1, 2018 ###
866 Other Interventional Allocation: Ra NL47293.041. ### October 2019
0 Other Interventional Allocation: Ra BSTEP January 2022 July 2024
0 Other Interventional Allocation: N/ HO162|2021-0January 2022 August 2024
23 Other|IndustryInterventional Allocation: N/ M17GEL ### May 1, 2022
413 Other Interventional Allocation: Ra Santeon-CAP| ### July 13, 2018
350 Other Interventional Allocation: Ra CRESCENT-1 July 2011 August 2014
70 Other Interventional Allocation: Ra NL36322.068. June 2011 June 2017
5 Other|NIH Interventional Allocation: No Chloroquine IV ### June 2016
43 Industry Interventional Allocation: N/ C1210 March 2013 October 2014
250 Other|IndustryInterventional Allocation: Ra N08AFT|Eudra July 2008 June 2022
62 Other Interventional Allocation: Ra NANOM PCI ### July 2012
156 Industry Interventional Allocation: Ra EC09-01 August 2010 ###
41 Other Interventional Allocation: Ra MEC-2013-460October 2014 April 2020
15 Industry Interventional Allocation: Ra TDR16536|DNL ### ###
9 Industry Interventional Allocation: Ra CSAF312A2202 January 2012 ###
20 Industry Interventional Allocation: N/ 906273 ### ###
318 Industry Interventional Allocation: Ra STENTYS May 2013 ###
6 Other Interventional Allocation: N/ J1214|NA_000 ### ###
26 Other Interventional Allocation: Ra FAST II April 2011 ###
36 Other Interventional Allocation: No EGPS-01|CSET ###
9 Industry Interventional Allocation: No 11089|H3E-E ### May 2008
24 Industry Interventional Allocation: Ra ELB139202-05 May 2006
968 Industry|OtherInterventional Allocation: Ra KRX-101-401 August 2005 March 2008
43 Other Interventional Primary PurpoEORTC-22971October 1998 July 2001
63 Other Interventional Allocation: Ra NL 61885.091. ### ###
78 Industry Interventional Allocation: Ra MDCO-BIV-12- ### ###
9 Other Interventional Allocation: Ra EORTC-26021 ### ###
13 Industry Interventional Allocation: Ra 3202V1-1001 ### ###
18 Industry Interventional Allocation: N/ 06-014|900000January 2008 January 2009
102 Industry Interventional Allocation: Ra NL04-90 October 2004
28 Other|IndustryInterventional Allocation: N/ M18TEO ### May 17, 2021
81 Other Interventional Allocation: Ra IMPROVE-II ### May 11, 2021
8 Other Interventional Allocation: Ra TIS2012 August 2012 ###
50 Other Interventional Allocation: No NL44181.068. ### ###
485 Other Interventional Allocation: Ra 2011-002211- January 2013 March 2017
14 Other Interventional Allocation: Ra 30756.041.10 March 2011 May 2015
12 Industry Interventional Allocation: N/ AUTO2-MM1|20May 5, 2017 ###
0 Other Interventional Allocation: N/ ITATI ### ###
14 Industry Interventional Allocation: Ra CR017992|TM June 2011 ###
16 Industry Interventional Allocation: N/ LV DDD ### July 2016
103 Other|NIH Interventional Allocation: Ra 2017P000333 ### ###
4 Other Interventional Allocation: N/ HREC 15/051 June 2015 June 2017
65 Industry Interventional Allocation: Ra ARCAAT-1001| ### ###
3 Industry Interventional Allocation: No CLOP628X210 ### March 2015
1 Other Interventional Allocation: Ra TRIDENT CO ### ###
72 Other Interventional Allocation: Ra 9202 ### July 27, 2016
2 Industry Interventional Allocation: N/ 300-09-007 April 2010 June 2010
226 Industry Interventional Allocation: N/ 01/04 October 1987 May 2011
26 Industry Interventional Allocation: No CA190-001 January 2008 March 2010
36 Industry Interventional Allocation: Ra CA165-030 ### ###
45 Industry Interventional Allocation: No 20130354|201 ### ###
28 Industry|OtherInterventional Allocation: Ra CA180-274|ProOctober 2009 May 2011
61 Industry Interventional Allocation: Ra PRO-106-0119April 13, 2017 May 31, 2018
29 Other Interventional Allocation: Ra NL48307.028. August 2015 October 2016
104 Other|IndustryInterventional Allocation: Ra IC-DEL/009 ### April 2010
120 Industry Interventional Allocation: Ra MRL 2002-002October 2003
0 Industry Interventional Allocation: N/ BAYPDC-14-0 ### ###
33 Other|IndustryInterventional Allocation: Ra iHIVARNA phasApril 4, 2017 ###
37 Industry Interventional Allocation: N/ 1401-0001|201 ### July 27, 2022
65 Other Interventional Allocation: Ra M15PAP|NL538 ### ###
200 Other Interventional Allocation: Ra NL76435 ### ###
86 Other|IndustryInterventional Allocation: Ra NL73489.078. April 8, 2020 July 1, 2020
7 Industry Interventional Allocation: No BMN-044-201| April 2016 ###
8 Other Interventional Allocation: Ra NL62110.068. June 4, 2018 ###
142 Other Interventional Allocation: Ra MEC-2017-115 ### ###
0 Other|IndustryInterventional Allocation: Ra BOOG-2017-02 ### ###
15 Industry Interventional Allocation: No PRO044-CLIN ### July 1, 2016
342 Other Interventional Allocation: Ra 62449 ### ###
45 Other Interventional Allocation: Ra NVALT 18 ### April 2019
78 Other|IndustryInterventional Allocation: N/ M14REP ### ###
246 Other Interventional Allocation: N/ SCAPURA-Stu August 2015 May 2019
216 Other Interventional Allocation: Ra 80-83600-98-2January 2015 July 19, 2018
31 Other Interventional Allocation: Ra 01-2015 July 2016 April 2019
70 Other Interventional Allocation: N/ UKE HH Endo April 2011 July 2012
151 Other Interventional Allocation: Ra NL44512.018. ### July 24, 2017
21 Other Interventional Allocation: N/ IRENE study - January 2014 January 2017
3 Other|IndustryInterventional Allocation: No AKF UMCN 12 May 2013 ###
24 Industry Interventional Allocation: Ra YA-MSP-0001 ### May 2012
67 Industry Interventional Allocation: N/ CIP-0001 January 2015 April 2017
240 Other Interventional Allocation: Ra 171102025;Z ### May 2016
331 Industry Interventional Allocation: Ra EFC10139|Eud April 2008 ###
76 Industry Interventional Allocation: Ra KCP-330-004 ### ###
31 Industry Interventional Allocation: Ra CSPA100A2201 ### ###
50 Other Interventional Allocation: Ra METc 2004/11October 2004
110 Other|IndustryInterventional Allocation: Ra HCV07-01|200 April 2008 June 2013
60 Other|IndustryInterventional Allocation: N/ MYOHERTAX August 2006 August 2015
131 Other|IndustryInterventional Allocation: Ra AZA-ANCA-1 June 2003 June 2014
199 Industry Interventional Allocation: Ra CV016-007 ### April 17, 2019
54 Industry Interventional Allocation: Ra FLE-007 April 26, 2022 May 22, 2023
765 Industry Interventional Allocation: Ra 20-214-29/CA July 27, 2020 ###
100 Other Interventional Allocation: Ra NL51318.078. April 30, 2015 April 30, 2020
0 Industry Interventional Allocation: Ra CA209-7UA|20 ### ###
676 Industry Interventional Allocation: Ra AP-recAP-AKI- ### ###
23 Industry Interventional Allocation: No 13070|B4Z-EW June 2010 May 2011
168 Industry Interventional Allocation: Ra MS200647_000 April 16, 2019 ###
1222 Industry Interventional Allocation: Ra EFC15156|201 ### June 5, 2020
943 Industry Interventional Allocation: Ra 200879|2017- ### ###
1630 Industry Interventional Allocation: Ra IP-15-001 ### July 17, 2020
781 Industry Interventional Allocation: Ra GLPG1690-CL- ### ###
10544 Industry|OtherInterventional Allocation: Ra K-877-302 ### July 27, 2022
748 Industry Interventional Allocation: Ra M16-298|2016 ### ###
52 Other Interventional Allocation: Ra ETAL-4 / HOV July 24, 2018 ###
6 Industry Interventional Allocation: N/ CL 03536 June 2012 June 2014
701 Industry Interventional Allocation: Ra GED-0301-CD ### ###
150 Industry Interventional Allocation: Ra CLR_15_05 ### March 2018
998 Industry Interventional Allocation: Ra B9991010|201May 19, 2016 ###
108 Industry Interventional Allocation: Ra RVT1601-CC- ### May 29, 2020
310 Industry Interventional Allocation: Ra GED-0301-CD July 25, 2016 ###
10584 Industry Interventional Allocation: Ra EFC14875|201 ### July 8, 2020
67 Other Interventional Allocation: Ra TOACT ### ###
380 Industry Interventional Allocation: Ra SHP647-301|2 ### July 22, 2020
10564 Industry Interventional Allocation: Ra B1481038|CV ### April 3, 2017
16784 Industry Interventional Allocation: Ra B1481022|CV ### ###
0 Industry Interventional Allocation: Ra IM101-604|201July 15, 2017 June 7, 2020
0 Industry Interventional Allocation: Ra 13650|I1F-M July 2014 April 2016
12092 Industry|OtherInterventional Allocation: Ra 11949|I1V-MCOctober 2012 March 2016
1722 Industry Interventional Allocation: Ra 16024|I8D-MC July 1, 2016 ###
432 Industry Interventional Allocation: Ra CBKM120F2303 ### May 23, 2016
79 Industry Interventional Allocation: Ra SPI-ZEV-11-3 April 19, 2012 ###
696 Industry Interventional Allocation: Ra 9090-14|2012- April 2013 ###
809 Industry Interventional Allocation: Ra WO29636|2014 ### ###
0 Industry Interventional Allocation: Ra 19225|2020-0 May 31, 2021 April 25, 2022
9 Industry Interventional Allocation: Ra PGFN-001 ### April 18, 2018
2046 Industry Interventional Allocation: Ra GV971-007 ### ###
50 Industry Interventional Masking: NoneMRL 2002-003October 2004
197 Industry Interventional Allocation: Ra PGX-III-AP-00 August 2011 April 2012
342 Industry Interventional Allocation: Ra KCI.2013.Prev ### ###
229 Industry Interventional Allocation: Ra 114157|2010- May 9, 2011 ###
5189 Industry Interventional Allocation: Ra AN-CVD2233 May 2010 March 2012
2336 Industry Interventional Allocation: Ra CSPP100G2301 January 2011 ###
889 Industry Interventional Allocation: Ra 101MS326|201 ### July 28, 2015
4509 Industry Interventional Allocation: Ra 20060359|200 June 2, 2010 ###
480 Industry Interventional Allocation: R 112517|COMB May 6, 2010 ###
8442 Industry Interventional Allocation: Ra CLCZ696B2314 ### May 2014
1280 Industry Interventional Allocation: Ra LF-0802 June 2011 January 2014
34 Industry Interventional Allocation: No 208471 ### ###
7 Industry Interventional Allocation: Ra CIDD001D240 July 11, 2018 ###
297 Industry Interventional Allocation: Ra CR017080|RE ### ###
56 Other Interventional Allocation: Ra EudraCT nr: 2 August 2010 July 2014
7484 Industry|OtherInterventional Allocation: Ra CV185-068|EU March 2009 March 2011
293 Industry Interventional Allocation: Ra CZPL389A220 ### July 15, 2020
334 Industry Interventional Allocation: Ra CR108399|201 ### ###
821 Industry Interventional Allocation: No MRZ 92579/TI/January 2009 ###
446 Industry Interventional Allocation: Ra CO39722|2016 ### April 15, 2019
1100 Industry Interventional Allocation: Ra 3133K1-3001| January 2008 October 2012
126 Other Interventional Allocation: Ra 2007-003514- January 2010 ###
447 Industry Interventional Allocation: R OMB110911 ### ###
3773 Industry Interventional Allocation: Ra EFC10295|200 ### October 2010
8606 Industry Interventional Allocation: Ra CSPP100E2337 October 2007 ###
901 Industry Interventional Allocation: Ra 3133K1-3000| June 2008 October 2012
0 Industry Interventional Allocation: No TAA-001
2577 Industry Interventional Allocation: Ra D4320C00015January 2008 January 2011
657 Industry Interventional Allocation: Ra TAK-475_306|October 2007 May 2008
970 Industry Interventional Allocation: Ra CFTY720D2306 July 28, 2008 ###
133 Other Interventional Allocation: Ra EORTC-62091| May 2011 June 2013
492 Industry Interventional Allocation: Ra HALO-109-301 ### ###
2157 Industry Interventional Allocation: Ra GFT505-315-1 March 2016 ###
1285 Industry Interventional Allocation: Ra CASA404A230 April 2008 May 2010
29 Industry Interventional Allocation: Ra D5170C00002| ### July 28, 2017
301 Industry Interventional Allocation: Ra NN1998-1390| ### ###
36 Industry Interventional Allocation: Ra AP REN 01-01 May 2008 ###
1461 Industry Interventional Allocation: N/ AVA102675 ### June 1, 2009
2000 Industry Interventional Allocation: No D6160C00038 March 2005
17802 Industry Interventional Allocation: Ra D3560L00030|J ### ###
361 Industry Interventional Allocation: N 1160.42 ### January 2009
580 Industry Interventional Allocation: Ra D6160C00029 August 2004 ###
796 Industry Interventional Allocation: Ra 505-205 ### March 2006
15067 Industry Interventional Allocation: Ra A5091043 July 2004 June 2007
1332 Industry|OtherInterventional Allocation: Ra 111960 May 2009 ###
3300 Industry Interventional Allocation: Ra D4003C00030 ### August 2006
713 Industry Interventional Allocation: Ra 20110265|201 ### ###
158 Other Interventional Allocation: Ra EORTC-08972 ### March 2003
1094 Industry Interventional Allocation: N/ 101-MS-321 March 2006 April 2014
0 Industry|OtherInterventional Allocation: Ra CR102576|201 ### October 2014
315 Industry Interventional Allocation: Ra A4451006 ###
5 Other Interventional Primary PurpoEORTC-08981 April 2001 October 2002
344 Industry Interventional Allocation: Ra VS-6063-202 ### January 2016
327 Industry Interventional Allocation: Ra PERSIST-1 (PJanuary 2013 January 2015
1831 Industry Interventional Allocation: Ra 20120103 August 2012 ###
119 Other Interventional Allocation: R EORTC-40004 May 2002 June 2007
1015 Industry Interventional Allocation: Ra 20101129|TRI January 2012 March 2016
839 Industry Interventional Allocation: Ra A8501002 ### June 2008
40 Industry Interventional Allocation: No BY1023/NL51 March 2007 October 2007
534 Industry Interventional Allocation: Ra EFC6058|2010January 2011 April 2013
800 Industry Interventional Allocation: Ra 20060540|GAM April 2011 ###
62 Industry Interventional Allocation: Ra AV608-106 June 2006 June 2007
598 Other Interventional Allocation: R EORTC-08021| May 2004 July 2008
0 Other Interventional Primary PurpoEORTC-13972 ###
494 Industry Interventional Allocation: No 3133K1-3003| ### October 2012
446 Industry Interventional Allocation: Ra Ptcl-01373 ### April 2012
2549 Industry Interventional Allocation: Ra 20070782|200 July 17, 2009 June 7, 2017
1100 Industry|OtherInterventional Allocation: Ra MORAb003-004 April 16, 2009 ###
204 Other Interventional Allocation: Ra EORTC-20971January 2001 March 2009
0 Other Interventional Primary PurpoEORTC-16985 April 1999
334 Industry Interventional Allocation: Ra D/P3/07/4 July 2008 May 2011
220 Industry Interventional Allocation: Ra 1184.14|2007- April 2008 ###
291 Industry Interventional Allocation: Ra CR014188|C05 August 2007 May 2009
232 Industry Interventional Allocation: Ra C32322|2006- May 2007 ###
699 Industry Interventional Allocation: Ra A5351028 January 2008 January 2009
560 Industry Interventional Allocation: Ra 3175A1-202 ### ###
227 Industry Interventional Allocation: N/ CR109007|67 ### ###
12 Industry|NIH|OInterventional Allocation: Ra BMT CTN 2002 ### ###
48 Industry Interventional Allocation: Ra M19-771|2020 ### June 5, 2023
29 Industry Interventional Allocation: Ra APD791-202 June 3, 2021 ###
104 Industry Interventional Allocation: Ra 0135-0347|202 ### July 19, 2022
66 Industry Interventional Allocation: Ra GLPG2737-CL- ### ###
211 Industry Interventional Allocation: Ra D3255C00001| ### ###
828 Industry Interventional Allocation: Ra A8501001 ### July 2008
26 Other Interventional Allocation: Ra EORTC-10974October 2001 ###
1038 Industry Interventional Allocation: No CQGE031C230April 8, 2020 ###
39 Industry Interventional Allocation: Ra QBGJ398-302| ### ###
76 Industry Interventional Allocation: Ra CINC280I1220 ### ###
155 Industry Interventional Allocation: Ra A4321001 January 2004
41 Industry Interventional Allocation: Ra D6580C00003 ### May 7, 2020
1480 Industry Interventional Allocation: Ra TRCA-303|201 ### ###
245 Industry Interventional Allocation: Ra CACZ885V2301 ### ###
1157 Industry Interventional Allocation: Ra KHB-1801 ### ###
109 Industry Interventional Allocation: Ra 203PF203|201 ### ###
30 Industry Interventional Allocation: Ra SHP647-305 ### July 7, 2020
0 Industry Interventional Allocation: Ra CR108378|201 ### April 30, 2019
193 Industry Interventional Allocation: Ra REDIV/002/17 July 2, 2018 ###
365 Industry Interventional Allocation: Ra JBT101-SSc-0 ### May 27, 2020
553 Industry Interventional Allocation: Ra CR108400|201 ### May 28, 2020
58 Other Interventional Allocation: Ra EORTC-30004 May 2002 May 2004
766 Industry Interventional Allocation: Ra 15789|2016-0 July 31, 2017 ###
161 Industry Interventional Allocation: Ra TCD14678|201June 9, 2017 ###
275 Industry Interventional Allocation: Ra TV48125-CNS-April 27, 2017 ###
52 Industry Interventional Allocation: No MS201781_003 ### ###
259 Industry Interventional Allocation: Ra TV48125-CNS- ### July 18, 2018
169 Industry Interventional Allocation: Ra TV48125-CNS- ### May 13, 2019
116 Industry Interventional Allocation: No INCB 59872-1 May 5, 2016 April 14, 2022
14 Industry Interventional Allocation: Ra MLN1117-1501June 3, 2015 ###
149 Industry Interventional Allocation: Ra CO-1686-020 ### ###
172 Industry Interventional Allocation: Ra GS-US-361-11 ### ###
906 Industry Interventional Allocation: Ra GX29176|2014 ### ###
46 Industry Interventional Allocation: Ra AG-CLI-0206| ### ###
86 Industry Interventional Allocation: Ra INCB 18424-3 June 2014 ###
44 Industry Interventional Allocation: Ra D4260C00008 ###
403 Industry Interventional Allocation: Ra EVP-6124-025October 2013 January 2017
545 Industry Interventional Allocation: Ra 1199.93|2012- ### ###
216 Industry|OtherInterventional Allocation: Ra 213551|1307- ### May 23, 2018
643 Industry Interventional Allocation: Ra 2012-PT023 ### ###
616 Industry Interventional Allocation: N/ 223AS304|EUD June 2012 ###
147 Industry Interventional Allocation: Ra ST261DM11005 April 2012 October 2013
240 Industry Interventional Allocation: Ra AZM-MD-302 ### May 2013
328 Industry Interventional Allocation: Ra 1160.113|2010October 2011 June 2013
83 Other|IndustryInterventional Allocation: Ra EAU RF 2010- August 2011 April 7, 2017
658 Industry Interventional Allocation: N/ TPS001 ### ###
617 Industry Interventional Allocation: Ra 1200.131|2011 ### ###
730 Industry Interventional Allocation: Ra CP-05-026 ### ###
0 Industry Interventional Allocation: Ra CR017743|CN July 2011 April 2014
1048 Industry Interventional Allocation: Ra ARQ197-A-U30 ### ###
113 Industry Interventional Allocation: Ra WA22908|2009October 2010 ###
102 Other Interventional Allocation: Ra EORTC-08092| July 2011 June 2015
130 Industry Interventional Allocation: Ra 20090072|201 ### ###
92 Industry Interventional Allocation: Ra E7389-702|20 April 16, 2010 May 8, 2015
1035 Industry Interventional Allocation: Ra M10-963|2009January 2010 July 2012
336 Industry Interventional Allocation: Ra 13101|H8K-M ### March 2011
208 Industry Interventional Allocation: No 3082B2-4432 May 2009 March 2013
74 Industry Interventional Allocation: Ra 28851 March 2009 ###
163 Industry Interventional Allocation: Ra HS044 May 2008 January 2014
2720 Industry Interventional Allocation: Ra A4091025|20 ### ###
415 Industry Interventional Allocation: Ra MORAb003-00 ### ###
207 Industry Interventional Allocation: Ra 1184.15|2007- April 2008 October 2008
255 Industry Interventional Allocation: Ra 28063 April 2008 ###
330 Industry Interventional Allocation: Ra A6061037 ### ###
143 Industry Interventional Allocation: Ra 12781|2007-0 June 2008 April 2010
500 Industry Interventional Allocation: No A6061046 ### May 18, 2009
169 Industry Interventional Allocation: Ra 110634|GEN4 January 2008 March 2011
86 Industry Interventional Allocation: Ra CR9108914 ### ###
87 Industry Interventional Allocation: Ra A3971013 January 2007 July 2008
18 Industry Interventional Allocation: N/ 070008|07-CHMay 15, 2007 April 4, 2012
451 Industry Interventional Allocation: Ra IM101-084 ### ###
54 Industry Interventional Allocation: Ra SL0004(IMMU-1 May 2005 March 2007
0 Industry Interventional Allocation: No SL0005|Eudra January 2007
800 Industry Interventional Allocation: Ra MPC-7869-05- May 2006
312 Industry Interventional Allocation: Ra D2450174 ###
408 Industry Interventional Allocation: Ra G-0034|VITAL July 2005 August 2008
49 Industry|OtherInterventional Allocation: Ra REX-001-005 April 25, 2017 ###
21 Industry Interventional Allocation: Ra R1500-HTG-20July 12, 2021 ###
2 Industry Interventional Allocation: Ra BP42698|2020April 19, 2021 ###
133 Industry Interventional Allocation: Ra ATR-002-202 April 12, 2021 June 6, 2022
82 Industry Interventional Allocation: Ra ME-401-004|2 ### ###
117 Industry Interventional Allocation: N/ WA42294|2020 ### ###
0 Industry Interventional Allocation: Ra CA209-79X|20April 15, 2021 ###
30 Industry Interventional Allocation: Ra 17306|J1S-MC ### ###
58 Industry Interventional Allocation: No 20180290|201 ### June 1, 2023
257 Industry Interventional Allocation: Ra TAK-994-1501| ### ###
3 Industry Interventional Allocation: No CTMX-M-072- ### May 21, 2020
123 Industry Interventional Allocation: Ra CZPL389A2203April 4, 2019 July 23, 2020
88 Industry Interventional Allocation: Ra CR108598|201May 31, 2019 ###
50 Industry Interventional Allocation: Ra CR108979|201 ### June 9, 2021
1147 Industry Interventional Allocation: Ra 16832|I4V-MC ### April 1, 2022
63 Industry|OtherInterventional Allocation: N/ Debio 1347-20 ### ###
158 Industry Interventional Allocation: Ra AZP01-CLI-00 ### ###
58 Industry Interventional Allocation: No ACT15320|201 ### ###
1 Industry Interventional Allocation: Ra BGB-A317-NSC May 22, 2019 ###
131 Industry Interventional Allocation: Ra AC-065B302|2 ### June 7, 2022
40 Industry Interventional Allocation: Ra SHP647-307|2 ### ###
830 Industry Interventional Allocation: Ra 16676|I4V-MC ### ###
40 Industry Interventional Allocation: No OMO1.01.02 ### May 25, 2020
22 Industry Interventional Allocation: N/ ACH471-205|2 ### ###
481 Industry Interventional Allocation: Ra 2125-MEL-301May 30, 2018 June 1, 2021
40 Industry Interventional Allocation: Ra M16-534|2017 July 30, 2018 ###
121 Industry Interventional Allocation: Ra 17472|2017-0 ### July 23, 2018
265 Industry Interventional Allocation: Ra 802NP206|201May 31, 2018 April 12, 2021
23 Industry Interventional Allocation: Ra ACT14884|201 ### ###
18 Industry Interventional Allocation: N/ CIP 2101-01 ### July 14, 2020
457 Industry Interventional Allocation: Ra GN39763|2017 ### ###
174 Industry|OtherInterventional Allocation: N/ IP-0020-16 ### ###
1145 Industry|OtherInterventional Allocation: Ra CCNP520A2202 ### ###
2538 Industry Interventional Allocation: Ra CQAW039A231 ### ###
0 Industry Interventional Allocation: Ra GED-0301-CD ### ###
49 Industry Interventional Allocation: Ra CR108217|201 ### July 17, 2018
240 Industry Interventional Allocation: Ra RVT-101-2002October 2016 ###
65 Industry Interventional Allocation: Ra CACZ885X2201 ### October 2015
255 Industry Interventional Allocation: Ra SNT-III-012 ### ###
80 Other|IndustryInterventional Allocation: Ra EORTC-1506-S July 7, 2017 ###
95 Industry Interventional Allocation: N/ CTMT212X2106 ### ###
30 Industry Interventional Allocation: Ra CER-001-CLIN ### October 2018
914 Industry Interventional Allocation: Ra TPS003 ### ###
252 Industry Interventional Allocation: No CMBG453X2101 ### ###
142 Industry Interventional Allocation: No CLXH254X2101 ### ###
39 Industry Interventional Allocation: Ra SHP616-302|2May 20, 2016 May 31, 2019
447 Industry Interventional Allocation: Ra WO29519|2014 ### April 24, 2020
96 Industry Interventional Allocation: No 20120252|201 ### ###
1643 Industry Interventional Allocation: Ra 221AD302|201 ### ###
246 Industry Interventional Allocation: N/ PTC124-GD-0 ### June 2, 2017
759 Industry Interventional Allocation: Ra IMPACT-EU March 2015 April 5, 2018
126 Industry Interventional Allocation: No CA008-002|20 ### ###
631 Industry Interventional Allocation: Ra GO29058|2014 April 9, 2015 ###
10 Industry Interventional Allocation: Ra CQGE031B2204 ### March 2016
260 Industry Interventional Allocation: Ra NEOD001-CL0 ### May 2018
110 Industry|OtherInterventional Allocation: N/ EP025 ### ###
975 Industry Interventional Allocation: Ra GX29185|2014 ### ###
9 Industry Interventional Allocation: Ra BP29420|2014 ### July 2015
246 Industry Interventional Allocation: No CP-MGD006-0 June 9, 2014 July 5, 2022
318 Industry Interventional Allocation: Ra CO-1686-019 ### July 30, 2019
56 Industry Interventional Allocation: Ra 191622-137|2 May 23, 2014 ###
311 Industry Interventional Allocation: Ra PERSIST-2 (P ### April 2016
43 Industry Interventional Allocation: No CINC280X2204 ### ###
331 Industry Interventional Allocation: Ra 15122|H6D-MC ### ###
5 Industry Interventional Allocation: Ra PREOB-NU3 June 2012 April 2018
59 Industry Interventional Allocation: Ra CAUY922A2207 ### ###
62 Industry Interventional Allocation: Ra CBEZ235Z2401 October 2012 ###
76 Industry Interventional Allocation: Ra CR100752|CN ### ###
158 Industry Interventional Allocation: No 1160.138|2011 ### June 2013
233 Industry Interventional Allocation: No 114349 ### March 2014
265 Industry Interventional Allocation: Ra AC-055C302 ### ###
0 Industry Interventional Allocation: Ra AI452-013|201 March 2012 March 2014
2867 Industry Interventional Allocation: N/ A3921061|201 ### June 2016
8 Industry Interventional Allocation: N/ 8-55-52060-00 ### ###
198 Industry Interventional Allocation: Ra 3133K1-3002| ### ###
839 Industry Interventional Allocation: N/ MS-LAQ-301E| ### July 1, 2017
1050 Industry Interventional Allocation: Ra BVF-324-301 August 2009 ###
112 Industry Interventional Allocation: Ra CR016474|421 ### July 2011
282 Industry Interventional Allocation: No BR1-127 ### March 2011
0 Industry Interventional Allocation: No CA180-083|EU ### January 2007
24 Industry Interventional Allocation: Ra WX21956|2008 March 2009 March 2013
14 Industry Interventional Allocation: Ra CIGE025A243 ### July 2010
30 Industry|OtherInterventional Allocation: N/ 08-010P October 2008 ###
418 Industry Interventional Allocation: Ra HL 0101 INT January 2003 January 2005
1680 Industry|OtherInterventional Allocation: Ra EchoCRT August 2008 March 2013
130 Industry Interventional Allocation: Ra A1481244|200 April 8, 2008 May 25, 2010
186 Industry Interventional Allocation: No CA165-026|EU July 2006 March 2007
57 Industry Interventional Allocation: Ra 12002|2005-0 ###
926 Industry Interventional Allocation: Ra 11961|2005-0 ### October 2007
127 Industry Interventional Allocation: Ra 291-415 ### August 2007
0 Industry Interventional Allocation: Ra 3082A-101711 April 2005 ###
Industry Interventional Allocation: Ra CA165-020 March 2006
626 Industry Interventional Allocation: Ra G-0029|(VITAL July 2004 October 2008
88 Other Interventional Allocation: Ra EORTC-22011 July 2003 ###
23 Other Interventional Allocation: Ra EORTC-18981 April 2001 May 2003
74 Industry Interventional Allocation: N/ TAS-119-102| ### August 2019
107 Industry Interventional Allocation: No CLXS196X210 ### ###
66 Industry Interventional Allocation: Ra FPA008-001|2October 2013 April 2016
9 Industry Interventional Allocation: No PRO053-CLIN June 2013 ###
15 Industry Interventional Allocation: No PRO045-CLINJanuary 2013 ###
653 Industry Interventional Allocation: Ra EFC4966|SR3 June 2002 January 2003
32 Industry Interventional Allocation: Ra PDY15079|201 ### ###
9 Industry Interventional Allocation: N/ Thoratec Hea October 2014 January 2017
1 Industry Interventional Allocation: Ra 10-390 ### April 2013
661 Industry Interventional Allocation: Ra EFC5828|2005 August 2005 April 2009
0 Other Interventional Allocation: No 1297368|No gra ### ###
60 Industry Interventional Allocation: Ra MRL 2002-001 ###
0 Other Interventional Allocation: No INSPIRE study ### ###
2 Other|IndustryInterventional Allocation: N/ EORTC 1762-S ### July 30, 2020
56 Industry Interventional Allocation: Ra CX-401/FATT2 ### ###
1 Industry Interventional Allocation: Ra PN-1007-001 ### ###
46 Other Interventional Allocation: N/ VHIO16001 - ### ###
220 Other|IndustryInterventional Allocation: Ra DIAN-TU-002| ### ###
160 Industry Interventional Allocation: No 1463-0001|202 ### July 28, 2025
72 Industry Interventional Allocation: N/ CY 5032|2021 July 25, 2022 ###
0 Industry Interventional Allocation: Ra AK802 May 6, 2022 ###
39 Industry Interventional Allocation: Ra CQGE031E1230 ### ###
486 Industry Interventional Allocation: Ra CY 5031|2020 ### ###
24 Industry Interventional Allocation: N/ LTS15823|202 ### July 13, 2021
14 Industry Interventional Allocation: No DYN101-C101 ### ###
115 Industry Interventional Allocation: Ra IMR-SCD-301| ### ###
122 Industry Interventional Allocation: Ra IMR-BTL-201| ### ###
1379 Industry Interventional Allocation: No WN42171|2020 ### ###
12 Industry Interventional Allocation: N/ 1368-0007|201May 15, 2020 May 14, 2022
116 Industry Interventional Allocation: N/ WN41874 May 22, 2020 ###
107 Industry Interventional Allocation: N/ Pelle-926-301 June 3, 2020 July 14, 2021
75 Industry Interventional Allocation: No 245AS102|201April 28, 2020 May 3, 2022
382 Industry Interventional Allocation: Ra ALXN1210-ALS ### ###
37 Industry Interventional Allocation: Ra CLNP023D122 ### ###
27 Industry Interventional Allocation: Ra RA101495-02. ### ###
14 Industry Interventional Allocation: N/ D-FR-01087-0 May 3, 2018 April 3, 2020
104 Industry Interventional Allocation: Ra 204869 May 6, 2019 May 17, 2021
67 Industry Interventional Allocation: N/ ACT15378|PIP ### ###
120 Industry Interventional Allocation: N/ ORARIALS-02 ### July 2, 2021
493 Industry Interventional Allocation: Ra CRTH258C2302July 3, 2019 July 26, 2021
64 Industry Interventional Allocation: No CADPT01A1210 ### ###
211 Other|IndustryInterventional Allocation: Ra CL3-95008-00 ### ###
107 Industry Interventional Allocation: No ACT15377|201 ### May 11, 2022
982 Industry Interventional Allocation: Ra WN39658|2017 ### ###
193 Industry Interventional Allocation: Ra PVO-2A-201|2 ### ###
77 Industry Interventional Allocation: Ra ARRAY-797-30April 17, 2018 ###
140 Industry Interventional Allocation: Ra A3921288|RIV ### ###
182 Industry Interventional Allocation: Ra 20150183|201 ### April 18, 2019
263 Industry Interventional Allocation: Ra 215MS202|201 ### ###
149 Industry Interventional Allocation: Ra GS-US-205-18 ### May 27, 2020
317 Industry Interventional Allocation: No CNIR178X2201 ### ###
106 Industry Interventional Allocation: No CMIW815X2102 ### ###
150 Other Interventional Allocation: Ra 2015-003130-2 ### June 2023
54 Industry Interventional Allocation: Ra CCP-020-301 June 1, 2017 ###
28 Industry Interventional Allocation: No B-701-U22|20 April 20, 2017 ###
261 Industry Interventional Allocation: N/ RTA 402-C-16April 18, 2017 ###
63 Industry Interventional Allocation: Ra CR-AIR-009|2 ### ###
144 Other Interventional Allocation: Ra 2012-003005-1 July 6, 2016 April 20, 2019
13 Other|IndustryInterventional Allocation: Ra EORTC-1447-S ### June 5, 2020
98 Industry Interventional Allocation: Ra PTG-100-02 ### ###
174 Industry Interventional Allocation: Ra 15731|2013-0 ### May 26, 2016
68 Industry Interventional Allocation: No BO17004 ### ###
38 Industry Interventional Allocation: Ra CMEK162X220August 2013 May 2015
350 Industry Interventional Allocation: Ra CLJN452A2202 ### April 6, 2020
112 Industry Interventional Allocation: N/ LYC-30937-20 ### July 18, 2018
161 Industry Interventional Allocation: Ra CS-100 May 2016 October 2019
994 Industry Interventional Allocation: No GX30191|2016July 21, 2016 ###
207 Industry|OtherInterventional Allocation: Ra PULSE-PAH-0 April 2016 August 2018
0 Industry Interventional Allocation: N/ 2015-14 ### October 2019
17 Industry Interventional Allocation: Ra SHP610-201|2 April 8, 2015 April 12, 2019
175 Industry Interventional Allocation: Ra WA18230|2004October 2005 ###
152 Industry Interventional Allocation: N/ SD-006|2014- June 9, 2015 ###
202 Industry Interventional Allocation: Ra RTA 402-C-15 ### May 7, 2020
42 Industry Interventional Allocation: N/ EP0073|2015- ### ###
2607 Other|IndustryInterventional Allocation: Ra NOAH - AFNET ### ###
2016 Industry Interventional Allocation: Ra 8342B-062|20 ### ###
480 Industry|OtherInterventional Allocation: Ra CAPI015A2201 ### April 30, 2020
87 Industry Interventional Allocation: N/ GO29664|2014 ### June 6, 2019
40 Industry Interventional Allocation: Ra ISIS 304801-C ### ###
868 Industry Interventional Allocation: Ra 000133|2014- July 2015 ###
248 Industry Interventional Allocation: N/ TV7820-CNS-2 ### ###
58 Industry Interventional Allocation: Ra 109MS308|201 May 2015 January 2016
90 Industry Interventional Allocation: Ra CR106978|548 July 2, 2015 ###
1 Industry Interventional Allocation: N/ BSTE-0144 April 2014 July 2014
41 Industry Interventional Allocation: No GS-US-372-12 ### ###
0 Other|IndustryInterventional Allocation: Ra C12-75|2013- January 2015 January 2017
913 Industry Interventional Allocation: N/ TRx-237-020 August 2014 May 2017
75 Industry Interventional Allocation: No O-12-M1 July 2013 ###
37 Industry Interventional Allocation: N/ CD-ON-CAT-8 August 2014 ###
1425 Industry Interventional Allocation: Ra S2282 ### ###
191 Industry Interventional Allocation: Ra IG1104|2013- ### ###
198 Industry Interventional Allocation: Ra D4300C00004 ### July 2013
102 Industry Interventional Allocation: N/ CLN0016 ### June 2017
348 Industry Interventional Allocation: Ra EVP-6124-026 June 2014 August 2017
91 Industry Interventional Allocation: N/ 1301.4|2013-0May 31, 2013 ###
80 Industry Interventional Allocation: N/ CR2P01127|DOctober 2013 July 2014
0 Industry Interventional Allocation: Ra SCD-206 October 2013 June 2015
24 Industry Interventional Allocation: N/ 701-301|2013- April 2014 ###
68 Industry Interventional Allocation: N/ CSOM230B24 ### ###
33 Industry Interventional Allocation: Ra 115811 ### March 2015
17 Industry Interventional Intervention MCR102071|DA ### ###
152 Industry Interventional Allocation: No GO29642|2014 ### ###
29 Industry Interventional Allocation: Ra CR100957|KET June 2013 July 2014
28 Industry Interventional Allocation: No CLEE011X210 July 2013 April 2015
12 Industry Interventional Allocation: N/ AdOPT CRT Su ### March 2012
34 Other|IndustryInterventional Allocation: Ra EudraCT 2005 ### ###
294 Industry Interventional Allocation: Ra 1301.1|2011-0 ### ###
307 Industry Interventional Allocation: Ra AP24534-12-3 June 2012 October 2013
130 Industry Interventional Allocation: N/ CRAD001O21 ### June 2011
315 Industry Interventional Allocation: Ra CLN0009 October 2012 ###
26 Industry Interventional Allocation: N/ PCIA202/10|2 April 2012 August 2015
38 Industry Interventional Allocation: N/ CLCQ908B2305 ### July 2015
70 Industry Interventional Allocation: Ra 13735|I4O-MC March 2012 August 2013
59 Industry Interventional Allocation: N/ VA0444 May 2011 January 2013
41 Industry Interventional Allocation: Ra E2090-E044-4 ### ###
72 Industry Interventional Allocation: Ra IM133-005|201 June 2012 ###
38 Other|NIH Interventional Allocation: Ra GOG-0277|NCIJune 4, 2012 ###
244 Industry Interventional Allocation: Ra SP 488/2009 ### January 2014
44 Other|IndustryInterventional Allocation: Ra EORTC-40091| June 2013 ###
433 Other Interventional Allocation: Ra H-A-2008-086 ### ###
300 Industry Interventional Allocation: Ra 03-C11-003PL June 2012 ###
18 Industry Interventional Allocation: N/ 20110100|201 ### June 3, 2016
119 Industry Interventional Allocation: N/ CAFQ056B2278 ### ###
102 Industry Interventional Allocation: Ra C10-001|2010- ### May 13, 2014
159 Industry Interventional Allocation: No 114375 ### ###
160 Industry Interventional Allocation: Ra CSOM230I2201 June 2011 ###
225 Industry Interventional Allocation: No AV-951-09-90 June 2010 June 2015
813 Industry Interventional Allocation: Ra A4001095|201 ### August 2013
10 Industry Interventional Allocation: Ra A6281289 March 2008 January 2009
21 Industry Interventional Allocation: No 14244|CP15-1 August 2011 May 2012
1052 Industry Interventional Allocation: N/ C38072/3085| June 2011 January 2015
644 Industry Interventional Allocation: Ra D4300C00004|January 2011 October 2012
173 Industry Interventional Allocation: Ra CR017089|CNT ### ###
129 Other|IndustryInterventional Allocation: Ra 2005-002011- May 2004 January 2015
67 Industry Interventional Allocation: N/ 20100008|201 ### ###
13 Industry Interventional Allocation: No CV185-079 July 26, 2011 ###
3236 Industry Interventional Allocation: Ra EFC11405|201 July 2010 ###
223 Industry Interventional Allocation: N/ LTS11298|201 June 2010 ###
144 Industry Interventional Allocation: No CQTI571A2301 April 2010 April 2014
325 Industry Interventional Allocation: Ra GBMET.CR.G March 2010 ###
198 Other Interventional Allocation: No Densiprobe-08 ### ###
12 Other Interventional Allocation: Ra MORD-STG4SU ### ###
109 Industry Interventional Allocation: Ra 2-55-52060-00October 2009 ###
389 Industry Interventional Allocation: Ra CR016468|421 ### May 2011
40 Industry Interventional Allocation: N/ CR-AIR-004|EuAugust 2009 ###
577 Industry Interventional Allocation: Ra AC-054-302 July 1, 2009 ###
84 Industry|OtherInterventional Allocation: Ra CACZ885G2305 July 2009 ###
546 Industry Interventional Allocation: N/ 12789|I3E-BM ### ###
1192 Industry Interventional Allocation: No B1321007|FP March 2003 July 2011
409 Industry Interventional Allocation: Ra HS043 ### July 21, 2016
643 Industry Interventional Allocation: Ra EFC10841|EudOctober 2008 April 2009
1015 Industry Interventional Allocation: Ra EFC6910|Eudr July 2008 June 2009
421 Industry Interventional Allocation: Ra EFC10572|200 July 2008 March 2009
222 Industry|OtherInterventional Allocation: Ra 3206K1-2203| March 2008 ###
452 Industry Interventional Allocation: Ra 7182007 October 2007 April 2011
153 Industry Interventional Allocation: Ra SCI-RP-Pan-P ### August 2009
191 Industry Interventional Allocation: Ra IM101-158|EU ### ###
11 Industry Interventional Allocation: Ra CACZ885A220 August 2007 May 2009
91 Industry Interventional Allocation: No 300-06-008 April 2007 ###
13 Industry Interventional Allocation: N/ GEN204 April 2007 October 2008
68 Industry Interventional Allocation: No SPD405-403|2May 22, 2007 ###
255 Industry Interventional Allocation: Ra CBPD952A230 May 2007 July 2009
645 Industry Interventional Allocation: Ra RIMON_R_0096 ### January 2009
256 Industry Interventional Allocation: Ra 1556-FLEC
2666 Industry Interventional Allocation: Ra RIMON_R_0096 ### ###
30 Industry Interventional Allocation: Ra ACH171-002 ###
190 Industry Interventional Allocation: Ra 102.1 ### ###
69 Industry Interventional Allocation: Ra H3A106104 ### January 2008
656 Other|NIH Interventional Allocation: Ra U01NS052220| August 2006 July 2012
360 Industry|OtherInterventional Allocation: Ra PX115.1.1-302 June 2006 August 2008
58 Industry Interventional Allocation: Ra A2171035 ### June 2008
70 Other|IndustryInterventional Allocation: Ra SPOG 2003 FN| January 2004 ###
136 Industry Interventional Allocation: Ra A6391003 July 2006 ###
25 Industry Interventional Allocation: Ra 291-417 August 2006 August 2007
18695 Industry Interventional Allocation: Ra EFC5826|2005 ### April 2009
6706 Industry Interventional Allocation: Ra EFC4912 W July 2003 ###
143 Industry Interventional Allocation: Ra MGU - 002 ### June 2006
554 Industry Interventional Allocation: Ra F7TRAUMA-171 October 2005 ###
277 Industry Interventional Allocation: Ra NTI-ASP-0502 ### ###
2 Industry Interventional Allocation: No TG-M-003 ### July 2007
510 Industry Interventional Allocation: Ra SL0003 (IMMU- June 2005 March 2007
607 Industry Interventional Allocation: Ra 0468H1-313 ### July 2008
93 Other Interventional Allocation: Ra EORTC-21011|January 2003 May 2010
47 Other Interventional Allocation: R EORTC-22996 March 2001 April 2003
144 Other Interventional Allocation: R EORTC-40954 July 1999 ###
340 Other Interventional Allocation: Ra EORTC-22952 ### ###
Industry Interventional Allocation: Ra 598-CL-008
Enrollment Funded Bys Study Type Study DesignOther IDs Start Date Primary Comp
April 22, 2022 ### ### Amsterdam UMC, location AM https://ClinicalTrials.gov/sho
### April 20, 2022 ### Leiden University Medical Cehttps://ClinicalTrials.gov/sho
May 1, 2024 ### ### Netherlands, Nijmegen, Geldhttps://ClinicalTrials.gov/sho
### ### ### Radboud university medical chttps://ClinicalTrials.gov/sho
### April 14, 2021 ### Maastricht University Medicahttps://ClinicalTrials.gov/sho
### ### ### Radboudumc, Nijmegen, Geld https://ClinicalTrials.gov/sho
June 8, 2020 April 24, 2020 ### UMCU, Utrecht, Netherlands https://ClinicalTrials.gov/sho
April 2, 2020 ### ### June 1, 2022 PRA Health Sc"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### UMCG, Groningen, Netherla https://ClinicalTrials.gov/sho
### ### ### Leiden University Medical Cehttps://ClinicalTrials.gov/sho
### ### June 9, 2020 Leiden University Medical Cehttps://ClinicalTrials.gov/sho
### ### ### UMC Utrecht, Utrecht, Nethehttps://ClinicalTrials.gov/sho
July 1, 2019 ### July 16, 2020 Catharina Hospital, Eindhovehttps://ClinicalTrials.gov/sho
### ### ### Maastricht University Medicahttps://ClinicalTrials.gov/sho
### ### ### Rijnstate, Arnhem, Gelderlanhttps://ClinicalTrials.gov/sho
May 11, 2020 July 12, 2017 July 20, 2020 Rijnstate Hospital, Arnhem, https://ClinicalTrials.gov/sho
### July 7, 2017 ### Academisch Medisch Centrum https://ClinicalTrials.gov/sho
April 23, 2018 May 12, 2017 April 17, 2019 University Medical Center Utrhttps://ClinicalTrials.gov/sho
### ### April 8, 2022 Maastricht university medicalhttps://ClinicalTrials.gov/sho
### ### ### Netherlands Cancer Institut https://ClinicalTrials.gov/sho
May 4, 2020 ### May 6, 2020 A. Elvan, Zwolle, Overijssel, https://ClinicalTrials.gov/sho
June 2016 ### June 9, 2016 University Medical Center G https://ClinicalTrials.gov/sho
May 2017 ### ### MAASTRO Clinic, Maastricht,https://ClinicalTrials.gov/sho
January 2016 ### ### Netherlands Institute for Pi https://ClinicalTrials.gov/sho
### ### April 6, 2016 Medisch Spectrum Twente (M https://ClinicalTrials.gov/sho
### ### May 23, 2017 Zon en Schild, Amersfoort, Uhttps://ClinicalTrials.gov/sho
### ### ### Amphia Ziekenhuis, Oosterhohttps://ClinicalTrials.gov/sho
### ### ### Gelderse Vallei Hospital, Ed https://ClinicalTrials.gov/sho
October 2017 ### ### Máxima Medisch Centrum, Eihttps://ClinicalTrials.gov/sho
### ### Maastricht University, Maastrhttps://ClinicalTrials.gov/sho
January 2021 ### ### Rijnstate Hospital, Arnhem, https://ClinicalTrials.gov/sho
May 2018 ### ### MAASTRO clinic, Maastricht,https://ClinicalTrials.gov/sho
April 2017 ### April 5, 2017 Catharina Hospital, Eindhovehttps://ClinicalTrials.gov/sho
### June 2, 2014 July 31, 2018 Medical Center Alkmaar, Alk https://ClinicalTrials.gov/sho
April 10, 2014 ### University Medical Center G https://ClinicalTrials.gov/sho
### June 1, 2016 University Medical Center G https://ClinicalTrials.gov/sho
May 2017 ### ### University Medical Center Utrhttps://ClinicalTrials.gov/sho
### ### ### University Medical Centre G https://ClinicalTrials.gov/sho
### ### ### Maastricht University, Maastrhttps://ClinicalTrials.gov/sho
June 2012 ### ### Maastricht University Medicahttps://ClinicalTrials.gov/sho
June 2009 ### ### St Elisabeth Hospital, Tilbur https://ClinicalTrials.gov/sho
May 2014 May 26, 2011 July 7, 2016 Medisch Spectrum Twente, En https://ClinicalTrials.gov/sho
August 2016 April 5, 2011 ### University Medical Center G https://ClinicalTrials.gov/sho
### ### July 7, 2016 Medisch Spectrum Twente, Ehttps://ClinicalTrials.gov/sho
October 2012 ### May 11, 2012 University Medical Centre Ni https://ClinicalTrials.gov/sho
April 2012 ### ### Catharina Ziekenhuis, Eindh https://ClinicalTrials.gov/sho
### April 20, 2010 ### Academic Medical Center, Unhttps://ClinicalTrials.gov/sho
July 2012 ### May 29, 2013 Sanofi-Aventis Administrativ https://ClinicalTrials.gov/sho
January 2012 ### ### Princess Amalia Children's Clhttps://ClinicalTrials.gov/sho
### ### July 26, 2018 Vrije Universiteit Medisch C https://ClinicalTrials.gov/sho
### ### April 21, 2015 University Medical Center, U https://ClinicalTrials.gov/sho
January 2011 ### July 22, 2013 University Medical Center Utrhttps://ClinicalTrials.gov/sho
### ### Radboud University Nijmegenhttps://ClinicalTrials.gov/sho
### ### May 16, 2017 May 16, 2017 Isala Klinieken, Zwolle, Neth https://ClinicalTrials.gov/sho
### June 2, 2008 ### VU University Medical Cente https://ClinicalTrials.gov/sho
June 2009 June 2, 2008 ### ### For additional information r https://ClinicalTrials.gov/sho
July 2017 ### ### Rijnstate Hospital, Arnhem, https://ClinicalTrials.gov/sho
May 2008 ### ### University Medical Center, U https://ClinicalTrials.gov/sho
October 2009 ### May 28, 2014 UMC St. Radboud, Nijmegen,https://ClinicalTrials.gov/sho
August 2009 July 19, 2007 ### Erasmus MC, Rotterdam, Nethttps://ClinicalTrials.gov/sho
January 2011 May 30, 2007 ### ### Medtronic Bakken Research https://ClinicalTrials.gov/sho
C
May 2008 ### ### LUMC, Leiden, Netherlands https://ClinicalTrials.gov/sho
June 2010 ### July 16, 2014 July 16, 2014 Amsterdam, Netherlands https://ClinicalTrials.gov/sho
October 2007 ### ### Isala Klinieken, Zwolle, Overihttps://ClinicalTrials.gov/sho
October 2007 ### June 3, 2015 University Medical Center Utrhttps://ClinicalTrials.gov/sho
### ### ### Research Site, Utrecht, Nethhttps://ClinicalTrials.gov/sho
June 2008 ### ### Radboud University Nijmegenhttps://ClinicalTrials.gov/sho
June 2008 ### ### AMC, Amsterdam, Netherlanhttps://ClinicalTrials.gov/sho
January 2008 ### April 15, 2008 Utrecht Institute for Pharmachttps://ClinicalTrials.gov/sho
### ### ### Erasmus MC-Daniel den Hoed https://ClinicalTrials.gov/sho
January 2007 ### ### HIV Outpatient Clinic, Acad https://ClinicalTrials.gov/sho
### ### ### Department of Otorhinolarynghttps://ClinicalTrials.gov/sho
### ### April 29, 2019 Reumazorg Zuidwest Nederlan https://ClinicalTrials.gov/sho
January 2018 ### ### Academic Medical Center, Am https://ClinicalTrials.gov/sho
July 2012 ### ### Atrium Medical Center Parksthttps://ClinicalTrials.gov/sho
### June 7, 2012 ### Academic Medical Centre Ams https://ClinicalTrials.gov/sho
April 2015 ### April 22, 2015 Academic Medical Center, Am https://ClinicalTrials.gov/sho
May 2009 ### ### Medisch Centrum Haaglanden, https://ClinicalTrials.gov/sho
### ### ### Universitaets klinikum Erla https://ClinicalTrials.gov/sho
### ### April 12, 2017 Department of Internal Medichttps://ClinicalTrials.gov/sho
### ### ### Universitätsklinikum des Saahttps://ClinicalTrials.gov/sho
July 5, 2022 ### ### HagaZiekenhuis, Den Haag, https://ClinicalTrials.gov/sho
N
### ### ### Meander Medical Center, Amer https://ClinicalTrials.gov/sho
July 2013 ### ### St. Antonius Hospital, Nieu https://ClinicalTrials.gov/sho
August 2010 ### ### Research site, Amsterdam, Ne https://ClinicalTrials.gov/sho
March 2010 ### July 7, 2010 Radboud University Nijmegenhttps://ClinicalTrials.gov/sho
July 21, 2021 ### April 26, 2023 HagaZiekenhuis, The Hague,https://ClinicalTrials.gov/sho
May 30, 2018 ### July 26, 2018 Dutch Cancer Institute/ A v https://ClinicalTrials.gov/sho
### May 17, 2013 ### Academic Medical Center, Am https://ClinicalTrials.gov/sho
### ### ### Leiden University Medical C https://ClinicalTrials.gov/sho
### ### ### University of Bonn, Bonn, Gehttps://ClinicalTrials.gov/sho
July 2015 April 29, 2009 ### University hospital Gent, Ge https://ClinicalTrials.gov/sho
### May 12, 2017 May 28, 2021 May 28, 2021 Research Site,"Study Protocohttps://ClinicalTrials.gov/sho
May 2019 ### ### ZNA, Antwerp, Belgium|Univer https://ClinicalTrials.gov/sho
### ### ### Aarhus Universitetshospital, https://ClinicalTrials.gov/sho
### ### ### ### HELIOS Klinike"Study Protocohttps://ClinicalTrials.gov/sho
July 28, 2022 ### ### Insitute for Stroke and Demehttps://ClinicalTrials.gov/sho
March 2016 ### ### Elkerliek Hospital, Helmond https://ClinicalTrials.gov/sho
### ### ### GSK Investigational Site, Le https://ClinicalTrials.gov/sho
May 1, 2016 May 31, 2013 ### Aarhus University Hospital, https://ClinicalTrials.gov/sho
May 25, 2021 April 6, 2020 ### Jeroen Bosch Ziekenhuis, 's https://ClinicalTrials.gov/sho
May 2, 2019 ### ### Radboudumc, Nijmegen, Gelde https://ClinicalTrials.gov/sho
### April 20, 2015 ### Medisch Spectrum Twente, En https://ClinicalTrials.gov/sho
March 2018 April 14, 2014 May 9, 2018 Maastricht University Medicahttps://ClinicalTrials.gov/sho
### ### June 8, 2023 University Health Network T https://ClinicalTrials.gov/sho
January 2014 July 12, 2011 ### Medisch Centrum Alkmaar, Alk https://ClinicalTrials.gov/sho
### ### April 22, 2015 OLVZ Aalst, Aalst, Belgium|Chttps://ClinicalTrials.gov/sho
May 1, 2018 ### May 31, 2017 NKI/AvL, Amsterdam, Netherla https://ClinicalTrials.gov/sho
### July 24, 2015 ### Regionshospitalet Midtjyllan https://ClinicalTrials.gov/sho
June 2008 ### ### Vrije Universiteit Medisch https://ClinicalTrials.gov/sho
### ### ### Princess Alexandra Hospital https://ClinicalTrials.gov/sho
May 19, 2021 July 26, 2018 ### ### Investigationa "Study Protocohttps://ClinicalTrials.gov/sho
March 2014 ### April 2, 2015 Universidad Autonoma de Nue https://ClinicalTrials.gov/sho
March 2014 ### ### AZ Sint-Lucas Brugge, Brugghttps://ClinicalTrials.gov/sho
May 4, 2018 ### May 22, 2019 May 22, 2019 Vascular Biolo"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### Mayo Clinic Ar"Study Protocohttps://ClinicalTrials.gov/sho
May 30, 2021 ### May 17, 2023 May 17, 2023 Heart Center R"Study Protocohttps://ClinicalTrials.gov/sho
### July 26, 2018 ### ### Investigationa "Study Protocohttps://ClinicalTrials.gov/sho
January 2011 ### June 3, 2015 Research Site, Copenhagen https://ClinicalTrials.gov/sho
S,
June 6, 2018 May 15, 2017 ### ### Novartis Invest"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Site105, Pula, Croatia|Site1 https://ClinicalTrials.gov/sho
### ### ### St Vincent's Hospital, Melbo https://ClinicalTrials.gov/sho
April 2017 ### ### Massachusetts General Hospit https://ClinicalTrials.gov/sho
August 2015 June 5, 2013 ### Yale University School of Mehttps://ClinicalTrials.gov/sho
July 2008 ### May 17, 2010 ### ULB-Hôpital Erasme, Centre https://ClinicalTrials.gov/sho
d
### ### ### ### Hunter Pain Clinic, Broadmeahttps://ClinicalTrials.gov/sho
April 2014 July 26, 2011 ### City of Hope National Medicalhttps://ClinicalTrials.gov/sho
January 2011 ### ### ### BE004, Brugge, Belgium|BE00 https://ClinicalTrials.gov/sho
### ### ### ULB Hôpital Erasme, Brussels https://ClinicalTrials.gov/sho
### May 30, 2019 July 3, 2023 July 3, 2023 UCLA Oncology H Protocohttps://ClinicalTrials.gov/sho
"Study
### May 8, 2018 June 1, 2023 June 1, 2023 Local Instituti "Study Protocohttps://ClinicalTrials.gov/sho
August 2015 ### ### Rigshospitalet University Ho https://ClinicalTrials.gov/sho
### June 3, 2015 ### Krankenhaus Hietzing, Viennhttps://ClinicalTrials.gov/sho
### ### ### ### UAB School of"Study Protocohttps://ClinicalTrials.gov/sho
June 1, 2017 April 10, 2015 ### ### Duarte, Califo "Study Protocohttps://ClinicalTrials.gov/sho
January 2015 ### ### Allgemein öffentliches Krank https://ClinicalTrials.gov/sho
### July 16, 2010 April 3, 2015 University Hospital, Pilsen, https://ClinicalTrials.gov/sho
June 2012 ### ### ### CHU Amiens Hopital Nord, Am https://ClinicalTrials.gov/sho
June 2012 ### ### ### Pfizer Investigational Site, https://ClinicalTrials.gov/sho
June 2009 ### ### Departments of Rheumatology, https://ClinicalTrials.gov/sho
### ### ### ### Prince of Wales Hospital, Sh https://ClinicalTrials.gov/sho
April 6, 2020 ### April 12, 2022 CHU de Grenoble, Grenoble,https://ClinicalTrials.gov/sho
May 26, 2020 April 3, 2020 April 25, 2022 Investigational Site Number https://ClinicalTrials.gov/sho
### May 9, 2019 ### ### University of "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Institut Jules Bordet, Brusse https://ClinicalTrials.gov/sho
May 10, 2019 ### ### ### Children's Hos"Study Protocohttps://ClinicalTrials.gov/sho
### May 23, 2016 ### Hospital of Fridek-Mistek P. https://ClinicalTrials.gov/sho
### ### ### ### Los Angeles, C"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### July 6, 2022 Arizona Oncolo"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Florida Hospital, Orlando, F https://ClinicalTrials.gov/sho
### ### ### ### Site US10029,"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### Bakersfield, C "Statistical A https://ClinicalTrials.gov/sho
January 2014 ### ### GSK Investigational Site, Sa https://ClinicalTrials.gov/sho
### ### ### ### Phoenix Cardio"Study Protocohttps://ClinicalTrials.gov/sho
### May 18, 2012 May 21, 2018 ### Novartis Investigative Site, https://ClinicalTrials.gov/sho
April 2015 ### July 11, 2016 July 11, 2016 Ironwood Cancer and Research https://ClinicalTrials.gov/sho
October 2015 ### April 10, 2017 April 10, 2017 Otsuka Investigational Site, https://ClinicalTrials.gov/sho
### April 26, 2010 July 7, 2017 Medalp, Imst, Austria|Ortho https://ClinicalTrials.gov/sho
### ### April 1, 2021 Karl Brabants, MD, Antwerp, https://ClinicalTrials.gov/sho
January 2012 ### June 3, 2015 June 3, 2015 University of Colorado Schoohttps://ClinicalTrials.gov/sho
### May 5, 2010 ### A.Z. Middelheim, Antwerpen,https://ClinicalTrials.gov/sho
### ### ### ### Research Site, Stanford, Cal https://ClinicalTrials.gov/sho
May 14, 2018 May 22, 2007 ### ### Pinnacle Research Group; Llc https://ClinicalTrials.gov/sho
May 2016 ### May 13, 2016 Cardiovascular Research Insti https://ClinicalTrials.gov/sho
### ### ### Ccare San Marcos Cancer Cent https://ClinicalTrials.gov/sho
April 10, 2019 ### April 18, 2019 Department of Surgery, Medic https://ClinicalTrials.gov/sho
### ### ### Hospital Network Antwerp - shttps://ClinicalTrials.gov/sho
May 3, 2023 ### May 11, 2023 Rigshospitalet, Copenhagen,https://ClinicalTrials.gov/sho
### May 12, 2015 ### ### Pediatric Hematology and Onc https://ClinicalTrials.gov/sho
### ### ### ### GSK Investigat"Study Protocohttps://ClinicalTrials.gov/sho
### April 11, 2022 ### Clinques University Saint-Lu https://ClinicalTrials.gov/sho
### April 1, 2021 ### ### Jasper Summit"Study Protocohttps://ClinicalTrials.gov/sho
### May 11, 2020 ### Kepler Universitätsklinikum https://ClinicalTrials.gov/sho
July 6, 2018 ### ### Institute for Clinical and https://ClinicalTrials.gov/sho
July 23, 2018 ### July 11, 2019 ### Investigationa "Study Protocohttps://ClinicalTrials.gov/sho
### July 19, 2017 ### July 29, 2022 University of "Study Protocohttps://ClinicalTrials.gov/sho
July 28, 2021 ### ### Highlands Oncology Group, Fay https://ClinicalTrials.gov/sho
January 2014 April 23, 2012 ### Skejby University Hospital S https://ClinicalTrials.gov/sho
### July 28, 2015 ### Univerzita Karlova v Praze, https://ClinicalTrials.gov/sho
### ### ### Los Angeles Hematology/Oncolo https://ClinicalTrials.gov/sho
July 2009 ### April 27, 2010 April 3, 2015 Hopital Avicenne/University https://ClinicalTrials.gov/sho
April 30, 2017 April 10, 2014 ### Hôpital St André-CHU, Médeci https://ClinicalTrials.gov/sho
May 29, 2012 ### June 7, 2013 ### CUB Hôpital Erasme, Brussels https://ClinicalTrials.gov/sho
August 2012 ### ### ### Huntsville, Alabama, United https://ClinicalTrials.gov/sho
### ### ### ### Alaska Clinical Research Cenhttps://ClinicalTrials.gov/sho
June 2012 ### ### ### Universitair Ziekenhuis Gent https://ClinicalTrials.gov/sho
August 2012 ### ### Queen Elisabeth II Health S https://ClinicalTrials.gov/sho
July 18, 2016 ### ### ### Childrens Hospital Los Angele https://ClinicalTrials.gov/sho
May 2010 ### ### ### Westmead Private Hospital, S https://ClinicalTrials.gov/sho
January 2016 April 22, 2009 April 4, 2017 April 4, 2017 Institut Klinicke a Experimen https://ClinicalTrials.gov/sho
### ### ### ### Seattle Children's Hospital C https://ClinicalTrials.gov/sho
May 2013 ### ### ### Childrens Hospital Los Angelhttps://ClinicalTrials.gov/sho
### May 16, 2008 ### Bron, France|Cedex, France|https://ClinicalTrials.gov/sho
### ### ### ### City of Hope National Medicahttps://ClinicalTrials.gov/sho
July 2008 ### ### ### St. Vincents Hospital, Thora https://ClinicalTrials.gov/sho
October 2010 ### ### ### Oregon Health Sciences Cente https://ClinicalTrials.gov/sho
### ### ### ### Florida Heart Group, Orlandohttps://ClinicalTrials.gov/sho
June 2014 ### July 28, 2015 ### UCSD Medical Center - La Jol https://ClinicalTrials.gov/sho
### ### ### University of Alabama, Birmi https://ClinicalTrials.gov/sho
August 2007 April 12, 2006 ### University of Alabama, Birmi https://ClinicalTrials.gov/sho
August 2007 April 5, 2006 ### University of Alabama, Birmi https://ClinicalTrials.gov/sho
### ### University of Florida, Gaine https://ClinicalTrials.gov/sho
### July 11, 2005 ### Vitkovice Hospital Ostrava anhttps://ClinicalTrials.gov/sho
### ### ### UMCG, Groningen, Netherla https://ClinicalTrials.gov/sho
June 2018 ### ### Netherlands Cancer Institut https://ClinicalTrials.gov/sho
May 15, 2022 ### ### Universitair Medisch Centrumhttps://ClinicalTrials.gov/sho
### ### ### PRA Health Sciences, Groninhttps://ClinicalTrials.gov/sho
April 2020 ### ### Netherlands Cancer Institut https://ClinicalTrials.gov/sho
### ### May 18, 2023 UMC Utrecht, Utrecht, Nethehttps://ClinicalTrials.gov/sho
### ### July 25, 2022 Amsterdam UMC, Amsterdam, https://ClinicalTrials.gov/sho
### ### ### QPS Netherlands B.V., GZ Ghttps://ClinicalTrials.gov/sho
May 15, 2023 April 6, 2021 May 31, 2023 Radboudumc, Nijmegen, Geld https://ClinicalTrials.gov/sho
### ### ### PRA Health Sciences Onderzo https://ClinicalTrials.gov/sho
April 23, 2021 ### May 11, 2021 GPRI, Groningen, Netherlan https://ClinicalTrials.gov/sho
April 8, 2021 ### May 11, 2021 PRA Health Sciences, Groninhttps://ClinicalTrials.gov/sho
July 2025 July 9, 2020 ### Leiden University Medical Cehttps://ClinicalTrials.gov/sho
### June 9, 2020 ### M.V. Koning, Arnhem, M, Nethttps://ClinicalTrials.gov/sho
### June 4, 2020 ### Radboudumc, Nijmegen, Geld https://ClinicalTrials.gov/sho
### ### ### Radboudumc, Nijmegen, Nethttps://ClinicalTrials.gov/sho
### ### ### VUmc, Amsterdam, Noord Hol https://ClinicalTrials.gov/sho
May 22, 2020 ### ### Centre for Human Drug Resehttps://ClinicalTrials.gov/sho
April 10, 2020 ### July 7, 2020 PRA Health Sciences Onderzo https://ClinicalTrials.gov/sho
### ### April 19, 2021 Maastricht University Medicahttps://ClinicalTrials.gov/sho
May 1, 2022 ### July 1, 2022 University Medical Center G https://ClinicalTrials.gov/sho
### ### May 12, 2020 QPS Netherlands BV, Groninhttps://ClinicalTrials.gov/sho
May 12, 2021 ### ### Prinses Maxima Centrum voor https://ClinicalTrials.gov/sho
March 2017 ### ### Academic Medical Center, A https://ClinicalTrials.gov/sho
May 22, 2020 July 31, 2019 ### ### Up0071 001, L"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Academic Medical Centre, Am https://ClinicalTrials.gov/sho
April 8, 2020 June 7, 2019 June 4, 2021 June 4, 2021 PRA Health Sc"Study Protocohttps://ClinicalTrials.gov/sho
### June 6, 2019 April 22, 2020 PRA Health Sciences, Groninhttps://ClinicalTrials.gov/sho
July 14, 2020 May 16, 2019 ### NUTRIM School of Nutrition ahttps://ClinicalTrials.gov/sho
### ### ### PRA Health Sciences, Groninhttps://ClinicalTrials.gov/sho
### ### ### NKI-AVL, Amsterdam, Netherhttps://ClinicalTrials.gov/sho
### ### May 6, 2021 Zuyderland Medisch Centrum, https://ClinicalTrials.gov/sho
### ### May 11, 2022 May 26, 2023 Radboud univer "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Amsterdam UMC Locatie VUM https://ClinicalTrials.gov/sho
July 2017 ### ### Erasmus MC - Sophia Children https://ClinicalTrials.gov/sho
### ### ### Radboudumc, "Study
N Protocohttps://ClinicalTrials.gov/sho
August 2020 ### July 11, 2019 Investigational site, Rotterd https://ClinicalTrials.gov/sho
### July 18, 2018 ### PRA Health Sciences, Groninhttps://ClinicalTrials.gov/sho
### ### ### University Medical Center G https://ClinicalTrials.gov/sho
June 1, 2020 ### July 24, 2019 Antoni van Leeuwenhoek (NKhttps://ClinicalTrials.gov/sho
### ### ### NL001, Groningen, Netherla https://ClinicalTrials.gov/sho
June 2014 ### ### Maastricht UMC, Maastricht, https://ClinicalTrials.gov/sho
### ### ### LUMC/Centre For Human Drug https://ClinicalTrials.gov/sho
### ### ### ### Local Instituti "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Maastricht University, Maastrhttps://ClinicalTrials.gov/sho
### ### July 15, 2020 Academic Medical Center, Am https://ClinicalTrials.gov/sho
April 1, 2018 ### ### Erasmus University Medical https://ClinicalTrials.gov/sho
### April 14, 2017 ### VieCuri Medical Center, Venlhttps://ClinicalTrials.gov/sho
### April 13, 2017 ### Maastricht UMC, Maastricht, https://ClinicalTrials.gov/sho
### ### ### Department of Pulmonary dishttps://ClinicalTrials.gov/sho
### ### ### Academic Medical Center, A https://ClinicalTrials.gov/sho
May 14, 2019 ### ### Nipd / Amc, Amsterdam, Net https://ClinicalTrials.gov/sho
April 2020 ### ### Maastricht University Medicahttps://ClinicalTrials.gov/sho
### ### ### University Medical Center Utrhttps://ClinicalTrials.gov/sho
### ### ### Department of Orthopaedics,https://ClinicalTrials.gov/sho
April 2020 ### ### UMC Utrecht, Utrecht, Nethehttps://ClinicalTrials.gov/sho
### July 26, 2016 April 14, 2017 MAASTRO clinic, Maastricht,https://ClinicalTrials.gov/sho
April 2020 July 19, 2016 ### Academic Medical Center, Inhttps://ClinicalTrials.gov/sho
### July 1, 2016 Rijnstate location Arnhem, A https://ClinicalTrials.gov/sho
### April 29, 2016 ### Centre of intergrated rehabili https://ClinicalTrials.gov/sho
### April 15, 2016 ### ### Amsterdam, Ne "Study Protocohttps://ClinicalTrials.gov/sho
June 2021 April 13, 2016 May 23, 2017 MAASTRO clinic, Maastricht,https://ClinicalTrials.gov/sho
June 2017 ### April 26, 2018 Maastricht University Medicahttps://ClinicalTrials.gov/sho
April 2020 ### May 6, 2020 University Medical Center G https://ClinicalTrials.gov/sho
### ### April 7, 2017 University Medical Center Utrhttps://ClinicalTrials.gov/sho
January 2019 ### ### Meander Medical Center, Ame https://ClinicalTrials.gov/sho
June 2019 ### ### Erasmus MC Cancer Institutehttps://ClinicalTrials.gov/sho
May 1, 2017 ### May 24, 2017 Academic Medical Center, A https://ClinicalTrials.gov/sho
July 1, 2019 ### ### Maastricht UMC, Dept. Obst&https://ClinicalTrials.gov/sho
### ### ### ### Atrium Medical Center, Heerlhttps://ClinicalTrials.gov/sho
July 7, 2017 ### ### VU University Medical Cente https://ClinicalTrials.gov/sho
May 30, 2018 July 13, 2015 ### Leiden University Medical Cehttps://ClinicalTrials.gov/sho
April 22, 2016 May 4, 2015 July 2, 2017 PRA Health Sciences, Zuidlahttps://ClinicalTrials.gov/sho
June 2016 ### ### Maastricht University Medicahttps://ClinicalTrials.gov/sho
### ### April 5, 2017 Centre For Human Drug Rese https://ClinicalTrials.gov/sho
January 2017 ### ### Canisuis Wilhelmina Hospitalhttps://ClinicalTrials.gov/sho
April 26, 2018 ### May 10, 2019 St Antonius hospital, Nieuwe https://ClinicalTrials.gov/sho
### ### April 18, 2016 Academic Medical Centre, A https://ClinicalTrials.gov/sho
### ### ### Academisch Medisch Centru https://ClinicalTrials.gov/sho
### ### ### University Hospital Maastrichhttps://ClinicalTrials.gov/sho
### ### ### Maastricht Universitair Med https://ClinicalTrials.gov/sho
July 2017 ### ### Maastro Clinic, Maastricht, https://ClinicalTrials.gov/sho
### ### ### Erasmus MC, Rotterdam, Zuid https://ClinicalTrials.gov/sho
### July 10, 2014 ### Radboudumc, Nijmegen, Nethttps://ClinicalTrials.gov/sho
July 2020 July 8, 2014 ### Isala Klinieken, Zwolle, Neth https://ClinicalTrials.gov/sho
### ### April 7, 2017 VU Medical Center, Amsterd https://ClinicalTrials.gov/sho
### ### ### Maastricht Radiation Oncolo https://ClinicalTrials.gov/sho
### ### ### GSK Investigational Site, A https://ClinicalTrials.gov/sho
### ### ### ### QPS Netherland B.V., Groninhttps://ClinicalTrials.gov/sho
August 2014 ### May 18, 2016 Rijnstate Arnhem, Arnhem, Nhttps://ClinicalTrials.gov/sho
### ### ### Centre for Human Drug Resea https://ClinicalTrials.gov/sho
### ### ### University Medical Centre G https://ClinicalTrials.gov/sho
January 2018 ### ### Academic Medical Center, A https://ClinicalTrials.gov/sho
May 2013 April 16, 2013 ### University Medical Center G https://ClinicalTrials.gov/sho
October 2014 ### ### Maastricht University Medicahttps://ClinicalTrials.gov/sho
April 2014 ### ### Leiden University Medical Cehttps://ClinicalTrials.gov/sho
March 2015 ### May 25, 2015 University Eye Clinic, Maastr https://ClinicalTrials.gov/sho
### ### ### Department of Gastroenterol https://ClinicalTrials.gov/sho
October 2012 ### ### Center for Human Drug Resea https://ClinicalTrials.gov/sho
January 2016 ### ### Catharina Ziekenhuis Eindhohttps://ClinicalTrials.gov/sho
October 2013 ### ### Department Medical Microbiolhttps://ClinicalTrials.gov/sho
October 2014 July 31, 2012 April 1, 2015 Radboud University Nijmegenhttps://ClinicalTrials.gov/sho
### July 11, 2012 ### Maastricht University Medicahttps://ClinicalTrials.gov/sho
May 2016 June 1, 2012 ### Maastricht University Medic https://ClinicalTrials.gov/sho
### April 13, 2012 ### Radboud University Nijmegenhttps://ClinicalTrials.gov/sho
July 2017 April 11, 2012 July 18, 2017 MAASTRO clinic, Maastricht,https://ClinicalTrials.gov/sho
### ### ### VU university medical cente https://ClinicalTrials.gov/sho
### ### July 6, 2016 AMC University Hospital, Amhttps://ClinicalTrials.gov/sho
### ### ### VU University Medical Cente https://ClinicalTrials.gov/sho
May 2013 July 25, 2011 ### Erasmus Medical Center, Rothttps://ClinicalTrials.gov/sho
January 2012 ### April 17, 2012 Groningen, Netherlands https://ClinicalTrials.gov/sho
June 2015 June 7, 2011 ### Radboud University Nijmegenhttps://ClinicalTrials.gov/sho
### May 11, 2011 ### Department of Pulmonary Dishttps://ClinicalTrials.gov/sho
### May 10, 2011 ### Centre for Huma Drug Reseahttps://ClinicalTrials.gov/sho
January 2012 May 4, 2011 ### TweeSteden Hospital, Tilbur https://ClinicalTrials.gov/sho
July 2012 ### ### University Medical Center Utrhttps://ClinicalTrials.gov/sho
### ### ### University Medical Centre Utrhttps://ClinicalTrials.gov/sho
### July 15, 2013 University Medical Centre Ni https://ClinicalTrials.gov/sho
July 2011 ### ### St. Antonius Ziekenhuis, Nie https://ClinicalTrials.gov/sho
March 2017 ### ### MAASTRO clinic, Maastricht,https://ClinicalTrials.gov/sho
July 2009 ### ### Onze Lieve Vrouwe Gasthuishttps://ClinicalTrials.gov/sho
### May 17, 2010 ### Martini Hospital, Groningen, https://ClinicalTrials.gov/sho
July 2014 ### ### Lucas Andreas Ziekenhuis, https://ClinicalTrials.gov/sho
### ### Alysis Zorggroep, Rijnstate https://ClinicalTrials.gov/sho
### July 24, 2012 Dept. of Urology, Radboud Un https://ClinicalTrials.gov/sho
June 2011 ### May 30, 2017 GSK Investigational Site, A https://ClinicalTrials.gov/sho
October 2009 May 25, 2009 ### Utrecht, Netherlands https://ClinicalTrials.gov/sho
### April 15, 2009 May 17, 2013 University Medical Center G https://ClinicalTrials.gov/sho
October 2012 ### ### ### University Medical Center Utrhttps://ClinicalTrials.gov/sho
### ### ### University Hospital Maastrichhttps://ClinicalTrials.gov/sho
March 2009 ### June 4, 2015 UMC Utrecht, Utrecht, Nethehttps://ClinicalTrials.gov/sho
March 2016 ### ### UMC Utrecht, Utrecht, Nethehttps://ClinicalTrials.gov/sho
June 2011 ### ### VU University Medical Cente https://ClinicalTrials.gov/sho
### ### Maastricht Univeristy Hospitahttps://ClinicalTrials.gov/sho
### ### ### ### GSK Investigational Site, A https://ClinicalTrials.gov/sho
### ### AMPHA, Nijmegen, Netherla https://ClinicalTrials.gov/sho
May 2013 May 26, 2008 ### NKI-AVL, Amsterdam, Netherhttps://ClinicalTrials.gov/sho
March 2009 April 18, 2008 ### ### Netherlands Cancer Institut https://ClinicalTrials.gov/sho
### April 7, 2008 April 14, 2015 Maastricht University, Maastrhttps://ClinicalTrials.gov/sho
August 2011 ### ### Rijnstate Hospital, Arnhem, https://ClinicalTrials.gov/sho
### ### ### Alysis Rijnstate Hospital, A https://ClinicalTrials.gov/sho
January 2010 ### April 5, 2011 VU University Medical Cente https://ClinicalTrials.gov/sho
### ### ### St Antonius Hospital, Nieuwehttps://ClinicalTrials.gov/sho
June 2009 ### ### Maastricht Radiation Oncolo https://ClinicalTrials.gov/sho
January 2009 ### ### UMC St. Radboud, Nijmegen,https://ClinicalTrials.gov/sho
March 2010 July 31, 2007 ### UMC St.Radboud, Nijmegen,https://ClinicalTrials.gov/sho
### ### ### NKI-AVL, Amsterdam, Netherhttps://ClinicalTrials.gov/sho
### ### ### Radboud University Nijmegenhttps://ClinicalTrials.gov/sho
June 2009 ### ### UMC St. Radboud, Nijmegen,https://ClinicalTrials.gov/sho
August 2013 ### ### Universitair Medisch Centrumhttps://ClinicalTrials.gov/sho
August 2005 ### ### VU University Medical Cente https://ClinicalTrials.gov/sho
August 2003 ### ### GGD Amsterdam- Amsterdam https://ClinicalTrials.gov/sho
June 2007 June 2, 2006 ### GGZ Buitenamstel, Amsterdahttps://ClinicalTrials.gov/sho
### ### 476 Hematology, University https://ClinicalTrials.gov/sho
April 2007 ### April 19, 2007 Dept of intensive care, Medi https://ClinicalTrials.gov/sho
### ### ### FPC De Kijvelanden, Poortughttps://ClinicalTrials.gov/sho
### ### ### Atrium medical centre, Heerl https://ClinicalTrials.gov/sho
May 2007 ### ### St. Antonius Ziekenhuis, Nie https://ClinicalTrials.gov/sho
### ### ### VU University Medical Cente https://ClinicalTrials.gov/sho
July 2005 ### June 2, 2015 Sanquin Blood Bank South Whttps://ClinicalTrials.gov/sho
### ### University of Utrecht, Utrech https://ClinicalTrials.gov/sho
May 2005 ### ### University of Utrecht, Utrech https://ClinicalTrials.gov/sho
### ### ### Radboud University Medical https://ClinicalTrials.gov/sho
August 2005 ### ### UMC st Radboud, Nijmegen, https://ClinicalTrials.gov/sho
### ### ### Brain and Behaviour Institutehttps://ClinicalTrials.gov/sho
### ### June 8, 2009 Department of Allied health https://ClinicalTrials.gov/sho
### ### ### Radboud University, Nijmegehttps://ClinicalTrials.gov/sho
May 2008 ### ### Dept. Neurology, Erasmus Mhttps://ClinicalTrials.gov/sho
### ### ### Center for Man in Aviation, Shttps://ClinicalTrials.gov/sho
April 7, 2022 ### ### Amsterdam Universitair Medihttps://ClinicalTrials.gov/sho
### ### ### Wageningen University and Rhttps://ClinicalTrials.gov/sho
### July 1, 2019 ### Amsterdam UMC, Amsterdam, https://ClinicalTrials.gov/sho
### May 28, 2019 ### Brain Research Center, Ams https://ClinicalTrials.gov/sho
May 1, 2022 ### May 15, 2023 VU University Medical Cente https://ClinicalTrials.gov/sho
July 31, 2019 ### May 29, 2020 Radboudumc, Nijmegen, Gelde https://ClinicalTrials.gov/sho
### July 6, 2016 July 6, 2016 Rijnstate, Arnhem, Gelderlanhttps://ClinicalTrials.gov/sho
May 2017 April 6, 2016 May 20, 2019 Netherlands Cancer Institut https://ClinicalTrials.gov/sho
August 2014 April 10, 2014 July 25, 2019 Catharina Ziekenhuis, Eindh https://ClinicalTrials.gov/sho
### ### ### Canisius Wilhelmina Ziekenhhttps://ClinicalTrials.gov/sho
### ### ### VUmc, PET and neurology clihttps://ClinicalTrials.gov/sho
### ### ### ### Maastricht Uni"Study Protocohttps://ClinicalTrials.gov/sho
June 1, 2016 ### April 7, 2020 Amphia Hospital, Breda, Noohttps://ClinicalTrials.gov/sho
July 1, 2016 April 24, 2012 May 3, 2021 VUmc, Amsterdam, Netherlan https://ClinicalTrials.gov/sho
### ### ### ### Novartis Investigative Site, https://ClinicalTrials.gov/sho
### ### ### Medical Center Alkmaar, Alk https://ClinicalTrials.gov/sho
August 2010 ### ### Rotterdam, Netherlands|Utrehttps://ClinicalTrials.gov/sho
April 2016 ### ### Radboud University Nijmegenhttps://ClinicalTrials.gov/sho
January 2010 ### ### University Medical Center G https://ClinicalTrials.gov/sho
April 2009 July 9, 2007 ### Research Site, Amsterdam, Nhttps://ClinicalTrials.gov/sho
### April 4, 2007 April 17, 2015 GSK Investigational Site, Utr https://ClinicalTrials.gov/sho
May 2005 ### ### University Medical Center Grhttps://ClinicalTrials.gov/sho
### ### June 3, 2021 PRA Health Sciences, Groni https://ClinicalTrials.gov/sho
July 3, 2018 ### July 6, 2018 Department of Vascular Medihttps://ClinicalTrials.gov/sho
### ### April 12, 2023 Charité - Universitätsmedizinhttps://ClinicalTrials.gov/sho
April 2017 ### April 28, 2017 Slotervaart Hospital, Amste https://ClinicalTrials.gov/sho
October 2016 April 4, 2013 May 4, 2018 University Medical Center Grhttps://ClinicalTrials.gov/sho
April 2015 ### May 19, 2015 De Haar Research Foundation, https://ClinicalTrials.gov/sho
April 12, 2019 ### April 21, 2020 ### Emma Children' "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Bonn, Germany|Amsterdam, https://ClinicalTrials.gov/sho
October 2015 ### ### Philip Van Damme, Leuven, B https://ClinicalTrials.gov/sho
October 2015 ### ### Philip Van Damme, Leuven, B https://ClinicalTrials.gov/sho
### July 2, 2015 Sapienza University, Rome, Ihttps://ClinicalTrials.gov/sho
April 13, 2007 ### Department of Medical Oncolo https://ClinicalTrials.gov/sho
October 2013 May 7, 2012 ### Antwerp University Hospital https://ClinicalTrials.gov/sho
### July 2, 2012 Academisch Ziekenhuis Utrechttps://ClinicalTrials.gov/sho
April 23, 2009 ### Academic Hospital of Brusselhttps://ClinicalTrials.gov/sho
October 2010 ### ### ### UZ Brussel, Brussel, Belgiumhttps://ClinicalTrials.gov/sho
April 1, 2023 ### May 24, 2023 Netherlands Cancer Institut https://ClinicalTrials.gov/sho
### May 28, 2019 May 7, 2021 Maastricht Universitair Medi https://ClinicalTrials.gov/sho
July 1, 2021 ### ### Maastricht UMC+, Maastrichthttps://ClinicalTrials.gov/sho
July 1, 2022 July 11, 2016 July 18, 2022 Antoni van Leeuwenhoek, Ams https://ClinicalTrials.gov/sho
May 1, 2018 April 19, 2016 ### University Medical Center Grhttps://ClinicalTrials.gov/sho
January 2021 April 21, 2014 April 14, 2021 Radboud University Medical https://ClinicalTrials.gov/sho
### ### ### VU Medical Center, Amsterdahttps://ClinicalTrials.gov/sho
August 2015 ### ### Site NL31005 St. Antonius z https://ClinicalTrials.gov/sho
March 2017 July 22, 2013 ### Antoni van Leeuwenhoek Ziek https://ClinicalTrials.gov/sho
### ### ### Rijnstate Hospital, Arnhem, https://ClinicalTrials.gov/sho
May 2011 July 17, 2009 ### Ziekenhuis Rijnstate, Arnhemhttps://ClinicalTrials.gov/sho
January 2012 ### April 29, 2009 Department of Hematology Ra https://ClinicalTrials.gov/sho
### ### ### Antoni van Leeuwenhoek, Ams https://ClinicalTrials.gov/sho
### ### ### University of Bonn, Germany,https://ClinicalTrials.gov/sho
June 2020 ### ### Heart and Vascular Center Shttps://ClinicalTrials.gov/sho
### ### ### Medisch Centrum Heuvelrug,https://ClinicalTrials.gov/sho
D
### ### ### Amsterdam University Medica https://ClinicalTrials.gov/sho
### ### ### NL-Amsterdam-VUMC, Amsterd https://ClinicalTrials.gov/sho
July 1, 2022 May 10, 2017 July 19, 2022 Antoni van Leeuwenhoek, Ams https://ClinicalTrials.gov/sho
### ### April 18, 2019 Canisius Wilhelmina Hospitalhttps://ClinicalTrials.gov/sho
August 2014 July 13, 2011 ### MC Haaglanden, Leidschenda https://ClinicalTrials.gov/sho
June 2017 April 13, 2011 ### Academic Medical Centre Amst https://ClinicalTrials.gov/sho
June 2016 ### ### NKI/AvL, Amsterdam, Netherla https://ClinicalTrials.gov/sho
October 2014 ### ### St. Antonius Hospital, Nieuwehttps://ClinicalTrials.gov/sho
June 2024 ### ### Medisch Centrum Haaglanden, https://ClinicalTrials.gov/sho
October 2012 ### May 19, 2015 De Haar Research Foundation, https://ClinicalTrials.gov/sho
October 2012 ### ### Erasmus MC - Thoraxcenter,https://ClinicalTrials.gov/sho
R
April 2020 ### April 14, 2020 University Hospital Leuven, https://ClinicalTrials.gov/sho
### ### May 12, 2022 Bioclinica, Orlando, Florida https://ClinicalTrials.gov/sho
### May 15, 2012 ### Novartis Investigative Site, https://ClinicalTrials.gov/sho
### April 26, 2012 April 4, 2017 Samsung Medical Center, Seou https://ClinicalTrials.gov/sho
March 2017 ### April 20, 2017 Foundation Cardiovascular me https://ClinicalTrials.gov/sho
### July 12, 2012 ### ### Sidney Kimmel"Study Protocohttps://ClinicalTrials.gov/sho
### April 15, 2011 ### Dept of Cardiothoracic surge https://ClinicalTrials.gov/sho
### ### Institut Gustave-Roussy, Vi https://ClinicalTrials.gov/sho
May 2008 ### ### ### For additional information r https://ClinicalTrials.gov/sho
October 2006 May 8, 2006 ### Charité - University Clinics https://ClinicalTrials.gov/sho
March 2008 ### ### The Collaborative Study Group https://ClinicalTrials.gov/sho
April 9, 2004 ### Institut Bergonie, Bordeaux, https://ClinicalTrials.gov/sho
### June 1, 2017 May 31, 2022 Aalborg Universitetshospita https://ClinicalTrials.gov/sho
### ### ### ### Hopital Ambroise Paré, Boul https://ClinicalTrials.gov/sho
### ### University Hospital Schleswi https://ClinicalTrials.gov/sho
### July 10, 2009 April 13, 2012 Pfizer Investigational Site, https://ClinicalTrials.gov/sho
April 2011 ### July 27, 2012 ### Hospital de Erasme, Brusselshttps://ClinicalTrials.gov/sho
May 2006 ### ### BG Unfallklinik Halle, Klini https://ClinicalTrials.gov/sho
May 17, 2021 ### ### Maastricht UMC+, Maastrichthttps://ClinicalTrials.gov/sho
May 11, 2021 ### May 13, 2022 Jeroen Bosch Hospital, 's-Hehttps://ClinicalTrials.gov/sho
### ### ### Centrum Oosterwal, Alkmaar,https://ClinicalTrials.gov/sho
March 2017 ### ### Slotervaart Ziekenhuis, Ams https://ClinicalTrials.gov/sho
May 2015 ### ### Amphia Ziekenhuis, Breda, Nhttps://ClinicalTrials.gov/sho
### ### ### ### VU University "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Fondazione IRCCS Ca' Granda https://ClinicalTrials.gov/sho
### July 11, 2011 ### Zuidlaren, Netherlands|Krak https://ClinicalTrials.gov/sho
July 2016 ### ### ### London Teaching Hospital, Lo https://ClinicalTrials.gov/sho
### May 30, 2017 ### ### Johns Hopkins"Study Protocohttps://ClinicalTrials.gov/sho
June 2017 June 8, 2016 April 17, 2019 Prince of Wales Hospital, Sy https://ClinicalTrials.gov/sho
### ### ### ### Nucleus Network Ltd, Melbour https://ClinicalTrials.gov/sho
March 2015 ### April 5, 2016 Novartis Investigative Site, P https://ClinicalTrials.gov/sho
### ### April 1, 2021 Liverpool Hospital, Liverpoo https://ClinicalTrials.gov/sho
July 27, 2016 ### July 10, 2018 Department of Anesthesiology https://ClinicalTrials.gov/sho
July 2010 June 9, 2010 ### Allgemeines Krankenhaus, Abt https://ClinicalTrials.gov/sho
May 2011 ### ### ### Indiana University Medical Cehttps://ClinicalTrials.gov/sho
March 2010 ### ### Lombardi Comprehensive Cance https://ClinicalTrials.gov/sho
June 2, 2006 ### Local Institution, Newark, De https://ClinicalTrials.gov/sho
### ### ### ### Research Site "Study Protocohttps://ClinicalTrials.gov/sho
May 2011 July 29, 2009 ### ### Local Institution, Paris Cedexhttps://ClinicalTrials.gov/sho
May 31, 2018 ### ### Flevoziekenhuis, Almere, Fl https://ClinicalTrials.gov/sho
### July 29, 2015 ### IrisZorg, Arnhem, Gelderlandhttps://ClinicalTrials.gov/sho
### April 3, 2015 May 13, 2022 Radiotherapiegroep Arnhem,https://ClinicalTrials.gov/sho
May 2010 ### ### Medical Center Leeuwarden,https://ClinicalTrials.gov/sho
L
April 2005 ### ### Metabolic and Atheroscleros https://ClinicalTrials.gov/sho
### ### ### UZ Leuven, Leuven, Belgium|U https://ClinicalTrials.gov/sho
### ### ### ### Institute for "Study Protocohttps://ClinicalTrials.gov/sho
July 27, 2022 July 27, 2018 ### University of Southern Calif https://ClinicalTrials.gov/sho
### ### April 1, 2022 Erasmus Medical Center, Rothttps://ClinicalTrials.gov/sho
### ### ### Institut Curie, Saint-Cloud, https://ClinicalTrials.gov/sho
### ### ### OLVG, Amsterdam, Noord-Hol https://ClinicalTrials.gov/sho
### April 10, 2020 April 1, 2022 Erasmus Medical Center, Rothttps://ClinicalTrials.gov/sho
### ### ### Universitair Ziekenhuis Leuv https://ClinicalTrials.gov/sho
### ### ### Envida - De Wi"Study Protocohttps://ClinicalTrials.gov/sho
### ### May 11, 2022 Jeroen Bosch ziekenhuis, 's- https://ClinicalTrials.gov/sho
June 2023 May 22, 2018 ### Ziekenhuisgroep Twente (Twen https://ClinicalTrials.gov/sho
### ### ### UZ Leuven, Leuven, Belgium|S https://ClinicalTrials.gov/sho
### July 11, 2017 May 1, 2020 Rijnstate, Arn "Study Protocohttps://ClinicalTrials.gov/sho
### ### May 21, 2021 Noordwest Ziekenhuisgroep, https://ClinicalTrials.gov/sho
April 2019 May 17, 2016 April 30, 2019 VUmc Medical Center, Amster https://ClinicalTrials.gov/sho
### April 13, 2015 ### The Netherlands Cancer Instihttps://ClinicalTrials.gov/sho
May 2019 ### ### Nij Smellinghe Hospital, Dra https://ClinicalTrials.gov/sho
July 19, 2018 ### July 26, 2018 Radboud Medisch Centrum Nij https://ClinicalTrials.gov/sho
### ### June 1, 2020 VUmc, Amsterdam, Netherland https://ClinicalTrials.gov/sho
### July 29, 2011 June 7, 2019 Clinic for Visceral- and Tho https://ClinicalTrials.gov/sho
### ### ### Flevoziekenhui"Study Protocohttps://ClinicalTrials.gov/sho
June 2017 ### April 1, 2021 Ziekenhuis Groep Twente, Alm https://ClinicalTrials.gov/sho
### April 26, 2013 ### Academic Medical Centre Ams https://ClinicalTrials.gov/sho
May 2012 June 4, 2009 ### ### Centre Hospitalier Universit https://ClinicalTrials.gov/sho
April 2017 ### April 28, 2017 Slotervaart Hospital, Amster https://ClinicalTrials.gov/sho
May 2016 ### ### Flevoziekenhuis, Almere, Ne https://ClinicalTrials.gov/sho
### May 15, 2008 ### Sanofi-Aventis Administrativehttps://ClinicalTrials.gov/sho
### ### ### ### Massachusetts"Study Protocohttps://ClinicalTrials.gov/sho
### ### Free University Hospital, Am https://ClinicalTrials.gov/sho
### April 21, 2008 July 14, 2014 Rijnstate, Arnhem, Gelderlanhttps://ClinicalTrials.gov/sho
August 2015 ### ### Ziekenhuis Rijnstate, Arnhemhttps://ClinicalTrials.gov/sho
### ### ### VU University Medical Centrehttps://ClinicalTrials.gov/sho
April 17, 2019 ### ### Vseobecna Fakultni Nemocnice https://ClinicalTrials.gov/sho
May 22, 2023 ### June 9, 2023 UC Davis Medical Center, Dav https://ClinicalTrials.gov/sho
### June 1, 2020 April 21, 2023 April 21, 2023 Honor Health, "Study Protocohttps://ClinicalTrials.gov/sho
April 30, 2020 ### ### UH Antwerp, Antwerp, Belgiuhttps://ClinicalTrials.gov/sho
### July 31, 2020 ### Local Institution, Gilbert, Ar https://ClinicalTrials.gov/sho
### June 2, 2020 June 7, 2023 The University of Arizona Ca https://ClinicalTrials.gov/sho
May 2011 May 21, 2010 June 4, 2012 ### For additional information r https://ClinicalTrials.gov/sho
### ### ### University of California Irv https://ClinicalTrials.gov/sho
June 5, 2020 May 11, 2018 ### ### Investigationa "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### July 14, 2021 GSK Investigat"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Thomas Hospital, Fairhope, Ahttps://ClinicalTrials.gov/sho
### ### July 29, 2022 July 29, 2022 University of "Study Protocohttps://ClinicalTrials.gov/sho
July 27, 2022 ### ### https://ClinicalTrials.gov/sho
### ### ### July 29, 2021 Clearview Canc "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Robert Bosch Krankenhaus, https://ClinicalTrials.gov/sho
S
June 2014 ### ### Universidad Autonoma de Nue https://ClinicalTrials.gov/sho
### ### ### ### ADDC Research "Study Protocohttps://ClinicalTrials.gov/sho
June 2018 ### ### ### Sun Pharma Sit "Study Protocohttps://ClinicalTrials.gov/sho
May 16, 2019 ### ### July 14, 2020 Alabama Oncolo "Study Protocohttps://ClinicalTrials.gov/sho
June 5, 2020 ### ### University of Alabama, Birmi https://ClinicalTrials.gov/sho
### ### ### ### Medical Associ"Study Protocohttps://ClinicalTrials.gov/sho
July 8, 2020 ### ### ### Investigationa "Study Protocohttps://ClinicalTrials.gov/sho
October 2017 ### ### Centre hospitalier de l'univ https://ClinicalTrials.gov/sho
### ### May 7, 2021 ### Atria Clinical "Study Protocohttps://ClinicalTrials.gov/sho
April 3, 2017 ### ### May 1, 2019 "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### July 11, 2018 "Study Protocohttps://ClinicalTrials.gov/sho
### ### July 12, 2017 Local Institution, Phoenix, Ar https://ClinicalTrials.gov/sho
April 2018 June 6, 2013 ### For additional information r https://ClinicalTrials.gov/sho
July 2016 ### May 16, 2018 ### https://ClinicalTrials.gov/sho
### May 26, 2016 ### ### Xenoscience, P "Study Protocohttps://ClinicalTrials.gov/sho
### July 4, 2012 ### ### University of South Alabama https://ClinicalTrials.gov/sho
/
### ### ### ### Cancer Treatment Services Ar https://ClinicalTrials.gov/sho
### ### July 1, 2016 July 1, 2016 Arizona Oncology Associateshttps://ClinicalTrials.gov/sho
### May 21, 2015 ### ### HonorHealth Re "Study Protocohttps://ClinicalTrials.gov/sho
May 19, 2022 ### May 21, 2021 Konventhospital Barmherzigehttps://ClinicalTrials.gov/sho
May 22, 2018 ### ### Hôpital Saint Louis - Center https://ClinicalTrials.gov/sho
October 2026 ### ### Cognitive Clinical Trials, L https://ClinicalTrials.gov/sho
April 2012 ### May 1, 2012 Forest Investigative Site 138 https://ClinicalTrials.gov/sho
### July 21, 2014 ### April 10, 2023 Medizinische Universitat Gra https://ClinicalTrials.gov/sho
### ### ### ### GSK Investigational Site, Lit https://ClinicalTrials.gov/sho
### ### ### ### GSK Investigational Site, Lit https://ClinicalTrials.gov/sho
March 2012 May 25, 2010 ### Investigator Site 1064, Birmi https://ClinicalTrials.gov/sho
### ### April 8, 2014 April 8, 2014 Novartis Investigative Site, https://ClinicalTrials.gov/sho
April 13, 2016 ### ### ### Research Site, Phoenix, Ariz https://ClinicalTrials.gov/sho
### ### ### ### Research Site,"Study Protocohttps://ClinicalTrials.gov/sho
### ### April 21, 2015 July 30, 2019 Novartis Invest"Study Protocohttps://ClinicalTrials.gov/sho
May 2014 ### ### ### https://ClinicalTrials.gov/sho
### ### ### University of Alabama - Birm https://ClinicalTrials.gov/sho
### ### ### GSK Investigational Site, Duahttps://ClinicalTrials.gov/sho
### ### ### ### Novartis Inves"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### Birmingham, Alabama, United https://ClinicalTrials.gov/sho
July 2014 July 16, 2010 ### George Washington University https://ClinicalTrials.gov/sho
March 2011 ### ### ### Uab Medical Center, Birmingha https://ClinicalTrials.gov/sho
### May 7, 2018 July 20, 2021 ### Novartis Invest"Study Protocohttps://ClinicalTrials.gov/sho
April 30, 2020 ### April 14, 2021 April 14, 2021 University of "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Paradigm Clinical Research, https://ClinicalTrials.gov/sho
### ### June 9, 2020 ### University of "Study Protocohttps://ClinicalTrials.gov/sho
### May 12, 2008 ### ### Center for Psychiatric Medic https://ClinicalTrials.gov/sho
### ### ### The Alfred Hospital, Melbour https://ClinicalTrials.gov/sho
May 17, 2018 ### ### ### Novartis Investigative Site, https://ClinicalTrials.gov/sho
October 2010 ### ### Sanofi-Aventis Investigation https://ClinicalTrials.gov/sho
### ### ### April 21, 2014 Novartis Investigative Site, https://ClinicalTrials.gov/sho
August 2013 April 28, 2008 ### ### University of Alabama-Birminhttps://ClinicalTrials.gov/sho
May 20, 2011 ### Cliniques Universitaires Sai https://ClinicalTrials.gov/sho
May 2011 ### June 1, 2012 ### Research Site, Tucson, Arizohttps://ClinicalTrials.gov/sho
May 2008 ### May 24, 2012 Tallinn, Estonia|Tartu, Esto https://ClinicalTrials.gov/sho
June 2015 ### ### Sarcoma Oncology Center, Sa https://ClinicalTrials.gov/sho
### ### July 14, 2020 July 14, 2020 University of "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### University of "Study Protocohttps://ClinicalTrials.gov/sho
May 2010 April 21, 2008 ### University of South Alabama/M https://ClinicalTrials.gov/sho
### ### May 15, 2020 May 26, 2021 Arizona Arthri "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### Birmingham, Al"Study Protocohttps://ClinicalTrials.gov/sho
### July 6, 2006 ### Novo Nordisk Investigational https://ClinicalTrials.gov/sho
### ### April 2, 2012 University Medical Center Anhttps://ClinicalTrials.gov/sho
June 1, 2009 ### ### ### GSK Investigational Site, Li https://ClinicalTrials.gov/sho
January 2007 ### ### Research Site, Birmingham, A https://ClinicalTrials.gov/sho
### ### ### ### Research Site, Birmingham, A https://ClinicalTrials.gov/sho
### ### May 19, 2014 1160.42.10003 Boehringer Ing https://ClinicalTrials.gov/sho
### ### ### Research Site, Birmingham, A https://ClinicalTrials.gov/sho
March 2006 ### ### Santa Ana, California, Unite https://ClinicalTrials.gov/sho
June 2007 ### ### Pfizer Investigational Site, A https://ClinicalTrials.gov/sho
### April 13, 2009 ### April 18, 2017 GSK Investigational Site, Lo https://ClinicalTrials.gov/sho
August 2006 ### ### Research Site, Graz, Austria https://ClinicalTrials.gov/sho
### ### May 16, 2022 ### Research Site,"Study Protocohttps://ClinicalTrials.gov/sho
### July 18, 2012 Algemeen Ziekenhuis Middelh https://ClinicalTrials.gov/sho
April 2014 ### May 29, 2015 July 15, 2016 Research Site, Camperdown,https://ClinicalTrials.gov/sho
### ### ### Fresno, California, United S https://ClinicalTrials.gov/sho
### ### Pfizer Investigational Site, https://ClinicalTrials.gov/sho
### July 18, 2012 Algemeen Ziekenhuis Middelhe https://ClinicalTrials.gov/sho
January 2016 June 6, 2013 ### University of California San https://ClinicalTrials.gov/sho
April 2016 ### ### ### CTI Investigational Site 1000https://ClinicalTrials.gov/sho
### May 30, 2007 ### ### GSK Investigational Site, Bir https://ClinicalTrials.gov/sho
October 2015 ### ### ### Research Site, Birmingham, A https://ClinicalTrials.gov/sho
### ### Allgemeines Krankenhaus - Un https://ClinicalTrials.gov/sho
### ### ### Research Site, Birmingham, A https://ClinicalTrials.gov/sho
June 2008 ### ### Pfizer Investigational Site, B https://ClinicalTrials.gov/sho
### ### May 7, 2012 Altana Pharma/Nycomed, BThttps://ClinicalTrials.gov/sho
O
April 2013 ### May 22, 2014 June 9, 2014 Investigational Site Number https://ClinicalTrials.gov/sho
### ### ### Research Site, Fullerton, Ca https://ClinicalTrials.gov/sho
### ### ### Amsterdam, Netherlands|Nieu https://ClinicalTrials.gov/sho
### July 16, 2012 Ziekenhuis Netwerk Antwerpen https://ClinicalTrials.gov/sho
May 25, 2004 July 11, 2012 Innsbruck Universitaetsklini https://ClinicalTrials.gov/sho
### ### ### ### University Of Alabama at Bir https://ClinicalTrials.gov/sho
April 2012 May 6, 2009 ### Research Center of Southernhttps://ClinicalTrials.gov/sho
June 7, 2017 ### July 6, 2018 ### Research Site,"Study Protocohttps://ClinicalTrials.gov/sho
April 12, 2013 ### ### ### University Of Alabama At Bir https://ClinicalTrials.gov/sho
### July 16, 2012 U.Z. Gasthuisberg, Leuven, Bhttps://ClinicalTrials.gov/sho
### July 11, 2012 Innsbruck Universitaetsklini https://ClinicalTrials.gov/sho
August 2011 July 28, 2008 ### Helsingin yliopistollinen ke https://ClinicalTrials.gov/sho
April 21, 2008 May 16, 2014 1184.14.01013 Boehringer Ing https://ClinicalTrials.gov/sho
May 2009 ### ### ### Orange, California, United S https://ClinicalTrials.gov/sho
July 2010 ### ### Cullman, Alabama, United Sta https://ClinicalTrials.gov/sho
January 2009 June 6, 2007 ### Pfizer Investigational Site, L https://ClinicalTrials.gov/sho
### ### ### Huntsville, Alabama, United https://ClinicalTrials.gov/sho
### July 9, 2021 April 18, 2023 Bay Area Cardiology Associathttps://ClinicalTrials.gov/sho
### ### ### University of "Study Protocohttps://ClinicalTrials.gov/sho
June 5, 2023 April 21, 2021 ### Velocity Clinical Research / https://ClinicalTrials.gov/sho
### April 19, 2021 ### Tibor Rubin VA Medical Cente https://ClinicalTrials.gov/sho
July 25, 2022 ### ### LKH Klagenfurt am Woertherse https://ClinicalTrials.gov/sho
April 4, 2023 ### April 14, 2023 Cliniques Universitaires St. https://ClinicalTrials.gov/sho
### ### ### Research Site, Little Rock, https://ClinicalTrials.gov/sho
July 2008 ### ### Pfizer Investigational Site, L https://ClinicalTrials.gov/sho
May 26, 2023 July 20, 2020 June 2, 2023 Investigational Site Number https://ClinicalTrials.gov/sho
### July 18, 2012 Centre Hospitalier Etterbeek https://ClinicalTrials.gov/sho
### ### ### Novartis Investigative Site, https://ClinicalTrials.gov/sho
### ### ### Arizona Oncology Associates, https://ClinicalTrials.gov/sho
August 2006 ### May 27, 2011 Pfizer Investigational Site, M https://ClinicalTrials.gov/sho
May 7, 2020 ### July 19, 2021 July 19, 2021 Research Site,"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Investigative Site 4136, Azushttps://ClinicalTrials.gov/sho
### ### ### ### Emory Winship"Study
C Protocohttps://ClinicalTrials.gov/sho
May 19, 2021 July 5, 2018 ### Kanghong Investigative Site, https://ClinicalTrials.gov/sho
### ### ### ### Research Site,"Study Protocohttps://ClinicalTrials.gov/sho
### ### April 29, 2021 April 29, 2021 CATS Research "Study Protocohttps://ClinicalTrials.gov/sho
### May 14, 2018 ### ### Investigationa "Study Protocohttps://ClinicalTrials.gov/sho
### April 19, 2018 ### UCSF Fresno, Fresno, Califorhttps://ClinicalTrials.gov/sho
### ### ### Hôpital Avicenne Service Gashttps://ClinicalTrials.gov/sho
### ### ### University of California San https://ClinicalTrials.gov/sho
### ### May 24, 2021 May 24, 2021 University of "Study Protocohttps://ClinicalTrials.gov/sho
### ### Academisch Ziekenhuis der Vr https://ClinicalTrials.gov/sho
### ### June 7, 2023 Paratus Clinical Pty Ltd, Bl https://ClinicalTrials.gov/sho
### ### May 12, 2022 Investigational Site Number https://ClinicalTrials.gov/sho
### April 11, 2017 May 6, 2020 ### Teva Investiga"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### California Cancer Associateshttps://ClinicalTrials.gov/sho
July 18, 2018 ### ### ### Teva Investiga"Study Protocohttps://ClinicalTrials.gov/sho
May 13, 2019 ### April 13, 2020 ### Teva Investiga"Study Protocohttps://ClinicalTrials.gov/sho
April 14, 2022 ### ### ### University of "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### Los Angeles, C"Study Protocohttps://ClinicalTrials.gov/sho
### ### May 31, 2019 July 31, 2019 GSK Investigat"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### San Diego, Cal"Statistical A https://ClinicalTrials.gov/sho
### ### July 23, 2019 ### Comprehensive "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### Cedars-Sinai H"Study Protocohttps://ClinicalTrials.gov/sho
### ### April 23, 2019 ### Uni of Alabama"Statistical A https://ClinicalTrials.gov/sho
### May 22, 2014 ### ### Carondelet Heart and Vascula https://ClinicalTrials.gov/sho
October 2016 April 22, 2014 June 6, 2017 ### Huntsville, Alabama, United https://ClinicalTrials.gov/sho
August 2010 ### May 6, 2009 Research Site, Montreal, Ca https://ClinicalTrials.gov/sho
January 2017 ### May 3, 2016 Tucson, Arizona, United Stat https://ClinicalTrials.gov/sho
### July 24, 2013 ### ### University of "Study Protocohttps://ClinicalTrials.gov/sho
### July 23, 2013 ### ### GSK Investigat"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### Alabama Oncolo "Study Protocohttps://ClinicalTrials.gov/sho
### ### April 7, 2022 May 3, 2022 Barrow Neurological Institut https://ClinicalTrials.gov/sho
### ### ### Imelda Ziekenhuis, Bonheiden https://ClinicalTrials.gov/sho
June 2013 ### May 6, 2013 Forest Investigative Site 053 https://ClinicalTrials.gov/sho
June 2013 ### ### ### 1160.113.32007 Boehringer In https://ClinicalTrials.gov/sho
April 7, 2017 ### ### ### Faculty teachi "Study Protocohttps://ClinicalTrials.gov/sho
### June 8, 2011 July 8, 2022 Universitäts-Klinik für Chi https://ClinicalTrials.gov/sho
### May 2, 2011 ### ### 1200.131.00171 Boehringer In https://ClinicalTrials.gov/sho
### ### ### University of Alabama Birminhttps://ClinicalTrials.gov/sho
### ### ### Iowa City, Iowa, United Stat https://ClinicalTrials.gov/sho
### ### ### April 6, 2021 Tucson, Arizona, United Stat https://ClinicalTrials.gov/sho
### ### ### ### Huntington Beach, California https://ClinicalTrials.gov/sho
June 2015 ### July 12, 2018 Universitair Ziekenhuis Gent https://ClinicalTrials.gov/sho
July 20, 2016 May 20, 2010 ### ### Birmingham, Alabama, United https://ClinicalTrials.gov/sho
July 2012 ### ### Site Reference ID/Investigat https://ClinicalTrials.gov/sho
March 2011 ### July 17, 2018 July 17, 2018 For additional information re https://ClinicalTrials.gov/sho
March 2013 April 20, 2009 ### ### Pfizer Investigational Site, https://ClinicalTrials.gov/sho
### ### May 24, 2016 ### Research Site, Phoenix, Ariz https://ClinicalTrials.gov/sho
### ### ### ### A.Z. Middelheim, Antwerpen,https://ClinicalTrials.gov/sho
### ### ### ### Rheumatology Associates, P.C https://ClinicalTrials.gov/sho
January 2012 ### ### ### Southern Cancer Center, Mobi https://ClinicalTrials.gov/sho
April 29, 2008 May 16, 2014 1184.15.01069 Boehringer Ing https://ClinicalTrials.gov/sho
### ### May 24, 2016 May 24, 2016 Research Site, Phoenix, Ariz https://ClinicalTrials.gov/sho
### ### ### Pfizer Investigational Site, A https://ClinicalTrials.gov/sho
October 2010 ### ### July 15, 2013 Orange, California, United S https://ClinicalTrials.gov/sho
May 18, 2009 ### ### Pfizer Investigational Site, https://ClinicalTrials.gov/sho
July 2013 ### ### June 9, 2014 GSK Investigational Site, Ci https://ClinicalTrials.gov/sho
### ### April 12, 2017 GSK Investigational Site, Ci https://ClinicalTrials.gov/sho
July 2008 ### July 8, 2013 July 8, 2013 Pfizer Investigational Site, https://ClinicalTrials.gov/sho
April 4, 2012 ### ### ### National Institutes of Healt https://ClinicalTrials.gov/sho
### ### ### ### University Of Alabama Medical https://ClinicalTrials.gov/sho
March 2007 ### June 7, 2012 Birmingham, Alabama, United https://ClinicalTrials.gov/sho
### May 21, 2014 Birmingham, Alabama, United https://ClinicalTrials.gov/sho
### May 4, 2006 ### Phoenix, Arizona, United Stahttps://ClinicalTrials.gov/sho
April 2008 ### ### Ceska Lipa, Czech Republic|https://ClinicalTrials.gov/sho
### ### ### Pfizer Investigational Site, G https://ClinicalTrials.gov/sho
June 2009 ### ### Alaska Clinical Research Cenhttps://ClinicalTrials.gov/sho
### June 2, 2017 ### Fakultní nemocnice Ostrava,https://ClinicalTrials.gov/sho
O
### ### ### Medical Dermatology Specialihttps://ClinicalTrials.gov/sho
### April 28, 2021 ### Radin Cardivascular Medical https://ClinicalTrials.gov/sho
### ### ### The Alfred Hospital - Profes https://ClinicalTrials.gov/sho
### ### ### Atriva study site 49006, Augshttps://ClinicalTrials.gov/sho
### ### May 9, 2023 The Oncology Institute of Ho https://ClinicalTrials.gov/sho
### ### ### University of Alabama at Bir https://ClinicalTrials.gov/sho
May 13, 2026 ### ### Local Institution, Detroit, M https://ClinicalTrials.gov/sho
### ### April 10, 2023 Childrens Hospital of Alabamhttps://ClinicalTrials.gov/sho
June 1, 2023 ### ### City of Hope National Medicahttps://ClinicalTrials.gov/sho
### ### April 3, 2023 Wright Clinical Research, Al https://ClinicalTrials.gov/sho
May 21, 2020 ### ### ### City of Hope N"Study Protocohttps://ClinicalTrials.gov/sho
### May 13, 2019 July 20, 2021 ### Novartis Inves"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Banner MD Anderson Cancerhttps://ClinicalTrials.gov/sho
Ce
June 9, 2021 ### July 3, 2023 University of Southern Calif https://ClinicalTrials.gov/sho
April 1, 2022 ### May 16, 2023 May 16, 2023 Achieve Clinic "Study Protocohttps://ClinicalTrials.gov/sho
### ### April 4, 2022 Ironwood Cancer & Researchhttps://ClinicalTrials.gov/sho
C
May 25, 2020 ### ### ### University of "Statistical A https://ClinicalTrials.gov/sho
### ### ### Investigational Site Number https://ClinicalTrials.gov/sho
### ### July 15, 2020 July 15, 2020 USC Norris Com "Study Protocohttps://ClinicalTrials.gov/sho
June 7, 2022 ### July 7, 2022 University of California San https://ClinicalTrials.gov/sho
### ### ### ### Arizona Digest"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### Achieve Clinic "Study Protocohttps://ClinicalTrials.gov/sho
May 25, 2020 May 3, 2017 ### Mary Crowley Cancer Researc https://ClinicalTrials.gov/sho
### ### ### ### Clinical Study "Study Protocohttps://ClinicalTrials.gov/sho
June 1, 2021 ### ### ### University of "Study Protocohttps://ClinicalTrials.gov/sho
### ### April 14, 2021 April 14, 2021 Usc /Id# 16423"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Kepler Universitätsklinikum, https://ClinicalTrials.gov/sho
April 12, 2021 ### May 5, 2021 Research Site, Byala, Bulgarhttps://ClinicalTrials.gov/sho
### ### ### ### Investigationa "Study Protocohttps://ClinicalTrials.gov/sho
July 14, 2020 ### July 31, 2020 St Vincent's Hospital, Darli https://ClinicalTrials.gov/sho
### ### ### Imelda Hospital, Bonheiden, https://ClinicalTrials.gov/sho
### April 27, 2017 ### ### Banner Alzheime "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### Novartis Invest"Statistical A https://ClinicalTrials.gov/sho
### ### ### Dcr-Pi Pc, Litchfield Park, https://ClinicalTrials.gov/sho
July 17, 2018 ### ### ### Fresno, Califo "Study Protocohttps://ClinicalTrials.gov/sho
### ### April 18, 2018 US138, Phoenix, Arizona, Unihttps://ClinicalTrials.gov/sho
October 2015 ### ### ### Novartis Investigative Site, https://ClinicalTrials.gov/sho
April 14, 2021 ### ### Hopitaux Universitaires Bord https://ClinicalTrials.gov/sho
### ### ### Highlands Oncology Group, Fay https://ClinicalTrials.gov/sho
### ### ### Investigative Site, Salt Lake https://ClinicalTrials.gov/sho
July 31, 2020 ### July 27, 2022 July 27, 2022 St. Vincent He"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Sidney Kimmel Comprehensive https://ClinicalTrials.gov/sho
### ### ### Massachusetts General Hospita https://ClinicalTrials.gov/sho
### ### ### Kirksville, Missouri, United https://ClinicalTrials.gov/sho
May 31, 2019 ### July 13, 2020 July 13, 2020 Kidney Transpl"Study Protocohttps://ClinicalTrials.gov/sho
April 24, 2020 ### ### ### Northwell Heal"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### University of Alabama at Bi https://ClinicalTrials.gov/sho
June 2, 2017 May 28, 2015 April 15, 2020 April 27, 2020 University of "Study Protocohttps://ClinicalTrials.gov/sho
April 14, 2018 ### July 23, 2018 Aalborg Sygehus, Aalborg, De https://ClinicalTrials.gov/sho
May 7, 2020 ### ### ### Moores Cancer"Study
### ### ### July 12, 2022 Arizona Oncolo"Study Protocohttps://ClinicalTrials.gov/sho
March 2016 ### April 7, 2017 ### Novartis Investigative Site, https://ClinicalTrials.gov/sho
May 2018 ### May 29, 2019 ### Mayo Clinic Ar"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Ceske Budejovice Hospital, https://ClinicalTrials.gov/sho
### ### ### ### Associated Ret"Study Protocohttps://ClinicalTrials.gov/sho
July 2015 ### ### Stanford, California, United https://ClinicalTrials.gov/sho
July 5, 2022 June 2, 2014 ### City of Hope National Medicahttps://ClinicalTrials.gov/sho
### May 28, 2014 ### ### UCLA Medical"Study
### ### ### ### Alaska Urologi"Study Protocohttps://ClinicalTrials.gov/sho
April 2016 ### ### ### Mayo Clinic Arizona, Scottsd https://ClinicalTrials.gov/sho
### June 6, 2013 May 24, 2018 May 30, 2018 Dana Farber Cancer Institutehttps://ClinicalTrials.gov/sho
March 2016 May 30, 2013 ### ### Cedars Sinai Medical Center,https://ClinicalTrials.gov/sho
April 2019 ### ### Investigating site BE01, Andehttps://ClinicalTrials.gov/sho
### July 20, 2012 ### July 24, 2019 Cedars Sinai Medical Center https://ClinicalTrials.gov/sho
D
### ### April 7, 2016 April 7, 2016 Cedars Sinai Medical Center https://ClinicalTrials.gov/sho
S
### ### ### ### Tampa, Florida, United Stat https://ClinicalTrials.gov/sho
June 2013 ### July 11, 2014 July 11, 2014 1160.138.32003 Boehringer In https://ClinicalTrials.gov/sho
March 2014 ### ### GSK Investigational Site, Ci https://ClinicalTrials.gov/sho
### ### ### ### Stanford Univ. School of Medhttps://ClinicalTrials.gov/sho
August 2014 ### ### Local Institution, San Diego, https://ClinicalTrials.gov/sho
June 2016 July 15, 2010 ### ### Radiant Research, Inc., Birmhttps://ClinicalTrials.gov/sho
January 2011 ### ### ### University Hospital, Interna https://ClinicalTrials.gov/sho
### ### ### ### Pfizer Investigational Site, H https://ClinicalTrials.gov/sho
July 1, 2017 ### ### ### Teva Investiga"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Innsbruck Medical university https://ClinicalTrials.gov/sho
July 2011 ### May 2, 2016 Tucson, Arizona, United Stat https://ClinicalTrials.gov/sho
March 2011 June 1, 2009 April 25, 2012 Medical University Innsbruck https://ClinicalTrials.gov/sho
July 7, 2006 ### Local Institution, Budapest, https://ClinicalTrials.gov/sho
March 2013 ### ### ### Le Kremlin Bicetre, France| https://ClinicalTrials.gov/sho
### ### ### ### GSK Investigational Site, Bir https://ClinicalTrials.gov/sho
July 2010 ### ### ### Novartis Investigator Site, L https://ClinicalTrials.gov/sho
### ### ### Onze Lieve Vrouw Ziekenhuis https://ClinicalTrials.gov/sho
June 2005 ### ### Allgemeines Krankenhaus, Kli https://ClinicalTrials.gov/sho
March 2013 May 23, 2008 April 17, 2014 ### John Muir Medical Center, Cohttps://ClinicalTrials.gov/sho
May 25, 2010 ### May 17, 2011 ### Arizona Pulmonary Specialisthttps://ClinicalTrials.gov/sho
### ### Local Institution, Burlington https://ClinicalTrials.gov/sho
### June 8, 2006 ### Pfizer Investigational Site, https://ClinicalTrials.gov/sho
March 2007 ### ### Los Angeles, California, Un https://ClinicalTrials.gov/sho
August 2007 ### ### Los Angeles, California, Uni https://ClinicalTrials.gov/sho
### ### ### Washington, District of Colu https://ClinicalTrials.gov/sho
### ### Local Institution, Sacramento,https://ClinicalTrials.gov/sho
October 2008 ### ### Central Alabama Oncology, LL https://ClinicalTrials.gov/sho
### ### Ziekenhuis Netwerk Antwerpen https://ClinicalTrials.gov/sho
### ### Krankenhaus der Elisabethine https://ClinicalTrials.gov/sho
August 2019 May 19, 2015 ### University Hospitals - Seid https://ClinicalTrials.gov/sho
### ### ### Columbia University Medical https://ClinicalTrials.gov/sho
C
April 2016 ### ### BIK-Betegápoló Irgalmas rend https://ClinicalTrials.gov/sho
### ### ### UZ Leuven, Campus Gasthuisbe https://ClinicalTrials.gov/sho
### April 8, 2013 ### UZ Leuven, Leuven, Belgium|In https://ClinicalTrials.gov/sho
August 2003 ### ### Sanofi-aventis Administrativ https://ClinicalTrials.gov/sho
### ### May 11, 2021 May 11, 2021 Investigationa "Study Protocohttps://ClinicalTrials.gov/sho
January 2017 ### ### Na Homolce Hospital, Praguehttps://ClinicalTrials.gov/sho
April 2013 ### May 7, 2013 Austin Health, Heidelberg, V https://ClinicalTrials.gov/sho
April 2009 ### May 20, 2016 Sanofi-Aventis Administrativehttps://ClinicalTrials.gov/sho
### ### ### Lankenau Institute for Medic https://ClinicalTrials.gov/sho
### ### ### Marienhospital Kevelaer, Kevhttps://ClinicalTrials.gov/sho
July 30, 2020 ### ### IRCCS Istituto Ortopedico Rizhttps://ClinicalTrials.gov/sho
### ### April 12, 2019 University of Vienna, Vienna https://ClinicalTrials.gov/sho
### ### ### Service de Neurologie Centrehttps://ClinicalTrials.gov/sho
### ### ### KU Leuven, Leuven, Belgium|O https://ClinicalTrials.gov/sho
March 2034 ### ### University of Alabama in Bir https://ClinicalTrials.gov/sho
May 26, 2026 July 12, 2021 July 3, 2023 University of Arizona, Tucso https://ClinicalTrials.gov/sho
### July 5, 2022 April 14, 2023 St. Joseph's Hospital & Medi https://ClinicalTrials.gov/sho
June 2025 ### ### Tulane University Health Sci https://ClinicalTrials.gov/sho
### ### April 14, 2023 St. Joseph's Hospital & Medi https://ClinicalTrials.gov/sho
### ### ### Mayo Clinic, Rochester, Minnhttps://ClinicalTrials.gov/sho
July 13, 2021 ### ### ### Investigationa "Study Protocohttps://ClinicalTrials.gov/sho
### July 25, 2019 ### ### Antwerp Univer"Study Protocohttps://ClinicalTrials.gov/sho
May 4, 2022 July 16, 2020 May 13, 2022 University of Alabama at Bir https://ClinicalTrials.gov/sho
May 4, 2022 June 2, 2020 ### ### Herlev Hospita"Study Protocohttps://ClinicalTrials.gov/sho
### May 5, 2020 ### Banner Alzheimer?s Institutehttps://ClinicalTrials.gov/sho
### April 24, 2020 ### AKH - Medical University of https://ClinicalTrials.gov/sho
### April 9, 2020 ### Banner Sun Health Researchhttps://ClinicalTrials.gov/sho
I
July 14, 2021 ### May 31, 2023 PellePharm Investigative Sitehttps://ClinicalTrials.gov/sho
May 3, 2022 ### April 18, 2023 Research Site, La Jolla, Cal https://ClinicalTrials.gov/sho
### ### ### ### Barrow Neurolo "Study Protocohttps://ClinicalTrials.gov/sho
### ### April 14, 2023 April 14, 2023 Ronald Reagan "Study Protocohttps://ClinicalTrials.gov/sho
### July 19, 2019 May 16, 2022 July 27, 2022 University of "Study Protocohttps://ClinicalTrials.gov/sho
April 28, 2021 May 15, 2018 June 7, 2021 The University of Texas MD A https://ClinicalTrials.gov/sho
### May 13, 2019 ### ### Neuromuscular"Study Protocohttps://ClinicalTrials.gov/sho
May 17, 2021 ### April 27, 2022 April 27, 2022 GSK Investigat"Study Protocohttps://ClinicalTrials.gov/sho
May 26, 2023 ### ### Sarah Cannon Research Instit https://ClinicalTrials.gov/sho
July 2, 2021 ### July 12, 2021 St. Joseph's Hospital and Mehttps://ClinicalTrials.gov/sho
July 26, 2021 ### ### ### Novartis Invest"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Columbia University Medical https://ClinicalTrials.gov/sho
C
### ### ### Trial Tech em Pesquisas comhttps://ClinicalTrials.gov/sho
May 11, 2022 ### June 8, 2023 June 8, 2023 Investigationa "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Banner Alzheimer's Institute https://ClinicalTrials.gov/sho
### ### ### ### Children's Ort "Study Protocohttps://ClinicalTrials.gov/sho
### ### June 6, 2023 University of Alabama at Bir https://ClinicalTrials.gov/sho
### ### April 15, 2021 ### Surgicare of M"Study Protocohttps://ClinicalTrials.gov/sho
April 18, 2019 ### ### ### Research Site,"Study Protocohttps://ClinicalTrials.gov/sho
### July 19, 2017 April 28, 2022 April 28, 2022 Research Site,"Study Protocohttps://ClinicalTrials.gov/sho
### July 17, 2017 May 16, 2022 ### University of "Study Protocohttps://ClinicalTrials.gov/sho
### July 5, 2017 April 13, 2023 University of California, Los https://ClinicalTrials.gov/sho
### June 1, 2017 May 3, 2022 The Angeles Clinic and Resear https://ClinicalTrials.gov/sho
### May 24, 2017 ### Medizinische Universität Innshttps://ClinicalTrials.gov/sho
### May 16, 2017 ### ### Phoenix Childr"Statistical A https://ClinicalTrials.gov/sho
### April 21, 2017 ### ### Research Site,"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Banner University Medical Cehttps://ClinicalTrials.gov/sho
### ### ### ### Institute of L "Study Protocohttps://ClinicalTrials.gov/sho
### ### May 24, 2022 May 24, 2022 City of Hope N"Study Protocohttps://ClinicalTrials.gov/sho
April 25, 2021 ### May 31, 2022 Medical University of Vienna https://ClinicalTrials.gov/sho
June 5, 2020 ### ### Institut Bergonie, Bordeaux, https://ClinicalTrials.gov/sho
### ### ### ### Bleeding and C"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### Site Reference"Study Protocohttps://ClinicalTrials.gov/sho
July 22, 2016 July 7, 2015 June 4, 2019 Hannover, Niedersachsen, Ghttps://ClinicalTrials.gov/sho
### ### ### ### Lyon, France|Montpellier, Fr https://ClinicalTrials.gov/sho
May 2015 ### ### ### Dana Farber Cancer Institutehttps://ClinicalTrials.gov/sho
April 6, 2020 ### July 29, 2021 ### Novartis Invest"Study Protocohttps://ClinicalTrials.gov/sho
July 18, 2018 May 6, 2016 ### ### Lycera Investig"Study Protocohttps://ClinicalTrials.gov/sho
October 2019 April 22, 2016 ### St. Joseph's Hospital and Mehttps://ClinicalTrials.gov/sho
### April 20, 2016 ### ### Uni of Alabama"Study Protocohttps://ClinicalTrials.gov/sho
August 2018 April 1, 2016 ### ### Arizona Pulmon "Study Protocohttps://ClinicalTrials.gov/sho
October 2024 ### ### St. Paul's Hospital, Univers https://ClinicalTrials.gov/sho
April 12, 2019 ### April 20, 2020 ### University of "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Darlinghurst, New South Walhttps://ClinicalTrials.gov/sho
### ### ### ### Phoenix, Arizo"Study Protocohttps://ClinicalTrials.gov/sho
May 7, 2020 ### May 19, 2023 May 19, 2023 Banner Univers"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### Ep0073 103, B"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Several Sites, Multiple Locat https://ClinicalTrials.gov/sho
### ### ### ### MSD Osterreich GmbH, Vienn https://ClinicalTrials.gov/sho
April 30, 2020 ### July 8, 2021 July 8, 2021 Banner Alzheim "Study Protocohttps://ClinicalTrials.gov/sho
June 6, 2019 ### ### ### Arkansas Child"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### IONIS Investig"Study Protocohttps://ClinicalTrials.gov/sho
### ### April 10, 2019 April 10, 2019 Dothan, Alabama, United Stathttps://ClinicalTrials.gov/sho
### July 27, 2015 April 6, 2021 April 6, 2021 Memorial Hospi "Study Protocohttps://ClinicalTrials.gov/sho
### July 10, 2015 ### ### Teva Investiga"Study Protocohttps://ClinicalTrials.gov/sho
January 2016 April 30, 2015 ### April 26, 2017 Research Site, Long Beach, C https://ClinicalTrials.gov/sho
### April 1, 2015 ### June 5, 2023 Gent, Belgium"Study Protocohttps://ClinicalTrials.gov/sho
July 2014 ### ### ### Veterans Administration Medihttps://ClinicalTrials.gov/sho
### ### ### ### Mayo Clinic Rochester, Rochhttps://ClinicalTrials.gov/sho
January 2018 ### ### Centre Hospitalier Chrétien https://ClinicalTrials.gov/sho
May 2017 ### June 2, 2020 May 24, 2023 Xenoscience, I"Study Protocohttps://ClinicalTrials.gov/sho
March 2020 July 12, 2013 ### ### Dana Farber Ca "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### April 6, 2017 Research Site, Phoenix, Ariz https://ClinicalTrials.gov/sho
May 21, 2021 July 29, 2014 July 30, 2019 ### Banner Good Sa "Study Protocohttps://ClinicalTrials.gov/sho
### ### ### Washington University, Sainthttps://ClinicalTrials.gov/sho
July 2013 ### ### ### Research Site, Glendale, Ari https://ClinicalTrials.gov/sho
July 26, 2019 ### ### July 19, 2021 University of "Study Protocohttps://ClinicalTrials.gov/sho
August 2017 ### May 3, 2016 Phoenix, Arizona, United Stahttps://ClinicalTrials.gov/sho
### ### ### ### 1301.4.5585 Boehringer Ingelhttps://ClinicalTrials.gov/sho
July 2014 ### ### Krankenhaus der Barmherzigen https://ClinicalTrials.gov/sho
October 2015 ### ### Salmaniya Medical Complex,https://ClinicalTrials.gov/sho
M
### ### ### ### Neuromuscular Research Centr https://ClinicalTrials.gov/sho
### ### ### ### University of A"Statistical A https://ClinicalTrials.gov/sho
### July 9, 2013 June 8, 2017 ### GSK Investigational Site, Bo https://ClinicalTrials.gov/sho
March 2015 ### ### ### GSK Investigational Site, Bo https://ClinicalTrials.gov/sho
### May 14, 2013 ### ### Gent, Belgium"Study Protocohttps://ClinicalTrials.gov/sho
### April 4, 2013 ### ### Ucsd Medical C "Study Protocohttps://ClinicalTrials.gov/sho
July 2014 ### ### Duffel, Belgium|Lede, Belgi https://ClinicalTrials.gov/sho
April 2015 ### ### ### University of Colorado Dept https://ClinicalTrials.gov/sho
March 2012 ### ### ### Linz, Austria|Genk, Belgium https://ClinicalTrials.gov/sho
### ### April 3, 2015 Hopital St. Louis, Paris, Fra https://ClinicalTrials.gov/sho
### ### ### ### Rheumatology Associates, Bir https://ClinicalTrials.gov/sho
October 2013 July 26, 2012 ### ### US Oncology - Providence Hea https://ClinicalTrials.gov/sho
June 2011 ### April 11, 2013 City of Hope Medical Center,https://ClinicalTrials.gov/sho
July 26, 2019 May 31, 2012 ### July 19, 2021 University of Alabama Lung Hhttps://ClinicalTrials.gov/sho
January 2016 May 25, 2012 ### CHU de Nantes Hôtel Dieu, Na https://ClinicalTrials.gov/sho
July 2015 May 1, 2012 ### ### Novartis Investigative Site, https://ClinicalTrials.gov/sho
August 2013 ### May 18, 2018 May 18, 2018 For additional information re https://ClinicalTrials.gov/sho
June 2017 ### ### Hospital of Cardiology Louis https://ClinicalTrials.gov/sho
August 2011 ### ### ### Klinik und Polyklinik fur Ep https://ClinicalTrials.gov/sho
### ### ### ### University Of California, San https://ClinicalTrials.gov/sho
### ### April 6, 2020 April 28, 2020 Tennessee Vall"Study Protocohttps://ClinicalTrials.gov/sho
January 2014 ### ### ### Medizinische Universität Wiehttps://ClinicalTrials.gov/sho
### ### ### Allgemeines Krankenhaus der https://ClinicalTrials.gov/sho
### ### ### Cleveland Clinic - Outcomes https://ClinicalTrials.gov/sho
### ### ### The University of Alabama athttps://ClinicalTrials.gov/sho
June 3, 2016 ### ### ### Research Site, Birmingham, A https://ClinicalTrials.gov/sho
### July 22, 2011 April 19, 2017 ### Birmingham, Alabama, United https://ClinicalTrials.gov/sho
### ### ### May 24, 2021 Indianapolis, Indiana, Unite https://ClinicalTrials.gov/sho
### ### ### ### Novartis Invest"Study Protocohttps://ClinicalTrials.gov/sho
### ### ### ### Dana Farber Cancer Institutehttps://ClinicalTrials.gov/sho
October 2015 June 9, 2011 ### ### Translational Genomics Resea https://ClinicalTrials.gov/sho
January 2014 May 2, 2011 ### ### University of Alabama at Bir https://ClinicalTrials.gov/sho
January 2009 ### June 2, 2010 June 2, 2010 Pfizer Investigational Site, C https://ClinicalTrials.gov/sho
### ### ### ### ImClone Investigational Site https://ClinicalTrials.gov/sho
January 2015 ### June 6, 2016 June 6, 2016 Teva Investigational Site 58, https://ClinicalTrials.gov/sho
August 2013 ### May 6, 2014 May 6, 2014 Research Site, Birmingham, A https://ClinicalTrials.gov/sho
May 2014 ### ### April 4, 2016 Los Angeles, California, Uni https://ClinicalTrials.gov/sho
### ### April 3, 2015 University Hospital, Düsseld https://ClinicalTrials.gov/sho
July 16, 2012 ### April 7, 2017 Children'S Hospital Of Orange https://ClinicalTrials.gov/sho
### ### ### ### Sanofi-Aventis Administrativehttps://ClinicalTrials.gov/sho
### May 7, 2010 ### ### Sanofi-Aventis Administrativehttps://ClinicalTrials.gov/sho
April 2014 May 6, 2010 May 21, 2015 ### Novartis Investigative Site, https://ClinicalTrials.gov/sho
### ### ### Insall Scott Kelly Institute https://ClinicalTrials.gov/sho
### ### ### Medizinische Universität, In https://ClinicalTrials.gov/sho
### ### ### UC Davis Medical Center, Sac https://ClinicalTrials.gov/sho
### ### ### ### Pituitary Center, Los Angeleshttps://ClinicalTrials.gov/sho
May 2011 ### June 6, 2016 Birmingham, Alabama, United https://ClinicalTrials.gov/sho
### ### ### ### Ohio State University, Comprhttps://ClinicalTrials.gov/sho
### July 20, 2009 April 23, 2013 Liege, Belgium|Brno, Czech https://ClinicalTrials.gov/sho
### July 15, 2009 July 9, 2018 Glendale Adventist Medical Chttps://ClinicalTrials.gov/sho
January 2011 April 23, 2009 April 9, 2012 ### University of Alabama at Birmhttps://ClinicalTrials.gov/sho
### ### ### St. Michaels Hospital, Toron https://ClinicalTrials.gov/sho
July 2011 ### April 24, 2012 April 24, 2012 Pfizer Investigational Site, https://ClinicalTrials.gov/sho
### ### July 2, 2017 Heart Rhythm Management Inst https://ClinicalTrials.gov/sho
### ### April 8, 2014 April 8, 2014 University of Alabama at Bir https://ClinicalTrials.gov/sho
June 2009 ### May 16, 2016 Sanofi-Aventis Administrativehttps://ClinicalTrials.gov/sho
June 2009 ### May 16, 2016 Sanofi-Aventis Administrativ https://ClinicalTrials.gov/sho
March 2009 July 14, 2008 ### Sanofi-Aventis Administrativehttps://ClinicalTrials.gov/sho
October 2012 ### ### ### Pfizer Investigational Site, B https://ClinicalTrials.gov/sho
October 2009 ### June 8, 2011 University of Arizona Medica https://ClinicalTrials.gov/sho
May 2011 ### ### ### Rheumatology Associates Ofhttps://ClinicalTrials.gov/sho
No
July 20, 2007 ### Novartis Investigative site, https://ClinicalTrials.gov/sho
### July 4, 2007 ### Viborg County Hospital, Vibohttps://ClinicalTrials.gov/sho
October 2008 April 16, 2007 ### ### Towson, Maryland, United Sthttps://ClinicalTrials.gov/sho
### ### May 25, 2021 Landeskrankenhaus Feldkirch https://ClinicalTrials.gov/sho
July 2009 ### ### April 21, 2011 Novartis Investigative site, https://ClinicalTrials.gov/sho
January 2009 ### ### Sanofi-Aventis Administrativehttps://ClinicalTrials.gov/sho
### ### Imeldaziekenhuis, Imeldalaanhttps://ClinicalTrials.gov/sho
### ### ### Sanofi-Aventis Administrativehttps://ClinicalTrials.gov/sho
### ### ### Clinical Trial Site, Phoenix, https://ClinicalTrials.gov/sho
### ### ### University Hospital - AKH Viehttps://ClinicalTrials.gov/sho
January 2008 ### ### GSK Investigational Site, In https://ClinicalTrials.gov/sho
April 2013 ### ### ### University of Alabama Birminhttps://ClinicalTrials.gov/sho
August 2008 ### May 19, 2008 University of South Alabama https://ClinicalTrials.gov/sho
June 2008 July 26, 2006 ### ### Pfizer Investigational Site, https://ClinicalTrials.gov/sho
### April 5, 2005 ### Pediatric Hematology/Oncolog https://ClinicalTrials.gov/sho
### ### May 18, 2011 Pfizer Investigational Site, https://ClinicalTrials.gov/sho
August 2007 ### ### Atlanta, Georgia, United Sta https://ClinicalTrials.gov/sho
April 2009 ### May 20, 2016 Sanofi-Aventis Administrativehttps://ClinicalTrials.gov/sho
### ### ### Sanofi-Aventis Administrativehttps://ClinicalTrials.gov/sho
June 2008 ### July 13, 2009 Contact Medtronic for specifi https://ClinicalTrials.gov/sho
### ### ### ### Novo Nordisk Clinical Trial https://ClinicalTrials.gov/sho
### ### ### Mayo Clinic Hospital / Arizo https://ClinicalTrials.gov/sho
August 2008 July 22, 2005 April 7, 2014 UniversitÃ¤tsklinikum Erlan https://ClinicalTrials.gov/sho
March 2007 May 20, 2005 ### Birmingham, Alabama, United https://ClinicalTrials.gov/sho
### ### May 30, 2017 GSK Investigational Site, Phohttps://ClinicalTrials.gov/sho
July 2008 July 2, 2004 ### April 28, 2010 San Francisco, California, U https://ClinicalTrials.gov/sho
June 2011 ### July 9, 2018 Karl-Franzens-University Grahttps://ClinicalTrials.gov/sho
### ### Newcastle Mater Misericordiahttps://ClinicalTrials.gov/sho
### ### Institut Jules Bordet, Bruss https://ClinicalTrials.gov/sho
### July 2, 2012 Academisch Ziekenhuis der Vr https://ClinicalTrials.gov/sho
June 2004 ### June 7, 2012 Alaska Clinical Research Cenhttps://ClinicalTrials.gov/sho
Completion DFirst Posted Results First Last Update Locations Study DocumURL
ps://ClinicalTrials.gov/show/NCT05735756
1. Heart and Vascular Diseases (total number of items in this category: 40)
-- 1.1 Cardiovascular Diseases (number of occurances: 2)
-- 1.2 STEMI/Acute Myocardial Infarction (number of occurances: 2)
-- 1.3 Arrhythmias, Cardiac (number of occurances: 1)
-- 1.4 Atrial Fibrillation (number of occurances: 9)
-- 1.5 Heart; Dysfunction Postoperative, Cardiac Surgery/Anemia, Iron-Deficiency (number of occurances: 1)
-- 1.6 Heart Failure (number of occurances: 8)
-- 1.7 Arterial Occlusive Diseases (number of occurances: 1)
-- 1.8 Atherosclerotic Cardiovascular Disease (number of occurances: 1)
-- 1.9 Heart; Disease, Mitral(Valve)/Diseases of Mitral Valve/Mitral Valve Insufficiency (number of occurances: 1)
-- 1.10 Chronic Heart Failure/Iron Deficiency/Iron Deficiency Anemia/Anaemia (number of occurances: 1)
-- 1.11 Mitral Insufficiency/Heart Valve Disease/Cardiovascular Disease/Heart Disease (number of occurances: 1)
-- 1.12 Abdominal Aortic Aneurysm/AAA (number of occurances: 1)
-- 1.13 Tachycardia, Ventricular (number of occurances: 1)
-- 1.14 Bradyarrhythmia (number of occurances: 1)
-- 1.15 Persistent Atrial Fibrillation (number of occurances: 1)
-- 1.16 Atrial Fibrillation/Paroxysmal Atrial Fibrillation/Persistent Atrial Fibrillation (number of occurances: 1)
-- 1.17 Ventricular Arrhythmias (number of occurances: 1)
-- 1.18 Dilated Cardiomyopathy (number of occurances: 1)
-- 1.19 Mitral Regurgitation (number of occurances: 1)
-- 1.20 Microvascular Coronary Artery Disease (number of occurances: 1)
-- 1.21 Coronary Arteriosclerosis/Atrial Fibrillation/Coronary Artery Bypass Graft Surgery (number of occurances: 1)
2. Respiratory Diseases (total number of items in this category: 13)

-- 2.1 Chronic Obstructive Pulmonary Disease (COPD) (number of occurances: 4)
-- 2.2 ARDS (number of occurances: 1)
-- 2.3 Wheezing/Dyspnea (number of occurances: 1)
-- 2.4 Lung Cancer (number of occurances: 3)
-- 2.5 Asthma (number of occurances: 2)
-- 2.6 Bronchiectasis (number of occurances: 1)
3. Infectious Diseases (total number of items in this category: 8)

-- 3.1 COVID-19 (number of occurances: 3)
-- 3.2 Tuberculosis (number of occurances: 1)
-- 3.3 Staphylococcal Infections/Bacteremia (number of occurances: 1)
-- 3.4 HIV Infections
(number of occurances: 1)
-- 3.5 Hepatitis C (number of occurances: 1)
-- 3.6 Coronavirus Infection (number of occurances: 1)
-- 3.7 Adenovirus (number of occurances: 1)
-- 3.8 HIV-1 Infection (number of occurances: 1)
4. Neoplasms (total number of items in this category: 45)

-- 4.1 Ovarian Cancer (number of occurances: 1)
-- 4.2 Breast Cancer (number of occurances: 3)
-- 4.3 Gastric Cancer/Peritoneal Carcinomatosis/HIPEC (number of occurances: 1)
-- 4.4 Prostatic Neoplasms/Esophageal Neoplasms/Neoplasm Metastases, Brain/Rectal Neoplasms/Brain Neoplasm
-- 4.5 Prostate Cancer (number of occurances: 4)
-- 4.6 Cervix Cancer (number of occurances: 1)
-- 4.7 Colonic Neoplasms (number of occurances: 1)
-- 4.8 Lung Cancer (number of occurances: 2)
-- 4.9 Carcinoma, Non-Small-Cell Lung/Carcinoma, Small Cell Lung/Mesothelioma (number of occurances: 1)
-- 4.10 Non-small Cell Lung Cancer (NSCLC) (number of occurances: 4)
-- 4.11 Breast Neoplasms (number of occurances: 2)
-- 4.12 Metastatic Breast Cancer (number of occurances: 2)
-- 4.13 Head and Neck Neoplasms (number of occurances: 1)
-- 4.14 Melanoma/Brain Metastasis (number of occurances: 1)
-- 4.15 Giant Cell Tumor of Bone/Osteoclastoma (number of occurances: 1)
-- 4.16 Non-small Cell Lung Cancer/Non-small Cell Lung Cancer Metastatic/Non-small Cell Lung Cancer Recurrent
-- 4.17 Lymphoma, Non-Hodgkin (number of occurances: 1)
-- 4.18 Neuroendocrine Tumors in Lung (number of occurances: 1)
-- 4.19 Recurrent Head and Neck Squamous Cell Carcinoma/Metastatic Head and Neck Squamous Cell Carcinoma
-- 4.20 Cancer/Advanced Solid Malignancies (number of occurances: 1)
-- 4.21 Full-thickness Skin Loss Due to Burn, Unspecified Site (number of occurances: 1)
-- 4.22 Acute Lymphoblastic Leukemia/Acute Lymphoblastic Leukemia, Adult/Acute Lymphoblastic Leukemia, Pedia
-- 4.23 Osteosarcoma (number of occurances: 1)
-- 4.24 Myelodysplastic Syndrome (MDS) (number of occurances: 1)
-- 4.25 Colore
ctal Cancer (number of occurances: 1)

-- 4.26 Bladder Neoplasm/Neoplasm Recurrence, Local/Transitional Cell, Carcinoma/Carcinoma in Situ/Mycobacter
-- 4.27 Non-Small Cell Lung Cancer (number of occurances: 3)
-- 4.28 Urinary Bladder Neoplasms (number of occurances: 1)
-- 4.29 Lymphoma, Mantle-Cell/Lymphoma, Large B-Cell, Diffuse/Lymphoma, Follicular (number of occurances: 1)
-- 4.30 Relapsed T-Cell Acute Lymphoblastic Leukemia/Relapsed T-Cell Lymphoblastic Lymphoma (number of occ
5. Cardiovascular Diseases (total number of items in this category: 41)

-- 5.1 Stroke (number of occurances: 1)
-- 5.2 Cardiovascular Diseases (number of occurances: 2)
-- 5.3 STEMI/Acute Myocardial Infarction (number of occurances: 1)
-- 5.4 Arrhythmias, Cardiac (number of occurances: 1)
-- 5.5 Atrial Fibrillation (number of occurances: 8)
-- 5.6 Heart; Dysfunction Postoperative, Cardiac Surgery/Anemia, Iron-Deficiency (number of occurances: 1)
-- 5.7 Heart Failure (number of occurances: 6)
-- 5.8 Atherosclerotic Cardiovascular Disease (number of occurances: 1)
-- 5.9 Ventricular Arrhythmias (number of occurances: 1)
-- 5.10 Heart; Disease, Mitral(Valve)/Diseases of Mitral Valve/Mitral Valve Insufficiency (number of occurances: 1)
-- 5.11 Mitral Insufficiency/Heart Valve Disease/Cardiovascular Disease/Heart Disease (number of occurances: 1)
-- 5.12 Abdominal Aortic Aneurysm/AAA (number of occurances: 1)
-- 5.13 Bradyarrhythmia (number of occurances: 1)
-- 5.14 Mitral Regurgitation (number of occurances: 1)
-- 5.15 Microvascular Coronary Artery Disease (number of occurances: 1)
-- 5.16 Arterial Occlusive Diseases (number of occurances: 1)
-- 5.17 Coronary Arteriosclerosis/Atrial Fibrillation/Coronary Artery Bypass Graft Surgery (number of occurances: 1)
-- 5.18 Tachycardia, Ventricular (number of occurances: 1)
6. Respiratory Disorders (total number of items in this category: 11)

-- 6.1 Blunt Chest Trauma (number of occurances: 1)
-- 6.2 Chronic Obstructive Pulmonary Disease (COPD) (number of occurances: 4)
-- 6.3 ARDS (number of occurances: 1)
-- 6.4 Dyspnea/Coma/Hypotension and Shock (number of occurances: 1)
-- 6.5 Wheezing/Dyspnea (number of occurances: 1)
--
6.6 Asthma (number of occurances: 2)

-- 6.7 Bronchiectasis (number of occurances: 1)
7. Neurologic Diseases (total number of items in this category: 10)

-- 7.1 Parkinson's Disease (number of occurances: 3)
-- 7.2 Multiple Sclerosis (number of occurances: 2)
-- 7.3 Alzheimer Disease/Alzheimer's Disease 2 (number of occurances: 1)
-- 7.4 Amyotrophic Lateral Sclerosis (number of occurances: 1)
-- 7.5 Epilepsy (number of occurances: 1)
-- 7.6 Stroke (number of occurances: 2)
8. Digestive System Diseases (total number of items in this category: 13)

-- 8.1 Inflammatory Bowel Diseases (number of occurances: 1)
-- 8.2 Crohn Disease/Crohn's Disease/Inflammatory Bowel Disease (number of occurances: 1)
-- 8.3 Colonic Neoplasms (number of occurances: 1)
-- 8.4 Hepatitis C (number of occurances: 1)
-- 8.5 Non-alcoholic Steatohepatitis (NASH) (number of occurances: 1)
-- 8.6 Peptic Ulcer (number of occurances: 1)
-- 8.7 Gastric Ulcer (number of occurances: 1)
-- 8.8 Esophageal Cancer (number of occurances: 1)
-- 8.9 Liver Diseases (number of occurances: 1)
-- 8.10 Cirrhosis, Liver/Cirrhosis, Liver/Primary Biliary (number of occurances: 1)
-- 8.11 Chronic Liver Disease (number of occurances: 1)
-- 8.12 Gastroesophageal Reflux Disease (GERD) (number of occurances: 1)
-- 8.13 Dyspepsia (number of occurances: 1)
9. Rheumatologic Diseases (total number of items in this category: 5)

-- 9.1 Rheumatoid Arthritis (number of occurances: 2)
-- 9.2 Systemic Lupus Erythematosus (number of occurances: 1)
-- 9.3 Osteoarthritis (number of occurances: 1)
-- 9.4 Ankylosing Spondylitis (number of occurances: 1)
10. Endocrine and Metabolic Diseases (total number of items in this category: 8)
-- 10.1 Diabetes Mellitus, Type 2 (number of occurances: 3)
-- 10.2 Obesity (number of occurances: 2)
-- 10.3 Hypothyroidism (number of occurances: 1)
-- 10.4 Hyperthyroidism (number of occurances: 1)
-- 10.5 Diabetes Mellitus (number of occurances: 1)
r of occurances: 1)
mber of occurances: 1)
occurances: 1)
umber of occurances: 1)
of occurances: 1)
number of occurances: 1)
Neoplasms/Brain Neoplasm, Primary (number of occurances: 1)
er of occurances: 1)
ll Lung Cancer Recurrent (number of occurances: 1)
Squamous Cell Carcinoma (number of occurances: 1)
hoblastic Leukemia, Pediatric/Acute Lymphoblastic Leukemia, in Relapse/Acute Lymphoblastic Leukemia Recurrent (number o
cinoma in Situ/Mycobacterium (number of occurances: 1)
ymphoma (number of occurances: 1)
r of occurances: 1)
emia Recurrent (number of occurances: 1)

Overview - Clinical Trials

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Overview - Clinical Trials

Uploaded by

Copyright:

Available Formats

1 Terminated (The clinical trial has ended prema 1 NCT05735756

1 Terminated (too busy for recruitment) 2 NCT05338125

Title Status Conditions Interventions

Outcome Measures Sponsor/CollaGender Age Phases

2. Respiratory Diseases (total number of items in this category: 13)

3. Infectious Diseases (total number of items in this category: 8)

4. Neoplasms (total number of items in this category: 45)

ctal Cancer (number of occurances: 1)

5. Cardiovascular Diseases (total number of items in this category: 41)

6. Respiratory Disorders (total number of items in this category: 11)

6.6 Asthma (number of occurances: 2)

7. Neurologic Diseases (total number of items in this category: 10)

8. Digestive System Diseases (total number of items in this category: 13)

9. Rheumatologic Diseases (total number of items in this category: 5)

ll Lung Cancer Recurrent (number of occurances: 1)

Squamous Cell Carcinoma (number of occurances: 1)

cinoma in Situ/Mycobacterium (number of occurances: 1)

You might also like